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Abstract  
Considerable recent evidence supports the role of AMP-activated protein kinase 
(AMPK) as an anti-inflammatory mediator, yet the mechanisms of its anti-
inflammatory actions are only starting to be unravelled. Inappropriate cytokine-
stimulated Janus kinase (JAK)-signal transducer and activator of transcription 
(STAT) signalling is a key feature of many pro-inflammatory events, including 
atherogenesis. Previous unpublished studies in our group have investigated 
whether AMPK modifies cytokine stimulation of JAK-STAT signalling in HUVECs 
These preliminary investigations demonstrated that pre-treatment of HUVECs with 
AMPK activator, A769662, significantly inhibits both sIL-6Rα/IL-6 and IFN-α 
stimulation of STAT3 Tyr705 phosphorylation in HUVECs. IFN-α activates STATs via 
an IFNα/β receptor 1 (IFNAR1/IFNAR2) complex which is distinct from the sIL-
6Rα/IL-6/gp130 complex. The studies in this thesis therefore tested the hypothesis 
that AMPK was exerting its inhibitory effects at one or more common signalling 
loci downstream of IFNAR1/IFNAR2 and gp130 at a post-receptor level. First, it 
was investigated whether AMPK exerts its inhibitory effects on JAK-STAT signalling 
via a known regulator of JAK or STAT, or an AMPK downstream target known to 
either directly or indirectly impact on JAK-STAT signalling. A combination of 
genetic and pharmacological approaches was utilised to assess the role of each of 
the following AMPK targets: TC-PTP, SHP2, eNOS, PKCλ, SIRT1, CPT1 and mTOR. It 
was demonstrated that activation of AMPK in HUVECs inhibited sIL-6Rα/IL-6 
stimulated STAT3 Tyr705 phosphorylation via a mechanism independent of TC-PTP, 
eNOS, PKC, SIRT1 and mTOR. Furthermore, inhibition of mTOR and eNOS reduced 
sIL-6Rα/IL-6 stimulated STAT3 Tyr705 phosphorylation, independent of AMPK 
activation by A769662. Next, it was investigated whether AMPK acts directly on a 
signalling component of the JAK-STAT pathway. Specifically, it was hypothesised 
that AMPK could directly phosphorylate serine or threonine residues within JAK to 
inhibit IL-6 signalling. siRNA-mediated downregulation of JAK isoforms 
demonstrated that IL-6 induced STAT3 Tyr705 phosphorylation predominantly via 
JAK1 in human umbilical vein endothelial cells (HUVECs). In vitro kinase assays of 
JAK1-derived peptides demonstrated that AMPK can directly phosphorylate two 
residues, Ser515 and Ser518, within the JAK1 SH2 domain.  Subsequently, a GST-
14-3-3 pull down assay of cell lysates produced from A769662 treated JAK1-
defcient U4C cells transiently expressing either wild type or S515A/S518A double 
3 
 
mutant JAK1 demonstrated that pharmacological activation of AMPK promotes 14-
3-3 binding of JAK1 via a mechanism requiring Ser515 and Ser518. Furthermore, 
mutation of Ser515 and Ser518 abolishes the ability of AMPK to inhibit JAK-STAT 
signalling by an IL-6 trans-signalling complex and from a constitutively active 
Val658Phe-mutated JAK1. In this study it is proposed that AMPK phosphorylation 
of JAK1 at Ser515 and Ser518 inhibits IL-6 stimulated JAK1 phosphorylating STAT3 
by interfering with the ability of JAK1 to interact and phosphorylate the GP130 
receptor and /or STAT3 and STAT1. Therefore, AMPK phosphorylation of JAK1 
could potentially be a novel regulatory mechanism that could be developed as a 
therapy for treating chronic inflammatory diseases such as atherosclerosis.  
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Chapter 1 - Introduction 
1.1 Inflammation 
Inflammation is an essential immune response by the host that enables the 
removal of harmful stimuli as well as the healing of damaged tissue. Clinically, 
inflammation is characterised by heat, pain, swelling and redness, symptoms 
caused by increased blood flow to the affected area, leakage of fluid into tissues 
and the accumulation of activated leukocytes (Medzhitov, 2008). Inflammation is 
initiated on activation of the innate immune system by noxious stimuli and 
conditions, such as microbial infection and tissue injury. Innate immune cells 
residing in tissues, such as macrophages, mast cells, and dendritic cells, as well 
as circulating leukocytes, including monocytes and neutrophils, play important 
roles in inflammatory responses. In addition to immune cells, non-immune cells 
such as epithelial cells, endothelial cells and fibroblasts also contribute to 
inflammatory processes (Newton and Dixit, 2012). The innate immune cells 
immediately recognize pathogen invasion or cell damage with intracellular or 
surface-expressed pattern recognition receptors (PRRs) such as Toll-like receptors 
(TLR). These receptors detect, either directly or indirectly, pathogen-associated 
molecular patterns (PAMPs), such as microbial nucleic acids, lipoproteins, and 
carbohydrates, or damage-associated molecular patterns (DAMPs) released from 
injured cells (Newton and Dixit, 2012). Activated PRRs then initiate signalling 
cascades that triggers phagocytosis and induces changes in gene expression such 
as an increase in production of inflammatory cytokines (e.g. tumour necrosis 
factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6)), chemokines and 
vasoactive amines (Ahmed, 2011). These mediators rapidly accelerate the 
progression of inflammation through the modification of vascular endothelial 
permeability as well as the recruitment of neutrophils, lymphocytes and excess 
plasma (containing antibodies and complement factors) into the site of infection 
(Ahmed, 2011). The actions of activated innate immune cells and cytotoxic 
lymphocytes serve to remove pathogens and damaged tissues, clearing the way 
for healing and restoration of function. A successful acute inflammatory response 
results in the elimination of the infectious agents or injured cells followed by a 
resolution and repair phase (Medzhitov, 2008). The inflammatory response is 
normally terminated once the potential danger is eradicated. If inflammation 
progresses unresolved, the acute inflammation turns into a chronic stage. Whereas 
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acute inflammation is beneficial, chronic inflammation can result in undesirable 
effects and is critically involved in a variety of diseases such as atherosclerosis, 
rheumatoid arthritis, multiple sclerosis, and asthma (Ahmed, 2011). 
1.2 Atherosclerosis  
Atherosclerosis can be defined as a chronic inflammatory disease characterised by 
an inflammatory response of arterial wall to injuries promoted by risk factors such 
as dyslipidemia, diabetes, hypertension and systemic inflammation (Ross, 1999, 
Hadi et al., 2005). Atherosclerosis is the formation of lesions within the arterial 
intima due to the accumulation of lipids, macrophages, leukocytes and smooth 
muscle cells. Over time, these lesions may evolve to occlude the artery lumen or 
alternatively they may rupture, triggering thrombosis which is often followed by 
myocardial infarction or stroke (Langheinrich and Bohle, 2005, Glass and Witztum, 
2001). Figure 1.1 outlines that formation of atherosclerotic plaque (Autieri, 2012). 
Endothelial dysfunction is generally accepted as the main predisposing factor 
towards atherosclerosis and is detected prior to the appearance of clinical 
symptoms (Anderson, 1999). Endothelial dysfunction is triggered in response to 
risk factors such as dyslipidemia, diabetes, hypertension and systemic 
inflammation (Hadi et al., 2005). Clinically, endothelial dysfunction is defined as 
impairment of endothelium dependent vasodilation but is also characterised by 
conversion of the endothelium to an “activated” phenotype associated with 
increased endothelial permeability, proliferation, leukocyte adhesion and 
production of pro-inflammatory cytokines (Davignon and Ganz, 2004, Anderson, 
1999). Increased endothelial permeability, favours the migration of low density 
lipoprotein particles (LDL) through the vascular wall into the sub-endothelial 
intima. Trapped LDL is exposed to agents that trigger its conversion into modified 
forms like oxidized LDL (oxLDL). Oxidized LDL induces macrophage pro-
inflammatory gene expression, including TNF-α, IL-1β, and IL-6, to further 
exacerbate the endothelial dysfunctional phenotype (Malden et al., 1991, Tabas 
et al., 2007). Activated endothelial cells express on their luminal surface 
leukocyte adhesion molecules, such as E-selectin, vascular cell adhesion molecule 
(VCAM-1) and intercellular adhesion molecule (ICAM-1), which attracts leukocyte. 
Once leukocytes have attached, migration is stimulated by endothelial expressed 
chemokines and cytokines, such as monocyte chemoattractant protein-1 (MCP-1), 
macrophage colony-stimulating factor (M-CSF), IL-8 and TNF-α (Ross, 1999, Pober 
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and Sessa, 2007). Leukocytes adhere to the endothelial lumen and migrate through 
vascular wall to the sub-endothelial intima. In the arterial intima, monocytes can 
differentiate into macrophages under the influence of M-CSF or granulocyte-
macrophage colony stimulating factor (GM-CSF). Macrophages express scavenger 
receptors that permit the uptake of oxLDL.  Lipid loading of macrophages leads to 
the formation of foam cells, and ultimately leads to the mature lipid-laden 
macrophages of the plaque's core (Stephen et al., 2010). Also, T-lymphocytes 
infiltrate the atherosclerotic lesions. Activated T cells differentiate mainly into T-
helper 1 cells and begin producing interferon-γ (IFN-γ), which in turn increases 
the process of antigen presentation by macrophages to lymphocytes and 
stimulates synthesis of other cytokines like TNF-α and IL-1. Growth factors and 
cytokines released by immune and vascular cells contribute to the formation of a 
fibrous cap of smooth muscle and extracellular matrix (ECM) around the lipid core, 
which compromises the vascular lumen (Ross, 1999, Hansson et al., 2002, Libby, 
2002). Overall, atherosclerosis is not only the accumulation of fat in arterial walls 
but is also a complex process involving both innate and adaptive immune responses 
(Ross, 1999, Hansson et al., 2002). 
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Figure 1.1: Formation of an atherosclerotic plaque.  
Endothelial dysfunction is triggered in response to risk factors such as dyslipidemia, diabetes, 
hypertension and systemic inflammation. The endothelial monolayer becomes “leaky” allowing lipids 
to enter and accumulate within the intimal layer. Oxidised lipids promote the expression of leukocyte 
adhesion receptors and the production of chemokines by the now activated endothelial cells. Various 
inflammatory cells such as macrophages are recruited to this site promoting the inflammatory 
response and the formation of the atheromatous plaque. Smooth muscle cell migration from the 
media to the intima then contributes to fibrous cap formation and extracellular matrix around the lipid 
core. Over time, these lesions may evolve to occlude the artery lumen or alternatively vulnerable 
plaques, which are characterised by thin fibrous cap, rupture and may result in thrombus formation. 
(Figure taken from Autieri, 2012) 
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1.2.1 Pro-inflammatory cytokines in atherosclerosis: TNF-α, IL-1β and IL-6   
The innate and adaptive immune responses in atherosclerosis are orchestrated by 
a range of cytokines, which regulate all stages of the disease: initiation, 
progression and destabilisation of atherosclerosis plaques (reviewed by Ramji and 
Davies, 2015). All of the major cellular constituents of plaques; 
macrophage/monocytes, endothelial cells (ECs), and vascular smooth muscle cell 
(VSMCs) are capable of producing and responding to cytokines, thus promoting a 
vicious cycle of pro-inflammatory signalling. Mounting evidence suggests that TNF-
α, IL-1β and IL-6 are pro-inflammatory cytokines mediating the key processes 
involved in atherosclerosis.  
TNF-α plays a pivotal role in orchestrating the production of other pro-
inflammatory cytokines, thus TNF-α is considered to be a “master regulator” of 
pro-inflammatory cytokine production (Maini et al., 1995). TNF-α is produced by 
macrophages, ECs and VSMCs of atherosclerotic arteries (Barath et al., 1990). TNF-
α induces the expression of adhesion molecules ICAM-1 and VCAM-1, chemokine 
MCP-1 and enhances the production of cytokines such as IL-1β, IL-8 and growth 
factors in a variety of cell types including lymphocytes, macrophage, ECs, and 
VSMCs (Bevilacqua et al., 1987, Osborn et al., 1989, Rollins et al., 1990, Libby et 
al., 1986) TNF-α stimulates leukocyte adhesion to endothelial cells and 
chemotaxis (Bevilacqua et al., 1987, Osborn et al., 1989, Ming et al., 1987). TNF-
α is found in human atherosclerotic plaque and serum TNF-α levels correlate with 
atherosclerotic plaque burden (Skoog et al., 2002). In the atherosclerotic plaque, 
secretion of matrix metalloproteinases (MMPs) degrade various components of the 
ECM leading to instability of the plaque and rupture. Crucially, TNFα is associated 
with plaque rupture as it stimulates the production of several MMPs and its levels 
are increased in human atherosclerotic plaques (Galis et al., 1995). TNF-α 
deficient atherosclerosis prone mice have significantly reduced atherosclerotic 
lesions compared with WT atherosclerosis prone mice, which was associated with 
decreased expression of ICAM-1, VCAM-1, and MCP-1 (Ohta et al., 2005). 
IL-1β is produced by all the major cellular constituents of plaques; 
macrophage/monocytes, ECs, and VSMCs. IL-1β also induces the expression of 
cytokines, adhesion molecules, and is mitogenic for VSMCs and ECs (Suzuki et al., 
1989). IL-1β –treatment of endothelial monolayers increased the adhesion of 
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leukocytes (Bevilacqua et al., 1985). IL-1β is present in human atherosclerotic 
plaques (Frostegård et al., 1999). IL-1β deficiency induced an approximately 30% 
reduction in lesions in atherosclerosis prone mice, which was associated with 
significantly reduced mRNA levels of VCAM1 and MCP-1(Kirii et al., 2003). 
TNF-α and IL-1β trigger pro-inflammatory effects via simultaneous activation of 
the canonical NF-κB (nuclear factor kappa B) pathway and MAPK (mitogen 
activated protein kinase) intracellular signalling cascades. Briefly, TNF-α or IL-1β 
binding its cognate receptor stimulates an increase in IκB kinase (IKK) activity, 
which in turn phosphorylates inhibitor of κB (IκBα). Under basal conditions, IκBα 
is bound to the transcription factor NF-κB in the cytoplasm; however upon 
phosphorylation by IKK, NF-κB is released and translocates to the nucleus and 
initiates transcription of the target genes including cell adhesion molecules, 
chemokines and cytokines (Pamukcu et al., 2011). The MAPK pathway is activated 
in parallel following cytokine stimulation, leading to the phosphorylation and 
activation of c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase 
(ERK) and p38 MAPK. Active MAPKs can translocate to the nucleus, thereby 
influencing transcription by phosphorylation of transcription factors such as c-Jun, 
c-fos and ATF-2 (Plotnikov et al., 2011). Studies have shown that the pathways 
involving MAPKs regulate the proliferation and differentiation of VSMCs (ERK 1/2), 
expression of ECM protein in VSMCs (JNK), expression of chemokines and cytokines 
(p38) in ECs and macrophage foam cell formation (ERK/JNK/p38) (Muslin, 2008).  
The focus of this thesis is on the IL-6/Janus kinase (JAK)-signal transducer and 
activator of transcription (STAT) signalling pathway. Therefore, the IL-6/JAK-STAT 
pathway and its role in atherosclerosis are described in detail below.  
1.3 The JAK-STAT pathway  
1.3.1.1 Classic IL-6 signalling vs IL-6 trans-signalling 
IL-6 is a pleiotropic cytokine produced by various cell types including fibroblasts, 
ECs, VSMCs and immune cells such as monocytes and T-cells (Schaper and Rose-
John, 2015). IL-6 can interact with either a membrane bound IL-6 receptor (IL-
6Rα) or a soluble IL-6 receptor-α (sIL-6Rα), that then associates with the 
membrane glycoprotein 130 (gp130) receptor to initiate the JAK-STAT pathway. 
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gp130 is expressed ubiquitously whereas membrane bound IL-6Rα is limited to the 
cell surface of a few cell types including hepatocytes, monocytes, neutrophils and 
B-cells (Rose-John, 2012). These cells are able to respond to circulating IL-6 in 
what is known as classical IL-6 signalling. The sIL-6Rα is thought to be synthesised 
following either alternative splicing of IL6Rα mRNA or matrix metalloprotease 
(ADAM17 or ADAM10) shedding of a sIL-6Rα from the cell surface of IL6Rα 
expressing hepatocytes and monocytes (Muller-Newen et al., 1996, Mullberg et 
al.,1993 Matthews et al., 2003, Lust et al.,1992). The sIL-6R can bind to free IL-6 
in the circulation to form a sIL-6Rα/IL-6 complex. The sIL-6R/IL-6 complex can 
then the interact with gp130 on cells which do not express IL-6Rα to initiate cell 
signalling pathways, this process is called trans-signalling. This has been 
demonstrated in studies using human umbilical vein endothelial cells (HUVECs) 
where IL-6 alone did not elicit a response, while the sIL-6Rα/IL-6 complex induced 
the production MCP-1 (Romano et al., 1997). Interestingly, a review of the 
involvement of both signalling modes in the biology of IL-6 by Scheller et al 
revealed that anti-inflammatory and regenerative responses are mediated by IL-6 
classical signalling whereas pro-inflammatory responses of IL-6 are mediated by 
trans-signalling (Scheller et al., 2011).  
1.3.2 IL-6 mediated JAK-STAT signalling 
The gp130 signalling receptor lacks intrinsic kinase activity but is constitutively 
associated with JAK family tyrosine kinases. Binding of IL-6 to IL-6Rα induces 
dimerisation of the gp130 subunit leading to manoeuvring of receptor-associated 
JAKs into positions to facilitate their trans-phosphorylation and corresponding 
activation (Murakami et al., 1993). Subsequently, activated JAKs mediate 
phosphorylation of key tyrosine residues within the cytoplasmic regions of the 
receptor that provide docking sites for the Src homology 2 (SH2) domains of STATs, 
a family of latent cytoplasmic transcription factors. After docking, STATs are 
phosphorylated by activated JAKs, which enables them to dimerise and 
translocate to the nucleus where they bind to specific DNA elements, and regulate 
the transcription of thousands of genes (Rawlings et al., 2004, O’Shea et al., 2002, 
Kisseleva et al., 2002) (Figure 1.2). Studies using mutant cell lines deficient in 
JAK1, JAK2 or TYK2 have revealed that IL-6-mediated signalling absolutely 
depends on the presence of JAK1 whereas JAK2 and TYK2 are dispensable (Guschin 
et al., 1995). JAK1-mediated phosphorylation of gp130 at Tyr767, Tyr814, Tyr905 
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and Tyr915 at a pYXXQ consensus sequence enables binding of STAT3 which 
competes with STAT1 binding at Tyr905 and Tyr915 at a more constrained pYXLQ 
consensus sequence (Stahl et al., 1995, Gerhartz et al., 1996, Schmitz et al., 2000, 
Heinrich et al., 2003). This could account for the more potent activation and dimer 
formation of transcriptionally active STAT3 compared to STAT1. STATs are 
phosphorylated by JAKs on a single tyrosine residue: Tyr701 in STAT1 and Tyr705 in 
STAT3 (Shuai et al., 1994, Kaptein et al., 1996).  
STATs are not the only proteins that are recruited to the activated IL-6 receptor. 
The SHP2 (SH2 domain-containing phosphatase 2) binds to pTyr759 on gp130 and 
is phosphorylated by JAK1 (Schaper et al., 1998). Activated SHP2 can then induce 
ERK mediated gene transcription via the recruitment of Grb2 (growth factor 
receptor bound protein 2) which is bound to Sos (son of sevenless). Sos serves as 
a guanine nucleotide exchange factor (GEF) for the Ras protein and therefore 
activates Ras by generating Ras-GTP. Subsequently the ERK1/2-MAPK pathway is 
activated, driving the expression of genes involved in proliferation, differentiation 
and development (Mihara et al., 2012).  
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Figure 1.2: Activation of the JAK/STAT pathway by IL-6 
IL-6 activates the gp130 receptor subunits, initiating their dimerization and activation (trans-
autophosphorylation) of receptor associated JAK proteins. Activated JAKs phosphorylate tyrosine 
residues on the gp130 subunits which function as docking sites for SH2-containing proteins. STAT3 
binds, is phosphorylated by JAK which induces dimer formation. SHP-2 is also phosphorylated by 
JAKs and initiates the Ras/Raf/MEK signalling pathway, activating ERK1/2. STAT3 dimers and 
ERK1/2 translocate to the nucleus where they stimulate the transcription of genes. SOCS3 may 
compete with SHP-2 for pY759 on the gp130R and so inhibits activation of the Ras-ERK1/2 pathway 
by SHP-2. (Figure taken from Rutherford et al., 2012.) 
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1.3.3 JAK 
The JAK family consists of four mammalian members, JAK1 JAK2, JAK3 and TYK2. 
JAK1, JAK2 and Tyk2 are ubiquitously expressed while JAK3 is expressed 
predominantly in myeloid and lymphoid cells (Verbsky et al., 1996, Kisseleva et 
al., 2002). JAKs are relatively large kinases with a molecular weight of 130 kDa 
(Ihle et al., 1994). The JAK structure is characterized by the presence of seven 
conserved JAK homology (JH) domains. The kinase JH1 domain is at the C-terminus 
of JAKs, preceded by the pseudokinase JH2 domain. The N-terminal half of JAKs 
contains the FERM (FERM standing for: band-4.1 protein, ezrin, radixin, and 
moesin) domain, followed by the SH2 domain (Yamaoka et al., 2004). The 
unavailability of a crystal structure of a full-length JAK molecule limits our 
understanding on the functional roles of these domains. However biochemical and 
mutational studies coupled with some solved crystal structures of JAK fragments 
have started to unravel the basic functional roles of these domains. The kinase 
JH1 domain is a typical eukaryotic tyrosine kinase domain. Mutational analysis 
identified that the activation loop contains a conserved double tyrosine motif 
which is phosphorylated in response to cytokine stimulation: Y1022/Y1023 in JAK1, 
Y1007/Y1008 in JAK2, Y980/Y981 in JAK3 and Y1054/Y1055 in TYK2 (Liu et al., 
1997, Feng et al., 1997, Leonard and O’Shea, 1998). The pseudokinase JH2 domain 
has been shown to play a regulatory role by suppressing kinase activity via 
inhibitory interactions with the C-terminal kinase JH1 domain (Lupardus et al., 
2014, Shan et al., 2014, Tom et al., 2013, Ungureanu et al., 2011). Mutational 
analysis has indicated that the JAK SH2 domain does not function as a binding site 
for phosphorylated tyrosine residues, but instead interacts with the FERM domain 
to stabilise its conformation (Radtke et al., 2005, Haan et al., 2001). The N-
terminal FERM domain binds to the cytoplasmic region of cytokine receptors and 
may also regulate kinase activity (Girault et al., 1998, Haan et al., 2001, Haan et 
al., 2008, Hilkens et al., 2001, Zhao et al., 2010). The cytoplasmic domains of the 
cytokine receptors contain “box1” and “box2” motifs which are required for JAK 
engagement. Box1 is a membrane proximal proline-rich motif while box2 consists 
of a single negatively-charged residue followed by several hydrophobic residues 
(Murakami et al., 1991, Pelletier et al., 2006, Lebrun et al., 1995, Yan et al., 1996, 
Tanner et al., 1995, Usacheva et al., 2002, Royer et al., 2005, Haan et al., 2002). 
Receptor ligation triggers a conformational change in receptor complex that brings 
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associated JAKs into close proximity, permitting auto-phosphorylation (Remy et 
al., 1999). 
1.3.4 STAT 
In mammalian cells seven STAT proteins exist: STAT1, 2, 3, 4, 5a, 5b and 6 
(Kisseleva et al., 2002). They are ubiquitously expressed with the exception of 
STAT4 which is mainly found in the testis, thymus and spleen (Zhong et al., 1994). 
Each STAT has seven structurally and functionally conserved domains:  N-terminal, 
coiled-coil, DNA binding, linker, SH2 and a C-terminal transcriptional activation 
domain (Becker et al., 1998, Chen et al., 1998, Vinkemeier et al., 1998). The STAT 
SH2 domain is highly conserved and is important for specific contacts with the 
activated receptor and the formation of STAT dimers (Greenlund et al., 1994, Heim 
et al., 1995, Stahl et al., 1995, Shuai et al., 1994). The sequence surrounding the 
receptor phosphotyrosine site specifies which STAT is recruited and activated 
(Stahl et al., 1995). For example, STAT3 will bind to phospho (p)YXXQ while STAT1 
will only bind to pYXPQ (Stahl et al., 1995, Heim et al., 1995, Gerhartz et al., 
1996). Upon cytokine stimulation, STATs are recruited to the activated cytokine 
receptor via their SH2 domain, where by being in close proximity of the receptor 
associated JAK can then be phosphorylated by JAK, leading to the STATs forming 
an active dimer by reciprocal SH2 phosphotyrosine interaction, which then 
disengages from the receptor and translocate to the nucleus (Shuai et al., 1992, 
Schindler et al., 1992a, Schindler et al., 1992b). STATs are phosphorylated by JAKs 
on a single tyrosine residue at the C-terminus end of the SH2 domain (Tyr701 in 
STAT1 (Shuai et al., 1994) and Tyr705 in STAT3 (Kaptein et al., 1996). STAT dimers 
translocate to the nucleus and bind DNA motifs known as GAS (γ-activated 
sequence) elements that are characterized by the consensus sequence, 
TTNCNNNAA. IFN-α/β induces the formation of a heterotrimeric complex 
consisting of STAT1, STAT2, and IFN regulatory factor (IRF) 9 that binds to the IFN-
α/β–stimulated response element (ISRE) (AGTTN3TTTC) (O’Shea et al., 2002). The 
STAT transcriptional activation domain is proposed to participate in modulation of 
transcription through interaction with additional transcription factors and co-
activators such as c-Jun, BRCA1 and the cAMP-response-element-binding (CREB)-
binding protein (CBP)/p300 family of histone acetyltransferases (Horvath, 2000).  
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In addition to canonical tyrosine phosphorylation, serine phosphorylation and 
acetylation has recently emerged as covalent modifications regulating STAT 
functions. All STATs except STAT2 are phosphorylated on at least one serine residue 
in their C-terminal transactivation domain:  Ser727 in STAT 1 and 3, Ser721 in 
STAT4, Ser725 in STAT5a, Ser730 in STAT5b, Ser756 in STAT6 (Decker and Kovarik, 
2000). Reporter gene studies have determined that serine phosphorylation 
enhances transcriptional activity of STAT1 and STAT3 (Kovarik et al., 2001). 
Consistent with this, mice expressing a STAT1 S727A mutant exhibit defective IFN-
γ-mediated innate immunity (Varinou et al., 2003). Several serine kinases have 
been reported to phosphorylate STATs, for example MAPK (STATs 1, 3, 4), PKC-δ 
(STATs 1, 3), mTOR (STAT3) (Kojima et al., 2005). Reversible lysine acetylation has 
been reported for all STATs with the exception of STAT4 (reviewed by Zhuang, 
2013). STAT3 is acetylated by its coactivator p300/CBP, resulting in increased DNA 
binding and transcriptional activity (Wang et al., 2005). Several reports have 
demonstrated that acetylation is required for phosphorylation of STATs, including 
STAT3, however acetylation has been suggested to facilitate dephosphorylation 
and latency of STAT1 (Kramer et al., 2009, Zhaung, 2013). 
1.3.5 Negative regulation of the JAK-STAT pathway 
JAK-STAT signalling is central to many biological processes and so a number of 
regulatory mechanisms exist to modulate the pathway at different stages. Two 
major mechanisms for negative regulation are dephosphorylation by protein 
tyrosine phosphatases (PTP) and direct inhibition by suppressors of cytokine 
signalling (SOCS).  
1.3.5.1 Suppressors of cytokine signalling 
The SOCS family members were initially discovered on the basis of their ability to 
bind JAK (Endo et al., 1997) and inhibit cytokine signalling (Naka et al., 1997, 
Starr et al., 1997). The expression of the majority of SOCS proteins is induced by 
activation of the JAK-STAT pathway by cytokines such as IL-6, IFN-γ, G-CSF and IL-
11. They act as classical negative feedback inhibitors by inhibiting the 
phosphorylation of JAKs, which in turn prevents STAT activation (Chen et al., 
2004). There are eight family members, SOCS1–7 and cytokine-inducible SH2-
containing protein (CIS) (Starr et al., 1997, Hilton et al., 1998). All members of 
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the SOCS family consist of an N-terminal domain, a central SH2 domain and a C-
terminal SOCS box. The majority of the SOCS family inhibit cytokine signalling by 
inducing the proteasome-dependent degradation of JAK-associated cytokine 
receptors once they are activated. The SOCS box domain interacts with elongins 
B and C, recruiting Cullin5, and RING-box2 to form an E3 ubiquitin ligase complex 
(Babon et al., 2009). The SOCS proteins therefore function as adaptors to bring 
the E3 ligase into proximity with its substrate, promoting the ubiquitination and 
subsequent proteasomal degradation of SOCS binding partners (Kamura et al., 
1998, Zhang et al., 2001). In addition to their role as E3 ligases, SOCS1 and SOC3 
can inhibit JAK catalytic activity via its N-terminal kinase inhibitory region (KIR), 
a trait peculiar to SOCS1 and SOCS3 (Sasaki et al., 1999). Kershaw et al., 
demonstrated that the KIR of SOCS3 sits in the substrate binding groove of the JAK 
kinase. This partially occludes the substrate-binding site and prevents JAK from 
interacting with substrates, thus inhibiting its ability to initiate downstream 
signalling (Kershaw et al., 2013). A crystal structure of the SOCS3-JAK2-gp130 
complex demonstrated that while the SOCS3 KIR occupied the JAK substrate 
binding domain, the SOCS3 SH2 domain was occupied by a phosphorylated tyrosine 
receptor residue, thus SOCS3 binds JAK and receptor simultaneously (Kershaw et 
al., 2013). SOCS3 can inhibit JAK1, JAK2 and TYK2 via its KIR, but not JAK3 (Babon 
et al., 2012). Genetic studies have revealed that SOCS1 is particularly important 
in IFN-γ signalling while SOCS3 has specificity for IL-6 signalling. (Croker et al., 
2003, Lang et al.,2003). SOCS3 binds to the phospho-tyrosine motif 759 within 
gp130 to inhibit IL-6 signalling (Schmitz et al., 2000, Nicholson et al., 2000). 
1.3.5.2 Protein tyrosine phosphatases 
Since tyrosine phosphorylation by kinases is a key event in the JAK-STAT signalling 
pathway, dephosphorylation by PTP are involved in attenuating signalling. Several 
PTPs have been implicated in the regulation of JAK-STAT signalling; SH2 domain-
containing phosphatase (SHP) 1, SHP2, PTP 1B, T-cell PTP (TC-PTP) and CD45 
(reviewed by Xu and Qu, 2008).  
TC-PTP is ubiquitously expressed with the highest expression mainly in 
haematopoietic cells (Neel and Tonks, 1997). Phosphorylation of JAK1, STAT1 and 
STAT3 is enhanced in TC-PTP knockout cells (Yamamoto et al., 2002, ten Hoeve et 
al., 2002, Simoncic et al., 2002). TC-PTP exists as two splice variants: an 
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endoplasmic reticulum target 48 kDa form (TC48) and a nuclear 45 kDa form 
(TC45). Overexpression of TC45 in 293T cells was reported to suppress IL-6-
stimulated STAT3 phosphorylation (Yamamoto et al., 2002). Furthermore, JAK1, 
STAT1, and STAT3 were identified as direct substrates of TC-PTP as they each co-
immunoprecipitate with TC-PTP substrate trapping mutant, which is inactive but 
still binds to cognate substrates (Simoncic et al., 2002, Garton et al., 1996, 
Yamamoto et al., 2002).  
SHP1 and SHP2 are phosphatases that both consist of a C-terminal phosphatase 
and two N-terminal SH2 domains. SHP1 is a non-transmembrane phosphatase 
primarily expressed by haematopoietic cells and genetic knockout mice display a 
range of haematopoietic abnormalities. SHP1 can directly interact with receptors 
for erythropoietin (Epo) and IFN-α to inhibit phosphorylation of JAK1 and JAK2 
(Klingmuller et al., 1995, David et al., 1995). SHP1 can also interact with the IL-3 
receptor, expression of a negative SHP-1 variant (R459M) BaF/3 cells reduced IL-3 
induced tyrosine phosphorylation of STAT5 and cell proliferation (Bone et al., 
1997, Paling and Welham, 2002). 
In contrast with SHP1, SHP2 is ubiquitously expressed. SHP2 negatively regulates 
cytokine stimulation of JAK-STAT signalling, but also positively regulates IL-6 
stimulation of ERK signalling (Schaper et al., 1998). SHP2 is rapidly recruited to 
Tyr759 in gp130 following IL-6 stimulation (Stahl et al., 1995). Disruption of SHP2 
recruitment, by the substitution of Tyr757 in gp130 with phenylalanine, was shown 
to enhance JAK-STAT signalling but reduce ERK activation (Stahl et al., 1995, 
Schaper et al., 1998). In addition, IL-6 treatment of mouse fibroblasts expressing 
a truncated SHP2 mutant (SHP2-/-), which is unable to bind the receptors 
including gp130, was shown to potentiate STAT3 activation in comparison to WT 
fibroblasts. SHP2 also acts as a negative regulator of IFN-induced STAT activation. 
Treatment of SHP2-/- fibroblasts with IFN-α or IFN-γ resulted in increased 
phosphorylation of STAT1 and STAT2 activity, and were hypersensitive to the 
cytotoxic effect of both IFN-α or IFN-γ. Reintroduction of wild type SHP2 protein 
reversed the hypersensitivity of SHP2-/- fibroblasts to the cytotoxic effect of IFN-
alpha and IFN-gamma. (You et al, 1999). Furthermore, SHP2 has been described 
as a dual-specificity phosphatase that dephosphorylates STAT1 at both Tyr701 and 
Ser727 (Wu et al., 2002). 
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1.3.6 Role of IL-6 and JAK-STAT signalling in atherosclerosis 
1.3.6.1 Role of IL-6 in atherosclerosis  
In the context of atherosclerosis, the pro-inflammatory role of IL-6 has been the 
most extensively studied due to substantial evidence indicating its involvement in 
the disease process. Studies have shown that elevated levels of IL-6 and one of its 
target gene products, C-reactive protein (CRP), are associated with the increased 
risk of cardiovascular disease (CVD) and events such as myocardial infarction 
(Tzoulaki et al., 2005, Ridker et al., 2000). Furthermore, both IL-6 and CRP have 
been detected in human atherosclerotic plaques (Torzewski et al., 2000, Schieffer 
et al., 2000). Importantly, human genetic studies have suggested a causal 
association between IL-6 receptor signalling and cardiovascular disease, and IL-6 
receptor blockade is a possible therapeutic approach in these patients 
(Collaboration, 2012, IL6R MR, 2012). Administration of exogenous IL-6 leads to 
plaque development in atherosclerosis prone mice (Huber et al., 1999). 
Conversely, selective pharmacological inhibition of IL-6 trans-signalling reduced 
the development and progression of plaques in atherosclerosis prone mice, and 
was associated with reduced expression of adhesion molecules, ICAM-1 and VCAM-
1, and consequently reduced macrophage infiltration into the vascular lesions 
(Schuett et al., 2012). Several in vitro studies have linked IL-6 stimulation of ECs 
and VSMCs with key mediators of atherosclerosis. In the presence of IL-6 trans-
signalling complex, sIL-6R/IL-6, endothelial cells have been shown to produce 
the adhesion molecules VCAM-1, ICAM-1 and E-selectin and release the 
chemokines MCP-1 and IL-8 (Modur et al., 1997, Romano et al., 1997). In VSMCs, 
upregulation of ICAM1 and MCP-1 was also observed in the presence of a sIL-
6R/IL-6 (Klouche et al., 1999). 
1.3.6.2 Role of STAT1 and STAT3 in atherosclerosis  
In the vasculature, a wide range of stimuli including cytokines and growth factors 
activate STAT1 and STAT3 in ECs and VSMCs. While STAT1 and STAT3 are both 
activated by IL-6, STAT3 is preferentially activated (Darnell et al., 1994). 
Leukocyte recruitment, neointima formation, and plaque angiogenesis, are key 
processes involved in the initiation, progression and destabilisation of 
atherosclerosis plaques. Several in vitro studies have linked activation of STAT1 
and STAT3 in ECs and VSMCs with key mediators of these processes. In ECs, STAT1 
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and STAT3 phosphorylation up-regulates the expression of MCP-1 and ICAM-1 (Lee 
et al., 2003, Sikorski et al., 2011, Chatterjee et al., 2009, Jougasaki et al., 2010). 
STAT3 activation in endothelial cells promoted the induction of neutrophil 
recruitment factors; growth related oncogene-alpha (GRO-α), GM-CSF and IL-8 
(Yuan et al., 2015). Endothelin-1 (ET-1), is a potent endothelium-derived 
vasoconstrictor, and is controlled by STAT1 activation in endothelial cells (Manea 
et al., 2010). Proliferation, migration and survival of VSMCs play a pivotal role in 
the development of neointima formation that occurs during atherosclerosis (Ross, 
1999). In VSMCs, the up-regulation of expression of the proliferative gene cyclin 
D1 and anti-apoptotic gene surviving have been shown to be dependent on STAT3 
activation (Daniel et al., 2012). STAT1 and STAT3 also upregulate expression of 
MCP-1 and RANTES in VSMCs (Potula et al., 2009, Kovacic et al., 2010 Singh et al., 
2011). These chemokines not only cause leukocyte infiltration, but also promote 
the migration of VSMCs from the media to the intima where they proliferate and 
deposit ECM components, thereby contributing to atherosclerotic lesion formation 
(Ross, 1999). In ECs, STAT3 also up-regulates the expression of vascular endothelial 
growth factor (VEGF) and the anti-apoptotic protein survivin (Yahata et al., 2003, 
Cheranov et al., 2008, Mahboubi et al., 2001, Botto et al., 2011). In the late stages 
of atherosclerosis development, these angiogenic mediators may cause plaque 
angiogenesis leading to plaque growth and instability (de Vries and Quax et al., 
2016).  
Gomez-Guerrero and co-workers have investigated the role of STAT1 and STAT3 in 
the pathogenesis of atherosclerosis using atherosclerosis prone mice (Ortiz-Munoz 
et al., 2009, Recio et al., 2015). These studies demonstrated that knockdown of 
STAT3 inhibitor, SOCS3, in atherosclerotic-prone mice results in elevated levels of 
Tyr-phosphorylated STAT1 and STAT3 in the atherosclerotic lesion. Increased 
activation of STAT1/STAT3 accelerated atherosclerotic lesion size, and increased 
leukocyte and VSMCs intra-plaque content (Ortiz-Muñoz et al., 2009). Conversely, 
enforced adenoviral-vector mediated expression of SOCS1 and SOCS3 in 
atherosclerotic-prone mice reduced the levels of Tyr-phosphorylated STAT1 and 
STAT3 in the atherosclerotic lesion. Inhibition of STAT1/STAT3 activation reduced 
atherosclerotic lesion size in the aorta, and reduced leukocyte and chemokine 
MCP-1 intra-plaque content (Recio et al., 2015). Furthermore, SOCS1 and SOCS3 
mediated inhibition of STAT1/STAT3 in cultured VSMCs reduced the gene 
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expression of chemokines (MCP-1 and RANTEs), ICAM-1 and pro-inflammatory 
cytokines (TNF-α and IFN-γ) (Recio et al., 2015). A pro-atherogenic role for STAT1 
and STAT3 was further supported by several observations made in in vivo studies. 
Tyr701-phosphorylated STAT1 levels are elevated in aortic atherosclerotic lesions 
from atherosclerosis-prone mice (Koga et al., 2007) and pharmacological 
inhibition of STAT1 activity reduced neointimal hyperplasia in vivo following 
vascular injury (Torella et al., 20070. Tyr705-phosphorylated STAT3 levels were 
elevated in both the adventitial and endothelial layers of the aortic 
atherosclerotic lesions from atherosclerosis-prone mice (Recinos et al., 2007). 
These observations in experimental mice were confirmed in a study of human 
carotid endarterectomy specimens demonstrating that Tyr705 –phosphorylated 
STAT3 are elevated in endothelium from inflamed compared to non-inflamed areas 
of atherosclerotic regions (Gharavi et al., 2007). Loss of STAT3 expression 
specifically in the vascular endothelium reduces atherosclerotic lesion size in the 
aorta compared with WT mice following a high fat diet (Gharavi et al., 2007). 
Overall, these studies underscore the critical the role of STAT1 and STAT3 
activation in the pathogenesis of atherosclerosis. 
Given the importance of IL-6 and STAT1/STAT3 signalling in regulating key 
processes in atherosclerosis and that interfering with the IL-6 and STAT1/STAT3 
signalling in vivo prevents atherosclerotic lesion formation, therapeutic strategies 
that inhibit the IL-6/JAK-STAT1/3 signalling pathway are likely to have a 
protective effect on the progression of atherosclerosis.  
1.4 AMPK 
1.4.1 Overview of AMPK 
AMP-activated protein kinase (AMPK) is an evolutionarily conserved, 
heterotrimeric serine/threonine protein kinase. AMPK is ubiquitously expressed in 
mammalian tissues and plays a key role in regulating energy balance at a cellular 
and whole-body level (Hardie and Ashford, 2014). AMPK is sensitive to cellular 
energy levels and is activated in response to a decrease in cellular energy, and 
functions to switch on catabolic adenosine triphosphosphate (ATP)-producing 
pathways such as glycolysis and fatty acid oxidation, while switching off anabolic ATP-
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consuming pathways such as fatty acid and protein synthesis in order to restore the 
energy balance (Hardie et al., 2012). 
1.4.2 AMPK structure and regulation  
The AMPK complex is a αβγ heterotrimer containing a catalytic α subunit and 
regulatory β and γ subunits. In mammals, there are seven genes encoding AMPK; 
i.e. two isoforms of α (α1 and α2), two of β, (β1 and β2), and three of γ (γ1, γ2, 
and γ3), thus 12 heterotrimeric complexes are theoretically possible (Kahn et al., 
2005). Expression levels of the different subunit isoforms vary between tissues and 
may dictate the subcellular localisation of the AMPK complex; the α1, β1 and γ1 
isoforms are ubiquitously expressed, while the α2 and β2 isoforms are 
predominantly expressed in striated muscle (Thornton et al., 1998, Verhoeven et 
al., 1995). The γ isoforms are expressed in several different tissues (Cheung et 
al., 2000). While endothelial cells express both the α1 and α2 subunit, the α1 
subunit is predominantly expressed (Ewart and Kennedy, 2011). Figure 1.3 outlines 
the domain structures of the AMPK subunits. The α subunit contains an N-terminal 
serine/threonine kinase catalytic domain, which contains a conserved threonine 
residue at position 172, phosphorylation of which is essential for AMPK activity 
(Woods et al., 1994). The N-terminal kinase domain (KD) is immediately followed 
by an autoinhibitory domain (AID) (Pang et al., 2007). The three-dimensional 
structure shows that the AID interacts with the KD when AMP is not bound to the 
γ subunit and causes AMPK to be maintained in an inactive conformation (Chen et 
al., 2009). The AID is followed by the α-linker and the C-terminal domain (CTD). 
The α-linker interacts with γ subunit and is crucial in the mechanism for activation 
by AMP. The β subunit contains a carbohydrate-binding module (CBM) to which 
oligosaccharide components of glycogen can bind and inhibit AMPK (Hudson et al., 
2003, Polekhina et al., 2003, McBride et al., 2009). The β-CTD contains an α-CTD 
binding site followed by a site for interacting with the γ-subunit (Crute et al., 
1998, Hudson et al., 2003). The γ-subunit contains four cystathionine β-synthetase 
(CBS) motifs which occur as tandem pairs, known as Bateman domains (Bateman, 
1997, Kemp, 2004). An adenine nucleotide-binding pocket is located on each CBS 
motif. Of the four CBS motifs, only CBS1 and CBS3 can competitively bind AMP, 
ADP, or ATP. CBS2 always appears to be empty while CBS4 contains a tightly-bound, 
non-exchangeable molecule of AMP (Xiao et al., 2007, 2011).  
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The primary control of AMPK activity is through phosphorylation - 
dephosphorylation of Thr172 within the activation loop of the α subunit kinase 
domain (Hawley et al., 1996). Two upstream kinases that phosphorylate Thr172 
are: LKB1 (liver kinase B1) and CaMKKβ (Ca2+/calmodulin-dependent protein 
kinase kinaseβ). LKB1 exists in complex with two accessory subunits, STRAD and 
MO25 (Hawley et al., 2003, Woods et al., 2005). This complex appears to be 
constitutively active, but phosphorylates AMPK more rapidly when adenosine 
triphosphate (ADP)/adenosine monophosphate (AMP) is bound to the AMPK γ 
subunit (Sakamoto et al., 2004). Alternatively, CaMKKβ activates AMPK in an AMP-
independent manner, in response to an increase in cytosolic calcium (Hawley et 
al., 2005, Woods et al., 2005, Hurley et al., 2005) (Figure 1.4).  
Mammalian AMPK is activated through binding of ADP or AMP to the γ subunit. 
Binding of AMP has three complementary effects on AMPK: (i) promotion of Thr172 
phosphorylation by upstream kinases; (ii) protection against dephosphorylation of 
Thr172 by protein phosphatases; (iii) allosteric activation of the phosphorylated 
AMPK (Gowans et al., 2013) (Figure 1.4). Of these three effects, the first two may 
also be triggered by ADP binding of the γ subunit, but the third, allosteric 
activation, is specific to AMP (Oakhill et al., 2011, Xiao et al., 2011). Binding of 
ATP inhibits AMPK by antagonising the binding of AM(D)P (Xiao et al., 2011) (Figure 
1.4). Overall, AMPK is activated by increases in AMP and/or ADP relative to ATP, 
thus acting as a sensor of cellular energy status. Once activated by cellular stress 
it acts to restore energy homoeostasis by stimulating catabolic ATP-producing 
pathways, while suppressing anabolic ATP-consuming pathways. 
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Figure 1.3: Domain structure of AMPK subunit isoforms 
AMPKα subunits: kinase domain (α-KD) containing Thr-172 for the activation by upstream kinases; 
autoinhibitory domain (AID), α-linker and the C-terminal domain (α-CTD). AMPKβ subunits: 
carbohydrate-binding module (β-CBM), C-terminal domain (β-CTD). AMPKγ subunit: four 
cystathione-β-synthases domain (CBS 1- 4). Site 2 appears to be always empty and Site 4 to have 
a tightly bound AMP, whereas Sites 1 and 3 represent the regulatory sites that bind AMP, ADP or 
ATP in competition. (Figure adapted from Hardie, 2014)  
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Figure 1.4: Regulation of AMPK  
Mammalian AMPK is activated through binding of ADP or AMP to the γ subunit. Binding of AMP has 
three complementary effects on AMPK: (#1) promotion of Thr172 phosphorylation by upstream 
kinases; (#2) protection against dephosphorylation of Thr172 by protein phosphatases; (#3) allosteric 
activation of the phosphorylated AMPK (Gowans et al., 2013). Of these three effects, the first two 
may also be triggered by ADP binding of the γ subunit, but the third, allosteric activation, is specific 
to AMP. Binding of ATP inhibits AMPK by antagonising the binding of AM(D)P LKB1 appears to be 
constitutively active, while CaMKKβ activates AMPK in response to an increase in cytosolic calcium 
(Figure adapted from Hardie et al., 2016) 
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1.4.3 Pharmacological activators of AMPK activation 
The first pharmacological AMPK activator to be developed was AICAR (5’-
aminoimidazole-4-carboxamide ribonucleoside), an adenosine analogue which is 
taken up into cells by adenosine transporters. It is phosphorylated to the AMP 
mimetic ZMP (5’-aminoimidazole-4-carboxamide ribonucleoside monophosphate) 
by adenosine kinase, thereby activating AMPK without altering adenine nucleotide 
ratios (Corton et al., 1995). Similar to AMP, ZMP binds the AMPK γ subunit and 
activates AMPK in intact cells, tissues and animals. However, it should be noted 
that ZMP has the ability to regulate any enzyme which is sensitive to cellular AMP 
such as fructose-1,6-bisphosphate (Vincent et al., 1991).  
A769662 is a member of the thienopyridine family and can directly activate AMPK, 
independently of AMP (Cool et al., 2006). Although, in a manner similar to AMP, 
A769662 caused both allosteric activation and protection against Thr172 
dephosphorylation (Sanders et al., 2007, Göransson et al., 2007). A769662 
selectively activates AMPK complexes containing the β1, but not β2, regulatory 
subunit (Scott et al., 2008).  Mutation of Ser108 in β1 was reported to reduce 
A769662-mediated AMPK activation, suggesting that the binding site involved the 
β1 subunit (Sanders et al., 2007). Furthermore, when AMP and A769662 are added 
to AMPK together, they cause a synergistic allosteric activation of AMPK complexes 
(Sanders et al., 2007).  
Salicylate, a derivative of aspirin, has recently been demonstrated to stimulate 
AMPK activation (Hawley et al., 2012). Similar to A769662, salicylate caused both 
allosteric activation and protection against Thr172 dephosphorylation 
independently of alterations in adenine nucleotide concentrations (Hawley et al., 
2012). It is also likely that salicylate binds to the same site as A769962, as it was 
poor activator of β2-containing complexes and its effects on β1 were abolished by 
mutating Ser108 (Hawley et al., 2012).   
Metformin is a type of biguanide, a synthetic derivative of guanide that is a natural 
product from the plant Galega officinalis (Witters, 2001). Currently, Metformin is 
widely used as a treatment for type 2 diabetes because of its ability to reduce 
hepatic glucose production (Foretz et al., 2014). Metformin activates AMPK in 
hepatocytes via inhibition of NADH dehydrogenase (Complex I) of the 
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mitochondrial respiratory chain, which blocks ATP production leading to an 
increased AMP/ATP ratio, thus activating AMPK. (Zhou et al., 2001, Shaw et al., 
2005, Brunmair et al., 2004). Several plant-derived compounds including 
berberine, resveratrol and galgeine have also been reported to activate AMPK by 
altering adenine nucleotide ratios (Hawley et al., 2010). Interestingly, metformin 
and salicylate have been reported to synergistically activate AMPK to inhibit fatty 
acid synthesis in mouse and human hepatocytes, while little AMPK activation was 
observed with metformin or salicylate on their own (Hawley et al., 2012).  
1.4.4 AMPK and physiological role  
AMPK is activated under conditions in which cellular energy demands are increased 
or when fuel availability is decreased, such that intracellular ATP is reduced and 
AMP levels rise. Physiological stimuli which activate AMPK include metabolic 
stresses such as hypoxia, ischaemia, glucose deprivation and heat shock; all of 
which reduce ATP levels by inhibiting its production, while exercise stimulates 
AMPK activation in contracting muscles as it accelerates ATP consumption (Hardie, 
2011). AMPK phosphorylates and inactivates many key proteins concerned with the 
regulation of carbohydrate and lipid metabolism, resulting in inhibition of fatty 
acid synthesis, cholesterol and isoprenoid synthesis, hepatic gluconeogenesis, 
lipolysis and mammalian target of rapamycin (mTOR)-mediated protein translation 
in addition to stimulation of fatty acid oxidation, muscle glucose transport, 
mitochondrial biogenesis and caloric intake (Hardie et al., 2012). Thus, AMPK is 
thought to maintain cellular energy stores and regulate whole body energy 
balance by stimulating ATP-producing catabolic pathways while inhibiting 
nonessential ATP-consuming anabolic pathways (Hardie and Ashford, 2014). 
AMPK regulates a wide range of different pathways, which often involves switching 
off anabolic pathways by directly phosphorylating key metabolic enzymes and 
switching on catabolic pathways by directly phosphorylating transcription factors 
and co-regulators to promote expression of catabolic enzymes (Hardie et al., 
2012). For example, AMPK inhibits fatty acid synthesis by directly phosphorylating 
and inactivating the cytosolic isoform of acetyl-CoA carboxylase (ACC1) (Davies et 
al., 1992). Phospho-specific antibodies that recognize the key phosphorylation site 
(Ser79) on ACC1 are widely used as markers for AMPK activation. AMPK directly 
phosphorylates several sites on the forkhead box O3 (FOXO3) transcription factor, 
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activating transcription of many genes, including genes involved in resistance to 
oxidative stresss (Greer et al., 2007). Figure 1.5 below summarises many of the 
well-established AMPK downstream targets and processes activated by AMPK 
activation.  
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Figure 1.5: Targets for AMPK 
Summary of selected protein targets and processes downstream of AMPK. A green arrow signifies 
activation, and a red line with a crossbar signifies inhibition. Note that if AMPK inhibits a protein that 
in turn inhibits a downstream process (two successive red lines with crossbars), then the overall 
process (e.g. glucose uptake or fatty acid oxidation) will be activated. A question mark next to a 
protein signifies that it is not certain that the protein is a direct target for AMPK. (Figure taken from 
Hardie et al., 2014)  
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1.4.5 Cardiovascular protective role of metformin 
Coronary heart disease (CHD) is the leading cause of death in the UK (Townsend 
et al., 2015). Patients with diabetes are at about three times the risk of CHD 
compared to those without the condition (Fox et al., 2007). In part, this is 
explained by an accelerated development of atherosclerosis (Nicholls et al., 
2008). Metformin is the first-line oral treatment option for patients with type 2 
diabetes (T2D), which accounts for 90% of all diagnosed cases of diabetes (Inzucchi 
et al., 2015). Type 2 diabetes occurs when the beta cells of the pancreas can no 
longer produce enough insulin to overcome insulin resistance. Insulin resistance is 
associated with increased triacylglycerol content, particularly in liver and skeletal 
muscle. In conjunction with insulin resistance, resulting hyperglycaemia 
contributes to CHD risk. Metformin ameliorates hyperglycaemia by promoting 
glucose uptake by skeletal muscle and decreasing hepatic glucose production 
(Natali and Ferrannini, 2006). This drug also reduces insulin resistance in liver and 
skeletal muscle by promoting the oxidation of fatty acids and inhibiting synthesis 
of fatty acids and triacylglycerols (Natali and Ferrannini, 2006). In vivo studies 
with metformin and other pharmacological activators of AMPK has demonstrated 
that the anti-hyperglycaemic actions of metformin are mediated by AMPK (Zhou 
et al., 2001, Song et al., 2002, Iglesias et al., 2002, Cool et al., 2006). 
Interestingly, the United Kingdom Prospective Diabetes Study (UKPDS) 
demonstrated that despite similar glucose lowering effects, administration of 
metformin reduced all-cause mortality, myocardial infarction, and stroke more 
than insulin or sulfonylureas (Holman et al., 2008). This study and several other 
studies have concluded that treatment with metformin limits cardiovascular 
morbidity and mortality independent from its glucose-lowering action (Holman et 
al., 2008, Johnson et al., 2005, Mellbin et al., 2011, Roussel et al., 2010). Given 
that atherosclerosis is an inflammatory disorder, anti-inflammatory properties 
could contribute, at least in part, to the cardiovascular protective effects of 
metformin beyond glucose lowering. An increasing body of evidence suggests that 
metformin exhibits anti-inflammatory actions and that these actions are mediated 
through AMPK (reviewed by Salt and Palmer, 2012). 
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1.4.5.1 Inhibition of leukocyte infiltration 
Of particular interest are observations that AMPK can limit leukocyte infiltration 
and activation in the context of cardiovascular disease. Studies using AMPKα1-/- 
and AMPKα2-/- mice have suggested that both isoforms contribute to AICAR-
mediated inhibition of post-ischemic leukocyte adhesion to blood vessels in vivo 
(Gaskin et al., 2011). Consistent with a role for AMPK-dependent inhibition of 
leukocyte infiltration, aortae from AMPKα1-/- mice showed enhanced angiotensin 
(Ang) II-stimulated VCAM-1 expression (Schuhmacher et al., 2011).  Importantly, a 
clinical study has shown that metformin treatment of patients with T2D was 
associated with decreased levels of soluble ICAM-1, VCAM-1 and E-selection, and 
this decrease was independent of the anti-hyperglycaemic action of the drug (De 
Jager et al., 2005). Furthermore, AMPK activation is associated with reduced 
infiltration of inflammatory cells in murine models of acute and chronic colitis 
(Bai et al., 2010), and rheumatoid arthritis (Guma et al., 2015) as well as a rat 
model of autoimmune encephalomyelitis (Prasad et al., 2006). Taken together, 
these studies indicate that AMPK activation in several tissues, and the vasculature 
in particular, impairs leukocyte infiltration by mechanisms that may involve 
reducing the expression of chemokines and adhesion molecules. 
1.4.5.2 Regulation of pro-inflammatory signalling  
Studies have linked AMPK with suppression of pro-inflammatory signalling 
pathways. Inhibition of cytokine-stimulated NF-κB signalling by AMPK is the most 
studied and has been demonstrated in several cell types including ECs, astrocytes 
and macrophages (Cacicedo et al., 2004, Giri et al., 2004, Yang et al., 2010). 
Crucially, Hattori et al., demonstrated that activation of AMPK suppressed TNF-α 
and interleukin-1β-induced gene expression of adhesion molecules (VCAM-1, E-
selectin, ICAM-1) and MCP-1 in ECs by suppressing NF-κB activity (Hattori et al., 
2006). Consistent with a role for AMPK-mediated inhibition of NF-κB signalling, 
aortic ECs from AMPKα2-/- mice showed increased nuclear NF-κB levels (Wang et 
al., 2010). Subsequently, potential mechanisms have been proposed to explain 
AMPK-mediated inhibition of cytokine-stimulated NF-κB signalling. First, Zhang et 
al reported that in ECs AMPK phosphorylates the transcriptional co-activator p300 
at Ser89 to inhibit p300-mediated acetylation of NF-κB p65, leading to inhibition 
of TNF-α-stimulated NF-κB DNA binding (Zhang et al., 2011). Second, Bess et al 
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proposed that AMPK hyperphosphorylates IKKβ to inhibit subsequent 
phosphorylation of Iκα and p65 in COS-7 cells, resulting in suppression of TNF-α-
stimulated NF-κB-mediated transcription (Bess et al., 2011). Both studies 
demonstrated that AMPK activation markedly reduced monocyte adhesion and 
adhesion molecule expression in TNF-α-stimulated endothelial cells, leading to 
the attenuation of the endothelial pro-inflammatory response (Bess et al., 2011, 
Zhang et al., 2011). A few studies have identified AMPK-dependent suppression of 
cytokine-stimulated MAPK phosphorylation/activation. A769662-mediated AMPK 
activation inhibited TNF-α/IL-1-β-stimulated phosphorylation of JNK, ERK1/2 and 
p38 MAPKs in adipocytes (Sarah Mancini; personal communication). Berberine was 
found to inhibit lipopolysaccharide (LPS)-stimulated phosphorylation of JNK, 
ERK1/2 and p38 MAPK in macrophages in an AMPK-dependent manner (Jeong et 
al., 2009). AICAR and metformin were also reported to inhibit JNK activation in 
HUVECs in response to TNF-α (Schulz et al. 2008). Increased JNK phosphorylation 
was observed not only in HUVECs following siRNA-mediated downregulation of 
either AMPKα1 or AMPKα2, but also in aortic endothelial cells isolated from 
AMPKα2-/- mice (Dong et al., 2010). A few studies have indicated that AMPK 
activation can inhibit JAK-STAT signalling, with two reports showing AMPK-
dependent inhibition of IL-6-stimulated STAT3 phosphorylation, SOCS3 expression 
and expression of pro-inflammatory genes in hepatocyte cell lines (Handy et al., 
2010, Nerstedt et al., 2010, Kim et al., 2012). Recently, Vasamsetti et al proposed 
that metformin inhibits monocyte-to-macrophage differentiation by reducing 
STAT3 activity due to increased AMPK activation (Vasamsetti et al., 2015). 
However, the effect of AMPK on JAK-STAT signalling in ECs have yet to be fully 
characterised. Previous unpublished studies in our group have investigated 
whether AMPK modifies IL-6 stimulation of JAK-STAT signalling in HUVECs (Claire 
Rutherford, Marie-Ann Ewart, Ian Salt, Tim Palmer, personal communication). 
Those studies, performed by Dr. Claire Rutherford and Dr. Marie-Ann Ewart 
(University of Glasgow) are described in detail in the appendix (section 6.1) and 
form the basis of the studies described in this thesis. 
1.5 Aims 
Our preliminary investigations (appendix, section 6.1) clearly demonstrated that 
activation of AMPK by multiple stimuli triggered a rapid and significant reduction 
in the ability of sIL-6R/IL-6 to stimulate STAT3 phosphorylation on Tyr705 (Figure 
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6.1). The aim of this study was to identify the mechanism of AMPK-mediated 
inhibition of STAT3 phosphorylation. Our preliminary experiments provided the 
initial step in this investigation: it is a post receptor effect. Pre-treatment of 
HUVECs with the direct AMPK activator, A769662, significantly inhibited both sIL-
6Rα/IL-6 and IFN-α stimulation of STAT3 Tyr705 phosphorylation in HUVECs (Figure 
6.5A). IFN-α activates STATs via an IFN receptor 1 (IFNAR1/IFNAR2) complex 
which is distinct from the sIL-6Rα/IL-6/gp130 complex (Borden et al., 2007). The 
studies in this thesis therefore tested the hypothesis that AMPK was exerting its 
inhibitory effects at one or more common signalling loci downstream of 
IFNAR1/IFNAR2 and gp130 at a post-receptor level. In particular, the studies 
described examine whether AMPK acts: 
1. Directly on a known regulator of JAK or STAT protein function.  
2. On an already established AMPK downstream target which then either 
directly or indirectly impacts on JAK-STAT signalling. 
3. Directly to phosphorylate and influence the activity/function of one or 
more JAK isoforms.  
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Chapter 2 - Methods  
2.1 Cell Culture Procedures  
2.1.1 Cell culture plastic ware  
Human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (one 
batch of pooled donor) and cultured in Corning T150 flasks, 10 cm diameter plates 
and 6 well plates. 
Human fibrosarcoma cell lines 2C4 (parental cell line for U4C), U4C (JAK1-
deficient) and U4C.JAK1 (stably expressing transfected human JAK1 construct) 
(Muller et al., 1993); a kind gift from Dr Ana P. Costa-Pereira, Imperial College 
London [London, UK]) were cultured in Corning T150 flasks, 10 cm plates and 6 
well plates. 
HEK293 cells were cultured in Corning T150 flasks, 10 cm diameter plates and 6 
well plates. HEK293 cells poorly attach to cell culture plastic ware. Therefore, 10 
cm diameter plates and 6 well plates were coated with poly-D-lysine prior to 
seeding HEK293 cells. Plastic surfaces that are coated with the poly-D-lysine 
possess a uniform net positive charge, which enhances the electrostatic 
interaction between the negatively-charged ions of the cell membrane and the 
coated plastic surface. Here, the culture plates were aseptically coated with 0.1 
mg/ml poly-D-lysine solution. After 2-3 minutes, the excess solution was aspirated 
and the plates were allowed to dry before seeding cells. 
2.1.2 Cell culture growth media for HUVECs  
HUVECs were maintained in T150 flasks in endothelial growth medium (EGM) 
consisting of endothelial basal media (EBM) supplemented with 2% (w/v) fetal 
bovine serum, 0.04% (v/v) hydrocortisone, 0.1% (v/v) ascorbate and recombinant 
growth factors as recommended by the supplier (Lonza). Cells were cultured at 37 
°C in a humidified atmosphere containing 5% (v/v) CO2 in media replaced every 
48 hrs. 
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2.1.3 Cell culture growth media for HEK293 cells   
HEK293 cells were each maintained in Dulbecco’s modified Eagles’s medium 
(DMEM) supplemented with 10% (v/v) FBS, 1 mM glutamine, 100 U/ml penicillin 
and 100 µM streptomycin. Cells were cultured at 37 °C in a humidified atmosphere 
containing 5% (v/v) CO2 in media replaced every 48 hrs. 
2.1.4 Cell culture growth media for 2C4 and U4C cells  
2C4 and U4C cells were each maintained in Dulbecco’s modified Eagles’s medium 
(DMEM) supplemented with 10% (v/v) FBS, 1 mM glutamine, 100 U/ml penicillin, 
100 µM streptomycin and 400 μg/ml G418 to maintain selection pressure. Cells 
were cultured at 37 °C in a humidified atmosphere containing 10% (v/v) CO2 in 
media replaced every 48 hrs. 
2.1.5 Cell culture growth media for U4C.JAK1 cells 
U4C.JAK1 cells were each maintained in Dulbecco’s modified Eagles’s medium 
(DMEM) supplemented with 10% (v/v) FBS, 1 mM glutamine, 100 U/ml penicillin, 
100 µM streptomycin, 400 μg/ml G418 and 0.5 μg/ml puromycin to maintain 
selection pressure. Cells were cultured at 37°C in a humidified atmosphere 
containing 10% (v/v) CO2 in media replaced every 48 hrs. 
2.1.6 Passaging of HUVECs  
Cells were passaged on reaching ~80% confluence, which was approximately once 
a week. EGM was aspirated and the cell monolayers were washed twice with 
sterile PBS before 2 ml of sterile endothelial grade trypsin-EDTA solution (5 U/ml 
porcine trypsin, 1.8 % (w/v) EDTA) was added to each T150 flask. Cells were then 
incubated at room temperature for 5 minutes until the cells began to detach from 
the flask surface. Gentle tapping of the flask dislodged all of adherent cells from 
the flask surface. Addition of fresh EGM neutralises the trypsin and cells were 
pelleted by centrifugation (200 g, 5 mins, RT). Cell pellets were resuspended in a 
volume of EGM determined to give a suitable cell density for counting using a 
haemocytometer, typically 6 ml per T150 flask. Wells were then seeded at an 
appropriate level according to the experiment performed. HUVECs were used for 
experiments between passages 2 and 5. Beyond passage 5, HUVECs rapidly alter 
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in culture conditions (Muller et al., 2002), therefore the cells were discarded at 
this stage. 
2.1.7 Passaging of HEK293, 2C4, U4C, U4C.JAK1cells  
Cells were passaged on reaching ~80% confluence, which was approximately twice 
a week. DMEM growth medium was aspirated and the cells were washed briefly 
with sterile PBS before 2 ml of sterile trypsin (0.05% (v/v) in diaminothanetetra-
acetic acid, disodium salt [EDTA]) was added to each T150 flask. Cells were then 
incubated at 37 °C for 2-3 minutes until the cells began to detach from the flask 
surface, which was further facilitated by gentle tapping of the flask to dislodge 
all of the adherent cells from the surface. Fresh DMEM growth medium was then 
asdded to neutralise the trypsin and cells were pelleted by centrifugation (200 g, 
5 mins, room temperature [RT]). Cell pellets were resuspended in a volume of 
DMEM growth medium determined to give a suitable cell density for counting using 
a haemocytometer, typically 10 ml per T150 flask. Wells were then seeded at an 
appropriate level according to the experiment performed. 
2.1.8 Transfection of HUVECs with short interfering RNA (siRNA) 
Target-specific short interfering RNAs (siRNAs) designed to knockdown individual 
specific JAK isoforms; JAK1, JAK2 or TYK2 (Qiagen), and control non-targeting 
siRNA were introduced into HUVECs using HiPerFect transfection reagent (Qiagen) 
as per manufacturer’s instructions. Briefly, 24 hrs prior to transfection, HUVECs 
were seeded at a density of 2 x 105 cells/well in 6 well plates. For each well, 300 
ng siRNA was mixed with 100 μl Opti-MEM serum-free media followed by the 
addition of 12 μl HiPerFect and mixed by slowly pipetting up and down. The 
siRNA/HiPerFect mixture was incubated for 10 minutes at room temperature to 
allow formation of transfection complexes. Meanwhile, cells were washed twice 
with 2 ml Opti-MEM which was then replaced with 700 μl fresh Opti-MEM. The 
siRNA/HiPerFect mixture was added drop-wise over the surface of the cells. Cells 
were incubated for 3 hours at 37°C and 1500 μl EGM was added to each well. 24 
hours after transfection, the medium was replaced. siRNA transfected cells were 
subsequently incubated for an additional 24 hours and were treated as described 
in the figure legends. 
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2.1.9 Transient transfection of HEK 293, 2C4, U4C and U4C.JAK1 cells   
The appropriate plasmid DNA was introduced into HEK 293, 2C4, U4C or U4C.JAK1 
cells for transient expression using PolyFect transfection reagent (Qiagen) as per 
manufacturer’s instructions. Briefly, HEK 293, 2C4, U4C or U4C.JAK1 cells were 
seeded in 10 cm plates and grown until approximately 70% confluent.  For each 10 
cm plate, 2.5 μg of plasmid DNA was mixed with 400 μl Opti-MEM followed by the 
addition of 40μl PolyFect transfection reagent and mixed by slowly pipetting up 
and down. The DNA/PolyFect mixture was incubated for 10 minutes at room 
temperature to allow formation of transfection complexes. Meanwhile, 7 ml fresh 
DMEM growth medium was added to the 10 cm plate. 1 ml DMEM growth medium 
was then mixed with each DNA/PolyFect mixture prior to being added drop-wise 
over the surface of the cells. 24 hrs after transfection, each 10 cm plate of 
transfected cells was split between 4 wells of a 6 well plate in order to minimise 
variation in transfection efficiency between wells. Cells were subsequently 
incubated for an additional 24 hours prior to treatment as described in the figure 
legends. 
2.1.10 Cell treatments and subsequent incubations performed under serum-
free conditions  
Unless otherwise indicated in the figure legends, cell treatments and subsequent 
incubations were performed in serum-free conditions. Experiments on HUVECs 
were performed using serum-free Basal medium 199 (HEPES modification) 
supplemented with 1 mM glutamine, 100 U/ml penicillin, and 100 µM 
streptomycin. Experiments on HEK 293, 2C4, U4C and U4C.JAK1 cells were 
performed using serum-free DMEM supplemented with 1 mM glutamine, 100 U/ml 
penicillin and 100 µM streptomycin. Prior to cell treatments, cells were incubated 
in the appropriate serum-free media for 3 hours. 
2.2 Preparation of lysates from cultured cells  
Confluent cells grown on 6-well plates were first treated as described in figure 
legends and subsequently lysates were prepared as follows. Reactions were 
terminated by placing dishes on ice and washing twice with 1ml of ice-cold PBS 
prior to the addition of 100µl of RIPA buffer (50 mM HEPES pH7.4, 150 mM sodium 
chloride, 1% (v/v) Triton x100, 0.5% (v/v) sodium deoxycholate, 0.1% (w/v) SDS, 
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10m M sodium fluoride, 5 mM EDTA, 10 mM sodium phosphate, 0.1 mM PMSF, 
10µg/ml benzamidine, 10 µg/ml soybean trypsin inhibitor, 2% (w/v) EDTA-free 
complete protease inhibitor cocktail). The cells were then scraped off using a cell 
lifter and pipetted into 1.5 ml microcentrifuge tubes. Lysates were mixed for 30 
minutes at 4°C with rotation to aid solubilisation before centrifugation (21 000 g, 
15 mins, 4°C) to pellet insoluble debris. 80µl of supernatant was collected and 
stored at -20°C. To compensate for the low protein content of HUVECs, only 65 μl 
of RIPA buffer was added to each well of HUVECs and 50µl of the supernatant 
collected. The supernatant was subsequently assayed for protein concentration 
using a bicinchoninic acid assay (BCA) as described below.  
2.3 Determination of protein concentration using the 
bicinchoninic acid (BCA) assay 
The BCA assay was performed by preparing the following bovine serum albumin 
(BSA) standards in the appropriate lysis buffer: 2.0, 1.8, 1.6, 1.4, 1.2, 1.0, 0.8, 
0.6, 0.4, 0.2 and 0.0 mg/ml. Protein samples were diluted (1:3 – HUVEC and 1:5 – 
HEK 293, 2C4, U4C and U4C.JAK1 cells lysates) in the appropriate lysis buffer.  10μl 
of each BSA standard and protein sample were added to each well in duplicate to 
a 96-well plate. 200μL of BCA working solution (1% (w/v) 4,4 dicarboxy-2,2, 
biquinoline disodium salt, 2% (w/v) sodium carbonate, 0.16% (w/v) sodium 
potassium tartrate, 0.4% (w/v) sodium hydroxide, 0.95% (w/v) sodium bicarbonate 
[pH 11.25], 0.08% (w/v) copper (II) sulphate) was added to each well of the plate. 
The plate was then incubated at room temperature until a linear standard curve 
(r2 ~0.98) was produced. Absorbance was measured at 495 nm using a POLARstar 
OPTIMA (BMG LabTech) microplate reader. Upon mixing with protein, Cu2+ ions in 
the BCA reagent are reduced to Cu+ which then reacts with BCA to produce a 
colour change from blue to purple which is detectable at 495 nm. The extent of 
the colour change is directly proportional to the amount of protein in a sample. 
The absorbance measurements obtained for the BSA standards were used to derive 
a straight line graph from which the concentrations of the protein samples were 
quantified using POLARstar OPTIMA MARS data analysis package v.1.20 and 
GraphPad Prism v.4.  
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2.4 Immunoprecipitation  
2.4.1 Preparation of lysates from cultured cells for immunoprecipitation  
Confluent cells grown on 10 cm plates were first treated as described in figure 
legends and subsequently lysates were prepared. Reactions were terminated by 
placing dishes on ice and washed twice with ice-cold PBS. Using a cell lifter, cells 
were scraped into 500 μl of ice-cold PBS and pipetted into 1.5 ml microcentrifuge 
tubes. Cells were pelleted by centrifugation (1000 g, 5 mins, 4 °C) and 
resuspended in 250 μl immunoprecipitation (IP) buffer (50 mM HEPES pH7.4, 120 
mM sodium chloride, 5 mM EDTA, 10% (v/v) glycerol,  1% (v/v) Triton x100, 5 mM 
sodium fluoride, 1 mM sodium orthovanadate, 0.1 mM PMSF, 10 µg/ml 
benzamidine, 10 µg/ml soybean trypsin inhibitor and 2% (w/v) EDTA-free complete 
protease inhibitor cocktail). Lysates were mixed for 30 minutes at 4°C with 
rotation to aid solubilisation before centrifugation (21 000 g, 15 mins, 4°C) to 
pellet insoluble debris. Without disturbing the pellet, 220µl of supernatant was 
collected and stored at -20°C. The supernatant was assayed for protein 
concentration using a BCA assay as described above. 
2.4.2 Immunoprecipitation of JAK1 and phosphotyrosine proteins  
25 μl packed volume (per sample) of protein G-Sepharose beads were washed 3 
times (300  g, 1 min at 4°C) with 1 ml IP buffer and resuspended in 50μl IP buffer 
(50% [v/v] slurry). Cell lysate (500 μg) and 6 μl mouse anti-JAK1 antibody or 10 μl 
mouse 4G10 (anti-phosphotyrosine antibody) were added to 50 μl of 50% slurry 
(v/v) of protein G beads. The volume of the protein G/lysate/antibody mixture 
was made up to 500 μl with IP buffer and was mixed for overnight at 4°C with 
rotation. The immobilized immune complexes were isolated from the lysate by 
centrifugation (1000  g, 1 min at 4°C)  and the immunodeplete retained. The beads 
were then washed three times (21 000  g, 1 min at 4°C) with 1 ml IP buffer. 
Immunocomplexes were resuspended in 40 μl 12% (w/v) SDS sample buffer (section 
2.5) and eluted by vortexing and incubating samples at 67°C at 30 minutes. 
Samples were then boiled at 95° C for 5 minutes to denature and dissociate 
antibody heavy and light chains. Beads were pelleted by brief centrifugation (10 
000 g, 15 secs, RT) and supernatants were transferred to fresh 1.5 ml 
microcentrifuge tubes using a Hamilton syringe, prior to loading on sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) for analysis.  
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2.4.3 Immunoprecipitation of FLAG-tagged JAK1 from U4C cell lysates    
JAK1-deficient U4C cells were seeded in 10 cm dishes and transfected with human 
FLAG-tagged JAK1 DNA plasmid (section 2.1.9). Subsequently, confluent U4C cells 
expressing FLAG-tagged JAK1 were treated as described in figure legends and cell 
lysates were prepared for immunoprecipitation (section 2.4.1.) 
Immunoprecipitation of FLAG-tagged JAK1 was performed as described above 
(section 2.4.2) with the exception that 35µl packed volume (per sample) of pre-
conjugated anti-FLAG M2 agarose beads were used in place of protein G-Sepharose 
beads and primary antibodies. 
2.5 SDS-PAGE 
Equal quantities of soluble protein lysates (10-20 μg/sample) were denatured in 
an equal volume of 12% (w/v) SDS sample buffer (12% (w/v) SDS, 50 mM Tris, pH 
6.8, 10% (v/v) glycerol, 10 mM dithiothreitol (DTT), bromophenol blue). Samples 
were fractionated by SDS-PAGE on 8 - 10% (w/v) resolving gels (Table 2-1). To allow 
size estimation of immunoreactive protein bands, Biorad Rainbow molecular 
weight markers were fractionated alongside protein samples. Electrophoresis was 
performed in 1% (w/v) SDS running buffer (0.1% (w/v) SDS, 192 mM glycine, 25 mM 
Tris, pH 8.3) at a constant voltage of 150 V for approximately 1.5 hours until good 
separation of the molecular weight markers had been achieved. 
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Table 2-1: 10% resolving gel 
Chemical component Volume 
required 
dH2O 3.4 ml 
buffer 1 
(1.5M Tris, pH 8.8, 0.4% (w/v) SDS) 
2.5 ml 
50% (v/v) glycerol 0.65 ml 
ammonium persulphate  
(APS, 0.3mg/ml) 
0.032 ml 
TEMED 0.008 ml 
30% (w/v) acrylamide/bis-acrylamide 3.3 ml 
 
The percentage of the resolving gel was altered by adjusting the volumes of 
distilled deionised water (dH2O) and acrylamide/bis-acrylamide as follows:  
8% resolving gel: 4.07 ml dH20, 2.64 ml 30% (w/v) acrylamide/bis-acrylamide  
12% resolving gel: 2.74 ml dH20, 3.96 ml 30% (w/v) acrylamide/bis-acrylamide  
Table 2-2: Stacking gel  
Chemical component Volume 
required 
dH2O 3.4 ml 
buffer 2  
(0.5M Tris-HCl, pH 6.8, 0.4% (w/v) SDS) 
1.34 ml 
ammonium persulphate 
(APS, 0.3mg/ml) 
0.054 ml 
TEMED 0.007 ml 
30% (w/v) acrylamide/bis-acrylamide 0.63 ml 
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2.6 Immunoblotting for proteins  
2.6.1 List of Antibodies used for immunoblotting  
Table 2-3: Primary antibodies used for immunoblotting 
 
All membranes were incubated overnight at 4 °C. 
 
Antibody 
Reactivity 
Host 
Species 
Dilution Diluent Supplier 
Catalogue 
No. 
Phospho-STAT3 
(Tyr705)  
Mouse  1:1000 5% BSA 
Cell Signalling 
Technology 
9145 
STAT3 Rabbit  1:1000 5% milk 
Cell Signalling 
Technology 
9132 
Phospho-STAT1 
(Tyr701) 
Rabbit 1:1000 5% BSA 
Cell Signalling 
Technology 
9171 
STAT1 Mouse 1:1000 5% milk 
Cell Signalling 
Technology 
9176 
Phospho-ACC 
(S79) 
Rabbit 1 :1000 5% BSA 
Cell Signalling 
Technology 
3661 
JAK1 Mouse 1 :1000 5% BSA 
BD transduction 
laboratories 
610232 
JAK2 Rabbit  1:1000 5% BSA 
Cell Signalling 
Technology 
3230S 
TYK2  Mouse 1:1000 5% BSA 
BD transduction 
laboratories 
610173 
Phospho-JAK1 
(Y1022/1023) 
Rabbit 1:200 5% BSA 
Santa Cruz 
Biotechnology 
SC-16773 
Phospho-JAK1 
(Y1022/1023) 
Rabbit 1:200 5% BSA Invitrogen 44-422G 
Phospho-
tyrosine (clone 
4G10) 
Mouse 1:1000 5% BSA Merck Millipore 05-321 
GAPDH Mouse 
1: 
80000  
 
5% milk  Abcam 4300 
p70 S6 kinase 
phospho-S371 
Rabbit 1:1000 5% BSA 
Cell Signalling 
Technology 
9208 
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Table 2-4: Secondary antibodies used for immunoblotting 
 
All membranes were incubated for 1 hr at room temperature. 
 
Linked 
molecule 
Antibody 
Reactivity 
Host 
Species 
Dilution Diluent Supplier 
Catalogue 
No. 
HRP Mouse IgG  Goat 1:1000 5% milk 
Sigma-
Aldrich 
A4416 
HRP Rabbit IgG Goat 1:1000 5% milk 
Sigma-
Aldrich 
A9169 
HRP Goat IgG Rabbit  1:2000 5% milk 
Sigma-
Aldrich 
A5420 
 
2.6.2  Electrophoretic transfer  
Proteins were electrotransferred from the gel on to a nitrocellulose membrane 
(0.2 mm pore size) for 75 min at a constant current of 400 mA in a transfer buffer 
(192 mM glycine, 25 mM Tris, pH 8.3 and 20% (v/v) methanol).  
2.6.3 Blocking of membranes and probing with primary antibodies 
Non-specific protein-binding sites on nitrocellulose membranes were blocked by 
incubation in immunoblotting buffer (10 mM Tris, pH 7.6, 150 mM NaCl, 0.1% (v/v) 
Tween 20, 5% (w/v) milk proteins) for 1 hr at room temperature with shaking. 
After washing (3 x 5 min) the membrane in Tris-buffered saline -Tween (TBST; 10 
mM Tris, pH 7.6, 150 mM NaCl, 0.1% (v/v) Tween 20), the membrane was incubated 
in a specific primary antibody overnight at 4°C with shaking. Antibodies used 
during this study are listed in Table 2-1. Primary antibodies were diluted in either 
immunoblotting buffer or 5% (w/v) BSA in TBST.  
2.6.4 Secondary antibodies and immunodetection of proteins using western 
blotting and the ECL detection system  
Following an overnight incubation in primary antibody, the membranes were 
washed (3 x 5 min) in TBST prior to incubation for 1 hr at room temperature with 
the corresponding horseradish peroxidase (HRP)-conjugated secondary antibody 
diluted 1:1000 in immunoblotting buffer (Table 2-2). Membranes were then 
washed (2 x 5 min) with shaking in immunoblotting buffer followed by washing (3 
x 5 min) in TBST. Following this, immunoreactive proteins were visualised using 
Perkin-Elmer enhanced chemiluminescence (ECL) detection reagents, according 
to the manufacturer’s instructions. Briefly, the membrane was incubated in 2 ml 
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ECL reagent for 1 minute and blotted onto paper towel to remove excess liquid. 
Membrane was mounted onto an autoradiography cassette for exposure to Medical 
X-ray Blue/MXBE Film (Carestream Health, 7710783) and developed using a X-
OMAT 2000 processor (Kodak). 
2.6.5 Stripping of antibodies from nitrocellulose membranes  
The stripping solution removes antibodies bound to the membrane without 
removing SDS-PAGE fractionated proteins. In order to re-probe the membrane with 
a different primary antibody, the membrane was washed (2 x 10 min) in stripping 
buffer (0.75% (w/v) glycine, 0.87% (w/v) NaCl [pH 2]) at room temperature with 
shaking. After washing the membrane (2 x 5 min) in TBST and re-blocking in 
immunoblotting buffer for 1 hour, membranes were then incubated with another 
primary antibody.  
2.6.6 Densitometric quantification of protein bands  
Immunoreactive protein bands on the developed film were scanned, 
Quantification was by densitometric scanning of non-saturating exposed films 
using TotalLab imaging software v2.0 (Phoretix, UK). 
2.7 Molecular Biology 
2.7.1 Plasmid DNA constructs 
Table 2-5: Plasmid DNA constructs  
Donor/Supplier cDNA  Vector  Tag AR 
Origene 
(Rockville, MD) 
Human JAK1 
(Cat.RC213878) 
pCMV6 FLAG K 
In-house  Human S515518A JAK1 pCMV6 FLAG K 
In-house  Human V658F JAK1 pCMV6 FLAG K 
In-house 
Human V658F S515518A 
JAK1 
pCMV6 FLAG K 
In-house  Human JAK1 SH2 domain 
pGEX-
2T 
FLAG, 
His6 
A 
Grahame 
Hardie, 
University of 
Dundee 
Rat ACC1, amino acid 
residues 60-94 
pGEX-
20T 
His6 A 
Antibiotic Resistance (AR): A = Ampicillin, K = Kanamycin 
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2.7.2 Transformation of competent E. coli cells  
Circular DNA plasmids were maintained and propagated by transforming XL1-Blue 
E.coli. Briefly, 50 µl XL1-Blue E.coli cells were aliquoted into pre-chilled 1.5ml 
microcentrifuge tubes prior to the addition of 30-50 ng DNA and incubated on ice 
for 15 minutes. Meanwhile Luria Bertani (LB) broth (1% (w/v)) bactotryptone, 0.5% 
(w/v) yeast extract, 1% (w/v) sodium chloride, pH7.4) was heated to 37°C.  The 
cell/DNA mixture was heat shocked for 90 seconds in 42°C water bath followed by 
immediate recovery on ice for 2 minutes. 450 μl LB-broth with no antibiotic 
selection was added to each tube and incubated for 1 hr at 37°C with shaking. 
Cells were gently pelleted by centrifugation (1000 g, 5 mins, RT) and resupended 
in a reduced volume of 100 μl LB-broth. 100 μl transformed cell suspension was 
spread onto dry LB-agar (1.5% (w/v) agar in LB-broth) plate supplemented with 
the appropriate selection antibiotic (ampicillin, 50µg/ml; kanamycin, 25µg/ml) 
and incubated overnight in a 37°C to allow growth of bacterial colonies. The 
following day, a single colony was picked for small scale liquid bacterial culture 
and subsequent plasmid DNA purification.  
2.7.3 Purification of plasmid DNA 
A single colony picked from a fresh bacterial transformation plate was used to 
inoculate 5 ml selection LB-broth and incubated for 8 hrs at 37°C with shaking. 
The plasmid DNA was isolated and purified from the 5ml culture (starter culture) 
using a Promega Wizard Plus Miniprep DNA purification system as per the 
manufacturer’s instructions, specifically the centrifugation protocol. For large-
scale preparations of plasmid DNA, the 5 ml starter culture was used to inoculate 
250 ml selection LB-broth and incubated for 16 hrs at 37°C with shaking. The 
plasmid DNA was isolated and purified from the 250ml culture using a Qiagen 
EndoFree Plasmid Maxi Kit as per the manufacturer’s instructions. The plasmid 
DNA concentration was determined at A260 using a NanoDropTM 1000 
Spectrophotometer prior to storage at -20°C. 
2.7.4 Preparation of glycerol stocks 
Glycerol stocks were prepared for long-term storage of plasmid DNA. For each 
glycerol stock, 1 ml overnight (250 ml) culture was added to 0.4 ml sterile 50% 
(v/v) glycerol in a sterile cryovial. The mixture was by pipetted up and down to 
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ensure even dispersal of glycerol. Glycerol stocks were then rapidly frozen by 
immersion in dry ice before storage at -80°C freezer.  To culture plasmid DNA from 
a glycerol stock, 5 ml selection LB-broth is inoculated with a scraping of the 
glycerol stock and incubated for 8 hrs at 37°C with shaking.      
2.7.5 Determination of DNA concentration using NanoDropTM 1000 
Spectrophotometer  
The purified plasmid DNA concentration was determined at A260 using a 
NanoDropTM 1000 Spectrophotometer prior to storage at -20°C. DNA absorbs 
ultraviolet light most strongly at 260nm. A NanoDropTM 1000 Spectrophotometer 
spectrophotometer measures the amount of light that DNA absorbs at A260 and 
the number generated is an estimation of the sample concentration. The 
NanoDropTM 1000 Spectrophotometer software also calculates the A260/A280 and 
A260/A230 ratio of each DNA sample, which can be used as an indication of protein 
contamination and salt contamination, respectively. Good-quality DNA will have 
an A260/A280 ratio of 1.7–2.0 and an A260/230 ratio greater than 1.5.  
2.7.6 Sequencing  
The generation of new DNA constructs or mutated DNA plasmids was confirmed by 
DNA sequencing, performed by the University of Dundee Sequencing Service. 
2.7.7 Site Directed Mutagenesis  
Table 2-6: Primers and DNA templates for site-directed mutagenesis reactions  
Mutant Plasmid S515518A JAK1 
DNA template JAK1 
Forward Primer  5’CGGTTCGGACCGC GCC TTCCCC GCC TTGGGAGACCTC3’ 
Reverse Primer  5’GAGGTCTCCCAA GGC GGG GAA GGC GCGGTCCGAACCG3’                                                                    
 
Mutant Plasmid V658F JAK1  
DNA template JAK1 
Forward Primer  5’CTCTATGGCGTCTGT TTC CGCGACGTGGAG3’ 
Reverse Primer  5’CTCCACGTCGCG GAA ACAGACGCCATAGAG3’                                                                     
 
Mutant Plasmid V658F S515518A JAK1  
DNA template S515518A JAK1 
Forward Primer  5’CTCTATGGCGTCTGT TTC CGCGACGTGGAG3’ 
Reverse Primer  5’CTCCACGTCGCG GAA ACAGACGCCATAGAG3’                                                                     
Primers were synthesised by Biomers.net. 
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Site-directed mutagenesis is a method that uses custom designed oligonucleotide 
primers to introduce a desired mutation(s) in a double-stranded DNA plasmid. The 
oligonucleotide primers listed in the table above (Table 2-4) were used to 
introduce a desired mutation(s) in a pCMV6-JAK1 plasmid by following the 
instructions of the Agilent Technologies QuikChange Lightning site-directed 
mutagenesis kit. Briefly, each polymerase chain reaction (PCR) reaction was 
prepared on ice in thin walled  
PCR tubes as follows:  
10× reaction buffer   5 µl 
dsDNA template (50 ng/μl) 1 μl 
Forward primer (125 ng/μl) 1 μl 
Reverse Primer (125 ng/μl) 1 μl 
dNTP mix    1 µl 
QuikSolution reagent  1 µl 
Sterile dH2O final volume of  50 µl 
QuikChange Lightning Enzyme  1µl 
 
PCR reactions were carried out in a thermocycler using the following standard 
conditions: 
PCR step Temp.(⁰C) Time No. of cycles 
Initial 95 2 mins  1 
 
Denaturation 
 
95 
 
20 Secs 
 
 
18 Primer Anneal 60 10 Secs 
Extension 68 30Secs/Kb 
 
Final Extension 
 
68 
 
5 mins 
  
1 
Hold 4 hold 1 
 
After the reaction was complete, 1 µl of DpnI was added to each PCR reaction and 
incubated at 37 °C for 5 minutes to digest the parental supercoiled dsDNA. 4 µl of 
the reaction mix was then transformed into XL10-Gold ultracompetent cells and 
successful mutants were selected on antibiotic agar plates as per manufacturer’s 
instructions. The mutant DNA was amplified, isolated, purified and quantified as 
previously described in sections 2.7.2 - 2.7.5 and the mutation was confirmed by 
DNA sequencing (section 2.7.6).  
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2.7.8 Preparation of GST JAK1 SH2 construct 
The GST-fusion construct of the SH2 domain of human JAK1 (aa 439 – 544) was 
generated in house. In brief, oligonucleotide primers complementary to the 
boundaries of the SH2 domain (based on its assignment in the human JAK1 Uniprot 
entry (P23458)) within the human JAK1 were synthesised for PCR (section 2.7.8.1). 
These oligonucleotide primers, as shown in the Table 2-5, were designed to 
amplify the SH2 domain within pCMV6/human JAK1 while introducing an in-frame 
C terminal (His)6 tag and a stop codon, as well as BamHI and EcoRI compatible 
ends for subcloning. The resultant PCR product was then digested (section 2.7.8.2) 
with BamHI and EcoRI and ligated into similarly digested pGEX-2T bacterial 
expression plasmid (Section 2.7.8.5). The recombinant plasmid was transformed 
into XL10-Gold ultracompetent E. coli and the transformants analyzed for the 
presence of insert by BamHI/EcoRI restriction digestion and DNA sequencing. 
2.7.8.1 DNA amplification by Polymerase Chain Reaction (PCR) 
Table 2-7: Primers and DNA template for PCR reactions  
 
Plasmid Name GST JAK1 SH2 
DNA Template  Human WT JAK1 or S515518A JAK1  
Vector  pGEX-2T 
DNA insert  JAK1 SH2: aa 439 - 544 
Forward Primer  5’-TAAGCT GGATCC GGCTGTCATGGTCCAATCTG-3'  
Reverse Primer  5’-AGCTTA GAATTC TTA GTGATGGTGATGGTGATG  
GCAGCAGCGTTTTAGCATG-3' 
His tag underlined, stop codon in bold type, and restriction site italicise. Primers 
were synthesised by Biomers.net. 
 
PCR reactions were prepared on ice in thin walled PCR tubes as follows: 
 
Promega Pfu DNA polymerase 10X Buffer with MgSO4  5 µl 
NEB dNTP mix (dATP, dCTP, dGTP and dTTP; 10mM each)  1 μl 
Forward primer  25pmol 
Reverse primer  25pmol 
DNA template (10 ng/μl)  1 μl 
Promega Pfu DNA polymerase (2-3 U/μl)  0.42 μl 
Sterile dH2O   final volume of 50 µl 
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PCR reactions were carried out in a thermocycler using the following conditions: 
PCR step Temp.(°C) Time  No. of Cycles 
     
Initial Denaturation 95 2 mins  1 
   
 
 
Denaturation 95 1 min 
35 Primer Anneal 55 Tm - 5 °C 
Extension 72 2mins/Kb 
   
 
Final Extension 72 5 mins  1 
     
Hold 4 hold  1 
 
 
 
The optimal annealing temperature is generally calculated as 5 °C lower than the 
lowest melting temperature (Tm) of the two primers. The extension time for 
Promega pfu DNA polymerase was calculated as per manufacturer’s instruction at 
approximately 2 minutes for every 1 kb to be amplified.  After the PCR reaction 
was complete, the resultant PCR product was then digested (section 2.7.8.2) with 
BamHI and EcoRI. 
2.7.8.2 Restriction endonuclease digestion  
Restriction enzymes were purchased from Promega and digestions were performed 
in accordance with the manufacturer's instructions. The appropriate pair of 
enzymes was chosen to cut plasmids or PCR product in a 10x buffer compatible 
with both enzymes. Reactions were set up in 1.5 ml microcentrifuge tubes, for 
example: 
Restriction Enzyme 10X Buffer  3 µl 
Acetylated BSA (10μg/ul) 0.2 μl 
Plasmid(100ng/μl)/PCR product  10 µl/20 μl  
Restriction Enzyme #1 (10 U/μl) 1 µl   
Restriction Enzyme #2 (10 U/μl) 1 µl  
Sterile dH2O   final volume of 30 µl  
 
63 
 
Samples were mixed and spun briefly before incubation at 37 °C for 3-4 hrs. After 
the digestion was complete, the product was analysed using agarose gel 
electrophoresis. Both digested plasmid and digested PCR products were run on 
either a 0.5% or a 2% (w/v) agarose gel to confirm the size and digestion of the 
plasmid DNA or PCR product.  
2.7.8.3 DNA agarose gel electrophoresis  
Plasmid DNA and PCR products (DNA samples) were analysed by agarose gel 
electrophoresis using 0.5% (w/v) and 2% (w/v) gels respectively. To prepare the 
gels, 1 g or 4 g of agarose was dissolved in 200 ml TAE buffer (40 mM Tris, 1 mM 
EDTA, 40 mM glacial acetic acid) by boiling in a microwave. Once the solution had 
cooled to hand-warm, 0.5 μg/μl ethidium bromide was mixed with the solution 
and poured into a gel casting cassette containing the appropriate loading comb. 
Once the gels sets, the gel was transferred to a horizontal gel tank filled with TAE 
buffer. 6x loading dye (Promega) was added to each DNA sample and a 100 bp or 
1 kb DNA ladder (Promega) prior loading each sample into the wells of the gel. 
Electrophoresis was performed at a constant voltage of 100 V for approximately 1 
hour until good separation of the DNA ladder had been obtained. Ethidium bromide 
is a nucleic acid stain which allows DNA bands to be visualised on a UV light box 
(254 nm wavelength). The DNA bands were visualised and recorded using a BioRad 
Molecular Imager ChemiDoc XRS+ System. 
2.7.8.4 Gel extraction  
DNA bands of the appropriate size were extracted and purified from agarose gels 
using the Qiagen QIAquick Gel Extraction Kit as per the manufacturer’s instruction, 
specifically the centrifugation protocol. DNA was eluted in nuclease free water 
and stored at -20°C. The DNA concentration was determined at A260 using a 
NanoDropTM 1000 Spectrophotometer prior to storage at -20°C (section 2.7.5). 
2.7.8.5 Ligation reactions  
DNA ligase was purchased from Promega and ligation reactions were performed in 
accordance with the manufacturer's instructions. The insert DNA fragment (PCR 
product) and the target plasmid vector were digested with the appropriate 
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restriction enzymes (section 2.7.8.2) and subsequently isolated by gel extraction 
(section 2.7.8.3-4) prior to ligation. 
Ligation reactions were carried out in thin-walled PCR tubes and set up on ice: 
DNA insert: WT or S515518A JAK1 SH2    75ng 
Vector: pGEX-2T  25ng 
Ligase 10X Buffer   1µl  
T4 DNA Ligase 1µl   
Sterile dH2O  final volume of 10 µl  
 
Vector only, insert only, and DNA-free controls were also set up. The reactions 
were incubated at 15°C overnight. The reaction mixture was the transformed into 
XL10 cells and plated with appropriate selection antibiotic. The plasmid DNA 
concentration was determined at A260 using a NanoDropTM 1000 
Spectrophotometer prior to storage at -20°C (section 2.7.5). The generation of 
new DNA constructs was confirmed by DNA sequencing, performed by the 
University of Dundee Sequencing Service (section 2.7.6). 
2.7.9 GST fusion protein expression in E.coli  
E.Coli BL21 (Agilent) cells were transformed with pGEX-2T, pGEX-WT JAK1 SH2, 
pGEX S515A/S518A JAK1 SH2 or pGEX-ACC1-His6 and cultured shaking overnight in 
10mls of LB-broth (ampicillin, 50 μg/ml) at 37 °C. This culture was used to 
inoculate a large culture of 400mls in a 1 litre conical flask (1:50 dilution, 8 mls 
into 400mls) which was grown (shaking, 37 °C) until optical density readings at 
600 nm (OD600) reached 0.3. At this point GST-fusion protein expression was 
induced by the addition of isopropyl-ß-D-thio-galactopyranoside (ITPG, final 
concentration 1 mM achieved by a 1:100 dilution from 100 mM stock solution). 
Bacteria were allowed to grow for four hours when cells were collected by 
centrifugation (6700 x g, 15 mins, 4°C). Broth was removed, and cell pellets were 
frozen overnight at -80 °C. 
To monitor protein expression, hourly 1ml samples were removed from the broth 
during IPTG induction. These samples were pelleted and the pellet re-suspended 
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in 12 % (w/v) SDS sample buffer. Samples were probe sonicated on ice for 3 x 20 
seconds with 1 minute intervals to prevent build-up of heat followed by brief 
centrifugation. Samples were analysed by SDS-PAGE (section 2.5) and Coomassie 
Brilliant Blue R-250 (Section 2.7.12). 
2.7.10 Purification of His-tagged proteins  
Bacterial pellets were thawed and resuspended in 20 mls His lysis buffer (20mM 
Na3PO4, 500mM NaCl, 10mM imidazole, 1% (v/v) Triton-100, pH7.4) per 400mls of 
E.Coli broth. Samples were probe sonicated on ice for 6 x 20 seconds with 1 minute 
intervals to prevent build-up of heat and centrifuged (25 000 g, 30 mins, 4°C) to 
pellet insoluble material. The cleared lysate was mixed with 0.6 ml of a 50 % (v/v) 
Ni sepharose bead suspension in His lysis buffer and incubated for 1 hour at 4 °C 
with rotation in order to immobilise His-tagged proteins on the beads. The beads 
were pelleted by gentle centrifugation (500 g, 5 mins, 4 °C), washed twice in 10 
ml pre-elution buffer (20mM Na3PO4, 500mM NaCl, 20mM imidazole, pH7.4) and 
then transferred to a microfuge tube for a final wash in 1 ml pre-elution buffer. 
Beads were resuspended in 0.3mls elution buffer (20mM Na3PO4, 500mM NaCl, 
20mM imidazole, pH7.4) per one ml of beads and incubated on ice for 5-10 minutes 
with gentle agitation. Beads were pelleted (500 g, 5 mins, 4 °C) and eluate was 
gently removed and retained. Elution with 0.3 mls elution buffer, incubation and 
centrifugation was repeated twice and eluate sample two and three were 
retained. Pooled eluates were concentrated and buffer exchanged into kinase 
buffer (section 2.9.1) using Vivaspin sample concentrator (GE Healthcare). Protein 
concentration was assessed by BCA assay (section 2.3) Each His-tagged protein 
were analysed by SDS-PAGE (Section 2.5) and Coomassie Brillant Blue R-250 
(section 2.7.12). His-tagged proteins were stored in aliquots as required and 
stored at -80 °C. 
2.7.11 Purification of GST-tagged proteins  
Bacterial pellets were thawed and resuspended in 20 mls GST lysis buffer (50mM 
Hepes, 150 NaCl, 5mM EDTA, 1% (v/v) Triton-100) per 400mls of E.Coli broth. 
Samples were probe sonicated on ice for 6 x 20 seconds with 1 minute intervals to 
prevent build-up of heat and centrifuged (25 000 g, 30 mins, 4 °C) to pellet 
insoluble material. The cleared lysate was mixed with 0.6 ml of a 50 % (v/v) 
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Glutathione Sepharose 4B beads suspension in GST lysis buffer and incubated for 
1 hour at 4 °C with rotation in order to immobilise GST-tagged proteins on the 
beads. The beads were pelleted by gentle centrifugation (500 g, 5 mins, 4 °C), 
washed twice in 10 ml PBS and then transferred to a microfuge tube for a final 
wash in 1 ml PBS. The GST-tagged proteins were eluted from the beads by 
incubation with reduced Glutathione. PBS was aspirated from the tube and the 
beads were resuspended in 0.3 mls elution buffer (10 mM Glutathione, 50 mM Tris-
HCl, pH 8.0) per one ml of beads for 5-10 minutes on ice with gentle agitation. 
Beads were pelleted at 500 x g (4 °C, five minutes) and eluate was gently removed 
and retained. Elution with 0.3mls elution buffer, incubation and centrifugation 
was repeated twice and eluate sample two and three were retained. Pooled 
eluates were concentrated and buffer exchanged into kinase buffer using Vivaspin 
sample concentrator (GE Healthcare). Protein concentration was assessed by BCA 
assay (section 2.3) Each GST-tagged protein were analysed by SDS-PAGE (section 
2.5) and Coomassie Brilliant Blue R-250 (section 2.7.12). GST-tagged proteins were 
stored in aliquots as required and stored at -80 °C.  
An alternative approach used to purify GST-JAK1 SH2 proteins was to replace the 
lysis buffer prepared in-house with the commercially available protein extraction 
reagent, BugBuster (Merk Millipore). Following induction of protein expression in 
the E.coli cells (section 2.7.9), the cells were pelleted and lysed in BugBuster as 
per manufacturer’s instructions. In brief, bacterial pellets were thawed and 
resuspended in room temperature BugBuster reagent, using 5 ml reagent per gram 
of wet cell paste. The cell suspension was incubated on a rotating mixer at a slow 
setting for 10–20 minutes at room temperature. Insoluble cell debris was removed 
by centrifugation (16,000 g 20 mins, 4°C) and the supernatant was transferred to 
a fresh tube. For SDS-PAGE analysis, a small sample of the supernatant (25–50 μl) 
was combined with equal volume of 12 % (w/v) SDS sample buffer and heated for 
3 minutes at 85°C. Samples were analysed by SDS-PAGE (section 2.5) and 
Coomassie Brilliant Blue R-250 (section 2.7.12). 
A final approach to purifying GST-JAK1 SH2 proteins was to use the Rapid GST 
Inclusion Body Solubilization and Renaturation Kit (Cell Biolabs.), which was used 
as per manufacturer’s instructions. Briefly, GST-tagged protein expression was 
induced with 0.1 mM IPTG at 37ºC for 3 hrs (section 2.7.9). Cell pellet was lysed 
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in STE Extraction Buffer (500 mM Tris, pH 7.5, 1.5 M NaCl, 10 mM EDTA). To 
solubilize and renature GST-tagged proteins, the cell lysate/inclusion body 
mixture was mixed with Detergent Solubilization Solution (diluted 1:2 with STE 
extraction buffer (2 fold dilution). The cell lysate was then separated into soluble 
and insoluble fractions by centrifugation (12000 g, 15 mins, 4°C). The soluble 
fraction was then mixed with Detergent Neutralization Solution. Soluble GST-
tagged proteins were then purified from the renatured soluble protein fraction by 
GST-tag batch purification. Samples were analysed by SDS-PAGE (section 2.5) and 
Coomassie Brilliant Blue R-250 (section 2.7.12). 
2.7.12 Coomassie staining  
To detect proteins on an SDS PAGE gel, Coomassie Brilliant Blue R-250 (0.25 g 
Coomassie Brilliant Blue R in H2O: Methanol: Glacial Acetic Acid [4.5:4.5:1 v/v/v]) 
was used. After removal from the glass plates, the gel was immersed in Coomassie 
Brilliant Blue R-250 for at least 1 h with gently agitation. After this, the stain was 
poured off, and the gel washed in distilled water. To remove the excess stain from 
the gel and allow visualisation of the proteins, the gel was submerged in Destain 
Solution (5 % (v/v) Methanol, 10 % (v/v) Glacial Acetic Acid), typically overnight. 
2.8 Peptide array 
2.8.1 CelluSpot synthesis of peptide array  
Peptide arrays were kindly prepared by Professor G.S. Baillie (University of 
Glasgow, Institute of Cardiovascular and Medical Sciences) using automatic SPOT 
synthesis as described (Frank, 2002). Briefly, cellulose-conjugated peptides are 
synthesised and spotted in duplicate onto a nitrocellulose coated microscope slide 
producing a 3-dimensional library of peptides.  
Successive 25-mer peptides spanning the human JAK1, JAK2, JAK3 and TYK2 open 
reading frames were prepared and each consecutive peptide has a five amino-acid 
shift compared to the previous peptide (Tables 6.1-6.4).  
Peptide arrays were spotted with a wild-type (WT) and Ser-Ala mutant versions of 
the human JAK1 25-mer peptides identified as potential AMPK substrates, R-Y-S508-
L-H-G-S512-D-R-S515-F-P-S518-L-G-D-L-M-S524-H-L-K-K-Q-I (Tables 6.3-6.4). The JAK2, 
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JAK3 and TYK2 25-mer peptides that aligned with the JAK1 25-mer peptide (Figure 
4.11) identified as phosphorylated by AMPK were also spotted on the same peptide 
arrays to allow for direct comparison (Table 6.3-6.4). 
2.8.2 Peptide array overlays with HRP-conjugated human 14-3-3 
14-3-3ζ belongs to the 14-3-3 family of proteins that interact with a wide variety 
of proteins containing phosphoserine and phosphothreonine-motifs (Bridges and 
Moorhead, 2005). Peptide arrays consisting of Ser phosphorylated JAK 25-mer 
peptide identified as potential AMPK phosphorylation sites was overlaid with HRP-
conjugated recombinant human 14-3-3ζ. Briefly, prior to overlay with HRP-14-3-
3ζ, the peptide arrays were washed (2 x 5 mins) in TBST (10 mM Tris, pH 7.6, 150 
mM NaCl, 0.1% (v/v) Tween 20) and blocked in 5% (w/v) BSA in TBST for 1 hr at 
room temperature. Subsequently, peptide arrays were incubated with HRP-14-3-
3ζ (1:500) in 5% (w/v) BSA in TBST overnight at 4⁰C with shaking. Arrays were then 
washed (2 x 5 mins) in TBST. Reactive spots were visualised using Perkin-Elmer 
enhanced chemiluminescence (ECL) detection reagents, according to the 
manufacturer’s instructions. Briefly, the arrays were incubated in 2 ml ECL reagent 
for 1 minute and blotted onto paper towel to remove excess liquid. Peptide array 
was mounted onto an X-ray cassette for exposure to Medical X-ray Blue/MXBE Film 
(Carestream Health, 7710783) and developed using an X-OMAT 2000 processor 
(Kodak). 
2.9 In vitro AMPK phosphorylation assays 
2.9.1 JAK isoform peptide arrays  
In vitro AMPK phosphorylation of an immobilised library of full length human JAK1, 
JAK2 and TYK2, and Serine-Alanine mutated JAK1 25-mer peptides (Table 6.1-6.4) 
was under taken using AMPK purified from rat liver a generous gift from Prof. D.G. 
Hardie (University of Dundee) (Hawley et al., 1996) , and [γ-32P] ATP. In brief, 
0.5U/ml active AMPK and 1μCi/ml [γ-32P] ATP was diluted in kinase buffer (50mM 
HEPES pH7.4, 0.01% (v/v) Brij-35, 1mM DTT, 1mM ATP, 0.2mM AMP, 25mM MgCl2, 
1% (w/v) BSA) and incubated with arrays at 30⁰C for 30 minutes with agitation. 
Phosphorylation was detected by incorporation of radiolabelled 32P and signals 
were captured by autoradiography following exposure to Medical X-ray Blue/MXBE 
Film (Carestream Health, 7710783) for 2 days at -80oC and developed using a X-
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OMAT 2000 processor (Kodak). As a positive control, each peptide array contains a 
synthetic AMPK substrate called SAMS peptide (HMRSAMSGLHLVKRR) (Davies et al., 
1989). 
2.9.2 Full length human JAK1 protein 
In vitro AMPK phosphorylation of full length JAK1 protein was under taken using 
purified active rat liver AMPK, and [γ-32P] ATP. JAK1-deficient U4C cells were 
transfected with either a purified wild-type (WT) FLAG-tagged recombinant 
human JAK1 plasmid (section 2.1.9). FLAG-tagged JAK1 was immunoprecipitated 
(section 2.4.3) from protein equalised cell lysates by incubating with Anti-FLAG 
M2 affinity gel overnight at 4°C. Anti-FLAG M2 affinity gel precipitates were 
washed twice in RIPA buffer and twice with kinase buffer. Each precipitate was 
incubated for 10 minutes at 30 °C in the absence or presence of 0.5U/ml activated 
AMPK with or without 0.2mM AMP, and in the presence of 10μCi/ml [γ-32P] ATP. 
JAK1 was eluted (section 2.4.2) from the immunocomplexes and subjected to SDS-
PAGE on 8% (w/v) acrylamide resolving gels and transfer to nitrocellulose as 
described in sections 2.5 and 2.6.2. Phosphorylation of JAK1 was detected by 
autoradiography as described in section 2.9.1.  
2.9.3 Full length human ACC protein  
In vitro AMPK phosphorylation of full length ACC Ser79 was undertaken using 
purified active rat liver AMPK. ACC is a biotinylated enzyme; thus biotin-
streptavidin affinity purification can be used to isolate ACC (Chen et al., 2000).  
HEK293 cells were prepared for purification as described in section 2.4.1. 
Purification of biotinylated proteins was performed as described in section 2.4.2 
with the exception that 35µl packed volume (per sample) of streptavidin-
Sepharose beads were used in place of protein G-Sepharose beads and primary 
antibodies. Biotin-streptavidin affinity gel precipitates were washed twice in RIPA 
buffer and twice with kinase buffer. Each precipitate and streptavidin-depleted 
lysate was incubated for 10 minutes at 30 °C in the absence or presence of 
0.5U/ml activated AMPK with or without 0.2mM AMP, and in the presence of 
10μCi/ml [γ-32P] ATP. Biotinylated proteins were eluted from the Sepharose beads 
and subjected to SDS-PAGE (section 2.5) on 8% (w/v) acrylamide resolving gels and 
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phosphorylation of ACC was detected by immunoblotting (section 2.6) for 
phospho-ACC (Ser79) and Total ACC.  
2.9.4 GST-JAK1 SH2 fusion proteins  
Purified GST-ACC, WT GST-JAK1 SH2 and S515A/S518A mutant GST JAK1 SH2 fusion 
proteins, and GST alone (section 2.7.8-11) were subjected to in vitro kinase assays 
using purified active rat liver AMPK, and [γ-32P] ATP. Each GST fusion protein was 
incubated for 30 minutes at 30°C in the absence or presence of 0.5U/ml AMPK 
with or without 0.2mM AMP, and in the presence of 10μCi/ml [γ-32P] ATP. In vitro 
kinase reactions were subject to SDS-PAGE (section 2.5) on 12% (w/v) acrylamide 
resolving gels and transfer to nitrocellulose (section 2.6.2). Phosphorylation of 
GST fusion proteins was detected by autoradiography (section 2.9.1.), followed by 
probing the immunoblot (section 2.6) with GST-HRP to detect GST-fusion proteins. 
2.10 Statistical analysis 
Statistical analysis was performed using the InStat software v3.6 (GraphPad, USA). 
Statistical significance was evaluated with one-way ANOVA analysis followed by 
the Bonferroni multiple comparisons test. Data are presented as mean ± SEM.   
p < 0.05 was considered significant.  
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Chapter 3 - Molecular mechanism of AMPK mediated 
inhibition of IL-6 signalling: AMPK downstream 
targets  
3.1 Introduction  
3.1.1  IL-6 signalling via the JAK-STAT pathway  
As detailed in the introduction (section 1.3.2), activation of IL-6 signal 
transduction involves gp130 dimerization, ligand-dependent tyrosine 
phosphorylation of JAKs, followed by tyrosine phosphorylation of STATs, with 
subsequent translocation of STAT dimers into the nucleus to regulate the 
transcription of target genes, including CRP (Zhang et al., 1996) and MCP-1 
(Jougasaki et al., 2010), which are involved in the inflammatory response. While 
STAT1 and STAT3 are both activated by IL-6, STAT3 is preferentially activated 
(Darnell et al., 1994).  
3.1.2 Regulation of the JAK-STAT pathway by AMPK  
While AMPK has been found to inhibit MAPK/NF-κB pro-inflammatory pathways in 
endothelial cells (reviewed by Salt and Palmer, 2012), the effect of AMPK on JAK-
STAT pro-inflammatory signalling in endothelial cells had yet to be fully 
characterised. Previous unpublished studies in our group have investigated 
whether AMPK modifies cytokine stimulation of JAK-STAT signalling in HUVECs 
(section 6.1, Claire Rutherford, Marie-Ann Ewart, Ian Salt, Tim Palmer, personal 
communication). These preliminary investigations demonstrated that pre-
treatment of HUVECs with AMPK activator, A769662, significantly inhibits both sIL-
6Rα/IL-6 and IFN-α stimulation of STAT3 Tyr705 phosphorylation in HUVECs (Figure 
6.5A). IFN-α activates STATs via an IFNAR1/IFNAR2 complex which is distinct from 
the sIL-6Rα/IL-6/gp130 complex (Borden et al., 2007). The studies in this thesis 
therefore tested the hypothesis that AMPK was exerting its inhibitory effects at 
one or more common signalling loci downstream of IFNAR1/IFNAR2 and gp130 at 
a post-receptor level.  
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3.1.3 Potential downstream targets of AMPK mediating inhibition of IL-6 
signalling 
AMPK has been demonstrated to mediate its metabolic effects via a variety of 
downstream targets (Hardie et al., 2012). Therefore, it was important to 
investigate whether AMPK could act via a known downstream target to inhibit IL-
6 signalling. To narrow down the list of candidates, the current literature was 
studied to identify whether any of the AMPK targets have been linked with 
inflammatory signalling. Interestingly, TC-PTP and SHP2, negative regulators of 
JAK-STAT signalling, were identified as AMPK downstream targets (Lam et al., 
2001, Nerstedt et al., 2013). Furthermore, endothelial nitric oxide synthase 
(eNOS), protein kinase C λ (PKCλ), sirtuin 1 (SIRT1), carnitine palmitoyltransferase 
1 (CPT1), and mammalian target of rapamycin (mTOR) were identified as either 
directly or indirectly having an impact on JAK-STAT signalling and have been 
reported to be regulated by AMPK (Morrow et al., 2003, Zhang et al., 2011, Cantó 
and Auwerx, 2009, Dagher et al., 2001, Inoki et al., 2003).  
3.1.4 Aims  
The aim of this chapter was to determine whether AMPK acts directly on a known 
regulator of JAK or STAT or an AMPK downstream target known to either directly 
or indirectly impact on JAK-STAT signalling. In order to determine whether 
inhibition of IL-6 signalling by AMPK was mediated by downstream targets of AMPK, 
a combination of genetic and pharmacological approaches was utilised to assess 
the role of each of the following AMPK targets: TC-PTP, SHP2, eNOS, PKCλ, SIRT1, 
CPT1 and mTOR.  
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3.2 Effect of phosphatases on AMPK-mediated regulation of IL-6 
signalling 
3.2.1 Effect of TC-PTP knockdown on A769662-mediated inhibition of STAT3 
phosphorylation 
JAK1, STAT1 and STAT3 have been reported to be direct substrates of TC-PTP 
(Yamamoto et al., 2002, ten Hoeve et al., 2002, Simoncic et al. 2002), while AMPK 
activation has been reported to alter cellular localisation of TC-PTP (Lam et al., 
2001). Therefore, it was hypothesised that AMPK-mediated inhibition of STAT3 
Tyr705 phosphorylation could potentially occur via TC-PTP. 
A siRNA approach was used to specifically knockdown the expression of TC-PTP in 
order to determine the necessity of TC-PTP in AMPK-mediated inhibition of IL-6 
stimulation of STAT3 Tyr705 phosphorylation. Control non-targeting siRNA and 
siRNA targeting TC-PTP were separately transiently transfected into HUVECs for 
48 hours prior to pre-treatment with vehicle or 100µM A769662 for 40 minutes 
followed by stimulation with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-
6Rα/IL-6) for a further 30 minutes as indicated.  
In comparison to HUVECs treated with control siRNA, transfection of HUVECs with 
TC-PTP siRNA reduced TC-PTP expression by 60% (Figure 3.1). Activation of AMPK 
by A769662 was assessed by confirming AMPK-mediated ACC phosphorylation on 
Ser79 (Figure 3.1) (Davies et al., 1992).. sIL-6Rα/IL-6 treatment of HUVECs 
transfected with control or TC-PTP siRNA caused a significant (***p<0.001) 
stimulation of STAT3 Tyr705 phosphorylation, compared to the basal level (Figure 
3.1). In comparison to sIL-6Rα/IL-6 stimulation of HUVECs transfected with control 
siRNA, siRNA mediated knockdown of TC-PTP had no (p>0.05, not significant [NS]) 
significant effect on sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation. 
Pre-treatment with AMPK activator, A769662, caused a significant reduction of sIL-
6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation in both control and TC-PTP 
siRNA transfected HUVECs, relative to sIL-6Rα/IL-6 treatment alone, as STAT3 
Tyr705 phosphorylation levels were significantly reduced by 67 ± 9% (***p<0.001) 
and 64 ± 9% (***p<0.001), respectively (Figure 3.1). Overall, siRNA mediated 
knockdown of TC-PTP did not attenuate the inhibitory effect of AMPK activation 
on STAT3 Tyr705 phosphorylation (Figure 3.1). The data shown in figure 3.1 was 
generated and analysed by Dr Claire Rutherford, University of Glasgow.  
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3.2.2 Effect of SHP2 on A769662-mediated inhibition of STAT3 
phosphorylation 
SHP2 has been reported to negatively regulate IL-6-stimulated STAT3 
phosphorylation (Ohtani et al., 2000, Lehmann et al., 2003). Recently, it has been 
reported that AMPK activators, AICAR and metformin, reduced IL-6-stimulated 
SHP-2 phosphorylation in HepG2 cells (Nerstedt et al., 2013). Therefore, it was 
hypothesised that AMPK-mediated inhibition of STAT3 Tyr705 phosphorylation 
could potentially occur via SHP2. 
SHP2 exon 3-deletion (SHP2−/−) 3T3 fibroblasts from mice express small amounts 
of a truncated SHP2 that lacks the N-terminal SH2 domain and does not localize 
appropriately to activated receptors (Saxton et al., 1997, Shi et al., 2000). SHP2-
mediated inhibition of JAK-STAT signalling is dependent on its recruitment to the 
gp130 receptor (Stahl et al., 1994), therefore SHP2−/− 3T3 fibroblasts were used 
to assess a role for SHP2 in mediating AMPK’s effects on STAT3 Tyr705 
phosphorylation. SHP2+/+ 3T3 fibroblasts are SHP2–/– cells reconstituted with WT 
SHP2 (SHP2+/+) and SHP2-/- 3T3 fibroblasts were pre-treated with vehicle or 
100µM A769662 for 40 minutes followed by stimulation with vehicle or 25ng/ml 
sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 30 minutes as indicated.  
Immunoblotting of cell extracts with SHP2 antibody confirmed that SHP2 was 
effectively depleted in SHP2 -/- 3T3 fibroblasts, relative to levels in SHP2+/+ 3T3 
fibroblasts. sIL-6Rα/IL-6 treatment of SHP2 +/+ and SHP2-/- 3T3 fibroblasts caused 
a significant (**p<0.001) stimulation of STAT3 Tyr705 phosphorylation, compared 
to the basal level (Figure 3.2A). In comparison to sIL-6Rα/IL-6 stimulation of 
SHP2+/+ fibroblasts, depletion of SHP2 in SHP2-/- 3T3 fibroblasts had no effect on 
sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation. In SHP2+/+ 3T3 
fibroblasts, A769662 induced a marginal 14% reduction in STAT3 Tyr705 
phosphorylation compared to sIL-6Rα/IL-6 treatment alone; however this did not 
reach statistical significance (p>0.05, NS) (Figure 3.2A). In SHP2-/- 3T3 
fibroblasts, A769662 induced a substantial 31% reduction in STAT3 Tyr705 
phosphorylation compared to sIL-6Rα/IL-6 treatment alone; however this did not 
reach statistical significance (p>0.05, NS) (Figure 3.2). Overall, loss of SHP2 
function did not attenuate the inhibitory effect of AMPK activation on STAT3 Tyr705 
phosphorylation (Figure 3.2A). 
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While SHP2 has been reported to negatively regulate IL-6 stimulation of JAK-STAT 
signalling, SHP2 positively regulates IL-6 stimulation of ERK signalling (Fukada et 
al., 1996). SHP2-mediated activation of ERK signalling is dependent on its 
recruitment to the gp130 receptor (Stahl et al., 1994). Therefore, to confirm that 
recruitment of SHP2 to the gp130 receptor is impaired in SHP2-/- 3T3 fibroblasts, 
SHP2-/- and SHP2+/+ 3T3 fibroblasts were treated with or without sIL-6Rα/IL-6 
for 5, 10 and 15 minutes, followed by immunoblotting of whole cell extracts with 
phospho-ERK 1/2, total ERK, SHP2 antibody. As shown in Figure 3.2B, sIL-6Rα/IL-
6 stimulated ERK1/2 phosphorylation in both SHP2-/- and SHP2+/+ 3T3 fibroblasts. 
Despite that SHP2 was effectively depleted in SHP2-/- 3T3, these cells 
demonstrated increased levels of ERK1/2 phosphorylation, compared to SHP2+/+ 
3T3 fibroblasts (Figure 3.2B). The data shown in figure 3.2 was generated and 
analysed by Dr Claire Rutherford, University of Glasgow.  
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Figure 3.1: Effect of TC-PTP isoform knockdown on AMPK-mediated inhibition of sIL-6Rα/IL-
6 stimulated STAT3 Tyr705 phosphorylation in HUVECs.  
HUVECs were transfected with either 20nM TC-PTP or control siRNA 48hrs prior to pre-treatment 
with vehicle or 100µM A769662 for 40 minutes followed by stimulation with vehicle or 25ng/ml sIL-
6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 30 minutes as indicated. Control siRNA was used 
as a negative control. Protein-equalised cell extracts were then analysed by SDS-PAGE and 
immunoblotting with antibodies as indicated. STAT3 phosphorylation data were first normalized to 
total STAT3 levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation 
attained in vehicle pre-treated control siRNA transfected HUVECs. Total TC-PTP protein levels were 
first normalized to Total STAT3 levels and expressed as a percentage (%) of the maximal protein 
levels attained in sIL-6Rα/IL-6 stimulated control siRNA transfected HUVECs (set at 100%).  
Quantitative analysis from three experiments is presented. Columns are means ±SEM. *** p<0.001. 
A representative blot from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC 
(Data was generated and analysed by Dr. Claire Rutherford, University of Glasgow.) 
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Figure 3.2: Effect of SHP2 on AMPK-mediated inhibition of sIL-6Rα/IL-6 stimulated STAT3 
Tyr705 phosphorylation in 3T3 cells.  
(A) SHP2+/+ and SHP2-/- 3T3 fibroblasts were pre-treated with vehicle or 100µM A769662 for 40 
minutes followed by stimulation with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a 
further 30 minutes as indicated. Protein-equalised cell extracts were then analysed by SDS-PAGE 
and immunoblotting with antibodies as indicated. STAT3 phosphorylation data were first normalized 
to total STAT3 levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation 
attained in vehicle pre-treated SHP2+/+ or SHP2-/- 3T3 fibroblasts. Quantitative analysis from three 
experiments is presented. Columns are means ±SEM.  A representative blot from n=3 experiments 
is shown. (B) SHP2+/+ and SHP2-/- 3T3 fibroblasts were treated with 25ng/ml sIL-6Rα and 5ng/ml 
IL-6 (sIL-6Rα/IL-6) for 5, 10 and 15 minutes as indicated. Protein-equalised cell extracts were then 
analysed by SDS-PAGE and immunoblotting with antibodies as indicated. (Data was generated and 
analysed by Dr. Claire Rutherford, University of Glasgow.)  
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3.3 Effect of eNOS inhibition on AMPK-mediated regulation of IL-6 
signalling 
AMPK directly phosphorylates and activates endothelial nitric oxide synthase 
(eNOS) to stimulate nitric oxide (NO) production in endothelial cells (Morrow et 
al., 2003). NO has previously been implicated in suppressing IL-6 induced STAT3 
Tyr705 phosphorylation in response to shear stress (Ni et al., 2004) and 
subsequently shear stress was shown to induce AMPK to elevate NO production via 
phosphorylation and activation of eNOS (Zhang et al., 2006). Therefore, it was 
hypothesised that AMPK-mediated inhibition of STAT3 Tyr705 phosphorylation 
could potentially occur via eNOS. To test this, pharmacological and genetic 
approaches were utilised to assess a role for eNOS in mediating AMPK’s effects on 
STAT3 phosphorylation in HUVECs.  
3.3.1 Effect of L-NAME on A769662-mediated inhibition of STAT3 
phosphorylation  
NO is synthesised from L-arginine by eNOS in endothelial cells (Palmer et al., 
1988). The L-arginine analogue L-NAME (Nω-Nitro-L-arginine methyl ester 
hydrochloride) is a competitive inhibitor of NOS and D-NAME (Nω-Nitro-D-arginine 
methyl ester hydrochloride) is an inactive isomer utilised as a control (Pfeiffer et 
al., 1996). 0.1mM L-NAME for 30 minutes has previously been shown to effectively 
inhibit AMPK-mediated NO production in human aortic endothelial cells (HAOECs) 
(Morrow et al., 2003). To determine whether pharmacological inhibition of eNOS 
by L-NAME altered AMPK-mediated inhibition of STAT3 phosphorylation, HUVECs 
were pre-treated with vehicle, 0.1mM L-NAME or 0.1mM D-NAME in endothelial 
cell growth medium for 30 minutes, followed by sequential treatment with 
A769662 and sIL-6Rα/IL-6.  
Immunoblotting of whole cell extracts with phospho-ACC (Ser79) antibody 
confirmed AMPK activation by A769662, and that neither D-NAME nor L-NAME had 
any effect on A769662 activation of AMPK (Figure 3.3). sIL-6Rα/IL-6 treatment of 
vehicle pre-treated HUVECs caused a significant (***p<0.001) stimulation of STAT3 
Tyr705 phosphorylation, compared to basal levels (Figure 3.3). A769662 
significantly inhibited sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation 
levels by 52 ± 7% (***p<0.01) in vehicle pre-treated HUVECs (Figure 3.3). Pre-
treatment with either D-NAME and L-NAME induced a 14% and 25 ± 3% reduction 
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in STAT3 Tyr705 phosphorylation respectively, compared to sIL-6Rα/IL-6 treatment 
alone; however this did not reach statistical significance (p>0.05, NS) (Figure 3.3). 
In the presence of D-NAME, A769662 significantly (*p<0.05) inhibited sIL-6Rα/IL-6 
stimulation of STAT3 Tyr705 phosphorylation levels by 28 ± 4 % (Figure 3.3). In the 
presence of L-NAME, A769662 induced a substantial 28 ± 4% reduction in STAT3 
phosphorylation compared to sIL-6Rα/IL-6 treatment alone; however this did not 
reach statistical significance (p>0.05, NS) (Figure 3.3). Overall, pharmacological 
inhibiton of eNOS appeared to moderately reduce sIL-6Rα/IL-6 stimulation of 
STAT3 Tyr705 phosphorylation and the addition of A769662 further reduced the 
phosphorylation of STAT3, however this did not reach statistical significance 
(p>0.05, NS).  
3.3.2 Effect of siRNA-mediated eNOS knockdown on A769662-mediated 
inhibition of STAT3 phosphorylation 
An siRNA approach was used to specifically knockdown the expression of eNOS in 
order to determine the necessity of eNOS in AMPK-mediated inhibition of IL-6 
stimulation of STAT3 Tyr705 phosphorylation. Control non-targeting siRNA and 
siRNA targeting eNOS were separately transiently transfected into HUVECs for 48 
hours prior to pre-treatment with vehicle or 100µM A769662 for 40 minutes 
followed by stimulation with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-
6Rα/IL-6) for a further 30 minutes as indicated.  
In comparison to HUVECs treated with control siRNA, transfection of HUVECs with 
eNOS siRNA reduced eNOS expression by 50% (Figure 3.4). sIL-6Rα/IL-6 treatment 
of HUVECs transfected with control siRNA caused a significant (***p<0.001) 
stimulation of STAT3 Tyr705 phosphorylation, compared to the basal level (Figure 
3.4). Pre-treatment of control siRNA transfected HUVECs with A769662 
significantly (***p<0.001) inhibited sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 
phosphorylation by 62 ± 10%, compared to sIL-6Rα/IL-6 treatment alone (Figure 
3.4). siRNA-mediated knockdown of eNOS significantly (***p<0.001) inhibited sIL-
6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation by 38 ± 6% compared to 
control siRNA transfected HUVECs treated with sIL-6Rα/IL-6 treatment alone 
(Figure 3.4). Pre-treatment of eNOS siRNA transfected HUVECs with A769662 
significantly inhibited sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation by 
34 ± 6% (***p<0.001), compared to sIL-6Rα/IL-6 treatment alone (Figure 3.4). 
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Overall, siRNA-mediated knockdown of eNOS in HUVECs attenuated sIL-6Rα/IL-6 
stimulation of STAT3 Tyr705 phosphorylation, but did not attenuate the inhibitory 
effect of AMPK activation on STAT3 Tyr705 phosphorylation (Figure 3.4). The data 
shown in figure 3.4 was generated and analysed by Dr Claire Rutherford, University 
of Glasgow. 
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Figure 3.3: Effect of eNOS inhibitor L-NAME on AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulated STAT3 phosphorylation in HUVECs  
HUVECs were pre-treated with vehicle or 0.1mM L-NAME and as a negative control 0.1mM D-NAME 
for 30 minutes, and then treated with or without 100μM A769662 for 40 minutes prior to the addition 
of vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 30 minutes as indicated. 
Protein-equalised cell extracts were then analysed by SDS-PAGE and immunoblotting with 
antibodies as indicated. STAT3 phosphorylation data were first normalized to total STAT3 levels and 
expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation attained in vehicle pre-
treated HUVECs. Quantitative analysis from three experiments is presented. Columns are means 
±SEM. *** p<0.001, *p>0.05. A representative blot from n=3 experiments is shown. n=3 from one 
batch of pooled donor HUVEC   
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Figure 3.4: Effect of eNOS isoform knockdown on AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulated STAT3 Tyr705 phosphorylation in HUVECs.  
HUVECs were transfected with either 170nM eNOS or control siRNA 48hrs prior to pre-treatment 
with vehicle or 100µM A769662 for 40 minutes followed by stimulation with vehicle or 25ng/ml sIL-
6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 30 minutes as indicated. Control siRNA was used 
as a negative control. Protein-equalised cell extracts were then analysed by SDS-PAGE and 
immunoblotting with antibodies as indicated. STAT3 phosphorylation data were first normalized to 
total STAT3 levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation 
attained in vehicle pre-treated control siRNA transfected HUVECs. Total eNOS protein levels were 
first normalized to Total STAT3 levels and expressed as a percentage (%) of the maximal protein 
levels attained in sIL-6Rα/IL-6 stimulated control siRNA transfected HUVECs (set at 100%).  
Quantitative analysis from three experiments is presented. Columns are means ±SEM. *** p<0.001. 
A representative blot from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC 
(Data was generated and analysed by Dr. Claire Rutherford, University of Glasgow.)  
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3.4 Effect of PKC inhibition on AMPK-mediated regulation of IL-6 
signalling 
STAT3 is acetylated by its coactivator p300/CBP, resulting in increased DNA binding 
and transcriptional activity (Wang et al., 2005), and several reports have 
demonstrated that acetylation is required for phosphorylation of STATs (Zhuang, 
2013). AMPK has been reported to indirectly phosphorylate p300 via the atypical 
PKCλ, resulting in inhibition of the histone acetyltransferase activity of p300 
(Zhang et al., 2011). Therefore, it was hypothesised that AMPK-mediated 
inhibition of STAT3 Tyr705 phosphorylation could potentially occur via PKCλ. To 
test this hypothesis, pharmacological and genetic approaches were utilised to 
assess a role for PKC in mediating AMPK’s effects on STAT3 phosphorylation in 
HUVECs. 
3.4.1 Effect of GF109203X on A769662-mediated inhibition of STAT3 
phosphorylation  
GF109203X (3-[1-[3-(dimethylaminopropyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-
pyrrole-2,5-dione monohydrochloride), a bisindolylmaleimide, potently and 
selectively inhibits PKC isoforms by competing with enzyme-bound ATP (Toullec et 
al., 1991). phorbol 12-myristate 13-acetate (PMA) activation of novel and 
conventional isoforms of PKC results in activation of the ERK pathway 
(Schönwasser et al., 1998). 10µM GF109203X for 30 minutes abolished PMA-
induced ERK activation in HUVECs, (Tim Palmer; personal communication). To 
determine whether pharmacological inhibition of PKC by GF109203X altered AMPK-
mediated inhibition of STAT3 phosphorylation, HUVECs were pre-treated with 
vehicle or 10µM GF109203X for 30 minutes, followed by sequential treatment with 
A769662 and sIL-6Rα/IL-6.  
In vehicle pre-treated cells, phospho-ACC levels were substantially increased in 
the presence of A769662, relative to the absence of A769662 (Figure 3.5). In 
contrast, A769662-mediated phosphorylation of ACC was reduced in GF109203X 
pre-treated cells (Figure 3.5). sIL-6Rα/IL-6 induced a significant (***p<0.001) 
increase in STAT3 Tyr705 phosphorylation in both the presence and absence of 
GF109203X, compared to the basal level (Figure 3.5). In comparison to sIL-6Rα/IL-
6 stimulation of HUVECs in the absence of GF109203X, the presence of GF109203X 
had no significant effect on sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 
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phosphorylation (p>0.05, NS). Sequential treatment of HUVECs with A769662 and 
sIL-6Rα/IL-6 in the absence or presence of GF109203X caused a significant 53 ± 6% 
(***p<0.001) and 61 ± 6% (***p<0.001) inhibition of STAT3 Tyr705 phosphorylation, 
respectively, compared to IL-6Rα/IL-6 treatment alone (Figure 3.5). Overall, 
pharmacological inhibition of PKC by GF109203X did not attenuate the inhibitory 
effect of AMPK activation on STAT3 Tyr705 phosphorylation (Figure 3.5). 
3.4.2 Effect of siRNA-mediated PKCλ knockdown on A769662-mediated 
inhibition of STAT3 phosphorylation 
An siRNA approach was used to specifically knockdown the expression of PKCλ in 
order to determine the necessity of PKCλ in AMPK-mediated inhibition of IL-6 
stimulation of STAT3 Tyr705 phosphorylation. Control non-targeting siRNA and 
siRNA targeting PKCλ were separately transiently transfected into HUVECs for 48 
hours prior to pre-treatment with vehicle or 100µM A769662 for 40 minutes 
followed by stimulation with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-
6Rα/IL-6) for a further 30 minutes as indicated.  
In comparison to HUVECs treated with control siRNA, transfection of HUVECs with 
PKCλ siRNA reduced PKCλ expression by 40% (Figure 3.6). Immunoblotting of cell 
extracts with phospho-ACC (Ser79) antibody confirmed AMPK activation by 
A769662 and siRNA mediated knockdown of PKCλ had no effect on A769662 
activation of AMPK (Figure 3.6). sIL-6Rα/IL-6 treatment of HUVECs transfected 
with control or PKCλ siRNA caused a significant (***p<0.001) stimulation of STAT3 
Tyr705 phosphorylation, compared to the basal level (Figure 3.6). In comparison 
to sIL-6Rα/IL-6 stimulation of HUVECs transfected with control siRNA, siRNA 
mediated knockdown of PKCλ had no significant (p>0.05, NS) effect on sIL-6Rα/IL-
6 stimulation of STAT3 Tyr705 phosphorylation.  Pre-treatment with A769662 
caused a significant reduction of sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 
phosphorylation in both control and PKCλ siRNA transfected HUVECs, relative to 
sIL-6Rα/IL-6 treatment alone, as STAT3 Tyr705 phosphorylation levels were 
reduced by 74 ± 9% (***p<0.001) and 91 ± 11% (***p<0.001), respectively (Figure 
3.6). Overall, siRNA mediated knockdown of PKCλ did not attenuate the inhibitory 
effect of AMPK activation on STAT3 Tyr705 phosphorylation (Figure 3.6). The data 
shown in figure 3.6 was generated and analysed by Dr Claire Rutherford, University 
of Glasgow.   
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Figure 3.5: Effect of PKC inhibitor G109203FX on AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulated STAT3 Tyr705 phosphorylation in HUVECs  
HUVECs were pre-treated with vehicle or 10μM GF109203X for 30 minutes, and then treated with 
or without 100μM A769662 for 40 minutes prior to the addition of vehicle or 25ng/ml sIL-6Rα and 
5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 30 minutes as indicated. Protein-equalised cell extracts were 
then analysed by SDS-PAGE and immunoblotting with antibodies as indicated. STAT3 
phosphorylation data were first normalized to total STAT3 levels and expressed as a percentage (%) 
of the maximal sIL-6Rα/IL-6 stimulation attained in vehicle pre-treated HUVECs. Quantitative 
analysis from three experiments is presented. Columns are means ±SEM. ***p<0.001 A 
representative blot from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC  
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Figure 3.6: Effect of PKCλ isoform knockdown on AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulated STAT3 Tyr705 phosphorylation in HUVECs.  
HUVECs were transfected with either 10nM PKCλ or control siRNA 48hrs prior to pre-treatment with 
vehicle or 100µM A769662 for 40 minutes followed by stimulation with vehicle or 25ng/ml sIL-6Rα 
and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 30 minutes as indicated. Control siRNA was used as a 
negative control. Protein-equalised cell extracts were then analysed by SDS-PAGE and 
immunoblotting with antibodies as indicated. STAT3 phosphorylation data were first normalized to 
total STAT3 levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation 
attained in vehicle pre-treated control siRNA transfected HUVECs. Total PKCλ protein levels were 
first normalized to GAPDH levels and expressed as a percentage (%) of the maximal protein levels 
attained in sIL-6Rα/IL-6 stimulated control siRNA transfected HUVECs (set at 100%). Quantitative 
analysis from four experiments is presented. Columns are means ±SEM. ***p<0.001. A 
representative blot from n=4 experiments is shown. n=4 from one batch of pooled donor HUVEC 
(Data was generated and analysed by Dr. Claire Rutherford, University of Glasgow.) 
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3.5 Effect of SIRT1 inhibition on AMPK-mediated regulation of IL-6 
signalling 
SIRT1 is a histone/protein deacetylase, whose catalytic activity is dependent on 
the co-substrate nicotinamide adenine dinucleotide (NAD+) (Sauve et al., 2006). 
Activation of AMPK enhances SIRT1 activity by increasing production of cellular 
NAD+ (Cantó and Auwerx, 2009, Yang et al., 2010). Furthermore, it has been 
demonstrated that SIRT1 can directly deacetylate STAT3 and that this modification 
is coupled with the down-regulation of STAT3 phosphorylation (Nie et al., 2009). 
Therefore, it was hypothesised that AMPK-mediated inhibition of STAT3 Tyr705 
phosphorylation could potentially occur via SIRT1. To test this hypothesis, a 
pharmacological inhibitor of SIRT1, EX527 (6-chloro-2,3,4,9-tetrahydro-1H-
carbazole-1-carboxamide), was utilised to assess a role for SIRT1 in mediating 
AMPK’s effects on STAT3 phosphorylation in HUVECs. 
3.5.1 Effect of EX527 on A769662-mediated inhibition of STAT3 
phosphorylation  
EX527 is a specific small molecule inhibitor of SIRT1 catalytic activity and occupies 
the NAD+-binding sites of SIRT1, thereby limiting deacetylation of target proteins 
and histones (Napper et al., 2005, Gertz et al., 2013). 1μM EX527 for 4 hours has 
previously been shown to effectively inhibit SIRT1 to increase acetylation levels 
of its well-established substrate p53 in primary human epithelial cells and several 
cell lines (Solomon et al., 2006). HUVECs were pre-treated with vehicle or 1µM 
EX527 for 6 hours, followed by sequential treatment with A769662 and sIL-6Rα/IL-
6.  
This experiment was conducted under both serum-deprived (Figure 3.7) and 
serum-supplemented conditions (Figure 3.7). The presence of serum did not 
unmask any differences from the experiment conducted in the absence of serum 
(Figure 3.7), therefore only the results obtained in serum-deprived conditions are 
described below.  
sIL-6Rα/IL-6 induced a significant (***p<0.001) increase in STAT3 Tyr705 
phosphorylation in both the presence and absence of EX527, compared to the basal 
level (Figure 3.7). In comparison to sIL-6Rα/IL-6 stimulation of HUVECs in the 
absence of EX527, the presence of EX527 had no significant (p>0.05, NS) effect on 
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sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation. Sequential treatment of 
HUVECs with A769662 and sIL-6Rα/IL-6 in the absence or presence of EX527 caused 
a significant 85 ± 5% (***p<0.001) and by 82 ± 10% (***p<0.001) inhibition of STAT3 
Tyr705 phosphorylation, respectively, compared to IL-6Rα/IL-6 treatment alone 
(Figure 3.7). Overall, pharmacological inhibition of SIRT1 by EX527 did not 
attenuate the inhibitory effect of AMPK activation on STAT3 Tyr705 
phosphorylation (Figure 3.7). 
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Figure 3.7: Effect of SIRT1 inhibitor EX527 on AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulated STAT3 Tyr705 phosphorylation in HUVECs  
HUVECs were pre-treated for 6 hours with or without 1μM EX527 in endothelial cell growth medium 
(serum supplemented) or basal medium 199 (serum deprived), and then treated with or without 
100μM A769662 for 40 minutes prior to the addition of vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 
(sIL-6Rα/IL-6) for a further 30 minutes as indicated. Protein-equalised cell extracts were then 
analysed by SDS-PAGE and immunoblotting with antibodies as indicated. STAT3 phosphorylation 
data were first normalized to total STAT3 levels and expressed as a percentage (%) of the maximal 
sIL-6Rα/IL-6 stimulation attained in vehicle pre-treated HUVECs. Quantitative analysis from three 
experiments is presented. Columns are means ±SEM. ***p<0.001, **p<0.01, *p<0.05 A 
representative blot from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC 
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3.6 Effect of CPT1 inhibition on AMPK-mediated regulation of IL-6 
signalling 
Fatty acid palmitate significantly increased levels of STAT-3 phosphorylation in 
HAOECs (Mugabo et al., 2011), while activation of AMPK stimulates fatty acid 
oxidation in HUVECs (Dagher et al., 2001). Therefore, it was hypothesised that 
AMPK could inhibit STAT3 Tyr705 phosphorylation by promoting fatty acid 
oxidation, and thereby reducing palmitate-mediated stimulation of STAT3. To test 
this hypothesis, a pharmacological inhibitor of CPT1, Etomoxir, was used to assess 
a role for fatty acid oxidation in mediating AMPK’s effects on STAT3 
phosphorylation in HUVECs. 
3.6.1 Effect of Etomoxir on A769662-mediated inhibition of STAT3 
phosphorylation  
CPT1 is an enzyme found on the outer mitochondrial membrane and controls the 
transfer of long-chain fatty acids from the cytosol into the mitochondria for 
oxidation (McGarry and Brown, 1997). Etomoxir is an oxirane carboxylic acid 
derivative which irreversible inhibits CPT1 activity, thus decreasing fatty acid β-
oxidation (Abdel-aleem et al., 1994). Effective inhibition of fatty acid oxidation 
in HUVECs was achieved by our colleagues using 50µM Etomoxir for 4 hours (Ian 
Salt, personal communication).HUVECs were pre-treated with vehicle or 50 μM 
Etomoxir for 4 hours, followed by sequential treatment with A769662 and sIL-
6Rα/IL-6.  
This experiment was conducted under both serum-deprived (Figure 3.8) and 
serum-supplemented conditions (Figure 3.8). The presence of serum did not 
unmask any differences from the experiment conducted in the absence of serum 
(Figure 3.8), therefore only the results obtained in serum-deprived conditions are 
described below.  
sIL-6Rα/IL-6 induced a significant (***p<0.001) increase, compared to the basal 
level, in STAT3 Tyr705 phosphorylation in both the presence and absence of 
Etomoxir (Figure 3.8). In comparison to sIL-6Rα/IL-6 stimulation of HUVECs in the 
absence of Etomoxir, the presence of EX527 had no significant (p>0.05, NS) effect 
on sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation. Sequential treatment 
of HUVECs with A769662 and sIL-6Rα/IL-6 in the absence or presence of Etomoxir 
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caused a significant 66 ± 10% (***p<0.001) and by 57 ± 7% (***p<0.001) inhibition of 
STAT3 Tyr705 phosphorylation, respectively, compared to IL-6Rα/IL-6 treatment 
alone (Figure 3.8). Overall, pharmacological inhibition of fatty acid oxidation by 
Etomoxir did not attenuate the inhibitory effect of AMPK activation on STAT3 
Tyr705 phosphorylation (Figure 3.8).  
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Figure 3.8: Effect of CPT1 inhibitor Etomoxir on AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulated STAT3 Tyr705 phosphorylation in HUVECs  
HUVECs were pre-treated for 4 hours with or without 50μM Etomoxir in endothelial cell growth 
medium (serum supplemented) or basal medium 199 (serum deprived, then treated with or without 
100μM A769662 for 40 minutes prior to the addition of vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 
(sIL-6Rα/IL-6) for a further 30 minutes as indicated. Protein-equalised cell extracts were then 
analysed by SDS-PAGE and immunoblotting with antibodies as indicated. STAT3 phosphorylation 
data were first normalized to total STAT3 levels and expressed as a percentage (%) of the maximal 
sIL-6Rα/IL-6 stimulation attained in vehicle pre-treated HUVECs. Quantitative analysis from three 
experiments is presented. Columns are means ±SEM. ***p<0.001, **p<0.01. A representative blot 
from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC 
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3.7 Effect of mTOR inhibition on AMPK-mediated regulation of IL-
6 signalling 
mTOR exists in two distinct multiprotein complexes, mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2), which have distinct substrate specificities and 
are differentially regulated (Hara et al., 2002, Dos et al., 2004 Jacinto et al., 
2004, Gwinn et al 2008). AMPK inhibits mTOR activity, as measured by 
phosphorylation of S6 kinase (S6K) (Kimura et al., 2003). Furthermore, it has been 
demonstrated that pharmacological inhibition of the mTOR pathway can suppress 
STAT3 activation (Goncharova et al., 2009). Therefore, it was hypothesised that 
AMPK-mediated inhibition of STAT3 Tyr705 phosphorylation could potentially occur 
via inhibition of mTOR. To test this hypothesis, a pharmacological inhibitor of 
mTOR, PP242, was utilised to assess a role for mTOR in mediating AMPK’s effects 
on STAT3 phosphorylation in HUVECs. 
3.7.1 Effect of PP242 on A769662-mediated inhibition of STAT3 
phosphorylation  
PP242 specifically inhibits both mTORC1 and mTORC2, as it binds directly to the 
ATP binding site of either (Feldman et al., 2009). 2µM PP242 for 3 hours has 
previously been shown to effectively inhibit phosphorylation of its well-
established substrate S6K in mouse embryonic fibroblasts (MEFs) (Ian Salt, 
personal communication). HUVECs were pre-treated with vehicle or 2μM PP242 for 
3 hours, followed by sequential treatment with A769662 and sIL-6Rα/IL-6.  
This experiment was conducted under both serum-deprived (Figure 3.9) and 
serum-supplemented conditions (Figure 3.9). The presence of serum did not 
unmask any differences from the experiment conducted in the absence of serum 
(Figure 3.9), therefore only the results obtained in serum-deprived conditions are 
described below.  
Immunoblotting of whole cell extracts with phospho-p70 S6 kinase (Ser371) 
antibody confirmed PP242-mediated inhibition of mTOR as phospho-p70 S6 kinase 
was undetectable in the presence of PP242 and AMPK had no effect on 
phosphorylation of p70 S6 kinase (Figure 3.9). sIL-6Rα/IL-6 treatment of vehicle 
pre-treated HUVECs caused a significant (***p<0.001) stimulation of STAT3 Tyr705 
phosphorylation, compared to basal levels (Figure 3.9). A769662 significantly 
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inhibited sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation levels by 72 ± 
6% (***p<0.001) in vehicle pre-treated HUVECs (Figure 3.9). Pre-treatment with 
PP242 induced a 29 ± 10% (**p<0.01) reduction in sIL-6Rα/IL-6-stimulated STAT3 
Tyr705 phosphorylation, compared to sIL-6Rα/IL-6 treatment alone (Figure 3.9). 
Sequential treatment of HUVECs with A769662 and sIL-6Rα/IL-6 in the absence or 
presence of PP242 caused a significant 72 ± 6% (***p<0.001) and 55 ± 3% 
(***p<0.001) inhibition of STAT3 Tyr705 phosphorylation, respectively, compared to 
IL-6Rα/IL-6 treatment alone (Figure 3.9). Overall, pharmacological inhibiton of 
mTOR in HUVECs attenuated sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 
phosphorylation, but did not attenuate the inhibitory effect of AMPK activation on 
STAT3 Tyr705 phosphorylation (Figure 3.9).  
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Figure 3.9: Effect of mTOR inhibitor PP242 on AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulated STAT3 phosphorylation in HUVECs  
HUVECs were pre-treated for 3 hours with or without 2μM PP242 in endothelial cell growth medium 
(serum supplemented) or basal medium 199 (serum deprived), and then treated with or without 
100μM A769662 for 40 minutes prior to the addition of vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 
(sIL-6Rα/IL-6) for a further 30 minutes as indicated. Protein-equalised cell extracts were then 
analysed by SDS-PAGE and immunoblotting with antibodies as indicated. STAT3 phosphorylation 
data were first normalized to total STAT3 levels and expressed as a percentage (%) of the maximal 
sIL-6Rα/IL-6 stimulation attained in vehicle pre-treated HUVECs. Quantitative analysis from three 
experiments is presented. Columns are means ±SEM. ***p<0.001, **p<0.01, *p<0.05 A 
representative blot from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC   
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3.8 Discussion 
In this chapter, it was investigated whether AMPK exerts its inhibitory effects on 
JAK-STAT signalling via a known regulator of JAK or STAT, or an AMPK downstream 
target known to either directly or indirectly impact on JAK-STAT signalling. A 
combination of genetic and pharmacological approaches was utilised to assess the 
role of each of the following AMPK targets: TC-PTP, SHP2, eNOS, PKCλ, SIRT1, CPT1 
and mTOR. The key findings of this chapter suggest that AMPK activation in HUVECs 
inhibited sIL-6Rα/IL-6 stimulated STAT3 Tyr705 phosphorylation via a mechanism 
independent of TC-PTP, eNOS, PKC, SIRT1 and mTOR. Furthermore, inhibition of 
mTOR and eNOS reduced sIL-6Rα/IL-6 stimulated STAT3 Tyr705 phosphorylation, 
independent of AMPK activation by A769662. 
3.8.1 Role of TC-PTP 
JAK-STAT signalling involves a cascade of tyrosine phosphorylation events, 
therefore PTPs mediating dephosphorylation of signalling components are key 
negative regulators of JAK-STAT signalling (Shuai and Liu 2003, Tonks and Neel 
2001). Several PTPs, including SHP1, SHP2, CD45, PTP1B and TC-PTP, have been 
identified as regulators of JAK-STAT signalling. SHP2 and TC-PTP are ubiquitously 
expressed and the most studied PTPs in the JAK-STAT pathway (Xu and Qu, 2008). 
Therefore, it was hypothesised that AMPK-mediated inhibition of STAT3 Tyr705 
phosphorylation could potentially occur via TC-PTP or SHP2.  
JAK1, STAT1 and STAT3 have been reported to be direct substrates of TC-PTP 
(Yamamoto et al., 2002, ten Hoeve et al., 2002, Simoncic et al. 2002). TC-PTP 
exists as two splice variants: an TC48 and a TC45. Overexpression of TC45 in 293T 
cells was reported to suppress IL-6-stimulated STAT3 phosphorylation (Yamamoto 
et al., 2002). Lam et al., reported that pharmacological activation of AMPK 
induces the cytoplasmic accumulation of TC45 by inhibiting nuclear import (Lam 
et al., 2001). Therefore, it was hypothesised that AMPK-mediated inhibition of 
STAT3 Tyr705 phosphorylation could potentially occur via TC-PTP. An siRNA 
approach was used to specifically knockdown the expression of TC-PTP in order to 
determine the necessity of TC-PTP in AMPK-mediated inhibition of IL-6 stimulation 
of STAT3 Tyr705 phosphorylation. Figure 3.1 demonstrated that siRNA mediated 
knockdown of TC-PTP in HUVECs did not attenuate the inhibitory effect of AMPK 
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activation on STAT3 Tyr705 phosphorylation. Similar observations were made in 
MEFs by our colleague Sarah Mancini; IL-6-stimulated STAT3 Tyr705 
phosphorylation was significantly inhibited following AMPK activation in both wild 
type and TC-PTP-/- MEFs (Sarah Mancini, personal communication). Overall, 
inhibition of IL-6 stimulated STAT3 Tyr705 phosphorylation by AMPK was not via 
TC-PTP. The data shown in figure 3.1 was generated and analysed by Dr Claire 
Rutherford, University of Glasgow. 
3.8.2 Role of SHP2 
SHP2 has been reported to negatively regulate IL-6-stimulated STAT3 
phosphorylation (Ohtani et al., 2000, Lehmann et al., 2003). SHP2 is rapidly 
recruited to Tyr759 in gp130 following IL-6 stimulation (Stahl et al., 1995). 
Disruption of SHP2 recruitment, by the substitution of Tyr757 in gp130 with 
phenylalanine, was shown to increase STAT3-mediated gene expression (Ohtani et 
al., 2000, Nicholson et al., 2000, Schaper et al., 1998). Recently, Nerstedt et al., 
reported that both AICAR and metformin reduced IL-6 stimulated SHP-2 
phosphorylation in hepatoma cell line HepG2 (Nerstedt et al. 2013). Therefore, it 
was hypothesised that AMPK-mediated inhibition of STAT3 Tyr705 phosphorylation 
could potentially occur via SHP2. In order to assess a role for SHP2 in mediating 
AMPK’s effects on STAT3 Tyr705 phosphorylation, SHP2 exon 3-deletion (SHP2−/−) 
3T3 fibroblasts were utilised with genetically-matched wild-type cells. SHP2 exon 
3-deletion (SHP2−/−) 3T3 fibroblasts from mice are deficient in SHP2 and express 
small amounts of mutant SHP2 that is unable to bind to the receptor (Saxton et 
al., 1997, Shi et al., 2000, Lehmann et al., 2003). As shown in figure 3.2A, A769662 
inhibited IL-6 stimulation of STAT3 Tyr705 phosphorylation in both SHP2-/- and 
SHP2 +/+ 3T3 fibroblasts, however this did not reach statistical significance. SHP2 
acts to inhibit cytokine stimulated JAK-STAT signalling, but also potentiates 
cytokine-induced ERK signalling (Salmond et al., 2006). Mutation of the SHP2-
binding site, Tyr759, in GP130 receptor abolished IL-6 stimulation of ERK activation 
in embryonic fibroblasts (Ohtani et al., 2000). To confirm SHP2 loss of function in 
SHP2 -/- 3T3 fibroblasts, sIL-6Rα/IL-6 stimulation of ERK 1/2 phosphorylation was 
assessed in these cells. Surprisingly, IL-6 induced ERK1/2 phosphorylation levels 
were minimal in SHP2 +/+ 3T3 fibroblasts, whereas phospho-ERK 1/2 levels were 
potentiated in SHP2 -/- 3T3 fibroblasts, compared to SHP2 +/+ 3T3 fibroblasts. In 
comparison to basal levels in SHP2 +/+ 3T3 fibroblasts, IL-6 has minimal effect on 
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STAT3 and ERK1/2 phosphorylation which suggests that overexpression of SHP2 has 
increased the dephosphorylation of JAK and possible other signalling proteins. 
Overall, our results are inconclusive on whether AMPK-mediated inhibition of sIL-
6Rα/IL-6 signalling is via SHP2. The data shown in figure 3.2 was generated and 
analysed by Dr Claire Rutherford, University of Glasgow. 
3.8.3 Role of NO  
AMPK directly phosphorylates and activates eNOS to stimulate NO production in 
endothelial cells (Morrow et al., 2003). It has been reported that NO induces the 
inactivation of SHP-1, SHP-2, and PTP1B, but not TC-PTP (Hsu and Meng 2010). 
Also, AMPK activation of eNOS has been shown to inhibit TNF-α stimulation of MCP-
1 expression and secretion in vascular endothelial cells (Ewart et al., 2008). 
Therefore, it was hypothesised that AMPK-mediated inhibition of STAT3 Tyr705 
phosphorylation could potentially occur via eNOS. Our initial investigation into the 
role of eNOS in mediating AMPK’s inhibitory effects on IL-6 stimulation of STAT3 
Tyr705 phosphorylation utilised the eNOS inhibitor L-NAME and the negative 
control D-NAME. Figure 3.3 demonstrated that sIL-6Rα/IL-6 stimulation of STAT3 
Tyr705 phophorylation was moderately reduced in the presence of L-NAME and the 
addition of A769662 further reduced the phosphorylation of STAT3. However, these 
changes did not reach statistical significance. Furthermore, there was no positive 
control for this experiment demonstrating the inhibition of eNOS by L-NAME. 
However, 0.1mM L-NAME has previously been shown to effectively inhibit eNOS in 
HAOECs (Morrow et al., 2003). Therefore, to clarify the role of eNOS in mediating 
AMPK’s inhibitory effects on STAT3 Tyr705 phosphorylation in HUVECs a siRNA 
approach was utilised. Figure 3.4 demonstrated that siRNA mediated knockdown 
of eNOS in HUVECs significantly (***p<0.001) reduced sIL-6Rα/IL-6 stimulation of 
STAT3 Tyr705 phosphorylation and the addition of A769662 further significantly 
(***p<0.001) reduced the phosphorylation of STAT3. These data suggest that both 
AMPK activation and eNOS inhibition suppress sIL-6Rα/IL-6 stimulated STAT3 
Tyr705 phosphorylation, and this is likely to occur via mutually exclusive 
mechanisms. Taken together, these data demonstrated that neither 
pharmacological inhibiton nor siRNA-mediated knockdown of eNOS attenuated the 
inhibitory effect of AMPK activation on STAT3 Tyr705 phosphorylation. To our 
knowledge, this is the first time eNOS inhibition has been linked to a reduction in 
STAT3 phosphorylation in endothelial cells. In contrast, Kim et al., have recently 
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proposed that NO produced by the inducible isoform of NOS (iNOS) inhibits STAT3 
Tyr705 phosphorylation by direct S-nitrosylation of STAT3 in microglia (Kim et al., 
2014). Overall, these data suggest that AMPK-mediated inhibition of STAT3 Tyr705 
phosphorylation is not via AMPK-induced eNOS-activity. The data shown in figure 
3.4 was generated and analysed by Dr Claire Rutherford, University of Glasgow.  
3.8.4 Role of PKCλ and SIRT1  
Acetylation of STATs is emerging as a key mechanism for regulating STAT signalling 
(Zhuang et al., 2013). STAT3 is acetylated by its coactivator p300/CBP, resulting 
in increased DNA binding and transcriptional activity (Wang et al., 2005), and 
several reports have demonstrated that acetylation is required for 
phosphorylation of STATs (Zhuang et al., 2013). Nie et al (2009) demonstrated that 
NAD+-dependent deacetylase SIRT1 can directly deacetylate STAT3 and that this 
modification is coupled with the down-regulation of STAT3 phosphorylation (Nie 
et al., 2009). AMPK indirectly phosphorylates p300 via the atypical PKCλ, resulting 
in inhibition of the histone acetyltransferase activity of p300 (Zhang et al., 2011). 
Activation of AMPK enhances SIRT1 activity by increasing the cellular levels of its 
activator NAD+ (Cantó and Auwerx, 2009, Yang et al., 2010). Therefore, it was 
hypothesised that AMPK-mediated inhibition of STAT3 Tyr705 phosphorylation 
could potentially occur via PKCλ mediated inhibition of p300 or SIRT1. 
Pharmacological and genetic approaches were utilised to investigate whether 
PKCλ mediated the inhibition of STAT3 Tyr705 phosphorylation by AMPK activation. 
Figure 3.5 demonstrated that inhibition of PKCλ in HUVECs using a 
pharmacological inhibitor, GF109203X, did not attenuate the inhibitory effect of 
AMPK activation on STAT3 Tyr705 phosphorylation. Under the same conditions, 
10µM GF109203X abolished PMA-induced ERK activation in HUVECs, thus 
confirming that the concentration used was sufficient to block PKC-mediated 
responses (Tim Palmer; personal communication). At concentrations of 10µM 
GF109203X is a nonselective inhibitor of PKC isoforms. As GF109203X binds to the 
ATP-binding site of PKC isoforms, it is perhaps unsurprising that it has been 
reported to inhibit other protein Ser/Thr kinases at high concentrations 
(http://www.kinase-screen.mrc.ac.uk/screening-compounds/341060). Indeed, at 
concentrations of 10µM, GF109203X has been reported to inhibit AMPK in vitro by 
96%. This may, therefore, underlie the inhibition of A769662-stimulated ACC 
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phosphorylation observed in HUVECs stimulated with GF109203X (Figure 3.5). 
Therefore, to specifically assess the role of PKCλ in mediating AMPK’s effects on 
STAT3 phosphorylation in HUVECs a siRNA approach was utilised. Figure 3.6 
demonstrated that siRNA mediated knockdown of PKCλ in HUVECs did not 
attenuate the inhibitory effect of AMPK activation on STAT3 Tyr705 
phosphorylation. Overall, these data suggest that inhibition of IL-6-stimulated 
STAT3 Tyr705 phosphorylation by AMPK was not via PKCλ. The data shown in figure 
3.6 was generated and analysed by Dr Claire Rutherford, University of Glasgow.  
A pharmacological inhibitor of SIRT1, EX527, was used to investigate whether SIRT1 
mediated the inhibition of STAT3 phosphorylation by AMPK activation. Figure 3.7 
demonstrated that pharmacological inhibition of SIRT1 in HUVECs did not 
attenuate the inhibitory effect of AMPK activation on STAT3 Tyr705 
phosphorylation. It is noted that there was no positive control for this experiment 
demonstrating the inhibition of SIRT1 activity by EX527, therefore data should be 
interpreted with care. However, 1μM EX527 has previously been shown to 
effectively inhibit SIRT1 to increase acetylation levels of its well-established 
substrate p53 in primary human epithelial cells and several cell lines (Solomon et 
al., 2006). Overall, these data suggest that AMPK-mediated inhibition of STAT3 
Tyr705 phosphorylation is not via AMPK-induced SIRT1-activity. These observations 
are based on the notion that AMPK activates SIRT1, however it has recently been 
demonstrated by Lee et al (2012) that activated AMPK inhibits SIRT1-mediated 
deacetylation of its well documented downstream target p53 tumour suppressor 
protein (Vaziri et al., 2001, Cantó and Auwerx, 2009, Lee et al., 2012). On the 
contrary, Lau et al (2014) has proposed that AMPK activates SIRT1-mediated 
deacetylation of p53 (Lau et al., 2014). These studies were performed in two 
different types of cancer cells and demonstrate that the effect of AMPK activation 
on SIRT1 activity needs to be further investigated, particularly in a cell specific 
manner. Intriguingly, Nin et al., observed that in cells incubated with AMPK 
activators for a short period of time (1-2hrs) AMPK modulates SIRT1 activity 
without any changes in NAD+ levels, whereas Cantó and Auwerx had previously 
observed that in cells incubated (8-12 hrs) with AMPK activators for a long period 
of time (7-12hrs) AMPK modulates SIRT1 activity by altering NAD+ levels (Nin et 
al., 2012, Cantó and Auwerx, 2009). In this study, AMPK-mediated inhibition of 
STAT3 Try705 is detected in cell lysates prepared from cells incubated with AMPK 
101 
 
activator A769662 for 70 minutes (Figure 3.7). Overall, these data suggest that 
inhibition of IL-6-stimulated STAT3 Tyr705 phosphorylation by AMPK was not via 
SIRT1.  
3.8.5 Role of fatty acids  
Increased levels of fatty acids have been associated with endothelial dysfunction 
and fatty acids have been shown to affect the activity of kinases, such as protein 
kinase C and AMPK (Watt et al., 2006, Egan et al., 1999, Hennig et al., 1994). 
Recently, it was reported that free fatty acid palmitate significantly increased 
levels of STAT-3 phosphorylation in human aortic endothelial cells (Mugabo et al., 
2011), while activation of AMPK stimulates fatty acid oxidation in HUVECs (Dagher 
et al., 2001). Therefore, it was postulated that AMPK could inhibit IL-6 signalling 
by promoting fatty acid oxidation. AMPK stimulates fatty acid oxidation by 
phosphorylating and inhibiting ACC activity, thus leading to decreased formation 
of malonyl-CoA which inhibits CPT1 to block transfer of fatty acids into the 
mitochondria for oxidation (Lopaschuk et al., 1994, Merrill et al., 1997, Vavvas et 
al., 1997). Etomoxir, a pharmacological inhibitor of CPT1, was used to promote 
fatty acid oxidation in HUVECs in order to assess a role for fatty acid oxidation in 
mediating AMPK’s effects on STAT3 phosphorylation in HUVECs. Figure 3.8 
demonstrated that pharmacological inhibition of CPT1 in HUVECs did not 
attenuate the inhibitory effect of AMPK activation on STAT3 Tyr705 
phosphorylation. Thus, these data suggest that AMPK-mediated inhibition of STAT3 
Tyr705 phosphorylation was not via AMPK-induced fatty acid oxidation. It should 
be noted that CPT1 inhibition by Etomoxir and stimulation of fatty acid oxidation 
by AMPK was not confirmed, yet effective inhibition of fatty acid oxidation in 
HUVECs was achieved by colleagues using the same lot of Etomoxir (Ian Salt, 
personal communication). Overall, our results are inconclusive on whether AMPK-
mediated inhibition of sIL-6Rα/IL-6 signalling is via fatty acid oxidation.  
3.8.6 Role of mTOR 
mTOR is a serine/threonine kinase found as two structurally and functionally 
different complexes, mTORC1 and mTORC2, and regulates cell growth and 
proliferation. Inoki et al., demonstrated that AMPK inhibits mTORC1 activity by 
directly phosphorylating and activating tuberous sclerosis protein 2 (TSC2), a 
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negative regulator of mTOR (Inoki et al., 2003). Alternatively, Gwinn et al., 
demonstrated that AMPK directly phosphorylates raptor, a component of mTORC1, 
which suppressed mTORC1 activity. Gwinn et al., 2008). Studies utilising TSC2-
deficient cells or siRNA-mediated knockdown of TSC2 have reported an increase 
in STAT3 Tyr705 phosphorylation (Chen et al., 2012, Goncharova et al., 2009), 
whereas pharmacological inhibition of mTOR with rapamycin ameliorated STAT3 
Tyr705 phosphorylation and transcriptional activity (Onda et al., 2002, Weichhart 
et al. 2008). It was of important, therefore, to investigate the role of mTOR in 
AMPK-mediated inhibition of IL-6-stimulated STAT3 phosphorylation in HUVECs 
using the pharmacological mTORC1/2 inhibitor PP242. Figure 3.9 demonstrated 
that PP242-mediated inhibition of mTOR significantly (***p<0.001) reduced sIL-
6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation, however STAT3 Tyr705 
phosphorylation levels are further reduced by the addition of A769662. The same 
experiments performed in MEFs by our colleague Sarah Mancini demonstrated a 
significant reduction in IL-6 stimulated STAT3 Tyr705 phosphorylation in response 
to A769662, while inhibition of mTOR with PP242 induced a moderate reduction in 
STAT3 Tyr705 phosphorylation (Sarah Mancini, personal communication). It can be 
seen in figure 3.9 that PP242 successfully inhibited mTOR activity in HUVECs as 
indicated by p70 S6 kinase phosphorylation. However, A769662-mediated 
activation of AMPK was not found to reduce phosphorylation of p70 S6 kinase 
(Figure 3.9). This was unexpected as AMPK had been reported to inhibit mTOR 
phosphorylation of p70 S6 kinase (Kimura et al., 2003). To our knowledge, this is 
the first time mTOR inhibition has been linked to a reduction in STAT3 
phosphorylation in HUVECs, and supports previous studies that reported that 
inhibition of mTOR with rapamycin suppressed STAT3 phosphorylation in other cell 
types (Weichhart et al., 2008, Onda et al., 2002, Goncharova et al., 2009, Chen 
et al., 2012). In HUVECs, PP242 mediated inhibition of IL-6 stimulation of STAT3 
Tyr705 phosphorylation was further reduced by the addition of A769662. Taken 
together, these data suggest that both AMPK activation and mTOR inhibition 
suppress IL-6-stimulated STAT3 phosphorylation, and this is likely to occur via 
mutually exclusive mechanisms. Overall, these data suggest that inhibition of IL-
6-stimulated STAT3 Tyr705 phosphorylation by AMPK was not via mTOR. 
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3.8.7 Effect of serum starvation  
To examine whether performing the experiments in the absence or presence of 
serum could affect our results, experiments investigating the effects of CPT1 
inhibitor Etomoxir, SIRT1 inhibitor EX527 and mTOR inhibitor PP242 on AMPK-
mediated inhibition of IL-6 signalling were conducted under both serum-
supplemented and serum-deprived conditions. It is recognised that the cell culture 
medium (endothelial cell growth medium and basal medium 199) used to create 
these conditions have additional differences other than serum, but for 
simplification these conditions are assigned as serum-supplemented and serum-
deprived. Overall, AMPK significantly inhibits sIL-6Rα/IL-6 stimulated STAT3 Tyr705 
phosphorylation in both serum-supplemented and serum-deprived conditions, 
though serum-deprivation appears to potentiate AMPK’s ability to inhibit STAT3 
Tyr705 phosphorylation (Table 3.1). It could be suggested that the serum 
supplements increased STAT3 Tyr705 phosphorylation or that serum-deprivation 
increased AMPK activation, however detailed analysis of AMPK activation or sIL-
6Rα/IL-6 stimulation under these conditions was not carried out and as noted 
earlier serum is not the only variable between the two conditions, thus definitive 
conclusions could not be made. Nevertheless, we have clearly demonstrated that 
under serum-deprived conditions, AMPK-mediated inhibition of STAT3 Tyr705 
phosphorylation is increased. 
Overall, the key findings of this chapter suggest that AMPK activation in HUVECs 
inhibited sIL-6Rα/IL-6 stimulated STAT3 Tyr705 phosphorylation via a mechanism 
independent of TC-PTP, eNOS, PKC, SIRT1 and mTOR. Furthermore, inhibition of 
mTOR and eNOS reduced sIL-6Rα/IL-6 stimulated STAT3 Tyr705 phosphorylation, 
independent of AMPK activation by A769662. However, it is noted that due to 
limitations in these studies it is not possible to draw definitive conclusions. One 
limitation is that siRNA-mediated knockdown of TC-PTP, eNOS and PKCλ was poor 
as immunoblotting with the appropriate specific antibody demonstrated that TC-
PTP, eNOS and PKCλ proteins levels was reduced to only 40%, 50% and 60%, 
respectively. A second limitation is that a positive control for pharmacological 
inhibition of each target, except mTOR, was not included in each study. Although, 
pharmacological inhibitors were used under the same conditions that had 
previously been shown to effectively inhibit its target (these studies are 
referenced in the results section). Another limitation is that in studies utilising 
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pharmacological inhibitors, the total levels of the target protein was not assessed. 
Therefore, STAT3 Tyr705 phosphorylation levels may have been effected by 
changes in target protein levels. 
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Table 3-1: Percentage (%) inhibition of sIL-6Rα/IL-6 stimulated STAT3 Tyr705 phosphorylation 
by AMPK in vehicle pre-treated HUVECs under both serum-supplemented and serum-
deprived conditions.  
Experiments investigating the effects of Etomoxir, EX527 and PP242 on AMPK-mediated inhibition 
of IL-6 signalling were conducted under both serum-supplemented and serum-deprived conditions. 
STAT3 phosphorylation data were first normalized to total STAT3 levels and expressed as a 
percentage (%) inhibition of STAT3 phosphorylation relative to maximal sIL-6Rα/IL-6 stimulation 
attained in vehicle pre-treated HUVECs. Data shown represent the mean ± SEM of three 
independent experiments 
  
Experiment 
Serum-
supplemented 
Serum -
deprived 
supplemented vs 
deprived  
(P-value) 
% inhibition of STAT3 Tyr705 
phosphorylation by AMPK 
PP242 27 ± 5 71 ± 6 ***p<0.001 
Etomoxir 38 ± 5 66 ± 10 *p<0.05 
EX527 48 ± 8 85 ± 5 ***p<0.001 
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Chapter 4 - Molecular mechanism of AMPK mediated 
inhibition of IL-6 signalling: direct phosphorylation 
of JAK1 
4.1 Introduction 
4.1.1 Regulation of the JAK-STAT pathway by AMPK  
At this point in the study, AMPK did not appear to act via a known regulator of 
JAK-STAT signalling, or an AMPK downstream target known to either directly or 
indirectly impact on JAK-STAT signalling. Therefore, the next line of inquiry was 
to assess whether AMPK could act directly on components of the JAK-STAT 
pathway. Preliminary investigations of the effects of AMPK on JAK-STAT signalling 
demonstrated that the inhibitory effect of AMPK on sIL-6R/IL-6 responses was 
not restricted to STAT3, as pre-incubation of HUVECs with AMPK activator, 
A769662, also abrogated sIL-6R/IL-6-stimulated phosphorylation of STAT1 (Figure 
6.5B). A769662 also suppressed STAT3 phosphorylation in response to IFN, which 
activates STATs via an IFNAR1/IFNAR2 complex distinct from the receptor complex 
formed by gp130 (Borden et al., 2007) (Figure 6.5A). These results suggested that 
AMPK was exerting its inhibitory effects at one or more common signalling loci 
downstream of IFNAR1/IFNAR2 and gp130 at a post-receptor level. AMPK is a 
Ser/Thr-directed protein kinase for which numerous distinct substrates continue 
to be identified (Schaffer et al., 2015). Thus, it was hypothesised that AMPK could 
directly phosphorylate serine or threonine residues within one or more JAKs to 
inhibit sIL-6R/IL-6 signalling. 
4.1.2 Aims 
The aims of this chapter were to determine whether or not one or more JAK 
isoforms were substrates of AMPK, assess whether AMPK-mediated phosphorylation 
of JAKs is required for inhibition of IL-6 signalling, and elucidate how AMPK 
phosphorylation of JAK might inhibit downstream signalling. 
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4.2 Results 
4.2.1 Effect of JAK isoform knockdown on JAK-STAT signalling 
The JAK-STAT signalling pathway can be activated in a variety of different cell 
types and within each cell type each cytokine activates a distinct subset of JAKs 
and STATs (Murray, 2007). In HUVECs, the individual components of the IFN-α or IL-
6-induced JAK-STAT signalling pathway have yet to be clearly defined. Therefore, 
before investigating a role for JAKs as targets of AMPK’s effect, the JAK isoform(s) 
through which IL-6 and IFN-α predominantly signal downstream in HUVECs needed 
to be identified.  
4.2.1.1 Efficiency of JAK siRNA transfection of HUVECs 
To begin testing this, a siRNA approach was used to specifically knockdown the 
expression of JAK1, JAK2 or TYK2 in order to investigate their individual 
contribution to IL-6- and IFN-α-stimulated downstream signalling. HUVECs express 
all four members of the JAK family, however the contribution of JAK3 was not 
investigated as expression levels are at a low basal level and a physiological role 
for JAK3 has not been shown in HUVECs (Verbsky et al., 1996). Control non-
targeting siRNA and siRNA targeting each JAK isoform were separately transiently 
transfected into HUVECs for 48 hours prior to stimulation with either sIL-6Rα/IL-6 
(25 ng/ml, 5 ng/ml) or IFN-α (25000 units/ml) for 30 or 15 minutes, respectively. 
In comparison to HUVECs treated with control siRNA, transfection of HUVECs with 
JAK1 siRNA significantly reduced JAK1 expression by 66 ± 11% (***p<0.001) (Figure 
4.1). Similarly, transfection of HUVECs with JAK2 siRNA significantly reduced JAK2 
expression by 60 ± 6% (***p<0.001) (Figure 4.2) and transfection of HUVECs with 
TYK2 siRNA significantly reduced TYK2 expression by 52 ± 7% (***p<0.001) (Figure 
4.3). JAK1, JAK2 and TYK2 protein levels did not alter significantly with sIL-
6Rα/IL-6 or IFN-α treatment. Overall, the siRNAs were effective in knocking down 
specific JAK isoforms. 
4.2.1.2 Effect of JAK isoform knockdown on sIL-6Rα/IL-6 and IFN-α 
signalling in HUVECs. 
IL-6 and IFN-α can each trigger STAT1 and STAT3 phosphorylation at Tyr701 and 
Tyr705, respectively, which are required for STAT1 and STAT3 activation 
respectively and can therefore be used as surrogate markers for their activation 
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(Shuai et al., 1994, Kaptein et al., 1996). Therefore, to determine the effect of 
JAK knockdown on sIL-6Rα/IL-6 and IFN-α signalling in HUVECs, whole-cell extracts 
were immunoblotted with phospho-STAT1 (Tyr701) and total-STAT1 or phospho-
STAT3(Tyr705) and total-STAT3 antibodies. 
In comparison to control siRNA-treated HUVECs, JAK1 siRNA treatment 
significantly inhibited sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation by 
61 ± 7% (***p<0.001) (Figure 4.4). In contrast, JAK2 siRNA treatment significantly 
inhibited sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation by only 20 ± 5% 
(**p<0.01) (Figure 4.5) and TYK2 siRNA treatment produced a statistically 
insignificant 7 ± 2% (p>0.05, NS) inhibition of sIL-6Rα/IL-6-stimulated STAT3 Tyr705 
phosphorylation (Figure 4.6). For each JAK siRNA transfection, sIL-6Rα/IL-6 
stimulation of STAT3 Tyr705 phosphorylation in untreated HUVECs compared with 
control siRNA treated HUVECs demonstrated that control siRNA treatment did not 
significantly alter sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation (Figure 
4.4, 4.5 and 4.6). Altogether, these data suggest that sIL-6Rα/IL-6 stimulation of 
STAT3 phosphorylation on Tyr705 mainly requires activation of JAK1 with some 
contribution of JAK2, and no contribution of TYK2 detectable. 
For both JAK1 and JAK2 siRNA experiments, IFN-α stimulation of HUVECs treated 
with control siRNA did not significantly stimulate STAT3 Tyr705 phosphorylation 
beyond the basal levels produced by unstimulated cells treated with control siRNA 
(Figure 4.4 and 4.5). For the TYK2 experiments, IFN-α stimulation of STAT3 Tyr705 
phosphorylation was found to be variable between and within individual 
experiments and therefore the data was inconclusive (Figure 4.6). As IFN-α signals 
predominantly through STAT1, immunoblots were also probed with antibodies 
versus phospho-STAT1 (Tyr701) and total-STAT1 (Ramana et al., 2000) (Figure 4.8). 
In comparison to untreated HUVECs, transfection of HUVECs with siRNA increased 
total STAT1 levels. Overall, it was not possible to compare the effects of JAK 
knockdown on STAT1 Tyr701 phosphorylation or IFN-α signalling. However previous 
reports have demonstrated IFN-α signals through JAK1 and TYK2 in multiple cell 
types (Borden et al., 2007, Gauzzi et al., 1996). Thus in conjunction with my data, 
JAK1 was identified as a common post receptor intermediately downstream of 
both IL-6 and IFN-α signalling.   
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Figure 4.1: siRNA-mediated knockdown of JAK1 isoform expression in HUVECs  
HUVECs were transfected with either 10nM JAK1 or control siRNA 48hrs prior to stimulation with or 
without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) or 25000 units/ml IFN-α for either 30 or 15 
minutes, respectively. Control siRNA was used as a negative control. Protein-equalised cell extracts 
were then analysed by SDS-PAGE and immunoblotting with antibodies specific for total JAK1 and 
GAPDH as indicated. GAPDH served as a loading control. Total JAK1 protein levels were first 
normalized to GAPDH levels and expressed as a percentage (%) of the maximal protein levels 
attained in unstimulated control siRNA transfected HUVECs (set at 100%). Quantitative analysis 
from three experiments is presented. Columns are means ±SEM, *** p<0.001. A representative blot 
from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC   
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Figure 4.2: siRNA-mediated knockdown of JAK2 isoform expression in HUVECs 
HUVECs were transfected with either 10nM JAK2 or control siRNA 48hrs prior to stimulation with or 
without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) or 25000 units/ml IFN-α for either 30 or 15 
minutes, respectively. Control siRNA was used as a negative control. Protein-equalised cell extracts 
were then analysed by SDS-PAGE and immunoblotting with antibodies specific for total JAK2 and 
GAPDH as indicated. GAPDH served as a loading control. Total JAK2 protein levels were first 
normalized to GAPDH levels and expressed as a percentage (%) of the maximal protein levels 
attained in unstimulated control siRNA transfected HUVECs (set at 100%). Quantitative analysis 
from three experiments is presented. Columns are means ±SEM, *** p<0.001. A representative blot 
from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC   
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Figure 4.3: siRNA-mediated knockdown of TYK2 isoform expression in HUVECs 
HUVECs were transfected with either 10nM TYK2 or control siRNA 48hrs prior to stimulation with or 
without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) or 25000 units/ml IFN-α for either 30 or 15 
minutes, respectively. Control siRNA was used as a negative control. Protein-equalised cell extracts 
were then analysed by SDS-PAGE and immunoblotting with antibodies specific for total TYK2 and 
GAPDH as indicated. GAPDH served as a loading control. Total TYK2 protein levels were first 
normalized to GAPDH levels and expressed as a percentage (%) of the maximal protein levels 
attained in unstimulated control siRNA transfected HUVECs (set at 100%). Quantitative analysis 
from three experiments is presented. Columns are means ±SEM, *** p<0.001. A representative blot 
from n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC 
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Figure 4.4: Effect of JAK1 isoform knockdown on sIL-6R/IL-6-stimulated STAT3 tyrosine 
(705) phosphorylation in HUVECs. 
HUVECs were transfected with either 10nM JAK1 or control siRNA 48hrs prior to stimulation with or 
without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) or 25000 units/ml IFN-α for either 30 or 15 
minutes, respectively. Control siRNA was used as a negative control. Protein-equalised cell extracts 
were then analysed by SDS-PAGE and immunoblotting with antibodies specific for phospho-STAT3 
(Tyr705) and total STAT3 as indicated. STAT3 phosphorylation data were first normalized to total 
STAT3 levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation attained 
in control siRNA transfected HUVECs (set at 100%). Quantitative analysis from three experiments is 
presented. Columns are means ±SEM, *** p<0.001. A representative blot from n=3 experiments is 
shown. n=3 from one batch of pooled donor HUVEC 
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Figure 4.5: Effect of JAK2 isoform knockdown on sIL-6R/IL-6-stimulated STAT3 tyrosine 
(705) phosphorylation in HUVECs. 
HUVECs were transfected with either 10nM JAK2 or control siRNA 48hrs prior to stimulation with or 
without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) or 25000 units/ml IFN-α for either 30 or 15 
minutes, respectively. Control siRNA was used as a negative control. Protein-equalised cell extracts 
were then analysed by SDS-PAGE and immunoblotting with antibodies specific for phospho-STAT3 
(Tyr705) and total STAT3 as indicated. STAT3 phosphorylation data were first normalized to total 
STAT3 levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation attained 
in control siRNA transfected HUVECs (set at 100%). Quantitative analysis from three experiments is 
presented. Columns are means ±SEM, *** p<0.001, **p<0.01. A representative blot from n=3 
experiments is shown. n=3 from one batch of pooled donor HUVEC 
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Figure 4.6: Effect of TYK2 isoform knockdown on STAT3 (705) tyrosine phosphorylation in 
HUVECs 
HUVECs were transfected with either 10nM TYK2 or control siRNA 48hrs prior to stimulation with or 
without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) or 25000 units/ml IFN-α for either 30 or 15 
minutes, respectively. Control siRNA was used as a negative control. Protein-equalised cell extracts 
were then analysed by SDS-PAGE and immunoblotting with antibodies specific for phospho-STAT3 
(Tyr705) and total STAT3 as indicated. STAT3 phosphorylation data were first normalized to total 
STAT3 levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation attained 
in control siRNA transfected HUVECs (set at 100%). Quantitative analysis from three experiments is 
presented. Columns are means ±SEM, not significant (NS), p>0.05 A representative blot from n=3 
experiments is shown. n=3 from one batch of pooled donor HUVEC   
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Figure 4.7: The effect of JAK isoform knockdown on STAT3 tyrosine (705) phosphorylation 
in HUVECs.  
HUVECs were transfected with either 10nM JAK1 or 10nM JAK2 or 10nM Tyk2 siRNA 48hrs prior to 
stimulation with or without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for 30 minutes. Control 
siRNA was used as a negative control. Protein-equalised cell extracts were then analysed by SDS-
PAGE and immunoblotting with antibodies specific for phospho-STAT3 (Tyr705) and total STAT3. 
STAT3 phosphorylation data were first normalized to total STAT3 levels and expressed as a 
percentage (%) inhibition of STAT3 phosphorylation relative to maximal sIL-6Rα/IL-6 stimulation 
attained in control siRNA transfected HUVECs. Quantitative analysis from three experiments is 
presented. Columns are means ±SEM, p>0.05 NS, **p<0.01 *** p<0.001. 
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Figure 4.8: Effect of JAK isoform knockdown on total STAT1 expression in HUVECs 
HUVECs were transfected with either 10nM JAK1 or 10nM JAK2 or 10nM Tyk2 siRNA 48hrs prior to 
stimulation with or without 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) or 25000 units/ml IFN-α 
for either 30 or 15 minutes, respectively. Control siRNA was used as a negative control. Protein-
equalised cell extracts were then analysed by SDS-PAGE and immunoblotting with an antibody 
specific for total STAT1 as indicated. GAPDH served as a loading control. A representative blot from 
n=3 experiments is shown. n=3 from one batch of pooled donor HUVEC   
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4.2.2 AMPK phosphorylation of JAK-derived peptides in vitro 
4.2.2.1 AMPK phosphorylation of full-length human JAK peptides in vitro 
It was hypothesised that AMPK could directly phosphorylate JAK1 to inhibit both 
sIL-6Rα/IL-6 and IFN-α stimulation of STAT3 phosphorylation on Tyr705. To test 
whether AMPK could directly phosphorylate Ser or Thr residues in JAK, in vitro 
AMPK assays were carried out using immobilised libraries of 25-mer peptides 
overlapping by 5 residues that span the entire ORFs of human JAK1, JAK2, JAK3 
and TYK2 (kindly prepared by Professor G.S. Baillie [University of Glasgow]), and 
using AMPK purified from rat liver (Hawley et al., 1996, a generous gift from Prof. 
Grahame Hardie [University of Dundee]). 
Using automatic SPOT synthesis, the full length primary sequences of each of the 
human JAK isoforms (JAK1, JAK2, JAK3, Tyk2) were spotted onto nitrocellulose 
coated microscope slides in overlapping 25-mer peptides that spanned the entire 
open reading frames to produce immobilised libraries of peptides (Frank, 2002). 
Each consecutive 25-mer peptide is a 5 amino-acid shift of the previous peptide 
and is spotted in duplicate (schematic representation shown in Figure 4.9). 
Peptide arrays were then incubated in the absence or presence of purified active 
rat liver AMPK in the presence of [γ-32P] ATP. 32P-Phosphate incorporation was 
detected by autoradiography following exposure to X-ray film, with duplicate dark 
spots representing potential sites of peptide phosphorylation by AMPK.  
Figures 4.10, 4.12, 4.13 and 4.14 show the autoradiogram of the full length human 
JAK peptide arrays subjected to in vitro AMPK phosphorylation; areas of interest 
have been highlighted and then magnified for clarity.  Tables 6-1 to 6-4 found in 
the appendix details the layout of each peptide array and the amino acid 
sequences corresponding to each peptide spot. As a positive control, each peptide 
array slide contained a synthetic AMPK peptide substrate termed “SAMS peptide” 
(HMRSAMSGLHLVKRR) which is derived from residues 73- 85 on rat ACC1 which 
includes known AMPK site Ser79 (Davies et al., 1989). (Figure 4.10, 4.12-14, 
highlighted and magnified in green). In comparison to the peptide arrays 
incubated without active AMPK, the SAMS peptide spots on the arrays incubated 
with active AMPK are darker, confirming that the AMPK preparation used was 
catalytically active (Figure 4.10, 4.12-14, highlighted and magnified in green). 
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On the full length human JAK1 peptide array, a cluster of darker spots can be 
observed in the presence of AMPK but not in its absence (Figure 4.10, highlighted 
and magnified in red). These comprise four consecutive overlapping peptides; K-
N-F-Q-I-E-V-Q-K-G-R-Y-S508-L-H-G-S512-D-R-S515-F-P-S518-L-G, E-V-Q-K-G-R-Y-S508-L-
H-G-S512-D-R-S515-F-P-S518-L-G-D-L-M-S524-H, R-Y-S508-L-H-G-S512-D-R-S515-F-P-S518-L-
G-D-L-M-S524-H-L-K-K-Q-I and G-S512-D-R-S515-F-P-S518-L-G-D-L-M-S524-H-L-K-K-Q-I-
L-R-T-D-N, which appear to be phosphorylated by active AMPK (Figure 4.10). These 
overlapping peptides span five putative AMPK phosphoacceptor sites; Ser508, 
Ser512, Ser515, Ser518 and Ser524 (Figure 4.10). 
Alignment of the primary sequences of all four JAK isoforms identified a related 
sequence similarly positioned within the SH2 domain of each protein (Figure 4.11). 
These 25-mer peptides are highlighted and magnified in red on the full length 
JAK2, JAK3 and TYK2 peptide arrays (Figure 4.12, 4.13 and 4.14). 
On initial inspection, the full length human JAK2 peptide array incubated with 
active AMPK, did not appear to be detectably phosphorylated when compared with 
the JAK2 peptide array incubated without AMPK (Figure 4.12). However, closer 
inspection of the JAK2 25-mer peptide that aligns with the JAK1 25-mer peptide 
identified as phosphorylated by AMPK demonstrates that these spots are slightly 
darker when compared with the JAK2 peptide array incubated without AMPK 
(Figure 4.12, highlighted and magnified in red). These comprise three consecutive 
overlapping peptides; H-C-L-I-T-K-N-E-N-E-E-Y-N-L-S465-G-T467-K-K-N-F-S472-S473-L-
K, K-N-E-N-E-E-Y-N-L-S465-G-T467-K-K-N-F-S472-S473-L-K-D-L-L-N-C, E-Y-N-L-S465-G-
T467-K-K-N-F-S472-S473-L-K-D-L-L-N-C-Y-Q-M-E-T, which appear to be phosphorylated 
by active AMPK. These overlapping peptides span four putative AMPK 
phosphoacceptor sites; Ser465, Thr467, Ser472, and Ser473 (Figure 4.12). 
Full length human JAK3 and TYK2 peptide arrays were also subjected to in vitro 
phosphorylation by activated AMPK. However, no phosphorylation was detectable 
when compared to the corresponding peptide array incubated without active AMPK 
despite positive AMPK-dependent phosphorylation of SAMS peptide on each array 
slide (Figure 4.13 and 4.14). To confirm this observation, the JAK2, JAK3 and TYK2 
25-mer peptides that aligned with the JAK1 25-mer peptide identified as 
phosphorylated by AMPK were spotted on the same peptide arrays to allow for 
direct comparison (Figure 4.15). These demonstrated that AMPK only 
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phosphorylated the JAK2 25-mer peptide, E-Y-N-L-S465-G-T467-K-K-N-F-S472-S473-L-
K-D-L-L-N-C-Y-Q-M-E-T, but not the JAK3 and TYK2 25-mer peptides, T-F-L-L-V-G-
L-S444-R-P-H-S448-S449-L-R-E-L-L-A-T456-C-W-D-G-G and A-F-V-L-E-G-W-G-R-S523-F-P-
S526-V-R-E-L-G-A-A-L-Q-GC-L, respectively (Figure 4.15). Overall, these data 
suggest that SH2 domain-derived peptides from JAK1 and JAK2, but not JAK3 and 
Tyk2, can serve as substrates for phosphorylation by AMPK in vitro.  
4.2.2.2 Identification of AMPK phosphoacceptor sites within JAK1-derived 
peptides  
Thus far, the data suggests that JAK1 could potentially be a substrate of AMPK as 
AMPK phosphorylated a 25-mer peptide of JAK1 which contains five serine residues 
in vitro. To identify whether some or all of the five serine residues are 
phosphorylated by AMPK, in vitro AMPK phosphorylation assays were conducted 
using peptide arrays spotted with wild-type (WT) and serine-to-alanine mutated 
versions of the JAK1 25-mer peptide identified as an AMPK substrate. The chemical 
structure of alanine is identical to serine, except it is missing the -OH group and 
therefore alanine is “non-phosphorylatable”. Consistent with Figure 4.10, the WT 
JAK1 peptide, was phosphorylated by AMPK as highlighted by the darker spots that 
appear in the presence of AMPK (Figure 4.16). In contrast, a mutated peptide in 
which all five Ser residues have been replaced by non-phosphorylatable Ala 
residues abolished AMPK-dependent phosphorylation (Figure 4.16). Mutant JAK1 
peptides containing Ala substitutions at each individual Ser residue were also 
spotted on the array. It can clearly be seen that AMPK phosphorylated the mutant 
JAK1 peptides containing Ala substitution at Ser508, Ser512 or Ser524, whereas 
Ala substitution at either Ser515 or Ser518 appear to have reduced 
phosphorylation by AMPK (Figure 4.16). Mutant JAK1 peptides containing Ala 
substitutions at two or more Ser residue were also prepared. The mutant JAK1 
peptide containing Ala substitutions at Ser508, Ser512 and Ser524 appears to be 
phosphorylated by AMPK equivalently to WT peptide, whereas Ala substitution of 
both Ser515 and Ser518 abolished AMPK-dependent phosphorylation similarly to 
the peptide in which all five Ser residues were mutated to Ala (Figure 4.16). 
Overall, these data indicate that AMPK can phosphorylate the identified JAK1 25-
mer peptide in vitro at Ser515 and Ser518.   
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Figure 4.9: Schematic representation of full length human JAK peptide array  
Using automatic SPOT synthesis, the full length primary sequences of each of the human JAK 
isoforms (JAK1, JAK2, JAK3, Tyk2) were spotted onto nitrocellulose coated microscope slides in 
overlapping 25-mer peptides that spanned the entire open reading frames to produce immobilised 
libraries of peptides (Frank, 2002). Each consecutive 25-mer peptide is a 5 amino-acid shift of the 
previous peptide and is spotted in duplicate.  
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Figure 4.10: In vitro AMPK phosphorylation of JAK1 peptide arrays 
Peptide arrays consisting of consecutive 25-mer peptides spanning the human JAK1 reading frame 
were incubated in 1μCi/ml γ-32P-ATP and in the presence of 0.5U/ml activated AMPK at 30 °C for 30 
minutes. As a control, a peptide array was incubated in radiolabelled γ-32P-ATP alone. 
Phosphorylation was detected by incorporation of radiolabelled 32P and radioactive signals were 
captured by autoradiography following exposure to Kodak X-ray film, and dark spots represent 
positive areas of phosphorylation by AMPK. Positive areas of phosphorylation of JAK1 peptides by 
AMPK are highlighted and magnified in red. As a positive control, each peptide array contains a 
synthetic AMPK substrate called SAMS peptide (HMRSAMSGLHLVKRR), highlighted in green. A 
representative autoradiogram from n=3 experiments is shown.  
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Figure 4.11: Alignment of JAK1 25-mer peptide identified as phosphorylated by AMPK with 
JAK2, JAK3, and TYK2 
NCBI BLAST program was used to align the primary sequences all four JAK isoforms to identify the 
JAK2, JAK3 and TYK2 25-mer peptides that align with the JAK1 25-mer peptide identified as 
phosphorylated by AMPK  
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Figure 4.12: In vitro AMPK phosphorylation of JAK2 peptide arrays 
Peptide arrays consisting of consecutive 25-mer peptides spanning the human JAK2 reading frame 
were incubated in 1μCi/ml γ-32P-ATP and in the presence of 0.5U/ml activated AMPK at 30 °C for 30 
minutes. As a control, a peptide array was incubated in radiolabelled γ-32P-ATP alone. 
Phosphorylation was detected by incorporation of radiolabelled 32P and radioactive signals were 
captured by autoradiography following exposure to Kodak X-ray film, and dark spots represent 
positive areas of phosphorylation by AMPK. Positive areas of phosphorylation of JAK2 peptides by 
AMPK are highlighted and magnified in red. As a positive control, each peptide array contains a 
synthetic AMPK substrate called SAMS peptide (HMRSAMSGLHLVKRR), highlighted in green. A 
representative autoradiogram from n=3 experiments is shown.  
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Figure 4.13: In vitro AMPK phosphorylation of JAK3 peptide arrays 
Peptide arrays consisting of consecutive 25-mer peptides spanning the human JAK3 reading frame 
were incubated in 1μCi/ml γ-32P-ATP and in the presence of 0.5U/ml activated AMPK at 30 °C for 30 
minutes. As a control, a peptide array was incubated in radiolabelled γ-32P-ATP alone. 
Phosphorylation was detected by incorporation of radiolabelled 32P and radioactive signals were 
captured by autoradiography following exposure to Kodak X-ray film, and dark spots represent 
positive areas of phosphorylation by AMPK. Positive areas of phosphorylation of JAK3 peptides by 
AMPK are highlighted and magnified in red. As a positive control, each peptide array contains a 
synthetic AMPK substrate called SAMS peptide (HMRSAMSGLHLVKRR), highlighted in green. A 
representative autoradiogram from n=3 experiments is shown.  
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Figure 4.14: In vitro AMPK phosphorylation of TYK2 peptide arrays 
Peptide arrays consisting of consecutive 25-mer peptides spanning the human TYK2 reading frame 
were incubated in 1μCi/ml γ-32P-ATP and in the presence of 0.5U/ml activated AMPK at 30 °C for 30 
minutes. As a control, a peptide array was incubated in radiolabelled γ-32P-ATP alone. 
Phosphorylation was detected by incorporation of radiolabelled 32P and radioactive signals were 
captured by autoradiography following exposure to Kodak X-ray film, and dark spots represent 
positive areas of phosphorylation by AMPK. Positive areas of phosphorylation of TYK2 peptides by 
AMPK are highlighted and magnified in red. As a positive control, each peptide array contains a 
synthetic AMPK substrate called SAMS peptide (HMRSAMSGLHLVKRR), highlighted in green. A 
representative autoradiogram from n=3 experiments is shown.  
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Figure 4.15: In vitro AMPK phosphorylation of JAK SH2 domain-derived peptides  
Peptide arrays consisting of JAK2, JAK3 and TYK2 SH2 domain-derived peptides were incubated in 
1μCi/ml γ-32P-ATP and in the presence of 0.5U/ml activated AMPK at 30 °C for 30 minutes. As a 
control, a peptide array was incubated in radiolabelled γ-32P-ATP alone. Phosphorylation was 
detected by incorporation of radiolabelled 32P and radioactive signals were captured by 
autoradiography following exposure to Kodak X-ray film, and dark spots represent positive areas of 
phosphorylation by AMPK. A representative autoradiogram from n=3 experiments is shown.  
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Figure 4.16: In vitro AMPK phosphorylation of Ser-Ala mutated JAK1 peptides 
Peptide arrays consisting of WT and Ser-Ala mutated human JAK1 25-mer peptides were incubated 
in 1μCi/ml γ-32P-ATP and in the presence of 0.5U/ml activated AMPK at 30 °C for 30 minutes. As a 
control a peptide array was incubated in radiolabelled γ-32P-ATP alone. Phosphorylation was 
detected by incorporation of radiolabelled 32P and radioactive signals were captured by 
autoradiography following exposure to Kodak X-ray film, and dark spots represent positive areas of 
phosphorylation by AMPK. The Ser-Ala mutated putative phosphoacceptor sites for the 
serine/threonine AMPK are indicated in bold and underlined in each peptide sequence. The arrows 
highlight the Ser-Ala mutated JAK1 peptides which have abolished AMPK phosphorylation of JAK1 
peptide. A representative autoradiogram from n=3 experiments is shown.  
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4.2.3 Effect of AMPK activator A769662 on IL-6 signalling in human 
fibrosarcoma cells 
JAK1-null U4C human fibrosarcoma cells were derived from parental cell 24C by 
Muller et al., (1993). These cells were used to investigate the role of JAK1 
phosphorylation in AMPK-mediated inhibition of IL-6 signalling. First, the effects 
of A769662 on sIL-6R/IL-6 signalling in these cells had to be assessed to ensure 
that AMPK could inhibit JAK1-mediated phosphorylation of STAT3. To test this, 2C4, 
U4C and U4C.JAK1 cells (U4C.JAK1 are U4C-derived cell line in which JAK1 had 
been stably re-expressed (Guschin et al., 1995)) were pre-treated with vehicle or 
A769662 for 40 minutes followed by stimulation with vehicle or sIL-6Rα/IL-6 for 
30 minutes.  
JAK1, JAK2 and TYK2 levels were assessed by by immunoblotting cell extracts with 
total JAK1, JAK2 and TYK2 antibodies, respectively. JAK1 was expressed in 
parental cells 24C and JAK1 rescue cells U4C.JAK1, but JAK1 was absent in U4C 
cells (Figure 4.17A). JAK2 and TYK2 expression was detected in both 2C4 and U4C 
cells. In comparison to 2C4 cells, expression of TYK2 and JAK2 was unchanged by 
the loss of JAK1 (Figure 4.17B). Whole-cell extracts were also immunoblotted with 
phospho-STAT3 (Tyr705) and total-STAT3 antibodies. In comparison to vehicle 
treated 2C4 and U4C.JAK1 cells, sIL-6Rα/IL-6 substantially stimulated STAT3 
Tyr705 phosphorylation (Figure 4.17A). A769662 activation of AMPK substantially 
inhibited sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation in 2C4 and 
U4C.JAK1 cells (even in rescue cells when JAK is highly over expressed) (Figure 
4.17A). sIL-6Rα/IL-6 treatment of U4C cells did not stimulate STAT3 
phosphorylation (Figure 4.17A). Overall, the results were consistent with those of 
Guschin et al. (1995) and demonstrated that JAK1 was required for IL-6 signalling 
in human fibrosarcoma-derived cells. A769662 activated AMPK to inhibit IL-6 
signalling in 2C4 and U4C.JAK1 cells, thus the U4C cells were a potentially a 
valuable tool for investigating the role of JAK1 in AMPK-mediated inhibition of IL-
6 signalling.  
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4.2.4 Role of JAK1 Ser515 and Ser518 in AMPK-mediated inhibition of JAK1-
dependent signalling 
4.2.4.1 Role of JAK1 Ser515 and Ser518 in AMPK-mediated inhibition of IL-6 
signalling 
So far in the current study it has been demonstrated that AMPK inhibits sIL-6R/IL-
6 signalling, which is predominantly via JAK1, and that AMPK phosphorylates JAK1 
on Ser515 and Ser518 in vitro (Figure 4.7 and 4.16). To determine whether AMPK-
mediated inhibition of sIL-6R/IL-6 signalling is dependent on Ser515 and Ser518, 
a human JAK1 expression plasmid in which Ser515 and Ser518 were mutated to 
non phosphorylatable Ala (S515A/S518A) was generated. The effects of AMPK 
activation on sIL-6Rα/IL-6 signalling in JAK1-null U4C transiently expressing 
S515A/S518A mutant JAK1 were then examined. U4C cells were transfected with 
either an empty plasmid control pcDNA3.1, WT JAK1 or S515A/S518A mutant JAK1 
plasmid 48 hours prior to pre-treatment with vehicle or A769662 for 40 minutes 
followed by stimulation with vehicle or sIL-6Rα/IL-6 for 30 minutes.  
Immunoblotting of cell extracts with Total JAK1 antibody revealed equivalent 
expression levels of WT and S515A/S518A mutant JAK1 (Figure 4.18). In 
comparison to vehicle treated WT JAK1 and S515A/S518A mutant JAK1 expressing 
cells, sIL-6Rα/IL-6 significantly stimulated STAT3 Tyr705 phosphorylation by 66 ± 
6% (***p<0.01) in WT JAK1 expressing cells and by 67 ± 6% (***p<0.01) in 
S515A/S518A mutant JAK1 expressing cells, respectively (Figure 4.18) While 
A769662 activation of AMPK significantly inhibited sIL-6Rα/IL-6 stimulation of 
STAT3 Tyr705 phosphorylation by 57 ± 5% (***p<0.01) in cells expressing WT JAK1, 
treatment of S515A/S518A mutant JAK1 expressing cells with A769662 prior to sIL-
6Rα/IL-6 stimulation had no significant effect on sIL-6Rα/IL-6 stimulation of STAT3 
Tyr705 phosphorylation (Figure 4.18). Overall, these data suggested that Ser515 
and Ser518 were required for effective AMPK-mediated inhibition of IL-6 signalling 
to STAT3. 
4.2.4.2 Role of JAK1 Ser515 and Ser518 in AMPK-mediated inhibition of 
constitutively active Val658Phe JAK1 signalling 
A constitutively active Val658Phe-mutated version of JAK1 has been identified in 
some patients with acute lymphoblastic leukaemia (ALL) (Staerk et al., 2005, 
Jeong et al., 2008). In order to study the effects of AMPK activation on signalling 
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independently of cytokine receptor stimulation, a human JAK1 plasmid containing 
a Phe substitution at Val658 (V658F) was generated. Additionally, a human JAK1 
plasmid containing V658F, S515A and S518A mutations (V658F/S515A/S518A) was 
also generated in order to determine whether any AMPK-mediated effects on 
constitutively active V658F JAK1 signalling were dependent upon Ser515 and 
Ser518 in JAK1. The effects of AMPK activation on constitutively active V658F JAK1 
signalling in JAK1-null U4C cells, transiently expressing either V658F mutant or 
V658F/S515A/S518A mutant JAK1 were examined. In brief, U4C cells were 
transfected with either an empty control plasmid, WT JAK1, V658F mutant JAK1 
or V658F/S515A/S518A mutant JAK1 plasmid 48 hours prior to treatment with 
vehicle or A769662 for 40 minutes. 
Immunoblotting of cell extracts with total JAK1 antibody detected equal 
expression of JAK1 in U4C cells transfected individually with WT JAK1, V658F 
mutant JAK1 or V658F/S515A/S518A mutant JAK1 plasmid, whereas U4C cells 
transfected with empty plasmid control do not express JAK1 (Figure 4.19).. Whole-
cell extracts were also immunoblotted with phospho-STAT3 (Tyr705), total-STAT3, 
phospho-STAT1 (Tyr701), total-STAT1 and GAPDH antibodies, and subsequently 
protein levels were quantified by densitometry as shown in Figure 4.19. 
Transfection of JAK1-null U4C cells with V658F mutant JAK1 significantly increased 
phosphorylation of STAT1 Tyr701 and STAT3 Tyr705 by 94 ± 11% (***p<0.001) and 78 
± 9% (***p<0.001), respectively, compared to cells transfected with WT JAK1 
(Figure 4.19). Treatment of V658F mutant JAK1 transfected cells with A769662 
significantly reduced STAT1 Tyr701 and STAT3 Tyr705 phosphorylation by 57 ± 6% 
(***p<0.001) and 41 ± 5% (**p<0.01), respectively, relative to the absence of 
A769662 (Figure 4.19). In comparison to vehicle treated V658F mutant JAK1 
transfected cells, STAT1 Tyr701 and STAT3 Tyr705 phosphorylation was significantly 
reduced by 64 ± 7% (***p<0.001) and 46 ± 5% (***p<0.01), respectively, in vehicle 
treated cells transfected with V658F/S515A/S518A mutant JAK1 (Figure 4.19). 
Treatment of V658F/S515A/S518A JAK1 transfected cells with A769662 had no 
significant effect on STAT3 Tyr705 and STAT1Tyr701 phosphorylation, relative to 
the absence of A769662, as STAT3 Tyr705 and STA1 Tyr701phosphorylation was 
reduced by only 5 ± 1% (p>0.05,NS) and 4% (p>0.05,NS), respectively (Figure 4.19). 
Overall, these data suggest that Ser515 and Ser518 are required for AMPK-
mediated inhibition of constitutively active V658F JAK1 signalling.  
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Figure 4.17: Effect of A769662 on sIL-6Rα/IL-6 stimulation of STAT3 tyrosine (705) 
phosphorylation in human fibrosarcoma cells.  
2C4, U4C, and U4C.JAK1 cells were pre-treated with vehicle or 100µM A769662 for 40 minutes 
followed by stimulation with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 
30 minutes. Protein-equalised cell extracts were then analysed by SDS-PAGE and immunoblotting 
with antibodies as indicated. (A) Immunoblotting with antibodies specific for phospho-STAT3 
(Tyr705), total STAT3, phospho-ACC (Ser79) and total JAK1 as indicated. (B) Immunoblotting with 
antibodies specific for JAK2 and TYK2 as indicated. 
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Figure 4.18: Role of JAK1 Ser515 and Ser518 in AMPK-mediated inhibition of IL-6 signalling.  
JAK1-null U4C cells were transfected with either wild type JAK1 or S515A/S518A mutant JAK1 48 
hours prior to pre-treatment with vehicle or 100µM A769662 for 40 minutes followed by stimulation 
with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for a further 30 minutes. Protein-
equalised cell extracts were then analysed by SDS-PAGE and immunoblotting with antibodies 
specific for phospho-STAT3 (Tyr705), total STAT3, phospho-ACC (Ser79) and total JAK1 as 
indicated. Immunoblots were probed for total JAK1 to confirm equivalent expression of WT and 
mutated JAK1 in transfected cells. STAT3 phosphorylation data were first normalized to total STAT3 
levels and expressed as a percentage (%) of the maximal sIL-6Rα/IL-6 stimulation attained in vehicle 
pre-treated U4C cells transiently expressing either WT JAK1 or S515518A JAK1 (Set at 100%). 
Quantitative analysis from three experiments is presented. Columns are means ±SEM. *** p<0.01. 
A representative blot from n=3 experiments is shown.   
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Figure 4.19: Effect of AMPK activation on constitutively active V658F-mutated JAK1-
meditated STAT3 phosphorylation on Tyr705 
JAK1-null U4C cells were transfected with either wild type JAK1, V658F mutant JAK1 or 
V658F/S515A/S518A mutant JAK1 48 hours prior to treatment with vehicle or 100µM A769662 for 
40 minutes. Protein-equalised cell extracts were then analysed by SDS-PAGE and immunoblotting 
with antibodies specific for phospho-STAT1 (Tyr701), total STAT1, phospho-STAT3 (Tyr705), total 
STAT3, Phospho-ACC (Ser79), total JAK1 and GAPDH as indicated. Immunoblots were probed for 
total JAK1 to confirm expression of JAK1. STAT1 and STAT3 phosphorylation data were first 
normalized to total STAT1 and STAT3 levels respectively, and expressed as a percentage (%) of the 
maximal phosphorylation levels attained in vehicle pre-treated U4C cells transiently expressing 
V658F JAK1 (set at 100%). Quantitative analysis from three experiments is presented. Columns are 
means ±SEM. ** p<0.01, *** p<0.01. A representative blot from n=3 experiments is shown.  
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4.2.5 14-3-3 binding as a strategy to detect AMPK phosphorylated JAK1 
A common mechanism for phosphorylation-mediated regulation of target protein 
function is phosphorylation-dependent binding to members of the 14-3-3 family of 
proteins (Bridges and Moorhead, 2005). The 14-3-3 family proteins bind to 
phosphoserine- and phosphothreonine-containing proteins and two consensus 14-
3-3 binding phosphopeptide motifs, RXXpS/pTXP and RXXXpS/pTXP, have been 
identified (Yaffe et al., 1997). AMPK phosphorylation of either Ser515 or Ser518 
within JAK1 creates a phosphopeptide motif that shares similarities with these 14-
3-3 binding motifs.   
4.2.5.1 14-3-3ζ binding of JAK1 phospho-peptides  
To assess whether phosphorylation of Ser515 and Ser518 could facilitate JAK1 
interaction with 14-3-3 protein in vitro, a peptide array spotted four times with 
the 25-mer JAK1 peptide, R-Y-S-L-H-G-S-D-R-S515-F-P-S518-L-G-D-L-M-S-H-L-K-K-Q-
I, phosphorylated at either or both of Ser515 and Ser518 was overlaid with HRP-
conjugated 14-3-3. As a positive control, the peptide array was spotted four 
times with the high-affinity non-phosphorylated ligand of 14-3-3, P-H-C-V-P-R-D-
L-S-W-L-D-L-E-A-N-M-C-L-P (termed R18), and as a negative control, the low-
affinity non-phosphorylated peptide ligand of 14-3-3, R-F-T-T-Q-G-E-R-G-I-T-H-L-
R-E-S-S-T-L-G (termed C01) was also spotted four times (Wang et al., 1999).  
As shown in Figure 4.20, HRP-14-3-3ζ-bound positive control peptide R18 but not 
negative control peptide C01. On the same arrays, HRP-14-3-3ζ did not bind either 
the non-phosphorylated JAK1 peptide or the peptide in which both Ser515 and 
Ser518 were phosphorylated (Figure 4.20). However, HRP-14-3-3ζ did bind JAK1 
peptide when monophosphorylated at either Ser515 or Ser518. In addition, the 
signal from bound HRP-14-3-3ζ was substantially stronger with the phospho-Ser515 
JAK1 peptide versus the phospho-Ser518 JAK1 peptide (Figure 4.20). In addition, 
the peptide array was also spotted four times with the 25-mer JAK-2 peptide, E-
Y-N-L-S465-G-T-K-K-N-F-S472-S473-L-K-D-L-L-N-C-Y-Q-M-E-T, phosphorylated at either 
or all three of Ser465, Ser472 and Ser473, and overlaid with HRP-14-3-3ζ to assess 
whether phosphorylation of these sites could facilitate JAK2 interaction with 14-
3-3 protein in vitro. HRP-14-3-3ζ bound to non-phosphorylated JAK2 peptide and 
phospho-Ser465 JAK2 peptide, and did not bind phospho-Ser472 or phospho-Ser473 
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JAK2 peptide (Figure 4.20). The signal from bound HRP-14-3-3ζ was stronger with 
the non-phosphorylated JAK2 peptide versus the phospho-Ser465 JAK2 peptide 
(Figure 4.20). Overall, these observations demonstrate that 14-3-3ζ interacts with 
JAK1 peptide at either phospho-Ser515 or phospho-Ser518, but not when both sites 
are phosphorylated. 14-3-3ζ also interacts with non-phosphorylated JAK2 peptide 
and phospho-Ser465 JAK2 peptide, but not with phospho-Ser472 or phospho-
Ser473 JAK2 peptides. 
4.2.5.2 Development of a GST/14-3-3 pull down assay for detecting AMPK 
phosphorylated JAK1 in intact cells 
Having demonstrated that phospho-Ser515 and phospho-Ser518 peptides strongly 
interacted with HRP-14-3-3 in vitro (Figure 4.20), bacterially expressed and 
purified GST-tagged 14-3-3ζ was used in pull down assays to detect AMPK-mediated 
phosphorylation of Ser515 and Ser518 in JAK1 in intact cells. Initial experiments 
in JAK1-null U4C human fibrosarcoma cells stably expressing recombinant JAK1 
(U4C.JAK1) demonstrated that GST-14-3-3ζ, but not GST alone, could specifically 
isolate JAK1 (Figure 4.21A). GST-14-3-3ζ was used in pull down assays with cell 
lysates produced from JAK1-null U4C cells transfected with either an empty 
plasmid control, WT JAK1 or S515A/S518A mutant JAK1 plasmid 48 hours prior to 
treatment with or without A769662. To assess levels of JAK1 protein captured by 
GST/14-3-3ζ, pull downs were immunoblotted with total JAK1 antibody. As shown 
in Figure 4.21B, GST-14-3-3ζ appears to bind basal levels of JAK1 in untreated WT 
JAK1 transfected cells. Upon treatment of WT JAK1 transfected cells with 
A769662, the amount of WT JAK1 bound by GST-14-3-3ζ was significantly (*p<0.05) 
increased (Figure 4.21C). In contrast, the amount of S515A/S518A mutant JAK1 
bound by GST-14-3-3ζ following A769662 treatment was significantly (*p<0.05) 
reduced (Figure 4.21C). Whole cell extracts were probed for total JAK1 and 
phospho-ACC to confirm that the levels of WT and S515A/S518A mutant expression 
were similar in transfected cells, and that A769662 activated AMPK equally (Figure 
4.21B). Overall, these data demonstrate that A769662 activates AMPK to promote 
14-3-3 binding of JAK1 in vitro, and confirms that Ser515 and Ser518 are critical 
for this interaction. The data shown in figure 4.21 was generated and analysed by 
Dr Claire Rutherford, University of Glasgow.  
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Figure 4.20: 14-3-3ζ binding of JAK1 and JAK2 phospho-peptides  
Peptide arrays consisting of Ser phosphorylated JAK1 and JAK2 25-mer peptide identified as 
potential AMPK phosphorylation sites was overlaid with HRP-conjugated recombinant human 14-3-
3ζ. Reactive spots were visualised using Perkin-Elmer enhanced chemiluminescence (ECL) 
detection reagents, according to the manufacturer’s instructions. The positive control, R18, and 
negative control, C01, peptides for 14-3-3ζ interaction were taken from Wang et al. Biochemistry 
(1999). Each 25-mer peptide was spotted four times on the glass slide. A representative blot from 
n=3 experiments is shown. 
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Figure 4.21: AMPK-mediated phosphorylation of JAK1 in intact cells. 
(A) Untreated U4C.JAK1 extracts were prepared and used in a pull-down assay using either GST or 
GST-14-3-3ζ as indicated. Protein complexes eluted from beads and whole-cell extracts (input) were 
then fractioned by SDS-PAGE for immunoblotting with antibodies specific for total JAK1 as indicated. 
Blot from n=1 experiment (B & C) JAK1-null U4C cells were transfected with either WT JAK1, 
S515A/S518A mutant JAK1, or an empty control expression plasmid 48 hours prior to treatment with 
or without 100µM A769662 AMPK activator for 40 minutes. Protein-equalised cell extracts were 
prepared and used in a pull-down assay using GST-14-3-3ζ. Protein complexes eluted from beads 
and whole-cell extracts (input) were then fractioned by SDS-PAGE for immunoblotting with 
antibodies specific for total JAK, phospho-ACC (Ser79) and GST as indicated. JAK1 pull-down levels 
were first normalized to total JAK1 and expressed as a percentage (%) of the maximal JAK1 pull-
down levels attained in vehicle pre-treated U4C cells transiently expressing WT JAK1. Quantitative 
analysis from three experiments is presented. Columns are means ±SEM. *p<0.05. A representative 
blot from n=3 experiment is shown. (Data generated and analysed by Dr Claire Rutherford, University 
of Glasgow)  
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4.2.6 Effect of A769662 on JAK1 tyrosine phosphorylation. 
4.2.6.1 Effect of sIL-6Rα/IL-6 on JAK1 phosphorylation  
Having established that STAT3 is predominantly activated by sIL-6Rα/IL-6 via JAK1 
in HUVECs, it was hypothesised that AMPK inhibits sIL-6Rα/IL-6 stimulation of 
STAT3 Tyr705 phosphorylation by inhibiting tyrosine phosphorylation of its 
predominant upstream activator, JAK1. sIL-6Rα/IL-6 induces JAK1 phosphorylation 
at Tyr1022/1023, an event which is required for JAK1 activation (Liu et al. 1997). 
To test this hypothesis, HUVECs were pre-treated with either vehicle or A769662, 
followed by stimulation with vehicle or sIL-6Rα/IL-6 for either 5 or 15 minutes. 
Whole-cell extracts were then immunoprecipitated with total-JAK1 antibody, 
fractionated by SDS-PAGE and immunoblotted with phospho-JAK1 (Tyr1022/1023) 
antibody and total-JAK1 antibody. Immunoblotting with total-JAK1 antibody 
revealed bands corresponding to approximately 130 kDa confirming that equal 
levels of JAK1 had been successfully immunoprecipitated (Figure 4.22). However, 
it was not possible to successfully detect sIL-6Rα/IL-6 stimulated JAK1 
Tyr1022/1023 phosphorylation in HUVECs using Santa Cruz and Invitrogen phospho-
specific antibodies against these sites on JAK1(Figure 4.22). As can be seen in 
Figure 4.22, phospho-JAK1 antibody typically failed to detect phospho-JAK1 either 
after enrichment of JAK1 by immunoprecipitation or in whole cell extracts. Thus, 
it was not possible to deduce any information from these experiments.  
As an alternative approach to detect tyrosine phosphorylated JAK1, anti-phospho-
tyrosine 4G10 monoclonal antibody was used to probe JAK1 immunoprecipitates. 
An initial time course of sIL-6R/IL-6 stimulation of JAK1 tyrosine phosphorylation 
was conducted (Figure 4.23). HUVECs were treated with or without sIL-6Rα/IL-6 
for 5, 15 and 30 minutes. Whole-cell extracts were then immunoprecipitated with 
total JAK1 antibody, fractionated by SDS-PAGE and immunoblotted with anti-
phospho-tyrosine 4G10 monoclonal antibody and total JAK1 antibody (Figure 
4.23). Probing with 4G10 can theoretically detect multiple phosphorylated Tyr 
residues in different contexts and is therefore not specific for JAK1 Tyr 1022/1023. 
Low basal tyrosine phosphorylation levels of JAK1 were detected in HUVECs. sIL-
6Rα/IL-6 stimulation of JAK1 tyrosine phosphorylation peaked at 15 minutes and 
remained above basal levels 30 minutes post-stimulation (Figure 4.23). The 
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hypothesis being tested was whether AMPK could inhibit sIL-6Rα/IL-6 stimulation 
of STAT3 Tyr705 phosphorylation by inhibiting tyrosine phosphorylation of its 
predominant upstream activator, JAK1. To test this hypothesis, HUVECs were pre-
treated with either vehicle or A769662, followed by stimulation with vehicle or 
sIL-6Rα/IL-6 for either 5 or 15 minutes. Whole-cell extracts were 
immunoprecipitated with total JAK1 antibody, followed by immunoblotting with 
anti-phospho-tyrosine antibody 4G10. In comparison to the basal levels of JAK1 
tyrosine phosphorylation detected in unstimulated HUVECs, sIL-6Rα/IL-6 
stimulation of HUVECs for 5 minutes appeared to have no detectable effect on 
JAK1 tyrosine phosphorylation, whereas sIL-6Rα/IL-6 stimulation for 15 minutes 
marginally increased JAK1 tyrosine phosphorylation levels (Figure 4.24). 
Treatment of HUVECs with A769662 prior to sIL-6Rα/IL-6 stimulation for 15 
minutes appears to slightly reduce JAK1 tyrosine phosphorylation (Figure 4.24). 
This would suggest that AMPK activation can inhibit sIL-6Rα/IL-6 stimulation of 
JAK1 tyrosine phosphorylation. Whole-cell extracts were also immunoblotted with 
phospho-STAT3 (Tyr705) and total-STAT3 antibodies to confirm AMPK-mediated 
inhibition of sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation (Figure 
4.24). Subsequently, protein levels were quantified by densitometry as shown in 
Figure 4.24. In HUVECs, sIL-6Rα/IL-6 significantly stimulated STAT3 Tyr705 
phosphorylation after only 15 minutes, and this was significantly inhibited by the 
activation of AMPK by A769662. 
As an alternative way to use 4G10 to detect tyrosine phosphorylated JAK1, 4G10 
antibody was used to immunoprecipitate tyrosine phosphorylated proteins from 
treated cells followed by SDS-PAGE and immunoblotting with total anti-JAK1 
antibody. Initial antibody titration experiments using 4G10 for 
immunoprecipitation were performed on JAK1 rescue cells (U4C.JAK1) and JAK1-
null cells (U4C) pre-treated with hydrogen peroxide and sodium vanadate to 
inhibit cellular protein tyrosine phosphatase activity and thus increase levels of 
tyrosine phosphorylated proteins (Hecht et al., 1992). Whole cell extracts were 
then immunoprecipitated with increasing concentrations of phospho-tyrosine 
4G10 antibody and total-JAK1 antibody as a positive control, followed by 
immunoblotting with total-JAK1 antibody to examine the effects on JAK1 tyrosine 
phosphorylation. Figure 4.25 demonstrates that total-JAK1 antibody detects 
tyrosine phosphorylated JAK1 protein in 4G10 immunoprecipitates derived from 
140 
 
U4C.JAK1 cell extracts only. The lack of any specific signal in 4G10 
immunoprecipitates derived from U4C (JAK1 null) cell extracts confirms the 
specificity of this approach for specifically assessing JAK1 Tyr phosphorylation. 
4G10 efficiently immunoprecipitates JAK1, with 6µl being the most efficient at 
immunoprecipitating JAK1 and immunoprecipitating to a similar extent as the 
total-JAK1 antibody (Figure 4.25). Having optimised this approach to detect 
tyrosine-phosphorylated JAK1, HUVECs were pre-treated with vehicle or A769662 
followed by stimulation with vehicle or sIL-6Rα/IL-6 for either 2, 5, 15 or 30 
minutes and immunoprecipitated with phospho-tyrosine 4G10 antibody, followed 
by SDS-PAGE and immunoblotting with total-JAK1 antibody. In comparison to 
probing JAK1 immunoprecipitates with 4G10 (Figure 4.24), this approach has 
substantially reduced the basal levels of tyrosine phosphorylated JAK1 detected 
(Figure 4.26). As shown in Figure 4.26, sIL-6Rα/IL-6 stimulation of JAK1 tyrosine 
phosphorylation peaked at 5 minutes, but was still above basal levels at 30 
minutes. Treatment of HUVECs with A769662 for 40 minutes prior to sIL-6Rα/IL-6 
stimulation for 5 minutes slightly reduced JAK1 tyrosine phosphorylation (Figure 
4.26). However this effect seemed to be transient as it was not reproducibly 
detected at any of the later time points. Immunoblotting of cell extracts with 
phospho-ACC (Ser79) antibody confirmed AMPK activation by A769662 (Figure 
4.26). Whole-cell extracts were also immunoblotted with phospho-STAT3 (Tyr705) 
and total-STAT3 antibodies to confirm AMPK-mediated inhibition of sIL-6Rα/IL-6 
stimulation STAT3 (Tyr705) phosphorylation at each time point (Figure 4.26)  
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Figure 4.22: Effect of sIL-6Rα/IL-6 on JAK1 phosphorylation  
HUVECs were pre-treated with vehicle or 100µM A769662 followed by stimulation with vehicle or 
25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for time period indicated. Protein-equalised cell 
extracts were then immunoprecipitated with anti-JAK1 antibody and protein A-Sepharose beads. 
Eluted immunoprecipitated (IP) proteins and whole cell extracts (WCE) were analysed by SDS-PAGE 
and immunoblotting with antibodies specific for phospho-JAK1 (Tyr1022/1023), total JAK1, as 
indicated.  
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Figure 4.23: Time-course of sIL-6Ra/IL-6-stimulated Tyr phosphorylation of JAK1 in 
HUVECs. 
HUVECs were stimulated with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for the time 
period indicated. Protein-equalised cell extracts were then immunoprecipitated with total JAK1 
antibody and protein A-Sepharose beads. Immunoprecipitated proteins were eluted from beads and 
fractionated by SDS-PAGE in parallel with whole cell extracts. After transfer to nitrocellulose, 
membranes were probed with either anti-p-Tyr 4G10 antibody or total JAK1 antibody and visualised 
by ECL.  
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Figure 4.24: Effect of A769662 on sIL-6Rα/IL-6 stimulated JAK1 and STAT3 phosphorylation 
in HUVECs (JAK1 immunoprecipitates) 
HUVECs were pre-treated with vehicle or 100µM A769662 for 40 minutes followed by stimulation 
with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for time period indicated. Protein-
equalised cell extracts were then immunoprecipitated with total JAK1 antibody and protein A-
Sepharose beads. Eluted immunoprecipitated proteins and whole cell extracts were analysed by 
SDS-PAGE and immunoblotting with 4G10 anti-p-Tyr antibody and antibodies specific for total JAK1, 
phospho-STAT3 (Tyr705), total STAT3 and phospho-ACC (Ser79) as indicated. STAT3 
phosphorylation data were first normalized to total STAT3 levels and expressed as a percentage (%) 
of the maximal sIL-6Rα/IL-6 stimulation attained in vehicle pre-treated HUVECs (Set at 100%). 
Quantitative analysis from three experiments is presented. Columns are means ±SEM. *** p<0.01.   
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Figure 4.25: Titration of p-Tyr 4G10 antibody for immunoprecipitation of tyrosine 
phosphorylated JAK1 
JAK1-null U4C and U4C.JAK1 cells were treated for with 1mM hydrogen peroxide for 2 hours and 
sodium vanadate treatment was performed for the final 30 minutes of this 2 hour period. Protein-
equalised cell extracts were then immunoprecipitated with pTyr 4G10 antibody and protein A-
Sepharose beads. Immunoprecipitated proteins were eluted from beads and analysed by SDS-
PAGE and immunoblotting with total JAK1 antibody. 
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Figure 4.26: Effect of A769662 on sIL-6Rα/IL-6 stimulated JAK1 phosphorylation in HUVECs 
(4G10 immunprecipitates) 
HUVECs were pre-treated with vehicle or 100µM A769662 for 40 minutes followed by stimulation 
with vehicle or 25ng/ml sIL-6Rα and 5ng/ml IL-6 (sIL-6Rα/IL-6) for time period indicated. Protein -
equalised cell extracts were then immunoprecipitated with pTyr 4G10 antibody and protein A-
Sepharose beads. Eluted immunoprecipitated proteins and whole cell extracts were analysed by 
SDS-PAGE and immunoblotting with antibodies as indicated.  
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4.2.7 AMPK phosphorylation of full-length human JAK in vitro  
Having demonstrated that AMPK phosphorylates a JAK1 peptide at both Ser515 and 
Ser518 in vitro, the next step was to investigate whether full-length JAK1 protein 
could be phosphorylated by AMPK in vitro.  
First, in vitro AMPK phosphorylation of ACC Ser79 was conducted to confirm in 
vitro kinase activity of rat liver purified AMPK. HEK293 cells were lysed and ACC 
was captured using streptavidin agarose beads. ACC is a biotinylated enzyme; thus 
biotin-streptavidin affinity purification can be used to isolate ACC (Chen et al., 
2000). Streptavidin purified ACC and streptavidin depleted lysates were then 
incubated in the absence or presence of purified rat liver AMPK with or without 
AMP. AMPK phosphorylation of ACC is detected by probing with anti phospho-ACC 
(Ser79) antibody (Figure 4.27A). The presence of AMPK alone caused a substantial 
increase, compared to the basal level, in ACC Ser79 phosphorylation (Figure 
4.27A). Moreover, phosphorylation of ACC (Ser79) by AMPK was further increased 
by the addition of AMP. Immunoblotting with total ACC antibody confirmed that 
ACC (265kDa) was successfully purified from cell lysates as total ACC is present in 
streptavidin purified lysates and absent from streptavidin depleted lysates (Figure 
4.27A). Overall, this positive control experiment confirms that these in vitro 
phosphorylation events were mediated by catalytically active AMPK. 
To test whether full-length JAK1 protein could be phosphorylated by purified 
active rat liver AMPK in vitro, JAK1-null U4C cells, were transfected individually 
with wild-type (WT) FLAG-tagged recombinant human JAK1 plasmid or an empty 
expression plasmid as a control. Cell lysates were then immunoprecipitated with 
anti-FLAG antibody, and the immunocomplexes were then incubated in the 
absence or presence of purified active rat liver AMPK with or without AMP, and in 
the presence of [γ-32P] ATP. Incorporation of radiolabelled phosphate from [γ-32P] 
ATP into a protein substrate was detected by autoradiography following exposure 
to X-ray film. Phosphorylated proteins are represented by dark bands on the 
autoradiogram which can be seen in Figure 4.27B. Phosphorylated proteins of 
approximately 110 and 130 kDa appear in lanes 3,4,7 and 8 which are reactions 
prepared from both control and JAK1 transfected U4C cells (Figure 4.27B). 
Immunoblotting with total-JAK1 antibody confirmed that JAK1 (130kDa) was only 
present in the reactions (lanes 5-8) prepared from U4C cells transfected with 
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FLAG-tagged JAK1 plasmid (Figure 4.27B). Therefore, it would appear that the 
FLAG antibody has immunoprecipitated proteins other than JAK1 from cell lysates 
and therefore the phosphorylated proteins detected at 130kDa were not 
specifically JAK1. These non-specific proteins were phosphorylated only in the 
presence of AMPK, which was greatly enhanced by the addition of AMP (Figure 
4.27B). Overall, it was not possible to determine whether AMPK phosphorylates 
full-length JAK1 in vitro from these experiments.  
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Figure 4.27: In vitro AMPK phosphorylation of full-length ACC and JAK1  
(A) HEK293 cell lysates were equalised for protein content and ACC was captured using streptavidin 
agarose beads. Streptavidin purified ACC and streptavidin depleted lysates were incubated in the 
absence or presence of 0.5U/ml activated AMPK with or without 0.2mM AMP. ACC was eluted from 
beads and fractionated by SDS-PAGE in parallel with streptavidin depleted lysates and whole cell 
extract. After transfer to nitrocellulose, membrane was probed with phospho-ACC (Ser79) and total 
ACC antibody as indicated. A blot from a single experiment is shown. (B) U4C cells were transfected 
with either Flag-tagged JAK1 plasmid or an empty expression plasmid as a control. Protein equalised 
cell lysates were immunoprecipitated with Anti-FLAG M2 affinity gel, and then each precipitate was 
incubated for 30 minutes in the absence or presence of 0.5U/ml activated AMPK with or without 
0.2mM AMP, and in the presence of 10μCi/ml γ-32P-ATP. JAK1 was eluted from the precipitate and 
analysed by SDS-PAGE and immunoblotting with anti-JAK1 antibody, and phosphorylated proteins 
were visualised by autoradiography.   
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4.2.8 AMPK phosphorylation of GST-JAK1 SH2 fusion protein in vitro 
In order to establish JAK1 protein as a bona fide in vitro AMPK substrate and to 
determine the specific site(s) of phosphorylation in JAK1 as Ser515/Ser518, this 
study next sought to determine the stoichiometry of phosphorylation of 
Ser515/Ser518 in JAK1 by AMPK in vitro. To determine this, human wild-type and 
S515A/S518A JAK1 SH2 domain, and rat ACC1 residues 60-94 were bacterially 
expressed as GST fusion proteins and subjected to in vitro kinase assays using α1- 
and α2-containing AMPK complexes immunoprecipitated from detergent-
solubilised rat liver homogenates, and [γ-32P] ATP. The incorporation of 
radiolabelled phosphate from [γ-32P] ATP into the GST-fusion proteins was to be 
determined by scintillation counting of phosphorylated proteins excised from 
dried SDS-PAGE gels.  
4.2.8.1.1 Construction of the pGEX recombinant plasmids  
The construction of recombinant wild-type and non phosphorylatable 
S515A/S518A pGEX-JAK1 SH2 plasmids is described in the Material and Methods. 
Briefly, site-directed mutagenesis of pCMV6/human JAK1 plasmid was performed 
to change Ser515 and Ser518 residues to a non-phosphorylatable alanine residues 
(S515A/S518A). Oligonucleotide primers complementary to the boundaries of the 
SH2 domain (residues 439 –544) within human JAK1 were synthesised for 
amplification by PCR. These oligonucleotide primers were designed to amplify the 
SH2 domain within WT and S515A/S518A mutant pCMV6/human JAK1 while 
introducing an in-frame C terminal His6 tag and a stop codon, as well as BamHI 
and EcoRI compatible ends for subcloning. The resultant PCR products were then 
digested with BamHI and EcoRI and ligated into similarly digested pGEX-2T 
bacterial expression plasmid in frame with the GST open reading frame. The pGEX-
ACC1-(His)6 plasmid was a kind gift from Prof. Grahame Hardie (Scott et al., 2002). 
This plasmid encodes residues 60-94 of rat liver ACC1, which contains the major 
AMPK phosphorylation site Ser79, and a C terminal (His)6 tag.  
4.2.8.1.2 GST fusion protein expression and purification  
Bacterial expression and purification of GST alone and WT GST JAK1 SH2, 
S515A/S518A mutant GST JAK1 SH2 and GST-ACC fusion proteins were described 
in the Materials and Methods. Briefly, E.coli BL21 cells transformed with pGEX-2T, 
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pGEX-WT JAK1 SH2, pGEX S515A/S518A JAK1 SH2 or pGEX-ACC1-His6 were grown 
until log phase. At this point, GST fusion protein expression was induced by the 
addition of 1 mM of IPTG. The cells were grown for a further 4 hours at 37°C and 
hourly 1ml samples were removed to monitor protein expression. These samples 
were pelleted and the pellet re-suspended in SDS sample buffer for analysis by 
SDS-PAGE and Coomassie staining (Figure 4.28). After 4 hours, the cells were 
pelleted and stored frozen at -80°C until ready for purification. Each GST fusion 
protein has a (His)6 tag at the C terminus, therefore expressed GST fusion proteins 
were isolated from bacterial lysates by batch purification with Ni-NTA agarose 
followed by elution with imidiazole and exchange into substrate buffer (Figure 
4.28). GST alone was isolated from bacterial lysates by batch purification with 
GSH, followed by elution with reduced glutathione (Figure 4.28).  
Figure 4.28 shows the expression and purification of the GST fusion proteins: WT 
and S515A/S518A mutant GST-JAK1 SH2, and GST-ACC, and GST alone. For GST 
alone and each GST fusion protein, the strongest band for each IPTG induction 
time-point corresponds with the predicted molecular weight of the GST fusion 
protein, suggesting that full length products are being expressed. The predicted 
molecular weight of WT and S515A/S518A mutant GST-JAK1 SH2 is 38 kDa, GST-
ACC is 34kDa, and GST is 26kDa. GST alone was successfully purified from the 
bacterial lysate as indicated by the single band in the eluted product (Figure 
4.28A). GST-ACC was also successfully purified, although there are two bands 
present in the eluted product, one band at about 34 kDa corresponding to GST-
ACC and one band at about 25 kDa suggesting that the protein is degrading to GST 
alone (Figure 4.28B). As shown in figure 4.28C and 4.28D, WT and S515A/S518A 
mutant GST JAK1 SH2 were not successfully purified by His-tag purification. GST-
JAK1 SH2 proteins were also absent from the cleared lysates, which suggests that 
the GST-JAK1 SH2 protein was not eluted efficiently or that the GST-JAK1 SH2 
protein was insoluble.  
Another approach used to purify GST-JAK1 SH2 proteins was to replace the lysis 
buffer prepared in-house with the commercially available protein extraction 
reagent, BugBuster. Following induction of protein expression in the E.coli cells, 
the cells were pelleted and lysed in BugBuster as per manufacturer’s instructions. 
The cell lysate was then separated into soluble and insoluble fractions by 
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centrifugation and each fraction was subject to SDS-PAGE analysis (Figure 4.29). 
Figure 4.29 shows that the expressed protein is accumulating in the insoluble 
pellet and thus absent from the soluble lysate. It appears that the expressed 
protein is insoluble and perhaps accumulating in inclusion bodies as a result of 
high level of protein expression. Reducing the rate of protein synthesis can help 
improve the solubility of the expressed protein (Rosano and Ceccarelli, 2014). 
Therefore, various inducing conditions were tried, such as reducing the growth 
temperature from 37 degrees to 25 degrees, reducing the inducer concentration 
from 1mM to 0.1mM IPTG, reducing the time of induction from 4 hours to 3 hours 
and varying the OD600 value for induction between 0.3 – 0.6. Various combinations 
of inducing conditions were tried, but none resulted in solubilisation of the 
expressed protein. 
A final approach to purifying GST-JAK1 SH2 proteins was to purify the protein under 
denaturing conditions. Conventional denaturing and renaturing protocols use 
denaturing buffers containing either 6 M guanidine hydrochloride (GdnHCl) and 8 
M urea, and renaturing methods such as dialysis or dilution steps (Singh and Panda, 
2004). To purify GST-JAK1 SH2 proteins from inclusion bodies, the Rapid GST 
Inclusion Body Solubilization and Renaturation Kit (Cell Biolabs.) was used as per 
manufacturer’s instructions. Briefly, WT GST-JAK1 SH2 expression was induced 
with 0.1 mM IPTG at 37ºC for 3 hrs. Cell pellet was lysed in STE Extraction Buffer 
(500 mM Tris, pH 7.5, 1.5 M NaCl, 10 mM EDTA). To solubilize and renature WT 
GST-JAK1 SH2 proteins, the cell lysate/inclusion body mixture was mixed with 
Detergent Solubilization Solution (diluted 1:2 with STE extraction buffer (2 fold 
dilution). The cell lysate was then separated into soluble and insoluble fractions 
by centrifugation. The soluble fraction was then mixed with Detergent 
Neutralization Solution. Figure 4.30 demonstrates that the WT GST-JAK1 SH2 
protein was present in the renatured soluble protein fraction at this final stage of 
the Rapid GST Inclusion Body Solubilization and Renaturation Kit protocol. Soluble 
WT GST-JAK1 SH2 proteins were then purified from the renatured soluble protein 
fraction by GST-tag batch purification. Figure 4.30 confirms that WT GST-JAK1 SH2 
is present in the eluted product following purification and concentration by buffer 
exchange. This method was also used to extract, solubilise, renature and purify 
S515A/S518A mutant GST-JAK1 SH2 protein. Figure 4.30 confirms that 
S515A/S518A mutant GST JAK1 SH2 is present in the eluted product following 
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purification and concentration by buffer exchange, however a second band is also 
present at about 25 kDa suggesting that the protein is degrading to GST alone. 
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Figure 4.28: Verification of GST fusion protein expression and purification by SDS PAGE 
and Coomassie staining.  
Bacterial expression of GST-fusion proteins were induced by IPTG for 0, 1, 2, 3 and 4 hrs. GST 
fusion proteins were purified by batch purification with Ni-NTA agarose, followed by elution with 
imidiazole. GST alone was purified by batch purification with glutathione-Sepharose, followed by 
elution with reduced glutathione. Samples were analysed by 12% SDS-PAGE and proteins visualised 
by staining with Coomassie Brilliant Blue R-250 (A) GST alone runs at 26 kDa (B) GST-ACC runs at 
34kDa (C) WT GST-JAK1 SH2 runs at 38 kDa (D) S515A/S518A mutant GST-JAK1 SH2 runs at 38 
kDa EP = Eluted protein and CL = clear lysate  
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Figure 4.29: Verification of GST fusion protein expression and protein extraction using 
BugBuster by SDS PAGE and Coomassie staining 
Bacterial expression of WT GST JAK1 SH2 fusion protein was induced by IPTG for 3 hrs. Bacterial 
pellet was lysed in BugBuster protein extraction reagent. Samples were analysed by 12% SDS-
PAGE and proteins visualised by staining with Coomassie Brilliant Blue R-250. WT GST-JAK1 SH2 
runs at 38 kDa. TU = total uninduced protein, TI = total induced protein, Insoluble pellet = IP and SL 
= soluble lysate. 
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Figure 4.30: Verification of GST fusion protein expression and purification under denaturing 
conditions by SDS PAGE and Coomassie staining 
Bacterial expression of WT GST JAK1 SH2 and S515A/S518A GST JAK1 SH2 fusion protein was 
induced by IPTG for 3 hrs. GST fusion proteins were purified by GST-batch purification under 
denaturing conditions using the Rapid GST Inclusion Body Solubilization and Renaturation Kit (Cell 
Biolabs.). Samples were analysed by 12% SDS-PAGE and proteins visualised by staining with 
Coomassie Brilliant Blue R-250 (A) WT GST-JAK1 SH2 runs at 38 kDa. (B) S515A/S518A mutant 
GST-JAK1 SH2 runs at 38 kDa TU = total uninduced protein, TI = total induced protein, RSP = 
renatured soluble protein and EP = Eluted protein.  
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4.2.8.1.3 In vitro AMPK phosphorylation of GST-JAK1 SH2 fusion protein 
The hypothesis being tested was whether JAK1 protein is as a bona fide in vitro 
AMPK substrate and that the specific site(s) of phosphorylation in JAK1 are 
Ser515/Ser518. Thus, this study sought to determine the stoichiometry of 
phosphorylation of Ser515/Ser518 in JAK1 by AMPK in vitro. To determine this, 
purified GST-ACC, WT GST-JAK1 SH2 and S515A/S518A mutant GST JAK1 SH2 fusion 
proteins, and GST alone were subjected to in vitro kinase assays using purified 
active rat liver AMPK, and [γ-32P] ATP. The incorporation of radiolabelled 
phosphate from [γ-32P] ATP into the GST-fusion proteins was to be determined by 
autoradiography of phosphorylated proteins and excision of gel slices for 
scintillation counting after fractionation by SDS-PAGE.  
Prior to stoichiometric analysis of protein phosphorylation by scintillation 
counting, it was important to visualise protein phosphorylation by autoradiography 
in order to confirm that the GST-fusion proteins of the corresponding molecular 
mass were phosphorylated (i.e that the GST alone contaminant was not 
phosphorylated). In vitro kinase reactions were resolved by SDS-PAGE and 
immunoblotted, followed by autoradiography. As shown in Figure 4.31, 
phosphorylated proteins are represented by dark bands on the autoradiogram. 
GST-ACC was potently phosphorylated in the presence, but not in the absence, of 
purified active rat liver AMPK, and the addition of AMP appeared to enhance AMPK 
phosphorylation of GST-ACC (Figure 4.31). In contrast, GST alone, WT JAK1, 
S515A/S518A JAK1 and the degradation products of GST-fusion protein were not 
phosphorylated under these same conditions, as indicated by the absence of 
phosphorylated protein bands of the corresponding molecular mass on the 
autoradiogram (Figure 4.31). Taken together, these data confirmed that AMPK is 
catalytically active and that AMPK phosphorylates only the ACC portion of the 
fusion protein. Following autoradiography, the immunoblot was probed with HRP-
conjugated anti-GST antibody to confirm the presence of GST and GST fusion 
proteins in each reaction (Figure 4.31). Recombinant GST fusion proteins of the 
expected molecular weight were present in each reaction: WT and S515A518A GST-
JAK1 SH2 at 38 kDa, GST alone at 26 kDa and GST-ACC at 34 kDa (Figure 4.31). 
Overall, phosphorylation of WT GST JAK1 SH2 by AMPK was not observed under in 
vitro conditions where GST ACC was robustly phosphorylated. Thus, these 
157 
 
experiments were not followed by in vitro AMPK kinase assays subject to 
stoichiometric analysis.   
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Figure 4.31: AMPK phosphorylation of GST-JAK1 SH2 fusion proteins in vitro  
Bacterially expressed and purified GST-ACC, WT GST-JAK1 SH2 and S515A/S518A mutant GST 
JAK1 SH2 fusion proteins, and GST alone were incubated for 30 minutes in the absence or presence 
of 0.5U/ml activated AMPK with or without 0.2mM AMP, and in the presence of 10μCi/ml γ-32P-ATP. 
In vitro kinase reactions were resolved by SDS-PAGE and immunoblotted, and phosphorylated 
proteins were visualised by autoradiography. The immunoblot was probed with GST-HRP to detect. 
A representative autoradiogram from n=2 experiments is shown.  
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4.3 Discussion 
In this chapter, it was investigated whether AMPK acts directly on a signalling 
component of the JAK-STAT pathway. Specifically, it was hypothesised that AMPK 
could directly phosphorylate serine or threonine residues within JAK to inhibit IL-
6 signalling. The key findings of this chapter are that in vitro kinase assays of 
JAK1-derived peptides demonstrated that AMPK can directly phosphorylate two 
residues, Ser515 and Ser518, within the JAK1 SH2 domain. In addition, 
pharmacological activation of AMPK promotes 14-3-3 binding to JAK1 via a 
mechanism requiring Ser515 and Ser518. Furthermore, mutation of Ser515 and 
Ser518 abolishes the ability of AMPK to inhibit JAK-STAT signalling by an IL-6 trans-
signalling complex and from a constitutively active Val658Phe-mutated JAK1. 
Having demonstrated that AMPK inhibits both sIL-6Rα/IL-6 and IFN-α (Figure 6.5A), 
the initial aim was to identify the JAK isoform(s) that mediate the actions of sIL-
6Rα/IL-6 and IFN-α in HUVECs. sIL-6Rα/IL-6 has been shown to signal 
predominantly through STAT3 in several cell types. SiRNA-mediated 
downregulation of JAK isoforms in HUVECs demonstrated that sIL-6Rα/IL-6 
stimulation of STAT3 Tyr705 phosphorylation does not require activation of TYK2, 
but mainly requires activation of JAK1 and to a lesser extent JAK2 (Figure 4.7). 
This is consistent with published data from Guschin et al., (1995) who reported 
that in JAK1-null human fibrosarcoma U4C cells, STAT3 activation is profoundly 
inhibited despite IL-6 activation of JAK2 and TYK2 (Guschin et al., 1995). IFN-α 
signals predominantly through STAT1 (Ramana et al, 2000), however in this study 
it was not possible to assess the effects of siRNA-mediated downregulation of JAK 
isoforms on IFN-α stimulation of STAT1 Tyr701 phosphorylation as transfection of 
HUVECs with siRNAs at levels required to knockdown JAK isoform expression 
resulted in an increase in total STAT1 levels (Figure 4.8). IFN-α also signals through 
STAT3 (Ho and Ivashkiv, 2006) but despite siRNA transfection of HUVECs appearing 
to have no effect on total STAT3 levels, IFN-α stimulation of STAT3 Tyr705 
phosphorylation in HUVECs was found to be variable between and within individual 
experiments (Figure 4.4, 4.5 and 4.6). Overall, it was not possible to assess the 
effects of siRNA-mediated downregulation of JAK isoforms in HUVECs on IFN-α 
signalling. siRNAs have been shown to induce an interferon (IFN) response which 
may explain why the total STAT1 levels in cells transfected with siRNA increased 
as STAT1 is an IFN-inducible gene (Reynolds et al., 2006, Satoh & Tabunoki, 2013). 
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siRNA stimulation of an interferon response could also explain why IFN-α did not 
reproducibly stimulate STATs as the cells had been desensitised to interferon 
stimulation following siRNA transfection 48 hrs prior to IFN-α treatment 
(Whitehead et al., 2011). Previous reports have demonstrated IFN-α signals 
through JAK1 and TYK2 (Borden et al., 2007, Gauzzi et al., 1996). 
Overall, JAK1 was identified as a post receptor intermediate of both IL-6 and IFN-
α signalling. Therefore, it was proposed that AMPK could potentially directly 
phosphorylate Ser or Thr site(s) within JAK1 to inhibit sIL-6Rα/IL-6 and IFN-α 
stimulation of STAT phosphorylation. Peptide arrays consisting of overlapping 25-
mer peptides spanning the entire open reading frame of human JAK1, JAK2, JAK3 
and TYK2 (Figure 4.9, schematic diagram) were subject to in vitro phosphorylation 
with AMPK purified from rat liver and [32P]ATP. No phosphorylation of TYK2 or 
JAK3 peptides by AMPK was observed when compared to the corresponding 
peptide array incubated without active AMPK (Figure 4.13 and 4.14). It was 
observed that SH2 domain-derived peptides from JAK1 and JAK2 can serve as 
substrates for phosphorylation by AMPK in vitro (Figure 4.10 and 4.12). Alignment 
of the primary sequences of JAK1 and JAK2 identified the JAK1 and JAK2 25-mer 
peptides phosphorylated by AMPK as related sequences similarly positioned within 
the SH2 domain of each protein (Figure 4.11). To confirm these observations, the 
JAK2, JAK3 and TYK2 25-mer peptides that aligned with the JAK1 25-mer peptide 
identified as phosphorylated by AMPK were spotted on the same peptide arrays to 
allow for direct comparison (Figure 4.15). These confirmed that SH2 domain-
derived peptides from JAK1 and JAK2, but not JAK3 and Tyk2, can serve as 
substrates for phosphorylation by AMPK in vitro. The JAK1 25-mer peptide, R-Y-
S508-L-H-G-S512-D-R-S515-F-P-S518-L-G-D-L-M-S524-H-L-K-K-Q-I, phosphorylated by 
AMPK in vitro contains five potential phospho-acceptor sites (indicated in red). 
The JAK2 25-mer peptide, Y-N-L-S465-G-T467-K-K-N-F-S472-S473-L-K-D-L-L-N-C-Y-Q-M-
E-T, phosphorylated by AMPK in vitro contains four potential phospho-acceptor 
sites (indicated in red). 
To identify which of the five potential phospho-acceptor sites within JAK1 were 
phosphorylated in vitro by AMPK, phosphorylation assays were performed on 
arrays spotted with the wild-type (WT) and mutant versions of the JAK1 25-mer 
peptide in which each Ser residue was substituted with a non-phosphorylatable 
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Ala residue either individually or in combination (Figure 4.16). Consistent with 
Figure 4.10, the WT JAK1 peptide was phosphorylated by active AMPK (Figure 
4.16). In contrast, substitution of all five Ser residues with Ala abolished AMPK 
phosphorylation (Figure 4.16). However, individual substitution of each Ser residue 
with Ala either did not alter or enhanced AMPK phosphorylation of the resulting 
peptides (Figure 4.16). Mutant JAK1 peptides containing Ala substitutions at two 
or more Ser residue were also prepared. The mutant JAK1 peptide containing Ala 
substitutions at Ser508, Ser512 and Ser524 was phosphorylated by AMPK, whereas 
Ala substitution of both Ser515 and Ser518 abolished AMPK phosphorylation 
similarly to the peptide in which all five Ser residues were mutated to Ala (Figure 
4.16). Taken together, these observations identified Ser515 and Ser518 in human 
JAK1 as potential sites of phosphorylation by AMPK in vitro. A search of scientific 
literature and the PhosphoSitePlus database (Cell Signalling Technology 
PhosphoSitePlus) revealed that phosphorylation of Ser515 and Ser518 sites has 
never been previously reported therefore this study has identified a novel 
phosphorylation site in JAK1.  
Peptide library screening, mutagenesis and molecular modelling studies (Scott et 
al., 2002, Gwinn et al., 2008) have all been used to identify optimal AMPK 
substrate motifs. Bioinformatic analysis of JAK1 orthologues revealed that 
phosphorylation sites equivalent to Ser518 in human JAK1 are conserved in 
multiple species (Figure 4.32). Importantly, residues at positions +3 and +4 
downstream of the phospho-acceptor sites which are known to be critical for 
substrate recognition are well conserved (Figure 4.32). In contrast, Ser515 is 
unique to human JAK1 and would only form a weak consensus for AMPK substrate 
recognition if Ser518 became negatively charged via prior phosphorylation. 
However other examples of AMPK substrates that only loosely follow the optimized 
consensus have also been documented (e.g. eNOS phosphorylation at Ser633) 
(Chen et al., 2009b). Thus, the potential role for both Ser515 and Ser518 were 
examined in more detail.  
Ser515 and Ser518 are found within SH2 domain of JAK1 (Figure 4.33). The SH2 
domain is preceded by the N-terminal FERM domain (FERM standing for: band-4.1 
protein, ezrin, radixin, and moesin) and immediately upstream of the 
pseudokinase JH2 domain (Figure 4.33). The unavailability of a crystal structure 
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of a full-length JAK1 molecule limits our understanding on the functional roles of 
these domains. However biochemical and mutational studies coupled with some 
solved crystal structures of JAK fragments have started to unravel the basic 
functional roles of these domains. The JH2 domain has been shown to play a 
regulatory role by suppressing kinase activity via inhibitory interactions with the 
C-terminal JH1 tyrosine kinase catalytic domain (Lupardus et al., 2014, Shan et 
al., 2014, Tom et al., 2013, Ungureanu et al., 2011). The N-terminal FERM domain 
binds to the cytoplasmic region of cytokine receptors and may also regulate kinase 
activity (Girault et al., 1998, Haan et al., 2001, 2008, Hilkens et al., 2001, Zhao 
et al., 2010). The cytoplasmic domains of the cytokine receptors contain “box1” 
and “box2” motifs which are required for JAK engagement. Box1 is a membrane 
proximal proline-rich motif while box2 consists of a single negatively-charged 
residue followed by several hydrophobic residues (Murakami et al., 1991, Pelletier 
et al., 2006, Yan et al., 1996, Tanner et al., 1995, Usacheva et al., 2002, Royer et 
al., 2005, Haan et al., 2002). A classical SH2 domain typically contains a conserved 
arginine residue that coordinates phosphotyrosine binding (Liu et al., 2012). 
However the JAK1 SH2 domain is not believed to maintain the phosphotyrosine-
binding function of classical SH2 domains as an in depth study by Radtke and co-
workers found no phenotype associated with mutation of the highly conserved 
arginine residue at position 466 to lysine within the SH2 domain (Radtke et al., 
2005). In contrast, a recent study suggested that the SH2 domain is required for 
full activation of JAK (Gorantla et al., 2010). They demonstrated that mutation of 
a highly conserved arginine residue at position 426 within the SH2 domain of JAK2 
had no effect on receptor and membrane association, but reduced cytokine-
induced JAK2 and STAT5 phosphorylation. Sequence analysis suggested that the 
SH2 domain interacts with the FERM domain to stabilise its conformation to allow 
it to associate with cytokine receptors (Radtke et al., 2005). Recently, Lupardus 
and co-workers have presented a crystal structure of the FERM-SH2 region of TYK2 
and JAK1 which confirms and provides structural details of such an interaction 
(Wallweber et al., 2014, Ferrao et al., 2016). These crystal structures revealed 
that the FERM subdomains (F1, F2 and F3) and SH2 domain are intimately linked 
to form a tightly integrated structural module. The TYK2 and JAK1 FERM-SH2 
crystal structures were determined in complex with a peptide derived from 
cytokine receptors interferon-α receptor 1 (IFNAR1) and interferon-λ receptor 1 
(IFNLR1), respectively (Figure 4.34 is a cartoon representation of these structures 
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adapted from Wallweber et al., 2014 and Ferrao et al., 2016). These crystal 
structures revealed that binding of receptor box1 motif is mediated by the FERM 
F2 subdomain and receptor box2 binding is primarily mediated by the SH2 domain. 
Previous studies have demonstrated that both box1 and box2 motifs are required 
for gp130 mediated JAK1 activation (Murakami et al., 1991, Haan et al., 2002). 
Lupardus also demonstrated that the receptor box1 is the primary binding site of 
JAK1 and box2 further stabilises the JAK1-receptor complex (Ferrao et al., 2016). 
The crystal structure of the FERM-SH2 region of TYK2 in complex with a fragment 
of IFNAR1 showed that the box2 motif of IFNAR1 binds to the SH2 domain in a 
manner that mimics a classical SH2-phosphopeptide interaction (Wallweber et al., 
2014). In this structure, a glutamic acid residue (Glu497) of the IFNAR1 box2 motif 
resides in the phosphotyrosine-binding pocket of the SH2 domain and a 
hydrophobic box2 segment C-terminal to the glutamic acid lies in a hydrophobic 
βG1-EF groove of the SH2 domain (Figure 4.35). Reciprocal His and GST pull-down 
assays confirmed that Glu497 is required for IFNAR1 peptide binding to the TYK2 
FERM-SH2 module. Thermal stability assays also demonstrated that simultaneous 
mutation of the glutamic acid residues at positions 497 and 496 in the IFNAR1 
peptide reduced the melting temperature of the interaction with Tyk2 FERM-SH2 
by more than 5οC indicating that Glu497 is important for the stability of the TYK2 
FERM-SH2 module (Wallweber et al., 2014). In summary, these studies indicate 
that the SH2 domain is an integral part of the JAK-receptor complex which serves 
to interact with the cytokine receptor and structurally support the FERM domain 
in order to stabilise the JAK-receptor complex. Mapping of the AMPK 
phosphorylation sites Ser515 and Ser518 of JAK1 to their analogous locations on 
the TYK2 FERM-SH2 crystal structure revealed that these residues lie beside the 
hydrophobic βG1-EF groove in the SH2 domain (Wallweber et al., 2014) (Figure 
4.35). The hydrophobic box2 segment of IFNAR1 is buried in the hydrophobic 
groove formed by the βG1 strand and EF loop of the SH2 domain. TYK2 Ser522/525, 
analogous to JAK1 Ser515/518, are C-terminal residues of the EF loop preceding 
the αB helix, which is followed by the βG1 strand (Figure 4.35). Preceding TYK2 
Ser522 and Ser525 are residues, Leu516, Glu517, Gly518 and Tryp519, which 
interact with the IFNAR1 hydrophobic box2 segment (Wallweber et al., 2014). The 
introduction of a negatively charged phosphate group may affect the orientation 
and stability of the αB helix and EF loop to disrupt the SH2 hydrophobic βG1-EF 
groove and its interaction with the receptor hydrophobic box2 segment. Taken 
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together with the current study, it is proposed that AMPK phosphorylation of 
Ser515 and Ser518 within the SH2 domain of JAK1 disrupts the cytokine receptor 
box2-JAK1 SH2 binding site to destabilise the JAK1-cytokine receptor complex 
leading to impaired JAK1 signalling.  
In addition to receptor association, studies have demonstrated that the FERM 
domain may also participate in regulation of kinase activity (Haan et al., 2008, 
Zhao et al., 2010). The TYK2-IFNAR1 crystal structure highlights the critical 
scaffolding function of the SH2 domain to structurally support the FERM domain 
(Wallweber et al., 2014). Altogether, this information suggests that AMPK 
phosphorylation of Ser515 and Ser518 at the cytokine receptor box2-JAK1 SH2 
binding site could also potentially restrain the kinase activity of JAK1 by 
destabilising the JAK1 FERM association with its cytokine receptor. There is 
growing evidence suggesting that the regulation of catalytic activity involves a 
complex interplay of the JAK domains (Haan et al., 2010). Therefore, it is 
conceivable that the cytokine receptor box2-JAK1 SH2 interface may enforce 
allosteric interactions essential for optimal enzymatic activity. In a previous study, 
Haan et al., (2002) demonstrate that alanine substitution of Tryp652 within the 
transmembrane region of gp130 has no effect on JAK1 association but abrogates 
JAK1 activation (Haan et al., 2002). It was postulated that the activation of JAKs 
involves structural re-organisation of the JAK/receptor binding interface, and that 
residues, such as W652 of gp130, are involved in the activation process and 
allosteric regulation of kinase activity (Haan et al., 2006). Thus, AMPK 
phosphorylation of Ser515 and Ser518 at the cytokine receptor box2-JAK1 SH2 
interface disrupts this interaction to abolish the allosteric capacity of the cytokine 
receptor box2-JAK1 SH2 interface to promote optimal enzymatic activity. It is 
likely that JAK-receptor interactions at multiple sites within the complex dictates 
the JAK position in a defined orientation. Therefore, it is also conceivable that 
AMPK phosphorylation of Ser515 and Ser518 at the cytokine receptor box2-JAK1 
SH2 binding site may alter the positioning of the kinase domain in the receptor 
complex, impairing the phosphorylation of substrates (e.g. gp130 cytoplasmic 
tyrosine residues and/or STAT1/3). 
The JAK SH2 domain might be a part of the machinery that activates JAK in 
response to cytokine engagement of its cognate receptor. The sequence of events 
165 
 
that lead to JAK activation within the JAK-receptor complex remain largely 
elusive. However, it is proposed that cytokine binding to the receptor induces a 
conformational change which relieves the inhibitory JH1-JH2 interaction to allow 
autophosphorylation of the JAKs and their activation and progression of signal 
transduction (Babon et al., 2014). The crystal structure of the TYK2 pseudokinase 
JH2 –kinase JH1 region revealed an extensive interface between the two domains 
and an interdomain linker connecting the SH2 domain to the JH2 domain bridges 
the two domains (Lupardus et al., 2014). Activating mutations located in the JH2 
domain and the SH2-JH2 linker suggest that this complex represents a 
physiological autoinhibitory conformation (Shan et al., 2014). A mutational study 
of the JAK2 SH2-JH2 linker by Zhao and co-workers demonstrated that the linker 
plays a crucial role in both autoinhibition and cytokine stimulated JAK2 activation 
(Zhao et al., 2009). This study also demonstrated that activating mutations are 
located within the C-terminal end of the SH2-JH2 linker, whereas mutation of 
residues located within the N-terminal end of the linker are essential for the 
interaction of JAK2 with the Epo receptor. Taken together, these studies propose 
that the cytokine-induced conformational changes in the JAK-receptor complex 
are propagated through the SH2-JH2 linker to relieve the autoinhibitory 
interaction, leading to JAK activation (Zhao et al., 2009). The crystal structure of 
the TYK2 FERM-SH2 region indicates that the FERM-SH2 interface also plays a key 
role in communicating cytokine receptor engagement to the kinase domain 
(Wallweber et al., 2014). The crystal structure reveals that the N-terminal end of 
the SH2-pseudokinase linker, labelled as L3, is sandwiched between the FERM and 
SH2 domains and lies in close proximity to the SH2 domain–receptor interface. 
This region appears to play a crucial role in facilitating effective communication 
between the FERM and SH2 domains as the SH2-JH2 linker interacts with each 
domain and other interdomain linkers (Wallweber et al., 2014). Thus, mutations 
within the N-terminal end of the SH2-JH2 linker are predicted to destabilise the 
FERM-SH2 interface and disrupt its interaction with the receptor. Overall, the 
crystal structure suggests that both the FERM-SH2 interface and SH2-JH2 linker 
play a key role in communicating cytokine receptor engagement to JAK activation. 
Taken together with the current study, these data suggest that AMPK 
phosphorylation of Ser515 and Ser518 in the SH2 domain could inhibit JAK1 
activation by destabilising the JAK1 FERM –SH2 interface, thus disrupting the 
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communication between the activated receptor and kinase domain resulting in 
partially activated JAK. 
Mutation of serine 512 for leucine in the SH2 domain was identified as a somatic 
JAK1 mutation in adult acute lymphoblastic leukaemia (ALL) (Flex et al., 2008). 
Interestingly, TYK2 Tryp519, analogous to JAK1 Ser512, is located within the SH2 
EF loop and lies within the SH2 hydrophobic βG1-EF groove to interact with the 
IFNAR1 hydrophobic box2 segment (Wallweber et al., 2014). Presumably, mutation 
of a polar residue serine to a hydrophobic residue leucine in Ser512 enhances the 
cytokine receptor box2-JAK1 SH2 interaction leading to aberrant JAK1 signalling 
and gives rise to ALL. Taken together with the current study, these data indicate 
that structural re-organisation of the cytokine receptor box2-JAK1 SH2 interface 
plays a key role in the regulation of JAK signalling.  
Potential functional roles of the JAK1 SH2 domain have been described: mediating 
and structurally supporting receptor association, dictating JAK orientation for 
efficient phosphorylation of substrates, facilitating JAK activation and 
allosterically regulating kinase activity. Interestingly, the JAK SH2 domain may not 
necessarily only function as a "passive" structural element of the JAK-receptor 
signalling complex, but “actively” influence JAK signalling via the the cytokine 
receptor box2-JAK1 SH2 interface. It is proposed that AMPK phosphorylation of 
Ser515 and Ser518 within the SH2 domain of JAK1 disrupts the cytokine receptor 
box2-JAK1 SH2 interface to affect one or a more of the potential functions of the 
SH2 domain, leading to impaired JAK1 signalling. Therefore, studying the effects 
of AMPK activation on each proposed functional role of the SH2 domain is crucial 
to establishing the mechanism of the inhibitory effect of AMPK. Structural studies 
of full-length JAK are also required to better establish the functional role of the 
SH2 domain, as it not clear if and how the FERM-SH2 module may interact with 
the JH2 and JH1 domains to participate in JAK activation and regulation of tyrosine 
kinase activity. Crucially, structural studies of full length JAKs bound to receptor 
chains, in both active and inactive states, will be required to address whether the 
JAK-receptor interface “actively” contributes to JAK signalling. 
So far this study indicates that AMPK phosphorylates JAK1 at Ser515 and Ser518 in 
vitro, therefore the next step was to determine whether AMPK-mediated 
inhibition of sIL-6Rα/IL-6 signalling is dependent on the phosphorylation of JAK1 
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by AMPK at Ser515 and Ser518. JAK1-null human fibrosarcoma U4C cells and a 
stable rescue form U4C.JAK1 were mutated from there parental cell 24C by Muller 
et al. (1993) (Muller et al., 1993). These cells were used to investigate the role of 
JAK1 in AMPK-mediated inhibition of sIL-6Rα/IL-6 signalling. First, the effects of 
AMPK activator A769662 on sIL-6Rα/IL-6 signalling in these cells had to be assessed 
(Figure 4.17). sIL-6Rα/IL-6 stimulated STAT3 Tyr705 phosphorylation in 24C and 
U4C.JAK1 cells. In contrast, sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 
phosphorylation was almost completely abolished in JAK1-null U4C cells (Figure 
4.17). This result is consistent with previous work by Guschin et al., (1995) and 
the siRNA experiments discussed earlier in the current study (Guschin et al., 1995). 
Taken together, these data demonstrate that JAK1 is required for IL-6 signalling in 
HUVECs and, human fibrosarcoma cells and its mutants. A769662 activates AMPK 
to inhibit sIL-6Rα/IL-6 signalling in 2C4 and U4C.JAK1, thus U4C cells are a 
valuable tool for investigating the role of JAK1 in AMPK-mediated inhibition of IL-
6 signalling. In order to determine whether AMPK-mediated inhibition of sIL-
6Rα/IL-6 signalling is dependent on Ser515 and Ser518, a human JAK1 plasmid 
containing non phosphorylatable alanine substitution at these sites (S515A/S518A) 
was generated. The effects of AMPK activation on sIL-6Rα/IL-6 signalling in JAK1-
null U4C cells transiently expressing WT and S515A/S518A mutant human JAK1 
were examined (Figure 4.18). sIL-6Rα/IL-6 treament of U4C cells transiently 
expressing WT or S515A/S518A mutant JAK1 significantly stimulated STAT3 Tyr705 
phosphorylation. While A769662 activation of AMPK significantly inhibited sIL-
6Rα/IL-6 stimulation of STAT3 Tyr705 phosphorylation in cells expressing WT JAK1, 
treatment of S515A/S518A JAK1 expressing cells with A769662 prior to sIL-6Rα/IL-
6 stimulation had no substantial effect on sIL-6Rα/IL-6 stimulation of STAT3 
phosphorylation (Figure 4.18). Overall, these data demonstrate that Ser515 and 
Ser518 of JAK1 are required for effective AMPK-mediated inhibition of IL-6 
signalling. 
The effects of AMPK activation on signalling downstream of a constitutively active 
mutant V658F mutant JAK1 was also examined (Jeong et al., 2008). The V658F 
mutation in the JAK1 has been identified in some patients with ALL (Staerk et al., 
2005) and is analogous to the V617F mutation in JAK2 responsible for several 
myeloproliferative neoplasms (MPN) (James et al., 2005). The V658F mutation 
within the JAK1 JH2 pseudokinase domain is thought to relieve an auto-inhibitory 
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interaction with the catalytic JH1 domain, thereby increasing Tyr kinase activity 
independent of cytokine stimulation (Lupardus et al., 2014, Shan et al., 2014, 
Toms et al., 2013, Ungureanu et al., 2011). The effects of AMPK activator A769662 
on U4C cells transiently expressing either WT, V658F mutant or V658F S515A/S518A 
mutant JAK1 were examined. In contrast to WT JAK1, transient expression of 
V658F JAK1 in U4C cells was sufficient to trigger detectable Tyr phosphorylation 
of STAT1 and STAT3 in the absence of added cytokine (Figure 4.19). Importantly, 
treatment with A769662 significantly inhibited STAT1 and STAT3 phosphorylation. 
Expression of the triple mutant V658F/S515A/S518A JAK1 also resulted in 
increased basal STAT1 and STAT3 phosphorylation, although this was significantly 
less than with single mutant V658F JAK1 (Figure 4.19). However, A769662 
treatment failed to significantly further inhibit the response despite increasing 
ACC phosphorylation (Figure 4.19). Overall, mutation of Ser515 and Ser518 
abolishes the ability of AMPK to inhibit JAK-STAT signalling from a constitutively 
active Val658Phe mutated JAK1. Together, these observations suggest that Ser515 
and Ser518 are required for effective AMPK-mediated inhibition of JAK-STAT 
signalling by an IL-6 trans-signalling complex and from a constitutively active 
Val658Phe-mutated JAK1. Intriguingly, mutation of Ser515 and Ser518 to Ala within 
the SH2 domain of WT JAK1 had no substantial effect on sIL-6Rα/IL-6 stimulated 
STAT3 Tyr705 phosphorylation (Figure 4.18), whereas the addition of these 
mutations into the SH2 domain of V658F JAK1 significantly inhibits V658F JAK1-
mediated phosphorylation of STAT3 (Figure 4.19). These results support the 
findings reported by Gorantla and co-workers (2010), who proposed that the SH2 
domain is critical for V617F JAK2-mediated constitutive signalling (Gorantla et al., 
2010) . Mutation of Arg426 to Lys (R426L) within the SH2 domain of WT human 
JAK2 reduced IL-3 stimulated STAT5 phosphorylation, whereas the incorporation 
of this mutation into the SH2 domain of V617F JAK2 abolished V617F JAK2-
mediated phosphorylation of STAT5 (Gorantla et al., 2010)  (Gorantla et al., 2010). 
Crucially, it was also reported that the SH2 domain in V617F JAK2 is critical for 
the induction of a myeloproliferative neoplasm-like disease. Myeloproliferative 
disease was only induced in mice transplanted with bone marrow cells expressing 
single mutant V617F JAK2 and not in induced in mice transplanted with bone 
marrow cells expressing double mutant V617F/R426L JAK2 (Gorantla et al., 2010). 
These data suggest that the SH2 domain is critical for both V658F-JAK1 and V617F-
JAK2 mediated constitutive signalling. The ability of AMPK to inhibit V658F JAK1 
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mediated phosphorylation of STATs via a mechanism requiring Ser515/Ser518 in 
the SH2 domain would support clinical studies to evaluate AMPK activators such as 
metformin as potential treatment options for ALL caused by activating JAK1 
mutations. These clinical studies could be expanded to include myeloproliferative 
neoplasms induced by V617F JAK2 as activated AMPK was also shown to 
phosphorylate SH2 domain-derived peptides and the SH2 domain is critical V617F-
JAK2 mediated constitutive signalling (Gorantla et al., 2010). However the effects 
of AMPK activation on signalling downstream of an endogenous ligand activated 
JAK2 or a constitutively active V617F mutant JAK2 have still to be examined. 
A common mechanism for phosphorylation-mediated regulation of target protein 
function is phosphorylation-dependent binding to members of the 14-3-3 family of 
proteins (Bridges & Moorhead, 2005). The 14-3-3 family proteins bind to phospho-
serine and phospho-threonine-containing proteins, and two consensus 14-3-3 
binding phospho-peptide motifs, RXXpS/pTXP and RXXXpS/pTXP, have been 
identified (Yaffe et al., 1997). AMPK phosphorylation of either Ser515 or Ser518 
within JAK1 creates a phospho-peptide motif that shares similarities with the 14-
3-3 binding motifs. AMPK has been shown to induce binding of 14-3-3 to many in 
vivo substrates of AMPK, including Raptor, ULK1, BRAF, and Atg9, although JAK1 
has never been identified before (Gwinn et al., 2008, Mack, Zheng, Asara, & 
Thomas, 2012, Shen et al., 2013, Weerasekara et al., 2014). Recently, the 
expression of 14-3-3ε in microglia cells has been reported to be induced by IL-6 
through the JAK-STAT3 pathway (Eufemi et al., 2015). To assess whether 
phosphorylation of Ser515 and Ser518 could facilitate JAK1 interaction with 14-3-
3 protein in vitro, a peptide array spotted with the 25-mer JAK1 peptide, R-Y-S-L-
H-G-S-D-R-S515-F-P-S518-L-G-D-L-M-S-H-L-K-K-Q-I, phosphorylated at either or both 
of Ser515 and Ser518 was overlaid with HRP-conjugated 14-3-3ζ. 14-3-3ζ strongly 
interacted with the JAK1 peptides individually phosphorylated at Ser515 and 
Ser518, but did not interact with either the non-phosphorylated JAK1 peptide or 
the peptide phosphorylated at both Ser515 and Ser518 (Figure 4.20). The signal 
from bound 14-3-3ζ was substantially stronger with the phospho-Ser515 JAK1 
peptide than the phospho-Ser518 JAK1 peptide (Figure 4.20). This was surprising 
as Ser518 is highly conserved among a wide variety of species, while Ser515 is not 
highly conserved (Radtke et al., 2005). Phospho-Ser518 may play a redundant role 
in the binding of 14-3-3, therefore binding 14-3-3 when phospho-Ser515 is not 
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available structurally or conservatively. The peptide array was also spotted with 
the 25-mer JAK-2 peptide, E-Y-N-L-S465-G-T-K-K-N-F-S472-S473-L-K-D-L-L-N-C-Y-Q-M-
E-T, phosphorylated at either or all three of Ser465, Ser472 and Ser473, and 
overlaid with 14-3-3ζ-HRP to assess whether phosphorylation of these sites could 
facilitate JAK2 interaction with 14-3-3 protein in vitro. 14-3-3ζ bound to non-
phosphorylated JAK2 peptide and phospho-Ser465 JAK2 peptide, and did not bind 
phospho-Ser472 or phospho-Ser473 JAK2 peptide (Figure 4.20). The signal from 
bound 14-3-3ζ was stronger with the non-phosphorylated JAK2 peptide than the 
phospho-Ser465 JAK2 peptide (Figure 4.20). These interactions are possible as 14-
3-3 binding of non-phosphorylated motifs, and divergent phospho-Ser/Thr motifs 
have been reported to occur between 14-3-3 and several proteins (Yaffe, 2002).  
To assess the role of AMPK activation on JAK1 phosphorylation in intact cells, WT 
and Ser515A/S518Ala mutated human JAK1 were transiently expressed in U4C cells 
prior to treatment with A769662 and preparation of cell extracts for pull down 
assays with GST-14-3-3ζ and immunoblotting with anti-JAK1 antibody (Figure 
4.21B and 4.21C). These demonstrated that A769662 treatment increased 14-3-3ζ 
interaction with JAK1 but not Ser515A/S518Ala mutated JAK1 despite equivalent 
activation of AMPK and expression of WT and mutated JAK1 proteins in transfected 
cells (Figure 4.21B). Overall, these data demonstrate that pharmacological 
activation of AMPK promotes 14-3-3 binding of JAK1 via a mechanism requiring 
Ser515 and Ser518. The data shown in figure 4.21 was generated and analysed by 
Dr Claire Rutherford, University of Glasgow. 
IL-6 induces phosphorylation of Tyr1022/1023 in the activation loop of the JAK1 
kinase domain, which is required for catalytic activation of JAK1 (Liu, 1997). 
Recently, Nerstedt et al (2013) used the phospho-JAK1 Tyr1022/1023 antibody 
from Cell Signalling Technology (#3331) to investigate the effect of AMPK 
activation on IL-6 stimulation of JAK1 activation in the human hepatocellular 
carcinoma cell line (HepG2) (Nerstedt et al., 2013). It was demonstrated that 
AMPK agonists, AICAR and metformin significantly inhibited IL-6 stimulation of 
JAK1 Tyr1022/1023 phosphorylation and STAT3 Tyr705 phosphorylation (Nerstedt 
et al., 2013) . With exception of the work recently published by Nerstedt and co-
workers (Nerstedt et al., 2013), there was no additional evidence in the literature 
regarding the effect of AMPK on JAK1 activity at the time of conducting this study. 
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It was hypothesised that AMPK inhibits sIL-6Rα/IL-6 stimulation of STAT3 Tyr705 
phosphorylation by inhibiting tyrosine phosphorylation of its predominant 
upstream activator, JAK1. Confirmation of AMPK-mediated inhibition of IL-6 
stimulated JAK1 tyrosine phosphorylation in HUVECs would suggest that this is the 
primary event which subsequently leads to inhibition of STAT3 Tyr705 
phosphorylation and the data presented in this study would further suggest this 
was achieved by AMPK directly phosphorylating and presumably inhibiting JAK1 
catalytic activation. However, it was not possible to successfully detect sIL-
6Rα/IL-6 stimulated JAK1 Tyr1022/1023 phosphorylation in HUVECs using Santa 
Cruz or Invitrogen phospho-specific antibodies against these sites on JAK1. As can 
be seen in Figure 4.22, phospho-JAK1 antibody typically failed to detect phospho-
JAK1 either after enrichment of JAK1 by immunoprecipitation or in whole cell 
extracts. Thus, it was not possible to deduce any information from these 
experiments. As an alternative approach to detect tyrosine phosphorylated JAK1, 
anti-phospho-tyrosine 4G10 monoclonal antibody was used to probe JAK1 
immunoprecipitates. Probing with 4G10 can theoretically detect multiple 
phosphorylated Tyr residues in different contexts and is therefore not specific for 
JAK1 Tyr 1022/1023. HUVECs were pre-treated with AMPK activator A769662, 
followed by stimulation with sIL-6Rα/IL-6 and then whole-cell extracts were 
immunoprecipitated with total JAK1 antibody, followed by immunoblotting with 
anti-phospho-tyrosine antibody 4G10. In comparison to the basal levels of JAK1 
tyrosine phosphorylation detected in unstimulated HUVECs, sIL-6Rα/IL-6 
stimulation of HUVECs for 15 minutes slightly increased JAK1 tyrosine 
phosphorylation levels (Figure 4.24). Treatment of HUVECs with A769662 prior to 
sIL-6Rα/IL-6 stimulation for 15 minutes appears to slightly reduce JAK1 tyrosine 
phosphorylation (Figure 4.24). However, the changes of JAK tyrosine 
phosphorylation observed with sIL-6Rα/IL-6 and A769662 treatment were modest; 
it is possible that the high basal level of JAK1 tyrosine phosphorylation is masking 
the inhibitory effects of A769662 on phosphorylation of Tyr 1022/1023. These data 
indicate that AMPK activation can inhibit sIL-6Rα/IL-6 stimulation of JAK1 tyrosine 
phosphorylation. As an alternative way to use 4G10 to detect tyrosine 
phosphorylated JAK1, 4G10 antibody was used to immunoprecipitate tyrosine 
phosphorylated proteins from treated cells followed by SDS-PAGE and 
immunoblotting with total anti-JAK1 antibody. In comparison to probing JAK1 
immunoprecipitates with 4G10 (Figure 4.24), this approach has substantially 
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reduced the basal levels of tyrosine phosphorylated JAK1 detected (Figure 4.26). 
As shown in Figure 4.26, sIL-6Rα/IL-6 stimulation of JAK1 tyrosine phosphorylation 
peaked at 5 minutes, but was still above basal levels at 30 minutes. Treatment of 
HUVECs with A769662 prior to sIL-6Rα/IL-6 stimulation for 5 minutes slightly 
reduced JAK1 tyrosine phosphorylation (Figure 4.26). Despite the low basal levels 
of JAK1 tyrosine phosphorylation, AMPK-mediated inhibition of JAK1 tyrosine 
phosphorylation remained modest. Furthermore, this effect seemed to be 
transient as it was not reproducibly detected at any of the later time points. 
Overall, these data indicate that inhibition of JAK1 tyrosine phosphorylation may 
not be the primary mechanism which subsequently leads to AMPK-mediated 
inhibition of STAT3 phosphorylation. AMPK may have no substantial effect on 
activation of JAK1 via tyrosine phosphorylation, but AMPK could still act via JAK1 
to inhibit IL-6 signalling by interfering with the ability of JAK1 to interact and 
phosphorylate the GP130 receptor and /or STAT3.  
Having demonstrated that AMPK phosphorylates a JAK1 peptide at both Ser515 and 
Ser518 in vitro, the next step was to investigate whether full-length JAK1 protein 
could be phosphorylated by AMPK in vitro. In a positive control experiment, in 
vitro AMPK phosphorylation of ACC purified from cell lysates confirmed that 
purified rat liver AMPK was catalytically active and phosphorylated full-length ACC 
Ser79 in vitro as detected by immunoblotting with phospho-ACC Ser79 antibody 
(Figure 4.27A). Subsequently FLAG-tagged JAK1 immunoprecipitates from cell 
lysates were subjected to in vitro AMPK reactions, however AMPK phosphorylation 
of JAK1 could not specifically be detected by incorporation of radiolabelled 32P as 
phosphorylation of a 130 kDa protein, the same molecular weight as JAK1, was 
detected in both JAK1 -deficient and –enriched reactions (Figure 4.27B). Thus, [γ-
32P] ATP was not selective for the detection of AMPK phosphorylated JAK1, unless 
JAK1 can be immunoprecipitated without binding non-specific proteins, a 
phospho-JAK1 Ser515/518 antibody is required for probing the in vitro AMPK 
reactions. Currently, a phospho-JAK1 Ser515/518 antibody is not available. Once 
in vitro phosphorylation of full-length JAK1 was demonstrated, the next step was 
to conduct an in vitro AMPK phosphorylation of full-length S515A/S518A mutant 
JAK1 to demonstrate that alanine substitution of Ser515 and Ser518 abolishes 
AMPK phosphorylation of full-length JAK1. Overall, the investigation of whether 
full-length JAK1 could be phosphorylated by AMPK at Ser515 and Ser518 in vitro is 
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inconclusive as the method for immunoprecipitating JAK1 and detecting in vitro 
AMPK phosphorylation of full-length JAK1 requires further optimisation. 
In order to establish JAK1 protein as a bona fide in vitro AMPK substrate and to 
determine the specific site(s) of phosphorylation in JAK1 as Ser515/Ser518, this 
study next sought to determine the stoichiometry of phosphorylation of 
Ser515/518 in JAK1 by AMPK in vitro. To determine this, human wild-type and 
S515A/S518A mutant JAK1 SH2 domain, and rat ACC1 residues 60-94 were 
bacterially expressed as GST fusion proteins and subjected to in vitro kinase assays 
using purified active rat liver AMPK, and [γ-32P] ATP. Prior to stoichiometric 
analysis, phosphorylated proteins were visualised by autoradiography. As shown in 
Figure 4.31, this experiment demonstrated that catalytically active AMPK 
phosphorylates only the ACC portion of the GST fusion protein, while 
phosphorylation of WT GST JAK1 SH2 by active AMPK was not observed under in 
vitro conditions. GST-ACC was purified under native conditions (Figure 4.28B) 
whereas GST-JAK1 SH2 proteins were purified under denaturing conditions (Figure 
4.30). Denaturing conditions were used to purify GST-JAK1 SH2 as the protein had 
become insoluble during bacterial expression (Figure 4.30). It is possible that AMPK 
may have not been able to phosphorylate WT GST-JAK1 SH2 protein as a result of 
the denaturing conditions of its purification. Denaturing and renaturing of GST-
JAK1 SH2 proteins has likely misfolded the protein, which has hidden the 
phosphorylation sites, Ser515 and Ser518, from AMPK. The secondary structural 
composition of a purified protein can be used as an indicator of the folding state 
of a protein. This information can be obtained by performing circular dichroism 
(CD) spectroscopy (Kelly et al., 2005). Unfortunately, the GST-fusion proteins were 
not analysed by CD before the end of this project. Following visual confirmation 
of in vitro AMPK phosphorylation of WT and S515A/S518A mutant GST JAK1 SH2, 
and GST-ACC, phosphorylation for each GST fusion protein was to be measured by 
scintillation counting and the stoichiometry of phosphorylation calculated. It was 
predicted that AMPK phosphorylates WT GST-JAK1 SH2 and GST-ACC proteins, but 
not S515A/S518A GST JAK1 SH2 protein. The stoichiometry of phosphorylation of 
WT GST-JAK1 SH2 by AMPK would be similar to that of GST-ACC, suggesting that 
JAK1 SH2 protein is a good in vitro substrate of AMPK (Scott et al., 2002). Mutation 
of Ser515 and Ser518 with alanine would abolish the phosphorylation of GST-JAK1 
SH2 by AMPK, suggesting that these sites are phosphorylated by AMPK in vitro. 
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Overall, this study has demonstrated that AMPK phosphorylates a JAK1 peptide at 
both Ser515 and Ser518 in vitro. Unfortunately, it remains undetermined whether 
AMPK phosphorylates full length JAK1 in vitro, and whether JAK1 is a bona fide in 
vitro AMPK substrate. In vitro phosphorylation assays were used for these 
experiments. However, this assay has limitations in that the phosphorylation in 
vitro may differ from what takes place physiologically. Thus, it is crucial that 
AMPK phosphorylation of JAK1 is confirmed in situ and most importantly in vivo.  
Taken together, the key findings of this chapter suggest that active AMPK can 
directly phosphorylate two residues, Ser515 and Ser518, within the JAK1 SH2 
domain. Pharmacological activation of AMPK promotes 14-3-3 binding of JAK1 via 
a mechanism requiring Ser515 and Ser518. Furthermore, mutation of Ser515 and 
Ser518 abolishes the ability of AMPK to inhibit JAK-STAT signalling by an IL-6 trans-
signalling complex and from a constitutively active Val658Phe-mutated JAK1. 
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Figure 4.32: Alignment of in vitro AMPK phosphorylation sites Ser515 and Ser518 in JAK1 
with the AMPK optimal phosphorylation motifs  
(A) Optimal and secondary selections for AMPK substrate recognition taken from Gwinn et al., 2008. 
AMPK phosphorylates Ser/Thr residues (indicated in bold) in the context of hydrophobic residues 
(green) at P-5 and P+4, basic residues (red) at P-4, P-3, or both, and polar or negatively charged 
residues (blue) at P+3. Strong selection for either Val (V), Arg (R) or Ser (S) (yellow) at P-2 was also 
noted. The sequence from rat ACC1 known to be phosphorylated by AMPK at Ser79 is shown for 
comparison (Davies et al., 1992) The conformity of the sequence surrounding Ser518 on human 
JAK1 to the AMPK consensus, and its evolutionary conservation, are shown. The sequence 
surrounding the Ser515 site on human JAK1 is also shown. The underlined Ser residue (equivalent 
to Ser518) indicates that this sequence would potentially conform to a weak AMPK consensus site 
following the acquisition of negative charge upon its phosphorylation.  
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Figure 4.33: In vitro AMPK phosphorylation sites Ser515 and Ser518 are found within the 
SH2 domain of human JAK1  
(A) A schematic representation of the primary structure of JAK1. JAKs consist of a FERM, SH2, 
pseudokinase and kinase domains. An alternative nomenclature for the putative domains is a series 
of Janus homology (JH) domains (Yamaoka et al., 2004). The location of the JAK1 25-mer peptide 
phosphorylated in vitro by AMPK is indicated. Ser515 and Ser518 (indicated in bold) are shown to 
be found in the JAK1 SH2 domain. 
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Figure 4.34: JAK interacts with cytokine receptor box1 and box2 motifs via distinct binding 
sites  
Cartoon representation of JAK1 FERM-SH2 domain bound to the box1 motif of IFNLR1 is shown on 
the left (adapted from Ferrao et al., 2016) and TYK2 FERM-SH2 domain bound to the box2 motif of 
IFNAR1 is shown on the right (adapted from Wallweber et al., 2014) The cytokine receptor fragment 
(IFNLR1 box1 or IFNAR1 box2), FERM subdomains (F1, F2, and F3) and SH2 domain are indicated. 
The box1 (orange) interaction is mediated by the FERM F2 subdomain (teal) and box2 (yellow) 
binding is primarily mediated by the SH2 domain (blue).  
  
178 
 
 
 
Figure 4.35: TYK2 Ser522/Ser525, analogous to JAK1 Ser515/Ser518, lie beside the receptor 
box2 binding site.  
Cartoon representation of TYK2 SH2 domain (blue), annotated with secondary structure elements, 
bound to the box2 motif of IFNAR1 (yellow) is shown on the left. Detailed views of the IFNAR1 E497 
(top panel) and hydrophobic box2 segment interactions (bottom panel) with TYK2 SH2 are shown 
on the right. Key residues are shown as stick models, and polar contacts are shown as dashed lines 
(adapted from Wallweber et al., 2014). IFNAR1 E497 interacts with the TYK2 SH2 domain via polar 
contacts with TYK2 S476 and T477, and a water-mediated hydrogen bond with TYK2 R482 (top 
panel). The hydrophobic box2 segment of IFNAR1, starting five residues C-terminal to E497 at C502, 
lies in a hydrophobic groove formed by the βG1 strand and EF loop of the SH2 domain. C502, F503 
and I504 form a short β-sheet with the βG1 strand (bottom panel). TYK2 Ser522/525, analogous to 
JAK1 Ser515/518, are C-terminal residues of the EF loop preceding the αB helix, which is followed 
by the βG1 strand. 
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Chapter 5 - Final Discussion  
Preliminary investigations of the effects of AMPK on JAK-STAT signalling 
demonstrated that AMPK can rapidly and profoundly inhibit activation of the JAK-
STAT pathway in response to multiple stimuli in vascular endothelial cells and in 
the current study the underlying molecular mechanism of this phenomenon was 
investigated. The current study has demonstrated that active AMPK can directly 
phosphorylate two residues, Ser515 and Ser518, within the JAK1 SH2 domain. 
Furthermore, mutation of Ser515 and Ser518 abolishes the ability of AMPK to 
inhibit JAK-STAT signalling by an IL-6 trans-signalling complex and from a 
constitutively active Val658Phe-mutated JAK1. 
 
Figure 5.1: A schematic model of AMPK-mediated inhibition of IL-6 signalling via JAK1.  
Active AMPK directly phosphorylate two residues, Ser515 and Ser518, within the JAK1 SH2 domain 
to inhibit JAK-STAT signalling by an IL-6 trans-signalling complex. Figure adapted from Rutherford 
et al., 2012 
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During the course of this study, only a small number of groups have reported an 
AMPK-mediated reduction in IL-6-stimulated STAT3 phosphorylation (Nerstedt et 
al., 2010, Kim et al., 2012, Nerstedt et al., 2013, Cansby et al., 2014). However, 
these studies were conducted in either liver-derived HepG2 hepatocellular 
carcinoma cells or primary hepatocytes. In contrast to endothelial cells, and 
indeed the majority of cells, hepatocytes do not require the presence of a soluble 
IL-6 receptor as IL-6 elicits its effects via binding a membrane-bound IL-6 receptor 
complexed with the co-receptor gp130 (classical signalling) (Rose-John, 2012). 
Work in the current study demonstrated that A769662-mediated AMPK activation 
inhibited STAT3 Tyr705 phosphorylation stimulated by a sIL-6Rα/IL-6 trans-
signalling complex in HUVECs. This finding was corroborated in adipocytes by our 
colleagues who demonstrated that A769662 inhibited sIL-6Rα/IL-6 stimulated 
STAT3 Tyr705 phosphorylation in 3T3-L1 adipocytes (Mancini et al., 2017). Kim et 
al (2012) and Nerstedt et al (2013) also investigated the molecular mechanism(s) 
underlying AMPK-mediated inhibition of IL-6 signalling in liver cells. Kim and co-
workers suggested that the mechanism by which long-term AMPK activation may 
suppress IL-6 signalling in the liver is via induction of the orphan nuclear receptor 
small heterodimer partner (SHP) (Kim et al., 2012). It was shown that chronic 
AMPK activation in hepatocytes with metformin for 12 hours can increase levels 
of SHP which can interact with the DNA binding domain of STAT3, thereby blocking 
its recruitment to target gene promoters such as the SOCS3 promoter following IL-
6 stimulation. However, this mechanism does not clarify the AMPK-mediated 
inhibition of STAT3 phosphorylation because SHP could interact with both phospho-
STAT3 and STAT3 (Kim et al., 2012). Nerstedt and co-workers reported that chronic 
AMPK activation in hepatocytes with AICAR inhibits IL-6 signalling by suppressing 
IL-6 stimulated phosphorylation of Tyr1022/1023 of JAK1 and its downstream 
targets STAT3 and SHP2. It was proposed that the reduction in phosphorylation of 
key sites (Tyr1022/1023) regulating the activity of JAK1 is the primary event which 
subsequently leads to inhibition of phosphorylation of its downstream targets SHP2 
and STAT3 (Nerstedt et al., 2013). In the current study, acute AMPK activation in 
endothelial cells with A769662 inhibited JAK1 tyrosine phosphorylation only 
slightly and was not statistically significant (Figure 4.24 and 4.26). Finally, He and 
co-workers reported during the course of writing this thesis that AICAR activated 
AMPK inhibits both IFN-γ and angiotensin (Ang)-II stimulation of STAT1 Tyr701 
phosphorylation in human aortic smooth muscle cells (HASMCs) (He et al., 2015). 
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Furthermore, activated AMPK diminished Ang-II-induced production of IL-6 and 
MCP-1 (He et al., 2015). Mechanistically, it was shown that chronic AMPK 
activation in HASMCs with AICAR for 4 hours can enhance mitogen-activated 
protein kinase phosphatase-1 (MKP-1) protein levels and siRNA-mediated 
knockdown of MKP-1 prevented AICAR-reduced STAT1 phosphorylation. (He et al., 
2015). MKP-1 is a dual specificity phosphatase that dephosphorylates phospho-
Ser/Thr and phospho-Tyr residues within the same substrate (Sun et al., 1993). 
MKP-1 has previously been shown to be involved in dephosphorylation of Ang-II-
activated STAT1, but not in the dephosphorylation of STAT3 (Venema et al., 1998, 
Liang et al., 1999). In contrast, the current study proposes that acute activation 
of AMPK directly phosphorylates JAK1 to rapidly inhibit JAK-STAT signalling by an 
IL-6 trans-signalling complex. The existence of several inhibitory mechanisms by 
which AMPK can suppress JAK-STAT signalling mirrors the multifaceted impact of 
AMPK on the mTOR signalling pathway, which it inhibits through direct 
phosphorylation of two components TSC2 on Ser1387 and Raptor on Ser722 and 
Ser792 (Inoki et al., 2003, Shaw et al., 2004, Gwinn et al., 2008). These 
observations suggest that, like the mTOR pathway, AMPK-mediated regulation of 
JAK-STAT signalling has also evolved, such that multiple mechanisms and targets 
are used to limit its activation. 
As discussed in Chapter 1 (1.3.6), a number of studies have described the critical 
role of IL-6 and STAT1/STAT3 signalling in regulating key processes in 
atherosclerosis and that interfering with the IL-6 and STAT1/STAT3 signalling in 
vivo prevents atherosclerotic lesion formation. As described (section 6.1), 
preliminary investigations demonstrated that activation of AMPK in HUVECs 
reduced sIL-6R/IL-6 induction of STAT3 target genes and STAT3-mediated 
monocyte chemotaxis (Figure 6.3 and 6.4). Similarly, He and co-workers 
demonstrated that activated AMPK reduced Ang-II induction of STAT1 target genes, 
including MCP-1, in HASMCs (He et al., 2015). Utilising AMPKα2 knockout mice, He 
and co-workers investigated the role of AMPK in the suppression of vascular 
inflammation and for the first time investigated whether AMPK suppresses 
inﬂammation through inhibition of STAT1 signalling in vivo (He et al., 2015). 
Compared to WT mouse aortas, deletion of AMPKα2 increased the expression of 
pro-inflammatory mediators and amplified Ang-II induction of these mediators (He 
et al., 2015). Administration of a STAT1 inhibitor, fludarabine, attenuated the 
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expression of pro-inflammatory mediators in AMPKα2 knockout mice in the 
absence and presence of Ang-II infusion (He et al., 2015). He and co-workers 
propose that AMPK suppression activates STAT1 signalling, resulting in aberrant 
inflammation in the vasculature and establishing an essential role for AMPK in 
promoting an anti-inflammatory phenotype that is vital for protection against the 
formation of atherosclerotic lesions (He et al., 2015). Taken together with the 
current study, these findings suggest that AMPK-mediated phosphorylation of JAK1 
may be a valid pharmacological target for the prevention and treatment of 
vascular inflammation. Importantly, preliminary investigations demonstrated that 
sIL-6R/IL-6 stimulation of STAT3 Tyr705 phosphorylation was significantly 
inhibited in HUVECs pre-treated with a combination of clinically utilized AMPK 
activators metformin and salicylate (the active metabolite of aspirin) (Figure 6.1). 
Overall, these findings provide a mechanistic rationale for the clinical evaluation 
of AMPK activators such as metformin or salicylate, as a potential therapeutic 
agent in the prevention and treatment of vascular inflammation, which could slow 
down the process of atherosclerosis and therefore decrease the incidence of 
cardiovascular events.  
In patients with type 2 diabetes, several observational studies have reported that 
treatment with metformin limits cardiovascular morbidity and mortality 
independent from its glucose-lowering action (Holman et al., 2008, Johnson et 
al., 2005, Mellbin et al., 2011, Roussel et al., 2010). This finding has led 
researchers to investigate whether metformin might potentially improve 
cardiovascular outcome in non-diabetic patients at risk for CVD. However, small 
short-term randomized controlled trials in non-diabetic patients suffering from 
coronary heart disease showed that treatment with metformin on top of optimal 
statin therapy did not improve cardiovascular risk profile or intima-media 
thickness (Lexis et al., 2015, Preiss et al., 2014). Further large long-term 
randomised controlled clinical trials of metformin monotherapy are necessary to 
definitively conclude about the cardiovascular protective effects of metformin 
treatment in non-diabetic CVD. With interest, we await the results of ongoing 
Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT; ISRCTN34875079), 
in which 12 000 patients with high cardiovascular risk and dysglycaemia but 
without diabetes, will be assigned to metformin or placebo for 5 years. Until then, 
the role of metformin for improving cardiovascular outcomes in non-diabetic 
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patients has promise, but is still largely unproven. Aspirin is an acetylated form of 
salicylate, which is rapidly broken down to salicylate within the bloodstream 
(Higgs et al., 1987). Aspirin is well recognized as an effective anti-platelet drug 
for secondary prevention in patients at high risk of cardiovascular events 
(Hennekens and Dalen, 2013). The mechanism of this treatment is through the 
transfer of aspirin’s acetyl group to a serine side chain at the cyclo-oxygenase 
(COX) active site which irreversibly inhibits the COX1 and COX2 enzymes and 
subsequently inhibit blood clotting caused by platelets (Vane et al., 1998). 
Interestingly, it has recently been shown that salicylate directly activates AMPK in 
a mechanism similar to A-769662 (Hawley et al., 2012), therefore activation of 
AMPK by salicylate may provide another mechanism in which aspirin is able to 
treat CVD. However, it remains to be fully determined whether the cardiovascular 
protective effects are directed through AMPK and also to what extent. The 
widespread use of metformin and salicylate suggests that AMPK-activating drugs 
could be relatively safe for the long-term management of chronic inflammatory 
conditions such as atherosclerosis. Given that metformin (indirect) and salicylate 
(direct) activate AMPK via distinct mechanisms (Hawley et al., 2012), the 
preliminary data suggests that metformin and salicylate may exert vascular 
protection through synergistic activation of AMPK-mediated inhibition of JAK-STAT 
signalling (Figure 6.1). However, future work is required to determine whether 
this inhibitory effect is evident at low doses as a very high dose of salicylate was 
used to treat HUVECs in these experiments and prolonged exposure to such high 
doses of aspirin used would have unacceptable side effects, especially potentially 
serious gastrointestinal bleeding. Interestingly, lower (clinically-relevant) doses of 
metformin and salicylate synergistically activate AMPK to inhibit lipogenesis in 
primary hepatocytes from mice and humans (Ford et al., 2015).  
Despite numerous reports suggesting that AMPK activators may be beneficial for 
the treatment of cardiovascular disease and a number of human pathologies 
(Hardie, 2014), no direct AMPK activators have reached clinical use. Therefore, it 
remains unknown whether a safe AMPK activator can be developed. While the 
AMPK subunits (α,β,γ) are expressed more or less ubiquitously and the AMPK 
heterotrimeric complex can come in twelve different possible combinations, the 
individual AMPK subunit isoform in humans and mice display considerable variation 
in tissue-specific expression and subcellular localisation (Ross et al., 2016). Thus, 
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the development of tissue-selective AMPK activators could offer a safety 
advantage. The discovery that A769662 could selectively target β1-containing 
AMPK complexes revealed that it may be feasible to design AMPK activators that 
are targeted to specific tissues, such as the vasculature, by exploiting tissue-
specific variation of subunit isoforms (Scott et al., 2008). Compound 2 ([C2] [5-(5-
hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid]) is another allosteric AMPK 
activator and activates AMPK by binding to the γ subunit Gómez-Galeno et al., 
2010, Hunter et al., 2014). C2 is an AMP-mimetic compound similar to AICAR 
(Gómez-Galeno et al., 2010, Hunter et al., 2014). Importantly, a crystal structure 
of the C2: AMPK complex revealed that the two C2-binding sites in the γ-subunit 
are distinct from nucleotide sites (Langendorf et al., 2016). Numerous small 
molecule direct AMPK activators have been identified from high throughput 
screens such as PF-06409577 (Cameron et al., 2016) and from studies investigating 
alternatives to the thienopyridone core in A769662 such as pyrrolopyridone 
derivatives (Mirguet et al., 2013) (reviewed by Cameron and Kurumbail, 2016). 
Crystallographic studies will provide insight into the molecular mechanism and 
site of action of these compounds. This knowledge provides a strong foundation 
for the design and development of isoform-selective AMPK activator.  
Atherosclerosis is primarily a disease of large conduit arteries and is initiated when 
cardiovascular risk factors through chemical, mechanical or immunological insult 
activate the endothelium. HUVECs are vein ECs derived from immune-privileged 
foetal tissue (Jaffe et al., 1973). Therefore, a limitation in the current study is 
that the effects of AMPK on IL-6 signalling have only been studied in HUVECs. 
Preferentially, human arterial ECs isolated from the coronary artery or aorta would 
have been used for in vitro studies. Unfortunately, the availability of these tissues 
are limited, however human saphenous vein ECs (HSVEC) are more widely 
available. HSVECs were shown to be more functionally similar to arterial ECs than 
HUVECs (Tan et al., 2004). Therefore, future work is required to confirm AMPK-
mediated inhibition of IL-6 signalling in HSVECs. Following these experiments, the 
effects of pharmacological AMPK activation on the development on atherosclerotic 
lesions and p-STAT3/1 levels in atherosclerotic prone mice are examined. These 
studies would also focus on determining whether AMPK-mediated phosphorylation 
of JAK1 or JAK2 is the molecular mechanism underlying AMPK-mediated inhibition 
of IL-6 signalling in situ and in vivo. A key tool for this work would be the 
185 
 
generation of phospho-specific antibodies against JAK1 Ser515/518 and JAK2 
Ser473 phosphorylation sites and use of these antibodies in immunoblotting, 
immunoprecipitation and immunohistochemistry applications. Mass spectrometry 
is another method that could be used to detect AMPK phosphorylation sites in each 
JAK isoform. 
In addition to atherosclerosis, aberrant activation of the JAK-STAT pathway has 
been reported in a variety of disease states, including autoimmune disease and 
haematological malignancies (Grote et al., 2005, Thomas et al., 2015, Banerjee 
et al., 2017). Therefore, the findings of the current study provide a mechanistic 
rationale for potential repurposing of AMPK activators such as metformin for the 
management and/or treatment of these diseases. Rheumatoid arthritis (RA), 
acute lymphoblastic leukaemia (ALL), and myeloproliferative neoplasms (MPNs) 
are associated with aberrant JAK-STAT signalling and are discussed below. For each 
disease: the pathological role of JAK-STAT signalling and the future work required 
to investigate the therapeutic potential of AMPK activators is discussed.  
ALL is an aggressive haematological malignancy characterised by the uncontrolled 
proliferation of lymphoid progenitor cells and classified into B-cell ALL (B-ALL) and 
T-cell ALL (T-ALL) (Chiaretti et al., 2014). ALL is the most common paediatric 
cancer, accounting for 26% of all cancer cases in children (Siegel et al, 2015, Siegel 
et al., 2012). Although T-ALL accounts for only 15% of paediatric ALL cases, T-ALL 
is generally more clinically aggressive than B-ALL (Chiaretti et al., 2014, You et 
al., 2015). Currently, patients with ALL receive an intensive combination of 
cytotoxic chemotherapies and long-term survival in paediatric ALL is currently 85–
90% (Schmiegelow et al., 2010, Hunger et al., 2012). However, chemotherapies 
often induce long-term side-effects, resulting in impairment of vital physiological 
functions among the survivors (Sioka and Kyritsis, 2009, Krishnan and Rajasekaran, 
2014). 20-25% of children with T-ALL experience relapse and are often resistant to 
further chemotherapy and the outcome at this point is much worse (Nguyen et al., 
2008). For patients who relapse allogeneic haematopoietic stem cell transplant 
(HSCT) therapy is also an option. However, HSCT is associated with high risks of 
treatment failure and treatment-related mortality (Gupta et al., 2012). The 
current therapeutic strategy to overcome the long-term side effects and 
relapse/resistance associated with chemotherapies is to specifically target the 
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aberrantly activated signalling pathways driving proliferation and survival of cells. 
Therefore, in order to identify therapeutic targets research has focused on 
characterising aberrations and molecular signatures of haematological 
malignancies. Aberrant JAK-STAT signalling is implicated in the pathogenesis of 
haematological malignancies including MPNs, acute myeloid leukaemia (AML) and 
ALL (Springuel et al., 2015). Activating mutations of JAK1 have been identified in 
6-27% of cases of T-ALL and less frequently in B-ALL (1.5%) (Flex et al., 2008, Jeong 
et al., 2008, Mullighan et al., 2009, Zhang et al., 2012) The V658F mutation in 
JAK1 has been identified in T-ALL patients (Jeong et al., 2008, Mullighan et al., 
2009). The V658F JAK1 mutation drives the ligand-independent activation of STAT 
molecules and transformation of Ba/F3 pro-B cells (Hornakova et al., 2011). 
Therefore, V658F JAK1 is an attractive therapeutic target for treating T-ALL. The 
current study demonstrated that pharmacological activation of AMPK inhibits 
constitutively active V658F-mutated JAK1 mediated phosphorylation of STATs via 
a mechanism requiring Ser515/Ser518 in the SH2 domain (Figure 4.19). Overall, 
our findings provide a mechanistic rationale for the clinical evaluation of AMPK 
activators such as metformin, as potential treatment options for ALL associated 
with constitutive JAK1 signalling. Metformin has previously been investigated as a 
candidate to target T-ALL through AMPK-mediated inhibition of mTOR (Grimaldi et 
al., 2012). About 85% of T-ALL patient’s display increased PI3K/mTOR activation, 
and this has a negative prognostic impact (Silva et al., 2008, Cardoso et al., 2009, 
Jotta et al., 2010). Grimaldi and co-workers demonstrated that metformin 
activates AMPK in T-ALL cells, leading to mTOR inhibition and induced apoptotic 
cell death (Grimaldi et al., 2012). Taken together with the current study, these 
findings suggest that AMPK activators would be most effective in treating T-ALL 
cases that depend on activation of JAK-STAT and PI3K/mTOR pathways for their 
proliferation and survival. Overall, these findings provide a strong rationale for 
the development of AMPK agonists as novel therapeutic agents for T-ALL patients. 
There is currently a clinical trial recruiting paediatric patients with relapsed ALL 
for treatment with a combination of metformin and chemotherapy 
(NCT01324180). Future work would focus on determining whether AMPK activators 
exert anti-leukemic effects on T-ALL cells and confirming that these effects are 
via AMPK-mediated inhibition of JAK-STAT signalling. Initial experiments would 
utilise the BaF3 cells, an IL-3 dependent murine pro B cell line. Previously, it has 
been confirmed that BaF3 cells transduced with retroviral constructs expressing 
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V658F JAK1 mutant resulted in constitutive JAK-STAT activation and promoted 
autonomous cell proliferation (Hornakova et al., 2011). Furthermore, treatment 
with ruxolitinib (JAK 1/2 inhibitor) completely blocked phosphorylation of JAK1 
and STAT5, and autonomous cell proliferation (Hornakova et al., 2011). Therefore, 
BaF3 cells transduced with V658F JAK1 mutant or V658F/S515A/S518A JAK1 
mutant could be used to determine the effects of a panel of AMPK activators on 
constitutive JAK-STAT signalling and autonomous cell proliferation versus JAK 
inhibitors. Following these experiments, the therapeutic efficacy of AMPK 
activators would be tested in T-ALL cell lines and T-ALL primary cells with JAK 
genomic lesions. Finally, the in vivo efficacy of AMPK activators would assessed in 
murine xenograft models of T-ALL derived from primary human T-ALL samples with 
JAK genomic lesions. This in vivo model will be used to evaluate whether AMPK 
activators are tolerated, can decrease leukemic burden and prolong survival.  
MPNs are a group of haematological malignancies characterised by the 
uncontrolled proliferation of myeloid progenitor cells such as platelets, 
erythrocytes, and neutrophils. Aberrant JAK2 signalling plays a key role in the 
pathogenesis of MPNs. V617F JAK2, which is a mutation analogous to the T-ALL-
associated V658F JAK1, is frequently found in patients with classical MPNs: 
polycythemia vera (PV) (>95%), essential thrombocythemia (ET) (∼50%), and 
primary myelofibrosis (PMF) (∼50%) (Baxter et al., 2005, James et al., 2005, 
Kralovics et al., 2005, Levine et al., 2005). In the current study the effects of 
AMPK activation on signalling downstream of an endogenous ligand activated JAK2 
or a constitutively active V617F mutant JAK2 were not examined. During the 
completion of this thesis, Kawashima and Kirito reported that metformin 
treatment of V617F JAK2 positive MPN cell lines induced AMPK activation, leading 
to decreased levels of STAT5 phosphorylation and induction of apoptotic cell death 
(Kawashima and Kirito, 2016). In the current study, AMPK was shown to 
phosphorylate SH2 domain-derived peptides from JAK1 and JAK2 but not JAK3 or 
Tyk2, and alignment of the primary sequences of JAK1 and JAK2 revealed that 
Ser473 in JAK2 aligns with Ser518 in JAK1 (Figure 4.11). Taken together, these 
findings suggest that pharmacological activation of AMPK inhibits constitutively 
active V617F-mutated JAK2 mediated phosphorylation of STATs via a mechanism 
requiring Ser473 in the SH2 domain. Therefore, clinical studies evaluating AMPK 
activators as potential treatment options for T-ALL should be expanded to include 
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MPNs associated with V617F JAK2. The effectiveness of targeting JAK-STAT 
signalling has been demonstrated in in patients with myelofibrosis. In 2011, 
ruxolitinib, a ATP-competitive JAK1/2 inhibitor, was approved by the U.S. Food 
and Drug Administration (FDA) for the treatment of intermediate/high-risk MF 
based on the results of two phase III clinical trials for myelofibrosis (COMFORT-I 
[Verstovsek et al., 2012] and COMFORT-II [Harrison et al., 2012]). Although 
treatment with ruxolitinib alleviated splenomegaly and other symptoms of MF, 
allele burden of the V617F JAK2 mutant clone was only minimally decreased 
(Cervantes et al., 2013, Verstovsek et al., 2013). These observations have 
prompted efforts to devise combinatorial treatment strategies to improve and 
extend the benefits of ruxolitinib therapy. Disease-related complications affecting 
survival in MPN include thrombohaemorrhagic events and disease transformation 
into AML (Tefferi and Barbuie, 2015). PV and ET are considered relatively benign 
diseases and thrombohaemorrhagic events are the main cause of morbidity and 
mortality in patients (Tefferi and Barbuie, 2015). Therefore, these patients 
require a treatment strategy mainly aimed at preventing thrombotic and bleeding 
complications. Currently, patients are managed with phlebotomy (PV patients 
only), lose dose aspirin for its inhibitory effects on platelet function and thrombus 
formation, and cytoreduction with either hydroxyurea or IFN-α (Tefferi and 
Barbuie, 2015). New treatment options are urgently required for those patients 
not adequately managed by current treatments. However, the pathogenesis of 
thrombosis and dysfunctional haemostasis in MPNs remains elusive. A recent study 
reported that a subpopulation of MPN patients express V617F JAK2 in ECs (Teofili 
et al., 2011). Following this report, Etheridge and co-workers utilised mouse 
models expressing V617F JAK2 specifically in ECs or haematopoietic cells to 
determine which cells contribute to thrombohaemorrhagic events in MPNs 
(Etheridge et al., 2014). Mice expressing V617F JAK2 in both endothelial and 
haematopoietic cells developed a MPN phenotype and these mice showed severely 
attenuated thrombosis following injury. Restricting V617F JAK2 expression to ECs 
or haematopoietic cells revealed that both cell types contribute to attenuated 
thrombosis (Etheridge et al., 2014). Overall, Etheridge and co-workers have 
identified endothelial cells expressing V617F JAK2 as a potential new cellular 
target for MPN therapies. Furthermore, the study proposes that the expression of 
V617F JAK2 in both haematopoietic and endothelial compartments contributes to 
the bleeding phenotype via dysregulation of von Willebrand factor (a pro-
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thrombotic molecule) (Etheridge et al., 2014). Taken together with the current 
study, these finding suggest AMPK activators could be a new treatment option to 
manage clotting defects in MPN patients. Thus, in addition to the evaluating the 
potential anti-proliferative effects of AMPK activators on V617F JAK2 MPNs, the 
anti-haemorrhagic potential of AMPK activators should also be evaluated in V617F 
JAK2 positive -MPNs and -endothelial cells. Future work would focus on 
investigating of anti-haemorrhagic potential of AMPK activators on V617F JAK2 
ECs. Lin et al., demonstrated that primary lung V617F JAK2 ECs, isolated from 
mice expressing V617F JAK2 in both endothelial and haematopoietic cells, 
proliferated to a greater extent than WT JAK2 ECs (Lin et al., 2016), which was 
consistent with a previous report on lentiviral-transduced V617F JAK2 HUVECs 
(Kilani et al., 2014). Therefore, HUVECs transduced with V617F JAK2 or 
V617F/S473A JAK2 could be used to determine the effects of a panel of AMPK 
activators on constitutive JAK-STAT signalling and V617F JAK2-mediated cell 
proliferation versus JAK inhibitors. This experiment would also determine whether 
Ser473 is required for AMPK-mediated inhibition of constitutively active V617F 
JAK2 signalling. The endothelium is a primary source of many of the major 
haemostatic regulatory molecules such as prothrombotic molecules vWF and 
factor VIII, and antiplatelet molecules prostacyclins and nitric oxide (Verhamme 
and Hoylaerts, 2006). The expression and secretion of these molecules should be 
examined in V617F JAK2 ECs treated with or without AMPK activators. Utilising the 
mouse models expressing V617F JAK2 specifically in ECs, haematopoietic cells, or 
both compartments (as described by Etheridge et al., 2014), to examine the ability 
of AMPK activators to prevent dysfunctional haemostasis in these models. 
RA is a common autoimmune disease characterised by synovial inflammation and 
hyperplasia, autoantibody production such as rheumatoid factor and anti-
citrullinated protein antibody, cartilage and bone destruction, and systemic 
features, including cardiovascular, pulmonary, psychological, and skeletal 
disorders (McInnes and Schett, 2011). Although the etiology of RA is not fully 
understood, evidence suggests that autoimmunity to citrullinated epitopes 
predominantly present on matrix proteins plays a central role in the pathology of 
RA (Wegner et al., 2010). In addition, evidence suggests that IL-6 plays a crucial 
role in RA pathogenesis, as elevated levels of IL-6 in RA patients’ sera and synovial 
fluid correlate with high disease activity (Madhok et al., 1993). While IL-6 may 
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perpetuate the inflammatory and degenerative process by inducing the hepatic 
acute-phase response, directly activating different cells such as B and T 
lymphocytes, macrophages and osteoclasts, promoting the infiltration of 
inflammatory cells and production matrix metalloproteinases, it may also play a 
role in the initiation stage of RA (Srirangan and Choy, 2010). The pathogenic 
potential of IL-6-STAT3 signalling in initiating RA is illustrated by findings 
demonstrating that activation of this pathway in CD4 + T cells predicts 
development of RA in a cohort of undifferentiated early arthritis (Pratt et al., 
2012). Interestingly, IL-6-mediated STAT-3 signalling in CD4 + T cells was most 
prominent in in patients with anti-citrullinated peptide antibody-negative RA 
(Pratt et al., 2012). Furthermore, using CD4 + T cells isolated from the peripheral 
blood and synovial fluid of RA patients, Ju et al showed that siRNA mediated 
knockdown of STAT3 in these cells prevented T helper type 17 (Th17) 
differentiation but increased the proportion of regulatory T cells (Tregs) (Ju et al., 
2012). Evidence suggests that keeping an adequate balance between pathogenic 
Th17 cells and protective Tregs is critical for preventing the development of RA 
and IL-6 has been considered a key cytokine that shifts the Th17/Treg balance the 
toward the pro-inflammatory Th17 phenotype (Pesce et al., 2012, Nistala and 
Wedderburn, 2009, Bettelli et al., 2006). Therefore, agents targeting IL-6 
signalling have attracted significant attention as a promising agent in RA 
prevention and treatment. The central role of IL-6 in RA pathogenesis has been 
confirmed by successful therapeutic blockade of membrane and soluble 
interleukin-6 receptor in RA patients with a humanized anti-IL-6R antibody 
(tocilizumab) (Mihara et al., 2005, Garnero et al., 2010, Kremer et al., 2011). Most 
recently, tofacitinib, a ATP-competitive JAK1/3 inhibitor, was approved by the US 
FDA for RA treatment of patients who are intolerant/resistant to first line 
therapies such as methotrexate (reviewed by Nakayamada et al., 2016). The 
current study demonstrated that pharmacological activation of AMPK inhibits sIL-
6R/IL-6 stimulation of the JAK-STAT pathway via a mechanism requiring 
Ser515/Ser518 in the JAK1 SH2 domain. Therefore, our findings provide a 
mechanistic rationale for the clinical evaluation of AMPK activators such as 
metformin, as a potential treatment option for the management of RA. In fact, a 
small number of studies have already shown that AMPK activators, metformin and 
A769662, suppressed inflammatory arthritis in murine models of RA (Kang et al., 
2013, Son et al., 2014, Guma et al., 2015). Interestingly, Kang and co-workers 
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demonstrated that metformin inhibits Th17-cell differentiation both in vivo and 
ex vivo, and metformin stimulates AMPK activation and inhibits STAT3 
phosphorylation in CD4 + T cells in vitro (Kang et al., 2013). Taken together with 
the current study, the data suggests that metformin suppresses Th17 cell 
differentiation by inhibiting STAT3 phosphorylation via AMPK-mediated 
phosphorylation of JAK1. Therefore, these findings provide a mechanistic 
rationale for targeted activation of AMPK as a therapeutic approach in RA. Future 
studies would focus on determining that AMPK-mediated phosphorylation of JAK1 
is the molecular mechanism underlying AMPK-induced inhibition of Th17-cell 
differentiation and attenuation of arthritis in vivo. A key tool in this study would 
be the generation of phospho-specific antibodies against JAK1 Ser515/518 and 
JAK2 Ser473 phosphorylation sites and use of these antibodies in immunoblotting, 
immunoprecipitation and immunohistochemistry applications.  
As described above, pharmacological JAK inhibitors are available; ruxolitinib (a 
ATP-competitive JAK1/JAK2 inhibitor) approved for use in MF and PV, and 
tofacitinib (a ATP-competitive JAK1/JAK3 inhibitor) approved for use in RA. By 
occupying the ATP-binding pocket in the kinase domain, these inhibitors abolish 
phosphoryl transfer from ATP to the substrate. Given the high sequence and 
structural identity between the JAK kinase domains, developing specific inhibitors 
against each JAK member represents a challenge. Thus, alternative and novel 
approaches to targeting JAK, not involving the ATP-binding pocket are required 
(reviewed by Leroy and Constantinescu, 2017). An alternative approach that might 
result in improved specificity would be to target the cytokine receptor - JAK 
interaction. However, currently there are no JAK inhibitors targeting the cytokine 
receptor-JAK interaction in development as lack of structural information has 
hindered this approach. As discussed in chapter 4, the recent advances made by 
the group of P. Lupardus has provided the first structural understanding of cytokine 
receptor – JAK association (Lupardus et al., 2014, Ferrao et al., 2016). Surprisingly, 
it was found that the SH2 domain interacts with the cytokine receptor box 2 motif 
(Lupardus et al., 2014). Given that Ser518 and Ser515 were found to lie beside 
this interaction, it was proposed that AMPK phosphorylation of Ser515 and Ser518 
of JAK1 disrupts the cytokine receptor box2-JAK1 SH2 binding site to destabilise 
the JAK1-cytokine receptor complex leading to impaired JAK1 signalling. 
Therefore, these findings suggest that the receptor box2-JAK1 SH2 interaction is 
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a potential target for designing small-molecule chemical probes that may induce 
disruption of the interaction. Crucially, targeting the SH2 domain may produce a 
small molecule that has selectivity for one specific JAK isoform and given SH2 
domains close interaction with the receptor this may also lead to targeting specific 
JAK isoforms in complex with distinct receptors. 
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Chapter 6 - Appendices 
6.1 AMPK-mediated inhibition of JAK-STAT signalling 
Previous unpublished studies in our group have investigated whether AMPK 
modifies IL-6 stimulation of JAK-STAT signalling in HUVECs (Claire Rutherford, 
Marie-Ann Ewart, Ian Salt, Tim Palmer, personal communication). Those studies, 
performed by Dr. Claire Rutherford and Dr. Marie-Ann Ewart (University of 
Glasgow) are described in more detail in sections 6.1.1-6.1.3 and form the basis 
of the studies described in this thesis. 
6.1.1 Pharmacological activation of AMPK inhibits sIL-6R/IL-6 signalling in 
vascular ECs 
Incubation of HUVECs with sIL-6R/IL-6 trans-signalling complex for 30 minutes 
increased STAT3 phosphorylation on Tyr705. Pharmacological activation of AMPK, 
using two chemically distinct agonists AICAR or A769662, significantly (**p<0.01) 
inhibited sIL-6R/IL-6 stimulation of STAT3 Tyr705 phosphorylation (Figure 6.1). In 
addition, sIL-6R/IL-6 stimulation of STAT3 Tyr705 phosphorylation was 
significantly (*p<0.05) inhibited in HUVECs pre-treated with a combination of 
clinically utilized AMPK activators metformin and salicylate (Hawley et al., 2012) 
(Figure 6.1). Activation of AMPK by each distinct stimulus was assessed by 
confirming AMPK-mediated ACC phosphorylation on Ser79 (Davies et al., 1992). 
Furthermore, AMPK activation on its own had no detectable effect on STAT3 
phosphorylation (Figure 6.1). Overall, these data demonstrate that 
pharmacological activators of AMPK inhibit sIL-6Rα/IL-6 signalling in vascular ECs. 
The data shown in figure 6.1 was generated and analysed by Dr Claire Rutherford, 
University of Glasgow.  
Targeted short interfering RNA (siRNA)-mediated knockdown of AMPK1 catalytic 
subunits attenuated the inhibitory effect of A769662 (Figure 6.2A) and AICAR 
(Figure 6.2B) on STAT3 Tyr705 phosphorylation. Immunoblotting of whole cell 
extracts with phospho-ACC (Ser79) antibody verified that treatment of cells with 
AMPK-siRNA inhibits AMPK activity in HUVECs as indicated by reduced phospho-
ACC (Ser79) levels relative to HUVECs transfected with the control siRNA (Figures 
6.2A and 6.2B). Overall, these data indicate that A769662- and AICAR- mediated 
inhibition of sIL-6R/IL-6 signalling is  via AMPK activation. The data shown in 
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figure 6.2 was generated and analysed by Dr Claire Rutherford, University of 
Glasgow. 
6.1.2 Activation of AMPK inhibits induction of STAT3 regulated genes and 
STAT3-mediated monocyte chemotaxis 
It was next sought to determine whether AMPK activation influenced the induction 
of STAT3 target genes SOCS3 and CCAAT/enhancer-binding protein δ (C/EBPδ in 
HUVECs (Cantwell et al., 1998, Yang et al., 2010). Total RNA was extracted from 
HUVECs incubated with sIL-6R/IL-6 in the presence or absence of A769662, and 
messenger RNA (mRNA) levels were then analysed by quantitative reverse 
transcription PCR. Incubation of HUVECs with sIL-6R/IL-6 in the absence of A769662 
caused a significant increase, compared to the basal level, in SOCS3 (**p<0.01) and 
C/EBPδ (***p<0.001) mRNA expression (Figure 6.3). Preincubation with A769662 
inhibited sIL-6R/IL-6 stimulation of SOCS3 and C/EBPδ mRNA expression, relative to 
sIL-6R/IL-6 treatment alone (Figure 6.3). Furthermore, treatment of HUVECs with 
A769662 alone had no significant (p>0.05, NS) effect on SOCS3 and C/EBPδ mRNA 
levels, compared to basal levels (Figure 6.3). Overall, A769662 reduced sIL-
6R/IL-6 -stimulated SOCS3 and C/EBPδ mRNA and protein expression. The data 
shown in figure 6.3 was generated and analysed by Dr Claire Rutherford, University 
of Glasgow. 
The effects of AMPK activation on sIL-6R/IL-6 -induced monocyte chemotaxis 
were also investigated. The ability of IL-6 to induce chemokine expression and 
thereby increase monocyte chemotaxis is well described (Jougasaki  et al., 2010, 
Ortiz-Muñoz et al., 2009, Romano et al., 1997). Conditioned media was collected 
from HUVECs following stimulation with or without sIL-6R/IL-6 in the presence 
or absence of A769662. To ensure that sIL-6R/IL-6 and A769662 were not present 
in the conditioned media, HUVEC monolayers were extensively washed prior to 
incubation and collection of conditioned medium. The capacity of the conditioned 
media to stimulate monocyte migration was assessed using a trans-well migration 
assay. It was found that the migration of U937 monocytic cells towards conditioned 
media from sIL-6R/IL-6-stimulated HUVECs was significantly (*p<0.05) increased 
(Figure 6.4). Conditioned medium from HUVECs pre-treated with A769662 for 30 
min prior to cytokine stimulation elicited significantly (*p<0.05) less U937 cell 
migration compared to conditioned media from sIL-6R/IL-6-stimulated HUVECs 
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(Figure 6.4). The data shown in Figures 6.4 was generated and analysed by Dr 
Marie-Ann Ewart, University of Glasgow. 
6.1.3 Activation of AMPK inhibits sIL-6R/IL-6 and IFNα responses in 
vascular ECs via a common post-receptor intermediate 
IFN-α stimulates the JAK-STAT signalling pathway via an IFNAR1/IFNAR2 complex 
which is distinct from the sIL-6Rα/IL-6/gp130 complex (Borden et al., 2007). 
A769662 significantly (**p<0.01) inhibits both sIL-6Rα/IL-6 and IFN-α stimulation of 
STAT3 Tyr705 phosphorylation in HUVECs (Figure 6.5A). Furthermore, the 
inhibitory effect of AMPK on sIL-6R/IL-6 responses was not restricted to STAT3, 
as pre-treatment of HUVECs with A769662 significantly (***p<0.001) inhibited sIL-
6R/IL-6 stimulated phosphorylation of STAT1 on Tyr701 (Figure 6.5B). The data 
shown in figures 6.5 was generated and analysed by Dr Claire Rutherford, 
University of Glasgow.Taken together, these data demonstrated that activation of 
AMPK by multiple stimuli triggered a rapid and significant reduction in the ability 
of sIL-6R/IL-6 to stimulate STAT3 phosphorylation on Tyr705. AMPK activation 
reduced sIL-6R/IL-6 induction of STAT3 target genes and STAT3-meditated 
monocyte chemotaxis. These results would suggest that AMPK exerts its inhibitory 
effects on multiple cytokine-activated signalling pathways at one or more common 
loci downstream of both IFNAR1/IFNAR2 and gp130-containing cytokine receptor 
complexes. 
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Figure 6.1: Pharmacological activation of AMPK inhibits sIL-6Rα/IL-6 signalling in HUVECs 
HUVECs were pre-incubated in the presence or absence of 1 mM AICAR (2 hr), 100 μM A769662 
(40 min) or a combination of 3 mM metformin and 5 mM salicylate (Met+Sal, 1 hr) prior to stimulation 
with sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml) for a further 30 min as indicated. Protein-equalized cell lysates 
were then analysed by SDS-PAGE and immunoblotting with the indicated antibodies. Densitometric 
analysis for STAT3 phosphorylation normalized to respective total levels is shown in each case. Data 
are shown as mean ±SEM for n=3 independent experiments. *p<0.05, **p<0.01. (Data was 
generated and analysed by Dr. Claire Rutherford, University of Glasgow.) 
  
197 
 
 
Figure 6.2: AMPK-mediated inhibition of STAT3 Tyr705 phosphorylation in HUVECs.  
(A) HUVECs were transfected with either non-targeting control or AMPKα1-specific siRNAs as 
indicated. Cells were then pre-incubated in the presence or absence of 100 μM A769662 (40 min) 
prior to stimulation with sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml) for a further 30 min as indicated. Protein-
equalized cell lysates were then analysed by SDS-PAGE and immunoblotting with the indicated 
antibodies. Densitometric analysis for STAT3 phosphorylation normalized to respective total levels 
is shown in each case. Data are shown as mean ±SEM for n=3 independent experiments. *p<0.05. 
(B) HUVECs were pre-incubated in the presence or absence of 1 mM AICAR (2 hr) prior to 
stimulation with sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml) for a further 30 min as indicated. Protein-equalized 
cell lysates were then analysed by SDS-PAGE and immunoblotting with the indicated antibodies. 
The data shown are representative of multiple experiments. (Data was generated and analysed by 
Dr. Claire Rutherford, University of Glasgow.)  
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Figure 6.3: A769662 inhibits sIL-6R/IL-6-mediated SOCS3 and CEBPD mRNA induction.  
HUVECs were pre-treated for 30 min with or without A769662 (100 M) prior to stimulation with sIL-
6R/IL-6 (25 ng/ml, 5 ng/ml) for either 1 hr (CEBPD) or 3 hr (SOCS3). Messenger RNA levels were 
then analyzed by quantitative reverse transcription PCR and normalized to GAPDH mRNA. Analysis 
of n=3 (CEBPD) or n=4 (SOCS3) independent experiments for SOCS3 and CEBPD normalized to 
GAPDH levels is shown. **p<0.01, ***p<0.001 (Data was generated and analysed by Dr. Claire 
Rutherford, University of Glasgow.)
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Figure 6.4: A769662 inhibits sIL-6Rα/IL-6-mediated U937 monocytic cell migration induced 
by conditioned medium from treated HUVECs in vitro  
HUVECs were pre-treated for 30 min with or without A769662 (100 M) prior to stimulation with sIL-
6R/IL-6 (25 ng/ml, 5 ng/ml) for 2 hr. After washing and incubation in fresh medium for a further 1 
hr, conditioned medium was removed and used for chemotaxis assays using U937 monocytic cells. 
Data are shown as mean ±SEM for n = 3 independent experiments. *p<0.05, (Data was generated 
and analysed by Dr. Marie-Ann Ewart, University of Glasgow.) 
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Figure 6.5: AMPK inhibits STAT1 and STAT3 activation by sIL-6R/IL-6 and STAT3 by IFNα.  
(A&B)HUVECs were incubated for 30 min with either vehicle (V) or A769662 (100 M) prior to 
stimulation with either vehicle (V), sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for 30 min or IFN (1000U/ml) 
for 15 min. Cell lysates were then analyzed by SDS-PAGE and immunoblotting with the indicated 
antibodies. Densitometric analysis for STAT3 or STAT1 phosphorylation normalized to respective 
total levels is shown in each case. Data are shown as mean ±SEM for n=3 independent experiments. 
**p>0.01, ***p<0.001. Data was generated and analysed by Dr. Claire Rutherford, University of 
Glasgow. 
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6.2 Materials 
Abcam, Cambridge, UK 
Anti-GST antibody 
 
Agilent Technologies, Santa Clara, CA, USA 
Quikchange II Site-Directed Mutagenesis kit  
BL21 (DE3) Competent Cells 
XL10-Gold ultracompetent cells 
 
Cayman Chemicals, Ann Arbor, MI, USA 
PP242 
 
Cell Biolabs, Inc., San Diego, CA, USA  
Rapid GST Inclusion Body Solubilization and Renaturation Kit 
 
Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK  
Precision Plus Protein Kaleidoscope Standards 
 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK  
2-[4-(2-hydroxyethyl)-1-piperazine] ethanesuphonic acid (HEPES) 
Ammonium Persulphate (APS)  
Corning tissue culture T75/T150 flasks, 10 cm plates and 6 well plates  
Ethanol 
Ethidium Bromide 
Glycine 
Methanol 
Tris base (tris(hydroxymethyl)aminoethane) 
 
Formendium, Hunstanton, Norfolk, UK  
Bacterial Agar  
Tryptone  
Yeast extract powder 
 
GE Healthcare, Little Chalfont, Buckinghamshire, UK 
Streptavidin-Sepharose beads, high performance 
Whatman Protran Nitrocellulose Membrane 
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Glutathine-S-Sepharose 4B  
Invitrogen (Life Technologies Ltd), Paisley, UK  
Dulbecco’s Modified Eagle Medium (DMEM) 
Endotoxin-free phosphate buffered saline (PBS) 
Opti-MEM, reduced serum media 
 
Kodak Company, Hemel Hampstead, Hertfordshire, UK 
Medical X-ray Film General Purpose Blue  
 
Lonza, Walkersville, MD, USA 
Endothelial Cell Basal Medium-2 (EBM-2)  
Endothelial cell growth media kit (EGM-2)  
Human umbilical vein endothelial cells (HUVECs) 
 
Merck Millipore, Watford, Hertfordshire, UK 
Anti-Phosphotyrosine, clone 4G10  
Bugbuster protein extraction reagent 
 
Melford Laboratories Ltd, Chelsworth, Ipswich, Suffolk, UK  
Dithiothreitol (DTT) 
Isopropyl-β-D-thiogalactopyranoside (IPTG) 
 
New England Bioscience (UK) Ltd, Hitchin, Hertfordshire, UK 
100 mM dNTPs (dATP, dTTP, dGTP, dCTG) 
 
Perkin-Elmer Life Sciences, Waltham, MA, USA 
Western Lightning Plus Enhanced chemiluminescence (ECL) substrate 
ATP, [γ-32P]- 3000Ci/mmol 10mCi/ml Lead 
 
Premier International Foods, Cheshire, UK  
Marvel dried skimmed milk 
 
Promega UK Ltd, Southampton, UK 
1 kb DNA Ladder 
100 bp DNA Ladder 
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6x DNA Loading Buffer 
Acetylated BSA 
BamHI  
EcoRI  
Pfu DNA polymer 10X buffer  
Pfu DNA polymerase 
Restriction Enzyme 10X Buffer  
T4 DNA Ligase 
T4 DNA Ligase 10X Buffer 
 
Promega, Madison, WI, USA  
Wizard® Plus SV Minipreps Kit 
 
Qiagen, Crawley, West Sussex, UK 
Endofree Plasmid Maxi Kit 
QIAquick Gel Extraction Kit 
Human JAK1 siRNA  
Human JAK2 siRNA 
Human TYK2 siRNA 
Ni-NTA Agarose 
 
R & D Systems, Abingdon Science Park, Abingdon, Oxford, UK  
Interleukin-6 (IL-6) (murine/human)  
Soluble interleukin-6 receptor-α (sIL-6α) (murine/human) 
GF109203X 
Recombinant Human 14-3-3 zeta, HRP-conjugated 
 
Roche Diagnostic Ltd, Burgess Hill, UK  
Complete, EDTA-free protease inhibitor cocktail tablets  
 
Sigma-Aldrich Ltd, Gillingham, Dorset, UK  
(+)-Etomoxir sodium salt hydrate (Etomoxir) 
30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide  
Ampicillin  
Anti-FLAG M2 affinity gel  
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Benzamidine 
Bovine serum albumin 
Bovine serum albumin (BSA)  
Bromophenol blue  
Dimethyl Suphoxide (DMSO) 
Ethylenediamine tetraacetic acid (EDTA)  
Fetal bovine serum (FBS) 
Glycerol 
Hydrogen peroxide (H2O2) 
Imidazole  
Interferon-α (IFN-α) 
Isopropanol 
Kanamycin 
L-glutamine  
Medium 199 with HEPES modification  
Nω-Nitro-D-arginine methyl ester hydrochloride (D-NAME)  
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME)  
Penicillin-Streptomycin  
phenylmethylsulphonyl fluoride (PMSF)  
Ponceau stain  
Potassium Hydroxide  
Protein-G-Sepharose4B Fast Flow recombinant protein  
Puromycin 
Reduced Glutathione  
Sodium Dodecyl Sulphate (SDS) 
Sodium deoxycholate  
Sodium orthovanadate 
Soybean trypsin inhibitor  
Sterile filtered cell culture water 
Triton X-100  
Trypsin-EDTA 
Trypsin-EDTA for endothelial cells 
Tween-20 
 
Sarstedt, Beaumont Leys, Leicester, UK 
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Tissue culture cell scraper 25 cm  
 
SelleckChem, Houston, TX, USA 
EX527 (Selisistat) 
 
ThermoScientific (Thermo), Boston, MA, USA 
Human non-targeting siRNA  
G418 
 
Tocris Bioscience, Ellisville, MO, USA 
A769662 (6,7-Dihydro-4-hydroxy-3-(2′-hydroxy[1,1′-biphenyl]-4-yl)-6-oxo-
thieno[2,3-b]pyridine-5-carbonitrile) 
 
VWR International Ltd., Lutterworth, Leicestershire, UK 
Glacial Acetic Acid 
Disodium hydrogen orthophosphate (Na2HPO4) 
Potassium Acetate 
Potassium Chloride (KCl) 
Potassium dihydrogen orthophosphate (KH2PO4) 
Sodium Carbonate (Na2CO3) 
Sodium Chloride (NaCl) 
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6.3 Full length JAK peptide array sequences and layout  
 
Table 6-1: Peptide array spanning the human JAK1 open reading frame  
(continued overleaf)  
  
Array Position Peptide Sequence Array Position Peptide Sequence
1   M-Q-Y-L-N-I-K-E-D-C-N-A-M-A-F-C-A-K-M-R-S-S-K-K-T 1 - 25 81   E-A-L-S-F-V-S-L-V-D-G-Y-F-R-L-T-A-D-A-H-H-Y-L-C-T 401 - 425
2   I-K-E-D-C-N-A-M-A-F-C-A-K-M-R-S-S-K-K-T-E-V-N-L-E 6 - 30 82   V-S-L-V-D-G-Y-F-R-L-T-A-D-A-H-H-Y-L-C-T-D-V-A-P-P 406 - 430
3   N-A-M-A-F-C-A-K-M-R-S-S-K-K-T-E-V-N-L-E-A-P-E-P-G 11 - 35 83   G-Y-F-R-L-T-A-D-A-H-H-Y-L-C-T-D-V-A-P-P-L-I-V-H-N 411 - 435
4   C-A-K-M-R-S-S-K-K-T-E-V-N-L-E-A-P-E-P-G-V-E-V-I-F 16 - 40 84   T-A-D-A-H-H-Y-L-C-T-D-V-A-P-P-L-I-V-H-N-I-Q-N-G-C 416 - 440
5   S-S-K-K-T-E-V-N-L-E-A-P-E-P-G-V-E-V-I-F-Y-L-S-D-R 21 - 45 85   H-Y-L-C-T-D-V-A-P-P-L-I-V-H-N-I-Q-N-G-C-H-G-P-I-C 421 - 445
6   E-V-N-L-E-A-P-E-P-G-V-E-V-I-F-Y-L-S-D-R-E-P-L-R-L 26 - 50 86   D-V-A-P-P-L-I-V-H-N-I-Q-N-G-C-H-G-P-I-C-T-E-Y-A-I 426 - 450
7   A-P-E-P-G-V-E-V-I-F-Y-L-S-D-R-E-P-L-R-L-G-S-G-E-Y 31 - 55 87   L-I-V-H-N-I-Q-N-G-C-H-G-P-I-C-T-E-Y-A-I-N-K-L-R-Q 431 - 455
8   V-E-V-I-F-Y-L-S-D-R-E-P-L-R-L-G-S-G-E-Y-T-A-E-E-L 36 - 60 88   I-Q-N-G-C-H-G-P-I-C-T-E-Y-A-I-N-K-L-R-Q-E-G-S-E-E 436 - 460
9   Y-L-S-D-R-E-P-L-R-L-G-S-G-E-Y-T-A-E-E-L-C-I-R-A-A 41 - 65 89   H-G-P-I-C-T-E-Y-A-I-N-K-L-R-Q-E-G-S-E-E-G-M-Y-V-L 441 - 465
10   E-P-L-R-L-G-S-G-E-Y-T-A-E-E-L-C-I-R-A-A-Q-A-C-R-I 46 - 70 90   T-E-Y-A-I-N-K-L-R-Q-E-G-S-E-E-G-M-Y-V-L-R-W-S-C-T 446 - 470
11   G-S-G-E-Y-T-A-E-E-L-C-I-R-A-A-Q-A-C-R-I-S-P-L-C-H 51 - 75 91   N-K-L-R-Q-E-G-S-E-E-G-M-Y-V-L-R-W-S-C-T-D-F-D-N-I 451 - 475
12   T-A-E-E-L-C-I-R-A-A-Q-A-C-R-I-S-P-L-C-H-N-L-F-A-L 56 - 80 92   E-G-S-E-E-G-M-Y-V-L-R-W-S-C-T-D-F-D-N-I-L-M-T-V-T 456 - 480
13   C-I-R-A-A-Q-A-C-R-I-S-P-L-C-H-N-L-F-A-L-Y-D-E-N-T 61 - 85 93   G-M-Y-V-L-R-W-S-C-T-D-F-D-N-I-L-M-T-V-T-C-F-E-K-S 461 - 485
14   Q-A-C-R-I-S-P-L-C-H-N-L-F-A-L-Y-D-E-N-T-K-L-W-Y-A 66 - 90 94   R-W-S-C-T-D-F-D-N-I-L-M-T-V-T-C-F-E-K-S-E-Q-V-Q-G 466 - 490
15   S-P-L-C-H-N-L-F-A-L-Y-D-E-N-T-K-L-W-Y-A-P-N-R-T-I 71 - 95 95   D-F-D-N-I-L-M-T-V-T-C-F-E-K-S-E-Q-V-Q-G-A-Q-K-Q-F 471 - 495
16   N-L-F-A-L-Y-D-E-N-T-K-L-W-Y-A-P-N-R-T-I-T-V-D-D-K 76 - 100 96   L-M-T-V-T-C-F-E-K-S-E-Q-V-Q-G-A-Q-K-Q-F-K-N-F-Q-I 476 - 500
17   Y-D-E-N-T-K-L-W-Y-A-P-N-R-T-I-T-V-D-D-K-M-S-L-R-L 81 - 105 97   C-F-E-K-S-E-Q-V-Q-G-A-Q-K-Q-F-K-N-F-Q-I-E-V-Q-K-G 481 - 505
18   K-L-W-Y-A-P-N-R-T-I-T-V-D-D-K-M-S-L-R-L-H-Y-R-M-R 86 - 110 98   E-Q-V-Q-G-A-Q-K-Q-F-K-N-F-Q-I-E-V-Q-K-G-R-Y-S-L-H 486 - 510
19   P-N-R-T-I-T-V-D-D-K-M-S-L-R-L-H-Y-R-M-R-F-Y-F-T-N 91 - 115 99   A-Q-K-Q-F-K-N-F-Q-I-E-V-Q-K-G-R-Y-S-L-H-G-S-D-R-S 491 - 515
20   T-V-D-D-K-M-S-L-R-L-H-Y-R-M-R-F-Y-F-T-N-W-H-G-T-N 96 - 120 100   K-N-F-Q-I-E-V-Q-K-G-R-Y-S-L-H-G-S-D-R-S-F-P-S-L-G 496 - 520
21   M-S-L-R-L-H-Y-R-M-R-F-Y-F-T-N-W-H-G-T-N-D-N-E-Q-S 101 - 125 101   E-V-Q-K-G-R-Y-S-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-S-H 501 - 525
22   H-Y-R-M-R-F-Y-F-T-N-W-H-G-T-N-D-N-E-Q-S-V-W-R-H-S 106 - 130 102   R-Y-S-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 506 - 530
23   F-Y-F-T-N-W-H-G-T-N-D-N-E-Q-S-V-W-R-H-S-P-K-K-Q-K 111 - 135 103   G-S-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I-L-R-T-D-N 511 - 535
24   W-H-G-T-N-D-N-E-Q-S-V-W-R-H-S-P-K-K-Q-K-N-G-Y-E-K 116 - 140 104   F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I-L-R-T-D-N-I-S-F-M-L 516 - 540
25   D-N-E-Q-S-V-W-R-H-S-P-K-K-Q-K-N-G-Y-E-K-K-K-I-P-D 121 - 145 105   D-L-M-S-H-L-K-K-Q-I-L-R-T-D-N-I-S-F-M-L-K-R-C-C-Q 521 - 545
26   V-W-R-H-S-P-K-K-Q-K-N-G-Y-E-K-K-K-I-P-D-A-T-P-L-L 126 - 150 106   L-K-K-Q-I-L-R-T-D-N-I-S-F-M-L-K-R-C-C-Q-P-K-P-R-E 526 - 550
27   P-K-K-Q-K-N-G-Y-E-K-K-K-I-P-D-A-T-P-L-L-D-A-S-S-L 131 - 155 107   L-R-T-D-N-I-S-F-M-L-K-R-C-C-Q-P-K-P-R-E-I-S-N-L-L 531 - 555
28   N-G-Y-E-K-K-K-I-P-D-A-T-P-L-L-D-A-S-S-L-E-Y-L-F-A 136 - 160 108   I-S-F-M-L-K-R-C-C-Q-P-K-P-R-E-I-S-N-L-L-V-A-T-K-K 536 - 560
29   K-K-I-P-D-A-T-P-L-L-D-A-S-S-L-E-Y-L-F-A-Q-G-Q-Y-D 141 - 165 109   K-R-C-C-Q-P-K-P-R-E-I-S-N-L-L-V-A-T-K-K-A-Q-E-W-Q 541 - 565
30   A-T-P-L-L-D-A-S-S-L-E-Y-L-F-A-Q-G-Q-Y-D-L-V-K-C-L 146 - 170 110   P-K-P-R-E-I-S-N-L-L-V-A-T-K-K-A-Q-E-W-Q-P-V-Y-P-M 546 - 570
31   D-A-S-S-L-E-Y-L-F-A-Q-G-Q-Y-D-L-V-K-C-L-A-P-I-R-D 151 - 175 111   I-S-N-L-L-V-A-T-K-K-A-Q-E-W-Q-P-V-Y-P-M-S-Q-L-S-F 551 - 575
32   E-Y-L-F-A-Q-G-Q-Y-D-L-V-K-C-L-A-P-I-R-D-P-K-T-E-Q 156 - 180 112   V-A-T-K-K-A-Q-E-W-Q-P-V-Y-P-M-S-Q-L-S-F-D-R-I-L-K 556 - 580
33   Q-G-Q-Y-D-L-V-K-C-L-A-P-I-R-D-P-K-T-E-Q-D-G-H-D-I 161 - 185 113   A-Q-E-W-Q-P-V-Y-P-M-S-Q-L-S-F-D-R-I-L-K-K-D-L-V-Q 561 - 585
34   L-V-K-C-L-A-P-I-R-D-P-K-T-E-Q-D-G-H-D-I-E-N-E-C-L 166 - 190 114   P-V-Y-P-M-S-Q-L-S-F-D-R-I-L-K-K-D-L-V-Q-G-E-H-L-G 566 - 590
35   A-P-I-R-D-P-K-T-E-Q-D-G-H-D-I-E-N-E-C-L-G-M-A-V-L 171 - 195 115   S-Q-L-S-F-D-R-I-L-K-K-D-L-V-Q-G-E-H-L-G-R-G-T-R-T 571 - 595
36   P-K-T-E-Q-D-G-H-D-I-E-N-E-C-L-G-M-A-V-L-A-I-S-H-Y 176 - 200 116   D-R-I-L-K-K-D-L-V-Q-G-E-H-L-G-R-G-T-R-T-H-I-Y-S-G 576 - 600
37   D-G-H-D-I-E-N-E-C-L-G-M-A-V-L-A-I-S-H-Y-A-M-M-K-K 181 - 205 117   K-D-L-V-Q-G-E-H-L-G-R-G-T-R-T-H-I-Y-S-G-T-L-M-D-Y 581 - 605
38   E-N-E-C-L-G-M-A-V-L-A-I-S-H-Y-A-M-M-K-K-M-Q-L-P-E 186 - 210 118   G-E-H-L-G-R-G-T-R-T-H-I-Y-S-G-T-L-M-D-Y-K-D-D-E-G 586 - 610
39   G-M-A-V-L-A-I-S-H-Y-A-M-M-K-K-M-Q-L-P-E-L-P-K-D-I 191 - 215 119   R-G-T-R-T-H-I-Y-S-G-T-L-M-D-Y-K-D-D-E-G-T-S-E-E-K 591 - 615
40   A-I-S-H-Y-A-M-M-K-K-M-Q-L-P-E-L-P-K-D-I-S-Y-K-R-Y 196 - 220 120   H-I-Y-S-G-T-L-M-D-Y-K-D-D-E-G-T-S-E-E-K-K-I-K-V-I 596 - 620
41   A-M-M-K-K-M-Q-L-P-E-L-P-K-D-I-S-Y-K-R-Y-I-P-E-T-L 201 - 225 121   T-L-M-D-Y-K-D-D-E-G-T-S-E-E-K-K-I-K-V-I-L-K-V-L-D 601 - 625
42   M-Q-L-P-E-L-P-K-D-I-S-Y-K-R-Y-I-P-E-T-L-N-K-S-I-R 206 - 230 122   K-D-D-E-G-T-S-E-E-K-K-I-K-V-I-L-K-V-L-D-P-S-H-R-D 606 - 630
43   L-P-K-D-I-S-Y-K-R-Y-I-P-E-T-L-N-K-S-I-R-Q-R-N-L-L 211 - 235 123   T-S-E-E-K-K-I-K-V-I-L-K-V-L-D-P-S-H-R-D-I-S-L-A-F 611 - 635
44   S-Y-K-R-Y-I-P-E-T-L-N-K-S-I-R-Q-R-N-L-L-T-R-M-R-I 216 - 240 124   K-I-K-V-I-L-K-V-L-D-P-S-H-R-D-I-S-L-A-F-F-E-A-A-S 616 - 640
45   I-P-E-T-L-N-K-S-I-R-Q-R-N-L-L-T-R-M-R-I-N-N-V-F-K 221 - 245 125   L-K-V-L-D-P-S-H-R-D-I-S-L-A-F-F-E-A-A-S-M-M-R-Q-V 621 - 645
46   N-K-S-I-R-Q-R-N-L-L-T-R-M-R-I-N-N-V-F-K-D-F-L-K-E 226 - 250 126   P-S-H-R-D-I-S-L-A-F-F-E-A-A-S-M-M-R-Q-V-S-H-K-H-I 626 - 650
47   Q-R-N-L-L-T-R-M-R-I-N-N-V-F-K-D-F-L-K-E-F-N-N-K-T 231 - 255 127   I-S-L-A-F-F-E-A-A-S-M-M-R-Q-V-S-H-K-H-I-V-Y-L-Y-G 631 - 655
48   T-R-M-R-I-N-N-V-F-K-D-F-L-K-E-F-N-N-K-T-I-C-D-S-S 236 - 260 128   F-E-A-A-S-M-M-R-Q-V-S-H-K-H-I-V-Y-L-Y-G-V-C-V-R-D 636 - 660
49   N-N-V-F-K-D-F-L-K-E-F-N-N-K-T-I-C-D-S-S-V-S-T-H-D 241 - 265 129   M-M-R-Q-V-S-H-K-H-I-V-Y-L-Y-G-V-C-V-R-D-V-E-N-I-M 641 - 665
50   D-F-L-K-E-F-N-N-K-T-I-C-D-S-S-V-S-T-H-D-L-K-V-K-Y 246 - 270 130   S-H-K-H-I-V-Y-L-Y-G-V-C-V-R-D-V-E-N-I-M-V-E-E-F-V 646 - 670
51   F-N-N-K-T-I-C-D-S-S-V-S-T-H-D-L-K-V-K-Y-L-A-T-L-E 251 - 275 131   V-Y-L-Y-G-V-C-V-R-D-V-E-N-I-M-V-E-E-F-V-E-G-G-P-L 651 - 675
52   I-C-D-S-S-V-S-T-H-D-L-K-V-K-Y-L-A-T-L-E-T-L-T-K-H 256 - 280 132   V-C-V-R-D-V-E-N-I-M-V-E-E-F-V-E-G-G-P-L-D-L-F-M-H 656 - 680
53   V-S-T-H-D-L-K-V-K-Y-L-A-T-L-E-T-L-T-K-H-Y-G-A-E-I 261 - 285 133   V-E-N-I-M-V-E-E-F-V-E-G-G-P-L-D-L-F-M-H-R-K-S-D-V 661 - 685
54   L-K-V-K-Y-L-A-T-L-E-T-L-T-K-H-Y-G-A-E-I-F-E-T-S-M 266 - 290 134   V-E-E-F-V-E-G-G-P-L-D-L-F-M-H-R-K-S-D-V-L-T-T-P-W 666 - 690
55   L-A-T-L-E-T-L-T-K-H-Y-G-A-E-I-F-E-T-S-M-L-L-I-S-S 271 - 295 135   E-G-G-P-L-D-L-F-M-H-R-K-S-D-V-L-T-T-P-W-K-F-K-V-A 671 - 695
56   T-L-T-K-H-Y-G-A-E-I-F-E-T-S-M-L-L-I-S-S-E-N-E-M-N 276 - 300 136   D-L-F-M-H-R-K-S-D-V-L-T-T-P-W-K-F-K-V-A-K-Q-L-A-S 676 - 700
57   Y-G-A-E-I-F-E-T-S-M-L-L-I-S-S-E-N-E-M-N-W-F-H-S-N 281 - 305 137   R-K-S-D-V-L-T-T-P-W-K-F-K-V-A-K-Q-L-A-S-A-L-S-Y-L 681 - 705
58   F-E-T-S-M-L-L-I-S-S-E-N-E-M-N-W-F-H-S-N-D-G-G-N-V 286 - 310 138   L-T-T-P-W-K-F-K-V-A-K-Q-L-A-S-A-L-S-Y-L-E-D-K-D-L 686 - 710
59   L-L-I-S-S-E-N-E-M-N-W-F-H-S-N-D-G-G-N-V-L-Y-Y-E-V 291 - 315 139   K-F-K-V-A-K-Q-L-A-S-A-L-S-Y-L-E-D-K-D-L-V-H-G-N-V 691 - 715
60   E-N-E-M-N-W-F-H-S-N-D-G-G-N-V-L-Y-Y-E-V-M-V-T-G-N 296 - 320 140   K-Q-L-A-S-A-L-S-Y-L-E-D-K-D-L-V-H-G-N-V-C-T-K-N-L 696 - 720
61   W-F-H-S-N-D-G-G-N-V-L-Y-Y-E-V-M-V-T-G-N-L-G-I-Q-W 301 - 325 141   A-L-S-Y-L-E-D-K-D-L-V-H-G-N-V-C-T-K-N-L-L-L-A-R-E 701 - 725
62   D-G-G-N-V-L-Y-Y-E-V-M-V-T-G-N-L-G-I-Q-W-R-H-K-P-N 306 - 330 142   E-D-K-D-L-V-H-G-N-V-C-T-K-N-L-L-L-A-R-E-G-I-D-S-E 706 - 730
63   L-Y-Y-E-V-M-V-T-G-N-L-G-I-Q-W-R-H-K-P-N-V-V-S-V-E 311 - 335 143   V-H-G-N-V-C-T-K-N-L-L-L-A-R-E-G-I-D-S-E-C-G-P-F-I 711 - 735
64   M-V-T-G-N-L-G-I-Q-W-R-H-K-P-N-V-V-S-V-E-K-E-K-N-K 316 - 340 144   C-T-K-N-L-L-L-A-R-E-G-I-D-S-E-C-G-P-F-I-K-L-S-D-P 716 - 740
65   L-G-I-Q-W-R-H-K-P-N-V-V-S-V-E-K-E-K-N-K-L-K-R-K-K 321 - 345 145   L-L-A-R-E-G-I-D-S-E-C-G-P-F-I-K-L-S-D-P-G-I-P-I-T 721 - 745
66   R-H-K-P-N-V-V-S-V-E-K-E-K-N-K-L-K-R-K-K-L-E-N-K-H 326 - 350 146   G-I-D-S-E-C-G-P-F-I-K-L-S-D-P-G-I-P-I-T-V-L-S-R-Q 726 - 750
67   V-V-S-V-E-K-E-K-N-K-L-K-R-K-K-L-E-N-K-H-K-K-D-E-E 331 - 355 147   C-G-P-F-I-K-L-S-D-P-G-I-P-I-T-V-L-S-R-Q-E-C-I-E-R 731 - 755
68   K-E-K-N-K-L-K-R-K-K-L-E-N-K-H-K-K-D-E-E-K-N-K-I-R 336 - 360 148   K-L-S-D-P-G-I-P-I-T-V-L-S-R-Q-E-C-I-E-R-I-P-W-I-A 736 - 760
69   L-K-R-K-K-L-E-N-K-H-K-K-D-E-E-K-N-K-I-R-E-E-W-N-N 341 - 365 149   G-I-P-I-T-V-L-S-R-Q-E-C-I-E-R-I-P-W-I-A-P-E-C-V-E 741 - 765
70   L-E-N-K-H-K-K-D-E-E-K-N-K-I-R-E-E-W-N-N-F-S-Y-F-P 346 - 370 150   V-L-S-R-Q-E-C-I-E-R-I-P-W-I-A-P-E-C-V-E-D-S-K-N-L 746 - 770
71   K-K-D-E-E-K-N-K-I-R-E-E-W-N-N-F-S-Y-F-P-E-I-T-H-I 351 - 375 151   E-C-I-E-R-I-P-W-I-A-P-E-C-V-E-D-S-K-N-L-S-V-A-A-D 751 - 775
72   K-N-K-I-R-E-E-W-N-N-F-S-Y-F-P-E-I-T-H-I-V-I-K-E-S 356 - 380 152   I-P-W-I-A-P-E-C-V-E-D-S-K-N-L-S-V-A-A-D-K-W-S-F-G 756 - 780
73   E-E-W-N-N-F-S-Y-F-P-E-I-T-H-I-V-I-K-E-S-V-V-S-I-N 361 - 385 153   P-E-C-V-E-D-S-K-N-L-S-V-A-A-D-K-W-S-F-G-T-T-L-W-E 761 - 785
74   F-S-Y-F-P-E-I-T-H-I-V-I-K-E-S-V-V-S-I-N-K-Q-D-N-K 366 - 390 154   D-S-K-N-L-S-V-A-A-D-K-W-S-F-G-T-T-L-W-E-I-C-Y-N-G 766 - 790
75   E-I-T-H-I-V-I-K-E-S-V-V-S-I-N-K-Q-D-N-K-K-M-E-L-K 371 - 395 155   S-V-A-A-D-K-W-S-F-G-T-T-L-W-E-I-C-Y-N-G-E-I-P-L-K 771 - 795
76   V-I-K-E-S-V-V-S-I-N-K-Q-D-N-K-K-M-E-L-K-L-S-S-H-E 376 - 400 156   K-W-S-F-G-T-T-L-W-E-I-C-Y-N-G-E-I-P-L-K-D-K-T-L-I 776 - 800
77   V-V-S-I-N-K-Q-D-N-K-K-M-E-L-K-L-S-S-H-E-E-A-L-S-F 381 - 405 157   T-T-L-W-E-I-C-Y-N-G-E-I-P-L-K-D-K-T-L-I-E-K-E-R-F 781 - 805
78   K-Q-D-N-K-K-M-E-L-K-L-S-S-H-E-E-A-L-S-F-V-S-L-V-D 386 - 410 158   I-C-Y-N-G-E-I-P-L-K-D-K-T-L-I-E-K-E-R-F-Y-E-S-R-C 786 - 810
79   K-M-E-L-K-L-S-S-H-E-E-A-L-S-F-V-S-L-V-D-G-Y-F-R-L 391 - 415 159   E-I-P-L-K-D-K-T-L-I-E-K-E-R-F-Y-E-S-R-C-R-P-V-T-P 791 - 815
80   L-S-S-H-E-E-A-L-S-F-V-S-L-V-D-G-Y-F-R-L-T-A-D-A-H 396 - 420 160   D-K-T-L-I-E-K-E-R-F-Y-E-S-R-C-R-P-V-T-P-S-C-K-E-L 796 - 820
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Table 6-1: Peptide array spanning the human JAK1 open reading frame  
  
Array Position Peptide Sequence Array Position Peptide Sequence
161   E-K-E-R-F-Y-E-S-R-C-R-P-V-T-P-S-C-K-E-L-A-D-L-M-T 801 - 825 195   N-K-N-K-I-N-L-K-Q-Q-L-K-Y-A-V-Q-I-C-K-G-M-D-Y-L-G 971 - 995
162   Y-E-S-R-C-R-P-V-T-P-S-C-K-E-L-A-D-L-M-T-R-C-M-N-Y 806 - 830 196   N-L-K-Q-Q-L-K-Y-A-V-Q-I-C-K-G-M-D-Y-L-G-S-R-Q-Y-V 976 - 1000
163   R-P-V-T-P-S-C-K-E-L-A-D-L-M-T-R-C-M-N-Y-D-P-N-Q-R 811 - 835 197   L-K-Y-A-V-Q-I-C-K-G-M-D-Y-L-G-S-R-Q-Y-V-H-R-D-L-A 981 - 1005
164   S-C-K-E-L-A-D-L-M-T-R-C-M-N-Y-D-P-N-Q-R-P-F-F-R-A 816 - 840 198   Q-I-C-K-G-M-D-Y-L-G-S-R-Q-Y-V-H-R-D-L-A-A-R-N-V-L 986 - 1010
165   A-D-L-M-T-R-C-M-N-Y-D-P-N-Q-R-P-F-F-R-A-I-M-R-D-I 821 - 845 199   M-D-Y-L-G-S-R-Q-Y-V-H-R-D-L-A-A-R-N-V-L-V-E-S-E-H 991 - 1015
166   R-C-M-N-Y-D-P-N-Q-R-P-F-F-R-A-I-M-R-D-I-N-K-L-E-E 826 - 850 200   S-R-Q-Y-V-H-R-D-L-A-A-R-N-V-L-V-E-S-E-H-Q-V-K-I-G 996 - 1020
167   D-P-N-Q-R-P-F-F-R-A-I-M-R-D-I-N-K-L-E-E-Q-N-P-D-I 831 - 855 201   H-R-D-L-A-A-R-N-V-L-V-E-S-E-H-Q-V-K-I-G-D-F-G-L-T 1001 - 1025
168   P-F-F-R-A-I-M-R-D-I-N-K-L-E-E-Q-N-P-D-I-V-S-E-K-K 836 - 860 202   A-R-N-V-L-V-E-S-E-H-Q-V-K-I-G-D-F-G-L-T-K-A-I-E-T 1006 - 1030
169   I-M-R-D-I-N-K-L-E-E-Q-N-P-D-I-V-S-E-K-K-P-A-T-E-V 841 - 865 203   V-E-S-E-H-Q-V-K-I-G-D-F-G-L-T-K-A-I-E-T-D-K-E-Y-Y 1011 - 1035
170   N-K-L-E-E-Q-N-P-D-I-V-S-E-K-K-P-A-T-E-V-D-P-T-H-F 846 - 870 204   Q-V-K-I-G-D-F-G-L-T-K-A-I-E-T-D-K-E-Y-Y-T-V-K-D-D 1016 - 1040
171   Q-N-P-D-I-V-S-E-K-K-P-A-T-E-V-D-P-T-H-F-E-K-R-F-L 851 - 875 205   D-F-G-L-T-K-A-I-E-T-D-K-E-Y-Y-T-V-K-D-D-R-D-S-P-V 1021 - 1045
172   V-S-E-K-K-P-A-T-E-V-D-P-T-H-F-E-K-R-F-L-K-R-I-R-D 856 - 880 206   K-A-I-E-T-D-K-E-Y-Y-T-V-K-D-D-R-D-S-P-V-F-W-Y-A-P 1026 - 1050
173   P-A-T-E-V-D-P-T-H-F-E-K-R-F-L-K-R-I-R-D-L-G-E-G-H 861 - 885 207   D-K-E-Y-Y-T-V-K-D-D-R-D-S-P-V-F-W-Y-A-P-E-C-L-M-Q 1031 - 1055
174   D-P-T-H-F-E-K-R-F-L-K-R-I-R-D-L-G-E-G-H-F-G-K-V-E 866 - 890 208   T-V-K-D-D-R-D-S-P-V-F-W-Y-A-P-E-C-L-M-Q-S-K-F-Y-I 1036 - 1060
175   E-K-R-F-L-K-R-I-R-D-L-G-E-G-H-F-G-K-V-E-L-C-R-Y-D 871 - 895 209   R-D-S-P-V-F-W-Y-A-P-E-C-L-M-Q-S-K-F-Y-I-A-S-D-V-W 1041 - 1065
176   K-R-I-R-D-L-G-E-G-H-F-G-K-V-E-L-C-R-Y-D-P-E-G-D-N 876 - 900 210   F-W-Y-A-P-E-C-L-M-Q-S-K-F-Y-I-A-S-D-V-W-S-F-G-V-T 1046 - 1070
177   L-G-E-G-H-F-G-K-V-E-L-C-R-Y-D-P-E-G-D-N-T-G-E-Q-V 881 - 905 211   E-C-L-M-Q-S-K-F-Y-I-A-S-D-V-W-S-F-G-V-T-L-H-E-L-L 1051 - 1075
178   F-G-K-V-E-L-C-R-Y-D-P-E-G-D-N-T-G-E-Q-V-A-V-K-S-L 886 - 910 212   S-K-F-Y-I-A-S-D-V-W-S-F-G-V-T-L-H-E-L-L-T-Y-C-D-S 1056 - 1080
179   L-C-R-Y-D-P-E-G-D-N-T-G-E-Q-V-A-V-K-S-L-K-P-E-S-G 891 - 915 213   A-S-D-V-W-S-F-G-V-T-L-H-E-L-L-T-Y-C-D-S-D-S-S-P-M 1061 - 1085
180   P-E-G-D-N-T-G-E-Q-V-A-V-K-S-L-K-P-E-S-G-G-N-H-I-A 896 - 920 214   S-F-G-V-T-L-H-E-L-L-T-Y-C-D-S-D-S-S-P-M-A-L-F-L-K 1066 - 1090
181   T-G-E-Q-V-A-V-K-S-L-K-P-E-S-G-G-N-H-I-A-D-L-K-K-E 901 - 925 215   L-H-E-L-L-T-Y-C-D-S-D-S-S-P-M-A-L-F-L-K-M-I-G-P-T 1071 - 1095
182   A-V-K-S-L-K-P-E-S-G-G-N-H-I-A-D-L-K-K-E-I-E-I-L-R 906 - 930 216   T-Y-C-D-S-D-S-S-P-M-A-L-F-L-K-M-I-G-P-T-H-G-Q-M-T 1076 - 1100
183   K-P-E-S-G-G-N-H-I-A-D-L-K-K-E-I-E-I-L-R-N-L-Y-H-E 911 - 935 217   D-S-S-P-M-A-L-F-L-K-M-I-G-P-T-H-G-Q-M-T-V-T-R-L-V 1081 - 1105
184   G-N-H-I-A-D-L-K-K-E-I-E-I-L-R-N-L-Y-H-E-N-I-V-K-Y 916 - 940 218   A-L-F-L-K-M-I-G-P-T-H-G-Q-M-T-V-T-R-L-V-N-T-L-K-E 1086 - 1110
185   D-L-K-K-E-I-E-I-L-R-N-L-Y-H-E-N-I-V-K-Y-K-G-I-C-T 921 - 945 219   M-I-G-P-T-H-G-Q-M-T-V-T-R-L-V-N-T-L-K-E-G-K-R-L-P 1091 - 1115
186   I-E-I-L-R-N-L-Y-H-E-N-I-V-K-Y-K-G-I-C-T-E-D-G-G-N 926 - 950 220   H-G-Q-M-T-V-T-R-L-V-N-T-L-K-E-G-K-R-L-P-C-P-P-N-C 1096 - 1120
187   N-L-Y-H-E-N-I-V-K-Y-K-G-I-C-T-E-D-G-G-N-G-I-K-L-I 931 - 955 221   V-T-R-L-V-N-T-L-K-E-G-K-R-L-P-C-P-P-N-C-P-D-E-V-Y 1101 - 1125
188   N-I-V-K-Y-K-G-I-C-T-E-D-G-G-N-G-I-K-L-I-M-E-F-L-P 936 - 960 222   N-T-L-K-E-G-K-R-L-P-C-P-P-N-C-P-D-E-V-Y-Q-L-M-R-K 1106 - 1130
189   K-G-I-C-T-E-D-G-G-N-G-I-K-L-I-M-E-F-L-P-S-G-S-L-K 941 - 965 223   G-K-R-L-P-C-P-P-N-C-P-D-E-V-Y-Q-L-M-R-K-C-W-E-F-Q 1111 - 1135
190   E-D-G-G-N-G-I-K-L-I-M-E-F-L-P-S-G-S-L-K-E-Y-L-P-K 946 - 970 224   C-P-P-N-C-P-D-E-V-Y-Q-L-M-R-K-C-W-E-F-Q-P-S-N-R-T 1116 - 1140
191   G-I-K-L-I-M-E-F-L-P-S-G-S-L-K-E-Y-L-P-K-N-K-N-K-I 951 - 975 225   P-D-E-V-Y-Q-L-M-R-K-C-W-E-F-Q-P-S-N-R-T-S-F-Q-N-L 1121 - 1145
192   M-E-F-L-P-S-G-S-L-K-E-Y-L-P-K-N-K-N-K-I-N-L-K-Q-Q 956 - 980 226   Q-L-M-R-K-C-W-E-F-Q-P-S-N-R-T-S-F-Q-N-L-I-E-G-F-E 1126 - 1150
193   S-G-S-L-K-E-Y-L-P-K-N-K-N-K-I-N-L-K-Q-Q-L-K-Y-A-V 961 - 985 227   K-C-W-E-F-Q-P-S-N-R-T-S-F-Q-N-L-I-E-G-F-E-A-L-L-K 1131 - 1155
194   E-Y-L-P-K-N-K-N-K-I-N-L-K-Q-Q-L-K-Y-A-V-Q-I-C-K-G 966 - 990 228 H-M-R-S-A-M-S-G-L-H-L-V-K-R-R
Amino Acid Position
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Amino Acid Position
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 225 226 227 228 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 225 226 227 228 n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
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Table 6-2: Peptide array spanning the human JAK2 open reading frame  
(continued overleaf)  
 
Array Position Peptide sequence Array Position Peptide sequence 
1 M-G-M-A-C-L-T-M-T-E-M-E-G-T-S-T-S-S-I-Y-Q-N-G-D-I 1 - 25 81 H-G-P-I-S-M-D-F-A-I-S-K-L-K-K-A-G-N-Q-T-G-L-Y-V-L 401 - 425
2 L-T-M-T-E-M-E-G-T-S-T-S-S-I-Y-Q-N-G-D-I-S-G-N-A-N 6 - 30 82 M-D-F-A-I-S-K-L-K-K-A-G-N-Q-T-G-L-Y-V-L-R-C-S-P-K 406 - 430
3 M-E-G-T-S-T-S-S-I-Y-Q-N-G-D-I-S-G-N-A-N-S-M-K-Q-I 11 - 35 83 S-K-L-K-K-A-G-N-Q-T-G-L-Y-V-L-R-C-S-P-K-D-F-N-K-Y 411 - 435
4 T-S-S-I-Y-Q-N-G-D-I-S-G-N-A-N-S-M-K-Q-I-D-P-V-L-Q 16 - 40 84 A-G-N-Q-T-G-L-Y-V-L-R-C-S-P-K-D-F-N-K-Y-F-L-T-F-A 416 - 440
5 Q-N-G-D-I-S-G-N-A-N-S-M-K-Q-I-D-P-V-L-Q-V-Y-L-Y-H 21 - 45 85 G-L-Y-V-L-R-C-S-P-K-D-F-N-K-Y-F-L-T-F-A-V-E-R-E-N 421 - 445
6 S-G-N-A-N-S-M-K-Q-I-D-P-V-L-Q-V-Y-L-Y-H-S-L-G-K-S 26 - 50 86 R-C-S-P-K-D-F-N-K-Y-F-L-T-F-A-V-E-R-E-N-V-I-E-Y-K 426 - 450
7 S-M-K-Q-I-D-P-V-L-Q-V-Y-L-Y-H-S-L-G-K-S-E-A-D-Y-L 31 - 55 87 D-F-N-K-Y-F-L-T-F-A-V-E-R-E-N-V-I-E-Y-K-H-C-L-I-T 431 - 455
8 D-P-V-L-Q-V-Y-L-Y-H-S-L-G-K-S-E-A-D-Y-L-T-F-P-S-G 36 - 60 88 F-L-T-F-A-V-E-R-E-N-V-I-E-Y-K-H-C-L-I-T-K-N-E-N-E 436 - 460
9 V-Y-L-Y-H-S-L-G-K-S-E-A-D-Y-L-T-F-P-S-G-E-Y-V-A-E 41 - 65 89 V-E-R-E-N-V-I-E-Y-K-H-C-L-I-T-K-N-E-N-E-E-Y-N-L-S 441 - 465
10 S-L-G-K-S-E-A-D-Y-L-T-F-P-S-G-E-Y-V-A-E-E-I-C-I-A 46 - 70 90 V-I-E-Y-K-H-C-L-I-T-K-N-E-N-E-E-Y-N-L-S-G-T-K-K-N 446 - 470
11 E-A-D-Y-L-T-F-P-S-G-E-Y-V-A-E-E-I-C-I-A-A-S-K-A-C 51 - 75 91 H-C-L-I-T-K-N-E-N-E-E-Y-N-L-S-G-T-K-K-N-F-S-S-L-K 451 - 475
12 T-F-P-S-G-E-Y-V-A-E-E-I-C-I-A-A-S-K-A-C-G-I-T-P-V 56 - 80 92 K-N-E-N-E-E-Y-N-L-S-G-T-K-K-N-F-S-S-L-K-D-L-L-N-C 456 - 480
13 E-Y-V-A-E-E-I-C-I-A-A-S-K-A-C-G-I-T-P-V-Y-H-N-M-F 61 - 85 93 E-Y-N-L-S-G-T-K-K-N-F-S-S-L-K-D-L-L-N-C-Y-Q-M-E-T 461 - 485
14 E-I-C-I-A-A-S-K-A-C-G-I-T-P-V-Y-H-N-M-F-A-L-M-S-E 66 - 90 94 G-T-K-K-N-F-S-S-L-K-D-L-L-N-C-Y-Q-M-E-T-V-R-S-D-N 466 - 490
15 A-S-K-A-C-G-I-T-P-V-Y-H-N-M-F-A-L-M-S-E-T-E-R-I-W 71 - 95 95 F-S-S-L-K-D-L-L-N-C-Y-Q-M-E-T-V-R-S-D-N-I-I-F-Q-F 471 - 495
16 G-I-T-P-V-Y-H-N-M-F-A-L-M-S-E-T-E-R-I-W-Y-P-P-N-H 76 - 100 96 D-L-L-N-C-Y-Q-M-E-T-V-R-S-D-N-I-I-F-Q-F-T-K-C-C-P 476 - 500
17 Y-H-N-M-F-A-L-M-S-E-T-E-R-I-W-Y-P-P-N-H-V-F-H-I-D 81 - 105 97 Y-Q-M-E-T-V-R-S-D-N-I-I-F-Q-F-T-K-C-C-P-P-K-P-K-D 481 - 505
18 A-L-M-S-E-T-E-R-I-W-Y-P-P-N-H-V-F-H-I-D-E-S-T-R-H 86 - 110 98 V-R-S-D-N-I-I-F-Q-F-T-K-C-C-P-P-K-P-K-D-K-S-N-L-L 486 - 510
19 T-E-R-I-W-Y-P-P-N-H-V-F-H-I-D-E-S-T-R-H-N-V-L-Y-R 91 - 115 99 I-I-F-Q-F-T-K-C-C-P-P-K-P-K-D-K-S-N-L-L-V-F-R-T-N 491 - 515
20 Y-P-P-N-H-V-F-H-I-D-E-S-T-R-H-N-V-L-Y-R-I-R-F-Y-F 96 - 120 100 T-K-C-C-P-P-K-P-K-D-K-S-N-L-L-V-F-R-T-N-G-V-S-D-V 496 - 520
21 V-F-H-I-D-E-S-T-R-H-N-V-L-Y-R-I-R-F-Y-F-P-R-W-Y-C 101 - 125 101 P-K-P-K-D-K-S-N-L-L-V-F-R-T-N-G-V-S-D-V-P-T-S-P-T 501 - 525
22 E-S-T-R-H-N-V-L-Y-R-I-R-F-Y-F-P-R-W-Y-C-S-G-S-N-R 106 - 130 102 K-S-N-L-L-V-F-R-T-N-G-V-S-D-V-P-T-S-P-T-L-Q-R-P-T 506 - 530
23 N-V-L-Y-R-I-R-F-Y-F-P-R-W-Y-C-S-G-S-N-R-A-Y-R-H-G 111 - 135 103 V-F-R-T-N-G-V-S-D-V-P-T-S-P-T-L-Q-R-P-T-H-M-N-Q-M 511 - 535
24 I-R-F-Y-F-P-R-W-Y-C-S-G-S-N-R-A-Y-R-H-G-I-S-R-G-A 116 - 140 104 G-V-S-D-V-P-T-S-P-T-L-Q-R-P-T-H-M-N-Q-M-V-F-H-K-I 516 - 540
25 P-R-W-Y-C-S-G-S-N-R-A-Y-R-H-G-I-S-R-G-A-E-A-P-L-L 121 - 145 105 P-T-S-P-T-L-Q-R-P-T-H-M-N-Q-M-V-F-H-K-I-R-N-E-D-L 521 - 545
26 S-G-S-N-R-A-Y-R-H-G-I-S-R-G-A-E-A-P-L-L-D-D-F-V-M 126 - 150 106 L-Q-R-P-T-H-M-N-Q-M-V-F-H-K-I-R-N-E-D-L-I-F-N-E-S 526 - 550
27 A-Y-R-H-G-I-S-R-G-A-E-A-P-L-L-D-D-F-V-M-S-Y-L-F-A 131 - 155 107 H-M-N-Q-M-V-F-H-K-I-R-N-E-D-L-I-F-N-E-S-L-G-Q-G-T 531 - 555
28 I-S-R-G-A-E-A-P-L-L-D-D-F-V-M-S-Y-L-F-A-Q-W-R-H-D 136 - 160 108 V-F-H-K-I-R-N-E-D-L-I-F-N-E-S-L-G-Q-G-T-F-T-K-I-F 536 - 560
29 E-A-P-L-L-D-D-F-V-M-S-Y-L-F-A-Q-W-R-H-D-F-V-H-G-W 141 - 165 109 R-N-E-D-L-I-F-N-E-S-L-G-Q-G-T-F-T-K-I-F-K-G-V-R-R 541 - 565
30 D-D-F-V-M-S-Y-L-F-A-Q-W-R-H-D-F-V-H-G-W-I-K-V-P-V 146 - 170 110 I-F-N-E-S-L-G-Q-G-T-F-T-K-I-F-K-G-V-R-R-E-V-G-D-Y 546 - 570
31 S-Y-L-F-A-Q-W-R-H-D-F-V-H-G-W-I-K-V-P-V-T-H-E-T-Q 151 - 175 111 L-G-Q-G-T-F-T-K-I-F-K-G-V-R-R-E-V-G-D-Y-G-Q-L-H-E 551 - 575
32 Q-W-R-H-D-F-V-H-G-W-I-K-V-P-V-T-H-E-T-Q-E-E-C-L-G 156 - 180 112 F-T-K-I-F-K-G-V-R-R-E-V-G-D-Y-G-Q-L-H-E-T-E-V-L-L 556 - 580
33 F-V-H-G-W-I-K-V-P-V-T-H-E-T-Q-E-E-C-L-G-M-A-V-L-D 161 - 185 113 K-G-V-R-R-E-V-G-D-Y-G-Q-L-H-E-T-E-V-L-L-K-V-L-D-K 561 - 585
34 I-K-V-P-V-T-H-E-T-Q-E-E-C-L-G-M-A-V-L-D-M-M-R-I-A 166 - 190 114 E-V-G-D-Y-G-Q-L-H-E-T-E-V-L-L-K-V-L-D-K-A-H-R-N-Y 566 - 590
35 T-H-E-T-Q-E-E-C-L-G-M-A-V-L-D-M-M-R-I-A-K-E-N-D-Q 171 - 195 115 G-Q-L-H-E-T-E-V-L-L-K-V-L-D-K-A-H-R-N-Y-S-E-S-F-F 571 - 595
36 E-E-C-L-G-M-A-V-L-D-M-M-R-I-A-K-E-N-D-Q-T-P-L-A-I 176 - 200 116 T-E-V-L-L-K-V-L-D-K-A-H-R-N-Y-S-E-S-F-F-E-A-A-S-M 576 - 600
37 M-A-V-L-D-M-M-R-I-A-K-E-N-D-Q-T-P-L-A-I-Y-N-S-I-S 181 - 205 117 K-V-L-D-K-A-H-R-N-Y-S-E-S-F-F-E-A-A-S-M-M-S-K-L-S 581 - 605
38 M-M-R-I-A-K-E-N-D-Q-T-P-L-A-I-Y-N-S-I-S-Y-K-T-F-L 186 - 210 118 A-H-R-N-Y-S-E-S-F-F-E-A-A-S-M-M-S-K-L-S-H-K-H-L-V 586 - 610
39 K-E-N-D-Q-T-P-L-A-I-Y-N-S-I-S-Y-K-T-F-L-P-K-C-I-R 191 - 215 119 S-E-S-F-F-E-A-A-S-M-M-S-K-L-S-H-K-H-L-V-L-N-Y-G-V 591 - 615
40 T-P-L-A-I-Y-N-S-I-S-Y-K-T-F-L-P-K-C-I-R-A-K-I-Q-D 196 - 220 120 E-A-A-S-M-M-S-K-L-S-H-K-H-L-V-L-N-Y-G-V-C-V-C-G-D 596 - 620
41 Y-N-S-I-S-Y-K-T-F-L-P-K-C-I-R-A-K-I-Q-D-Y-H-I-L-T 201 - 225 121 M-S-K-L-S-H-K-H-L-V-L-N-Y-G-V-C-V-C-G-D-E-N-I-L-V 601 - 625
42 Y-K-T-F-L-P-K-C-I-R-A-K-I-Q-D-Y-H-I-L-T-R-K-R-I-R 206 - 230 122 H-K-H-L-V-L-N-Y-G-V-C-V-C-G-D-E-N-I-L-V-Q-E-F-V-K 606 - 630
43 P-K-C-I-R-A-K-I-Q-D-Y-H-I-L-T-R-K-R-I-R-Y-R-F-R-R 211 - 235 123 L-N-Y-G-V-C-V-C-G-D-E-N-I-L-V-Q-E-F-V-K-F-G-S-L-D 611 - 635
44 A-K-I-Q-D-Y-H-I-L-T-R-K-R-I-R-Y-R-F-R-R-F-I-Q-Q-F 216 - 240 124 C-V-C-G-D-E-N-I-L-V-Q-E-F-V-K-F-G-S-L-D-T-Y-L-K-K 616 - 640
45 Y-H-I-L-T-R-K-R-I-R-Y-R-F-R-R-F-I-Q-Q-F-S-Q-C-K-A 221 - 245 125 E-N-I-L-V-Q-E-F-V-K-F-G-S-L-D-T-Y-L-K-K-N-K-N-C-I 621 - 645
46 R-K-R-I-R-Y-R-F-R-R-F-I-Q-Q-F-S-Q-C-K-A-T-A-R-N-L 226 - 250 126 Q-E-F-V-K-F-G-S-L-D-T-Y-L-K-K-N-K-N-C-I-N-I-L-W-K 626 - 650
47 Y-R-F-R-R-F-I-Q-Q-F-S-Q-C-K-A-T-A-R-N-L-K-L-K-Y-L 231 - 255 127 F-G-S-L-D-T-Y-L-K-K-N-K-N-C-I-N-I-L-W-K-L-E-V-A-K 631 - 655
48 F-I-Q-Q-F-S-Q-C-K-A-T-A-R-N-L-K-L-K-Y-L-I-N-L-E-T 236 - 260 128 T-Y-L-K-K-N-K-N-C-I-N-I-L-W-K-L-E-V-A-K-Q-L-A-W-A 636 - 660
49 S-Q-C-K-A-T-A-R-N-L-K-L-K-Y-L-I-N-L-E-T-L-Q-S-A-F 241 - 265 129 N-K-N-C-I-N-I-L-W-K-L-E-V-A-K-Q-L-A-W-A-M-H-F-L-E 641 - 665
50 T-A-R-N-L-K-L-K-Y-L-I-N-L-E-T-L-Q-S-A-F-Y-T-E-K-F 246 - 270 130 N-I-L-W-K-L-E-V-A-K-Q-L-A-W-A-M-H-F-L-E-E-N-T-L-I 646 - 670
51 K-L-K-Y-L-I-N-L-E-T-L-Q-S-A-F-Y-T-E-K-F-E-V-K-E-P 251 - 275 131 L-E-V-A-K-Q-L-A-W-A-M-H-F-L-E-E-N-T-L-I-H-G-N-V-C 651 - 675
52 I-N-L-E-T-L-Q-S-A-F-Y-T-E-K-F-E-V-K-E-P-G-S-G-P-S 256 - 280 132 Q-L-A-W-A-M-H-F-L-E-E-N-T-L-I-H-G-N-V-C-A-K-N-I-L 656 - 680
53 L-Q-S-A-F-Y-T-E-K-F-E-V-K-E-P-G-S-G-P-S-G-E-E-I-F 261 - 285 133 M-H-F-L-E-E-N-T-L-I-H-G-N-V-C-A-K-N-I-L-L-I-R-E-E 661 - 685
54 Y-T-E-K-F-E-V-K-E-P-G-S-G-P-S-G-E-E-I-F-A-T-I-I-I 266 - 290 134 E-N-T-L-I-H-G-N-V-C-A-K-N-I-L-L-I-R-E-E-D-R-K-T-G 666 - 690
55 E-V-K-E-P-G-S-G-P-S-G-E-E-I-F-A-T-I-I-I-T-G-N-G-G 271 - 295 135 H-G-N-V-C-A-K-N-I-L-L-I-R-E-E-D-R-K-T-G-N-P-P-F-I 671 - 695
56 G-S-G-P-S-G-E-E-I-F-A-T-I-I-I-T-G-N-G-G-I-Q-W-S-R 276 - 300 136 A-K-N-I-L-L-I-R-E-E-D-R-K-T-G-N-P-P-F-I-K-L-S-D-P 676 - 700
57 G-E-E-I-F-A-T-I-I-I-T-G-N-G-G-I-Q-W-S-R-G-K-H-K-E 281 - 305 137 L-I-R-E-E-D-R-K-T-G-N-P-P-F-I-K-L-S-D-P-G-I-S-I-T 681 - 705
58 A-T-I-I-I-T-G-N-G-G-I-Q-W-S-R-G-K-H-K-E-S-E-T-L-T 286 - 310 138 D-R-K-T-G-N-P-P-F-I-K-L-S-D-P-G-I-S-I-T-V-L-P-K-D 686 - 710
59 T-G-N-G-G-I-Q-W-S-R-G-K-H-K-E-S-E-T-L-T-E-Q-D-L-Q 291 - 315 139 N-P-P-F-I-K-L-S-D-P-G-I-S-I-T-V-L-P-K-D-I-L-Q-E-R 691 - 715
60 I-Q-W-S-R-G-K-H-K-E-S-E-T-L-T-E-Q-D-L-Q-L-Y-C-D-F 296 - 320 140 K-L-S-D-P-G-I-S-I-T-V-L-P-K-D-I-L-Q-E-R-I-P-W-V-P 696 - 720
61 G-K-H-K-E-S-E-T-L-T-E-Q-D-L-Q-L-Y-C-D-F-P-N-I-I-D 301 - 325 141 G-I-S-I-T-V-L-P-K-D-I-L-Q-E-R-I-P-W-V-P-P-E-C-I-E 701 - 725
62 S-E-T-L-T-E-Q-D-L-Q-L-Y-C-D-F-P-N-I-I-D-V-S-I-K-Q 306 - 330 142 V-L-P-K-D-I-L-Q-E-R-I-P-W-V-P-P-E-C-I-E-N-P-K-N-L 706 - 730
63 E-Q-D-L-Q-L-Y-C-D-F-P-N-I-I-D-V-S-I-K-Q-A-N-Q-E-G 311 - 335 143 I-L-Q-E-R-I-P-W-V-P-P-E-C-I-E-N-P-K-N-L-N-L-A-T-D 711 - 735
64 L-Y-C-D-F-P-N-I-I-D-V-S-I-K-Q-A-N-Q-E-G-S-N-E-S-R 316 - 340 144 I-P-W-V-P-P-E-C-I-E-N-P-K-N-L-N-L-A-T-D-K-W-S-F-G 716 - 740
65 P-N-I-I-D-V-S-I-K-Q-A-N-Q-E-G-S-N-E-S-R-V-V-T-I-H 321 - 345 145 P-E-C-I-E-N-P-K-N-L-N-L-A-T-D-K-W-S-F-G-T-T-L-W-E 721 - 745
66 V-S-I-K-Q-A-N-Q-E-G-S-N-E-S-R-V-V-T-I-H-K-Q-D-G-K 326 - 350 146 N-P-K-N-L-N-L-A-T-D-K-W-S-F-G-T-T-L-W-E-I-C-S-G-G 726 - 750
67 A-N-Q-E-G-S-N-E-S-R-V-V-T-I-H-K-Q-D-G-K-N-L-E-I-E 331 - 355 147 N-L-A-T-D-K-W-S-F-G-T-T-L-W-E-I-C-S-G-G-D-K-P-L-S 731 - 755
68 S-N-E-S-R-V-V-T-I-H-K-Q-D-G-K-N-L-E-I-E-L-S-S-L-R 336 - 360 148 K-W-S-F-G-T-T-L-W-E-I-C-S-G-G-D-K-P-L-S-A-L-D-S-Q 736 - 760
69 V-V-T-I-H-K-Q-D-G-K-N-L-E-I-E-L-S-S-L-R-E-A-L-S-F 341 - 365 149 T-T-L-W-E-I-C-S-G-G-D-K-P-L-S-A-L-D-S-Q-R-K-L-Q-F 741 - 765
70 K-Q-D-G-K-N-L-E-I-E-L-S-S-L-R-E-A-L-S-F-V-S-L-I-D 346 - 370 150 I-C-S-G-G-D-K-P-L-S-A-L-D-S-Q-R-K-L-Q-F-Y-E-D-R-H 746 - 770
71 N-L-E-I-E-L-S-S-L-R-E-A-L-S-F-V-S-L-I-D-G-Y-Y-R-L 351 - 375 151 D-K-P-L-S-A-L-D-S-Q-R-K-L-Q-F-Y-E-D-R-H-Q-L-P-A-P 751 - 775
72 L-S-S-L-R-E-A-L-S-F-V-S-L-I-D-G-Y-Y-R-L-T-A-D-A-H 356 - 380 152 A-L-D-S-Q-R-K-L-Q-F-Y-E-D-R-H-Q-L-P-A-P-K-W-A-E-L 756 - 780
73 E-A-L-S-F-V-S-L-I-D-G-Y-Y-R-L-T-A-D-A-H-H-Y-L-C-K 361 - 385 153 R-K-L-Q-F-Y-E-D-R-H-Q-L-P-A-P-K-W-A-E-L-A-N-L-I-N 761 - 785
74 V-S-L-I-D-G-Y-Y-R-L-T-A-D-A-H-H-Y-L-C-K-E-V-A-P-P 366 - 390 154 Y-E-D-R-H-Q-L-P-A-P-K-W-A-E-L-A-N-L-I-N-N-C-M-D-Y 766 - 790
75 G-Y-Y-R-L-T-A-D-A-H-H-Y-L-C-K-E-V-A-P-P-A-V-L-E-N 371 - 395 155 Q-L-P-A-P-K-W-A-E-L-A-N-L-I-N-N-C-M-D-Y-E-P-D-F-R 771 - 795
76 T-A-D-A-H-H-Y-L-C-K-E-V-A-P-P-A-V-L-E-N-I-Q-S-N-C 376 - 400 156 K-W-A-E-L-A-N-L-I-N-N-C-M-D-Y-E-P-D-F-R-P-S-F-R-A 776 - 800
77 H-Y-L-C-K-E-V-A-P-P-A-V-L-E-N-I-Q-S-N-C-H-G-P-I-S 381 - 405 157 A-N-L-I-N-N-C-M-D-Y-E-P-D-F-R-P-S-F-R-A-I-I-R-D-L 781 - 805
78 E-V-A-P-P-A-V-L-E-N-I-Q-S-N-C-H-G-P-I-S-M-D-F-A-I 386 - 410 158 N-C-M-D-Y-E-P-D-F-R-P-S-F-R-A-I-I-R-D-L-N-S-L-F-T 786 - 810
79 A-V-L-E-N-I-Q-S-N-C-H-G-P-I-S-M-D-F-A-I-S-K-L-K-K 391 - 415 159 E-P-D-F-R-P-S-F-R-A-I-I-R-D-L-N-S-L-F-T-P-D-Y-E-L 791 - 815
80 I-Q-S-N-C-H-G-P-I-S-M-D-F-A-I-S-K-L-K-K-A-G-N-Q-T 396 - 420 160 P-S-F-R-A-I-I-R-D-L-N-S-L-F-T-P-D-Y-E-L-L-T-E-N-D 796 - 820
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Table 6-2: Peptide array spanning the human JAK2 open reading frame  
  
Array Position Peptide sequence Array Position Peptide sequence 
161 I-I-R-D-L-N-S-L-F-T-P-D-Y-E-L-L-T-E-N-D-M-L-P-N-M 801 - 825 193 C-K-G-M-E-Y-L-G-T-K-R-Y-I-H-R-D-L-A-T-R-N-I-L-V-E 961 - 985
162 N-S-L-F-T-P-D-Y-E-L-L-T-E-N-D-M-L-P-N-M-R-I-G-A-L 806 - 830 194 Y-L-G-T-K-R-Y-I-H-R-D-L-A-T-R-N-I-L-V-E-N-E-N-R-V 966 - 990
163 P-D-Y-E-L-L-T-E-N-D-M-L-P-N-M-R-I-G-A-L-G-F-S-G-A 811 - 835 195 R-Y-I-H-R-D-L-A-T-R-N-I-L-V-E-N-E-N-R-V-K-I-G-D-F 971 - 995
164 L-T-E-N-D-M-L-P-N-M-R-I-G-A-L-G-F-S-G-A-F-E-D-R-D 816 - 840 196 D-L-A-T-R-N-I-L-V-E-N-E-N-R-V-K-I-G-D-F-G-L-T-K-V 976 - 1000
165 M-L-P-N-M-R-I-G-A-L-G-F-S-G-A-F-E-D-R-D-P-T-Q-F-E 821 - 845 197 N-I-L-V-E-N-E-N-R-V-K-I-G-D-F-G-L-T-K-V-L-P-Q-D-K 981 - 1005
166 R-I-G-A-L-G-F-S-G-A-F-E-D-R-D-P-T-Q-F-E-E-R-H-L-K 826 - 850 198 N-E-N-R-V-K-I-G-D-F-G-L-T-K-V-L-P-Q-D-K-E-Y-Y-K-V 986 - 1010
167 G-F-S-G-A-F-E-D-R-D-P-T-Q-F-E-E-R-H-L-K-F-L-Q-Q-L 831 - 855 199 K-I-G-D-F-G-L-T-K-V-L-P-Q-D-K-E-Y-Y-K-V-K-E-P-G-E 991 - 1015
168 F-E-D-R-D-P-T-Q-F-E-E-R-H-L-K-F-L-Q-Q-L-G-K-G-N-F 836 - 860 200 G-L-T-K-V-L-P-Q-D-K-E-Y-Y-K-V-K-E-P-G-E-S-P-I-F-W 996 - 1020
169 P-T-Q-F-E-E-R-H-L-K-F-L-Q-Q-L-G-K-G-N-F-G-S-V-E-M 841 - 865 201 L-P-Q-D-K-E-Y-Y-K-V-K-E-P-G-E-S-P-I-F-W-Y-A-P-E-S 1001 - 1025
170 E-R-H-L-K-F-L-Q-Q-L-G-K-G-N-F-G-S-V-E-M-C-R-Y-D-P 846 - 870 202 E-Y-Y-K-V-K-E-P-G-E-S-P-I-F-W-Y-A-P-E-S-L-T-E-S-K 1006 - 1030
171 F-L-Q-Q-L-G-K-G-N-F-G-S-V-E-M-C-R-Y-D-P-L-Q-D-N-T 851 - 875 203 K-E-P-G-E-S-P-I-F-W-Y-A-P-E-S-L-T-E-S-K-F-S-V-A-S 1011 - 1035
172 G-K-G-N-F-G-S-V-E-M-C-R-Y-D-P-L-Q-D-N-T-G-E-V-V-A 856 - 880 204 S-P-I-F-W-Y-A-P-E-S-L-T-E-S-K-F-S-V-A-S-D-V-W-S-F 1016 - 1040
173 G-S-V-E-M-C-R-Y-D-P-L-Q-D-N-T-G-E-V-V-A-V-K-K-L-Q 861 - 885 205 Y-A-P-E-S-L-T-E-S-K-F-S-V-A-S-D-V-W-S-F-G-V-V-L-Y 1021 - 1045
174 C-R-Y-D-P-L-Q-D-N-T-G-E-V-V-A-V-K-K-L-Q-H-S-T-E-E 866 - 890 206 L-T-E-S-K-F-S-V-A-S-D-V-W-S-F-G-V-V-L-Y-E-L-F-T-Y 1026 - 1050
175 L-Q-D-N-T-G-E-V-V-A-V-K-K-L-Q-H-S-T-E-E-H-L-R-D-F 871 - 895 207 F-S-V-A-S-D-V-W-S-F-G-V-V-L-Y-E-L-F-T-Y-I-E-K-S-K 1031 - 1055
176 G-E-V-V-A-V-K-K-L-Q-H-S-T-E-E-H-L-R-D-F-E-R-E-I-E 876 - 900 208 D-V-W-S-F-G-V-V-L-Y-E-L-F-T-Y-I-E-K-S-K-S-P-P-A-E 1036 - 1060
177 V-K-K-L-Q-H-S-T-E-E-H-L-R-D-F-E-R-E-I-E-I-L-K-S-L 881 - 905 209 G-V-V-L-Y-E-L-F-T-Y-I-E-K-S-K-S-P-P-A-E-F-M-R-M-I 1041 - 1065
178 H-S-T-E-E-H-L-R-D-F-E-R-E-I-E-I-L-K-S-L-Q-H-D-N-I 886 - 910 210 E-L-F-T-Y-I-E-K-S-K-S-P-P-A-E-F-M-R-M-I-G-N-D-K-Q 1046 - 1070
179 H-L-R-D-F-E-R-E-I-E-I-L-K-S-L-Q-H-D-N-I-V-K-Y-K-G 891 - 915 211 I-E-K-S-K-S-P-P-A-E-F-M-R-M-I-G-N-D-K-Q-G-Q-M-I-V 1051 - 1075
180 E-R-E-I-E-I-L-K-S-L-Q-H-D-N-I-V-K-Y-K-G-V-C-Y-S-A 896 - 920 212 S-P-P-A-E-F-M-R-M-I-G-N-D-K-Q-G-Q-M-I-V-F-H-L-I-E 1056 - 1080
181 I-L-K-S-L-Q-H-D-N-I-V-K-Y-K-G-V-C-Y-S-A-G-R-R-N-L 901 - 925 213 F-M-R-M-I-G-N-D-K-Q-G-Q-M-I-V-F-H-L-I-E-L-L-K-N-N 1061 - 1085
182 Q-H-D-N-I-V-K-Y-K-G-V-C-Y-S-A-G-R-R-N-L-K-L-I-M-E 906 - 930 214 G-N-D-K-Q-G-Q-M-I-V-F-H-L-I-E-L-L-K-N-N-G-R-L-P-R 1066 - 1090
183 V-K-Y-K-G-V-C-Y-S-A-G-R-R-N-L-K-L-I-M-E-Y-L-P-Y-G 911 - 935 215 G-Q-M-I-V-F-H-L-I-E-L-L-K-N-N-G-R-L-P-R-P-D-G-C-P 1071 - 1095
184 V-C-Y-S-A-G-R-R-N-L-K-L-I-M-E-Y-L-P-Y-G-S-L-R-D-Y 916 - 940 216 F-H-L-I-E-L-L-K-N-N-G-R-L-P-R-P-D-G-C-P-D-E-I-Y-M 1076 - 1100
185 G-R-R-N-L-K-L-I-M-E-Y-L-P-Y-G-S-L-R-D-Y-L-Q-K-H-K 921 - 945 217 L-L-K-N-N-G-R-L-P-R-P-D-G-C-P-D-E-I-Y-M-I-M-T-E-C 1081 - 1105
186 K-L-I-M-E-Y-L-P-Y-G-S-L-R-D-Y-L-Q-K-H-K-E-R-I-D-H 926 - 950 218 G-R-L-P-R-P-D-G-C-P-D-E-I-Y-M-I-M-T-E-C-W-N-N-N-V 1086 - 1110
187 Y-L-P-Y-G-S-L-R-D-Y-L-Q-K-H-K-E-R-I-D-H-I-K-L-L-Q 931 - 955 219 P-D-G-C-P-D-E-I-Y-M-I-M-T-E-C-W-N-N-N-V-N-Q-R-P-S 1091 - 1115
188 S-L-R-D-Y-L-Q-K-H-K-E-R-I-D-H-I-K-L-L-Q-Y-T-S-Q-I 936 - 960 220 D-E-I-Y-M-I-M-T-E-C-W-N-N-N-V-N-Q-R-P-S-F-R-D-L-A 1096 - 1120
189 L-Q-K-H-K-E-R-I-D-H-I-K-L-L-Q-Y-T-S-Q-I-C-K-G-M-E 941 - 965 221 I-M-T-E-C-W-N-N-N-V-N-Q-R-P-S-F-R-D-L-A-L-R-V-D-Q 1101 - 1125
190 E-R-I-D-H-I-K-L-L-Q-Y-T-S-Q-I-C-K-G-M-E-Y-L-G-T-K 946 - 970 222 W-N-N-N-V-N-Q-R-P-S-F-R-D-L-A-L-R-V-D-Q-I-R-D-N-M 1106 - 1130
191 I-K-L-L-Q-Y-T-S-Q-I-C-K-G-M-E-Y-L-G-T-K-R-Y-I-H-R 951 - 975 223 N-N-V-N-Q-R-P-S-F-R-D-L-A-L-R-V-D-Q-I-R-D-N-M-A-G 1111 - 1135
192 Y-T-S-Q-I-C-K-G-M-E-Y-L-G-T-K-R-Y-I-H-R-D-L-A-T-R 956 - 980 224  H-M-R-S-A-M-S-G-L-H-L-V-K-R-R SAMS Peptide
Full length JAK2 Peptide Array
Amino Acid Position Amino Acid Position 
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
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Table 6-3: Peptide array spanning the human JAK3 open reading frame  
(continued overleaf)  
  
Array position JAK Peptide Sequence Array position JAK3 Peptide Sequence 
1     R-Y-S-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 61     D-L-E-R-L-D-P-A-G-A-A-E-T-F-H-V-G-L-P-G-A-L-G-G-H 241 - 265
2     R-Y-A-L-H-G-A-D-R-A-F-P-A-L-G-D-L-M-A-H-L-K-K-Q-I 62     D-P-A-G-A-A-E-T-F-H-V-G-L-P-G-A-L-G-G-H-D-G-L-G-L 246 - 270
3     R-Y-A-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 63     A-E-T-F-H-V-G-L-P-G-A-L-G-G-H-D-G-L-G-L-L-R-V-A-G 251 - 275
4     R-Y-S-L-H-G-A-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 64     V-G-L-P-G-A-L-G-G-H-D-G-L-G-L-L-R-V-A-G-D-G-G-I-A 256 - 280
5     R-Y-S-L-H-G-S-D-R-A-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 65     A-L-G-G-H-D-G-L-G-L-L-R-V-A-G-D-G-G-I-A-W-T-Q-G-E 261 - 285
6     R-Y-S-L-H-G-S-D-R-S-F-P-A-L-G-D-L-M-S-H-L-K-K-Q-I 66     D-G-L-G-L-L-R-V-A-G-D-G-G-I-A-W-T-Q-G-E-Q-E-V-L-Q 266 - 290
7     R-Y-S-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-A-H-L-K-K-Q-I 67     L-R-V-A-G-D-G-G-I-A-W-T-Q-G-E-Q-E-V-L-Q-P-F-C-D-F 271 - 295
8     R-Y-S-L-H-G-S-D-R-A-F-P-A-L-G-D-L-M-S-H-L-K-K-Q-I 68     D-G-G-I-A-W-T-Q-G-E-Q-E-V-L-Q-P-F-C-D-F-P-E-I-V-D 276 - 300
9     R-Y-A-L-H-G-A-D-R-S-F-P-S-L-G-D-L-M-A-H-L-K-K-Q-I 69     W-T-Q-G-E-Q-E-V-L-Q-P-F-C-D-F-P-E-I-V-D-I-S-I-K-Q 281 - 305
10     E-Y-N-L-S-G-T-K-K-N-F-S-S-L-K-D-L-L-N-C-Y-Q-M-E-T 70     Q-E-V-L-Q-P-F-C-D-F-P-E-I-V-D-I-S-I-K-Q-A-P-R-V-G 286 - 310
11     T-F-L-L-V-G-L-S-R-P-H-S-S-L-R-E-L-L-A-T-C-W-D-G-G 71     P-F-C-D-F-P-E-I-V-D-I-S-I-K-Q-A-P-R-V-G-P-A-G-E-H 291 - 315
12     A-F-V-L-E-G-W-G-R-S-F-P-S-V-R-E-L-G-A-A-L-Q-G-C-L 72     P-E-I-V-D-I-S-I-K-Q-A-P-R-V-G-P-A-G-E-H-R-L-V-T-V 296 - 320
Array position JAK3 Peptide Sequence 73     I-S-I-K-Q-A-P-R-V-G-P-A-G-E-H-R-L-V-T-V-T-R-T-D-N 301 - 325
13     M-A-P-P-S-E-E-T-P-L-I-P-Q-R-S-C-S-L-L-S-T-E-A-G-A 1 - 25 74     A-P-R-V-G-P-A-G-E-H-R-L-V-T-V-T-R-T-D-N-Q-I-L-E-A 306 - 330
14     E-E-T-P-L-I-P-Q-R-S-C-S-L-L-S-T-E-A-G-A-L-H-V-L-L 6 - 30 75     P-A-G-E-H-R-L-V-T-V-T-R-T-D-N-Q-I-L-E-A-E-F-P-G-L 311 - 335
15     I-P-Q-R-S-C-S-L-L-S-T-E-A-G-A-L-H-V-L-L-P-A-R-G-P 11 - 35 76     R-L-V-T-V-T-R-T-D-N-Q-I-L-E-A-E-F-P-G-L-P-E-A-L-S 316 - 340
16     C-S-L-L-S-T-E-A-G-A-L-H-V-L-L-P-A-R-G-P-G-P-P-Q-R 16 - 40 77     T-R-T-D-N-Q-I-L-E-A-E-F-P-G-L-P-E-A-L-S-F-V-A-L-V 321 - 345
17     T-E-A-G-A-L-H-V-L-L-P-A-R-G-P-G-P-P-Q-R-L-S-F-S-F 21 - 45 78     Q-I-L-E-A-E-F-P-G-L-P-E-A-L-S-F-V-A-L-V-D-G-Y-F-R 326 - 350
18     L-H-V-L-L-P-A-R-G-P-G-P-P-Q-R-L-S-F-S-F-G-D-H-L-A 26 - 50 79     E-F-P-G-L-P-E-A-L-S-F-V-A-L-V-D-G-Y-F-R-L-T-T-D-S 331 - 355
19     P-A-R-G-P-G-P-P-Q-R-L-S-F-S-F-G-D-H-L-A-E-D-L-C-V 31 - 55 80     P-E-A-L-S-F-V-A-L-V-D-G-Y-F-R-L-T-T-D-S-Q-H-F-F-C 336 - 360
20     G-P-P-Q-R-L-S-F-S-F-G-D-H-L-A-E-D-L-C-V-Q-A-A-K-A 36 - 60 81     F-V-A-L-V-D-G-Y-F-R-L-T-T-D-S-Q-H-F-F-C-K-E-V-A-P 341 - 365
21     L-S-F-S-F-G-D-H-L-A-E-D-L-C-V-Q-A-A-K-A-S-G-I-L-P 41 - 65 82     D-G-Y-F-R-L-T-T-D-S-Q-H-F-F-C-K-E-V-A-P-P-R-L-L-E 346 - 370
22     G-D-H-L-A-E-D-L-C-V-Q-A-A-K-A-S-G-I-L-P-V-Y-H-S-L 46 - 70 83     L-T-T-D-S-Q-H-F-F-C-K-E-V-A-P-P-R-L-L-E-E-V-A-E-Q 351 - 375
23     E-D-L-C-V-Q-A-A-K-A-S-G-I-L-P-V-Y-H-S-L-F-A-L-A-T 51 - 75 84     Q-H-F-F-C-K-E-V-A-P-P-R-L-L-E-E-V-A-E-Q-C-H-G-P-I 356 - 380
24     Q-A-A-K-A-S-G-I-L-P-V-Y-H-S-L-F-A-L-A-T-E-D-L-S-C 56 - 80 85     K-E-V-A-P-P-R-L-L-E-E-V-A-E-Q-C-H-G-P-I-T-L-D-F-A 361 - 385
25     S-G-I-L-P-V-Y-H-S-L-F-A-L-A-T-E-D-L-S-C-W-F-P-P-S 61 - 85 86     P-R-L-L-E-E-V-A-E-Q-C-H-G-P-I-T-L-D-F-A-I-N-K-L-K 366 - 390
26     V-Y-H-S-L-F-A-L-A-T-E-D-L-S-C-W-F-P-P-S-H-I-F-S-V 66 - 90 87     E-V-A-E-Q-C-H-G-P-I-T-L-D-F-A-I-N-K-L-K-T-G-G-S-R 371 - 395
27     F-A-L-A-T-E-D-L-S-C-W-F-P-P-S-H-I-F-S-V-E-D-A-S-T 71 - 95 88     C-H-G-P-I-T-L-D-F-A-I-N-K-L-K-T-G-G-S-R-P-G-S-Y-V 376 - 400
28     E-D-L-S-C-W-F-P-P-S-H-I-F-S-V-E-D-A-S-T-Q-V-L-L-Y 76 - 100 89     T-L-D-F-A-I-N-K-L-K-T-G-G-S-R-P-G-S-Y-V-L-R-R-S-P 381 - 405
29     W-F-P-P-S-H-I-F-S-V-E-D-A-S-T-Q-V-L-L-Y-R-I-R-F-Y 81 - 105 90     I-N-K-L-K-T-G-G-S-R-P-G-S-Y-V-L-R-R-S-P-Q-D-F-D-S 386 - 410
30     H-I-F-S-V-E-D-A-S-T-Q-V-L-L-Y-R-I-R-F-Y-F-P-N-W-F 86 - 110 91     T-G-G-S-R-P-G-S-Y-V-L-R-R-S-P-Q-D-F-D-S-F-L-L-T-V 391 - 415
31     E-D-A-S-T-Q-V-L-L-Y-R-I-R-F-Y-F-P-N-W-F-G-L-E-K-C 91 - 115 92     P-G-S-Y-V-L-R-R-S-P-Q-D-F-D-S-F-L-L-T-V-C-V-Q-N-P 396 - 420
32     Q-V-L-L-Y-R-I-R-F-Y-F-P-N-W-F-G-L-E-K-C-H-R-F-G-L 96 - 120 93     L-R-R-S-P-Q-D-F-D-S-F-L-L-T-V-C-V-Q-N-P-L-G-P-D-Y 401 - 425
33     R-I-R-F-Y-F-P-N-W-F-G-L-E-K-C-H-R-F-G-L-R-K-D-L-A 101 - 125 94     Q-D-F-D-S-F-L-L-T-V-C-V-Q-N-P-L-G-P-D-Y-K-G-C-L-I 406 - 430
34     F-P-N-W-F-G-L-E-K-C-H-R-F-G-L-R-K-D-L-A-S-A-I-L-D 106 - 130 95     F-L-L-T-V-C-V-Q-N-P-L-G-P-D-Y-K-G-C-L-I-R-R-S-P-T 411 - 435
35     G-L-E-K-C-H-R-F-G-L-R-K-D-L-A-S-A-I-L-D-L-P-V-L-E 111 - 135 96     C-V-Q-N-P-L-G-P-D-Y-K-G-C-L-I-R-R-S-P-T-G-T-F-L-L 416 - 440
36     H-R-F-G-L-R-K-D-L-A-S-A-I-L-D-L-P-V-L-E-H-L-F-A-Q 116 - 140 97     L-G-P-D-Y-K-G-C-L-I-R-R-S-P-T-G-T-F-L-L-V-G-L-S-R 421 - 445
37     R-K-D-L-A-S-A-I-L-D-L-P-V-L-E-H-L-F-A-Q-H-R-S-D-L 121 - 145 98     K-G-C-L-I-R-R-S-P-T-G-T-F-L-L-V-G-L-S-R-P-H-S-S-L 426 - 450
38     S-A-I-L-D-L-P-V-L-E-H-L-F-A-Q-H-R-S-D-L-V-S-G-R-L 126 - 150 99     R-R-S-P-T-G-T-F-L-L-V-G-L-S-R-P-H-S-S-L-R-E-L-L-A 431 - 455
39     L-P-V-L-E-H-L-F-A-Q-H-R-S-D-L-V-S-G-R-L-P-V-G-L-S 131 - 155 100     G-T-F-L-L-V-G-L-S-R-P-H-S-S-L-R-E-L-L-A-T-C-W-D-G 436 - 460
40     H-L-F-A-Q-H-R-S-D-L-V-S-G-R-L-P-V-G-L-S-L-K-E-Q-G 136 - 160 101     V-G-L-S-R-P-H-S-S-L-R-E-L-L-A-T-C-W-D-G-G-L-H-V-D 441 - 465
41     H-R-S-D-L-V-S-G-R-L-P-V-G-L-S-L-K-E-Q-G-E-C-L-S-L 141 - 165 102     P-H-S-S-L-R-E-L-L-A-T-C-W-D-G-G-L-H-V-D-G-V-A-V-T 446 - 470
42     V-S-G-R-L-P-V-G-L-S-L-K-E-Q-G-E-C-L-S-L-A-V-L-D-L 146 - 170 103     R-E-L-L-A-T-C-W-D-G-G-L-H-V-D-G-V-A-V-T-L-T-S-C-C 451 - 475
43     P-V-G-L-S-L-K-E-Q-G-E-C-L-S-L-A-V-L-D-L-A-R-M-A-R 151 - 175 104     T-C-W-D-G-G-L-H-V-D-G-V-A-V-T-L-T-S-C-C-I-P-R-P-K 456 - 480
44     L-K-E-Q-G-E-C-L-S-L-A-V-L-D-L-A-R-M-A-R-E-Q-A-Q-R 156 - 180 105     G-L-H-V-D-G-V-A-V-T-L-T-S-C-C-I-P-R-P-K-E-K-S-N-L 461 - 485
45     E-C-L-S-L-A-V-L-D-L-A-R-M-A-R-E-Q-A-Q-R-P-G-E-L-L 161 - 185 106     G-V-A-V-T-L-T-S-C-C-I-P-R-P-K-E-K-S-N-L-I-V-V-Q-R 466 - 490
46     A-V-L-D-L-A-R-M-A-R-E-Q-A-Q-R-P-G-E-L-L-K-T-V-S-Y 166 - 190 107     L-T-S-C-C-I-P-R-P-K-E-K-S-N-L-I-V-V-Q-R-G-H-S-P-P 471 - 495
47     A-R-M-A-R-E-Q-A-Q-R-P-G-E-L-L-K-T-V-S-Y-K-A-C-L-P 171 - 195 108     I-P-R-P-K-E-K-S-N-L-I-V-V-Q-R-G-H-S-P-P-T-S-S-L-V 476 - 500
48     E-Q-A-Q-R-P-G-E-L-L-K-T-V-S-Y-K-A-C-L-P-P-S-L-R-D 176 - 200 109     E-K-S-N-L-I-V-V-Q-R-G-H-S-P-P-T-S-S-L-V-Q-P-Q-S-Q 481 - 505
49     P-G-E-L-L-K-T-V-S-Y-K-A-C-L-P-P-S-L-R-D-L-I-Q-G-L 181 - 205 110     I-V-V-Q-R-G-H-S-P-P-T-S-S-L-V-Q-P-Q-S-Q-Y-Q-L-S-Q 486 - 510
50     K-T-V-S-Y-K-A-C-L-P-P-S-L-R-D-L-I-Q-G-L-S-F-V-T-R 186 - 210 111     G-H-S-P-P-T-S-S-L-V-Q-P-Q-S-Q-Y-Q-L-S-Q-M-T-F-H-K 491 - 515
51     K-A-C-L-P-P-S-L-R-D-L-I-Q-G-L-S-F-V-T-R-R-R-I-R-R 191 - 215 112     T-S-S-L-V-Q-P-Q-S-Q-Y-Q-L-S-Q-M-T-F-H-K-I-P-A-D-S 496 - 520
52     P-S-L-R-D-L-I-Q-G-L-S-F-V-T-R-R-R-I-R-R-T-V-R-R-A 196 - 220 113     Q-P-Q-S-Q-Y-Q-L-S-Q-M-T-F-H-K-I-P-A-D-S-L-E-W-H-E 501 - 525
53     L-I-Q-G-L-S-F-V-T-R-R-R-I-R-R-T-V-R-R-A-L-R-R-V-A 201 - 225 114     Y-Q-L-S-Q-M-T-F-H-K-I-P-A-D-S-L-E-W-H-E-N-L-G-H-G 506 - 530
54     S-F-V-T-R-R-R-I-R-R-T-V-R-R-A-L-R-R-V-A-A-C-Q-A-D 206 - 230 115     M-T-F-H-K-I-P-A-D-S-L-E-W-H-E-N-L-G-H-G-S-F-T-K-I 511 - 535
55     R-R-I-R-R-T-V-R-R-A-L-R-R-V-A-A-C-Q-A-D-R-H-S-L-M 211 - 235 116     I-P-A-D-S-L-E-W-H-E-N-L-G-H-G-S-F-T-K-I-Y-R-G-C-R 516 - 540
56     T-V-R-R-A-L-R-R-V-A-A-C-Q-A-D-R-H-S-L-M-A-K-Y-I-M 216 - 240 117     L-E-W-H-E-N-L-G-H-G-S-F-T-K-I-Y-R-G-C-R-H-E-V-V-D 521 - 545
57     L-R-R-V-A-A-C-Q-A-D-R-H-S-L-M-A-K-Y-I-M-D-L-E-R-L 221 - 245 118     N-L-G-H-G-S-F-T-K-I-Y-R-G-C-R-H-E-V-V-D-G-E-A-R-K 526 - 550
58     A-C-Q-A-D-R-H-S-L-M-A-K-Y-I-M-D-L-E-R-L-D-P-A-G-A 226 - 250 119     S-F-T-K-I-Y-R-G-C-R-H-E-V-V-D-G-E-A-R-K-T-E-V-L-L 531 - 555
59     R-H-S-L-M-A-K-Y-I-M-D-L-E-R-L-D-P-A-G-A-A-E-T-F-H 231 - 255 120     Y-R-G-C-R-H-E-V-V-D-G-E-A-R-K-T-E-V-L-L-K-V-M-D-A 536 - 560
60     A-K-Y-I-M-D-L-E-R-L-D-P-A-G-A-A-E-T-F-H-V-G-L-P-G 236 - 260 121     H-E-V-V-D-G-E-A-R-K-T-E-V-L-L-K-V-M-D-A-K-H-K-N-C 541 - 565
JAK1 mutant: S515A
Amino Acid position 
Amino Acid position 
TYK2 Wild Type:                      
513 - 537
JAK1 mutant: S518A
JAK1 mutant: S524A
JAK1 mutant:                
S515A and S518A
JAK1 mutant:               
S508A, S512A and 
JAK2 Wild Type:           
461 - 485
JAK3 Wild Type:         
437 - 467
Amino Acid position 
JAK1 wild type:         
506 - 530
JAK1 mutant:                
S508A, S512A, S515A, 
JAK1 mutant: S508A
JAK1 mutant: S512A
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Table 6-3: Peptide array spanning the human JAK3 open reading frame 
  
Array position JAK3 Peptide Sequence Array position JAK3 Peptide Sequence 
122     G-E-A-R-K-T-E-V-L-L-K-V-M-D-A-K-H-K-N-C-M-E-S-F-L 546 - 570 178     S-Q-L-G-K-G-N-F-G-S-V-E-L-C-R-Y-D-P-L-G-D-N-T-G-A 826 - 850
123     T-E-V-L-L-K-V-M-D-A-K-H-K-N-C-M-E-S-F-L-E-A-A-S-L 551 - 575 179     G-N-F-G-S-V-E-L-C-R-Y-D-P-L-G-D-N-T-G-A-L-V-A-V-K 831 - 855
124     K-V-M-D-A-K-H-K-N-C-M-E-S-F-L-E-A-A-S-L-M-S-Q-V-S 556 - 580 180     V-E-L-C-R-Y-D-P-L-G-D-N-T-G-A-L-V-A-V-K-Q-L-Q-H-S 836 - 860
125     K-H-K-N-C-M-E-S-F-L-E-A-A-S-L-M-S-Q-V-S-Y-R-H-L-V 561 - 585 181     Y-D-P-L-G-D-N-T-G-A-L-V-A-V-K-Q-L-Q-H-S-G-P-D-Q-Q 841 - 865
126     M-E-S-F-L-E-A-A-S-L-M-S-Q-V-S-Y-R-H-L-V-L-L-H-G-V 566 - 590 182     D-N-T-G-A-L-V-A-V-K-Q-L-Q-H-S-G-P-D-Q-Q-R-D-F-Q-R 846 - 870
127     E-A-A-S-L-M-S-Q-V-S-Y-R-H-L-V-L-L-H-G-V-C-M-A-G-D 571 - 595 183     L-V-A-V-K-Q-L-Q-H-S-G-P-D-Q-Q-R-D-F-Q-R-E-I-Q-I-L 851 - 875
128     M-S-Q-V-S-Y-R-H-L-V-L-L-H-G-V-C-M-A-G-D-S-T-M-V-Q 576 - 600 184     Q-L-Q-H-S-G-P-D-Q-Q-R-D-F-Q-R-E-I-Q-I-L-K-A-L-H-S 856 - 880
129     Y-R-H-L-V-L-L-H-G-V-C-M-A-G-D-S-T-M-V-Q-E-F-V-H-L 581 - 605 185     G-P-D-Q-Q-R-D-F-Q-R-E-I-Q-I-L-K-A-L-H-S-D-F-I-V-K 861 - 885
130     L-L-H-G-V-C-M-A-G-D-S-T-M-V-Q-E-F-V-H-L-G-A-I-D-M 586 - 610 186     R-D-F-Q-R-E-I-Q-I-L-K-A-L-H-S-D-F-I-V-K-Y-R-G-V-S 866 - 890
131     C-M-A-G-D-S-T-M-V-Q-E-F-V-H-L-G-A-I-D-M-Y-L-R-K-R 591 - 615 187     E-I-Q-I-L-K-A-L-H-S-D-F-I-V-K-Y-R-G-V-S-Y-G-P-G-R 871 - 895
132     S-T-M-V-Q-E-F-V-H-L-G-A-I-D-M-Y-L-R-K-R-G-H-L-V-P 596 - 620 188     K-A-L-H-S-D-F-I-V-K-Y-R-G-V-S-Y-G-P-G-R-Q-S-L-R-L 876 - 900
133     E-F-V-H-L-G-A-I-D-M-Y-L-R-K-R-G-H-L-V-P-A-S-W-K-L 601 - 625 189     D-F-I-V-K-Y-R-G-V-S-Y-G-P-G-R-Q-S-L-R-L-V-M-E-Y-L 881 - 905
134     G-A-I-D-M-Y-L-R-K-R-G-H-L-V-P-A-S-W-K-L-Q-V-V-K-Q 606 - 630 190     Y-R-G-V-S-Y-G-P-G-R-Q-S-L-R-L-V-M-E-Y-L-P-S-G-C-L 886 - 910
135     Y-L-R-K-R-G-H-L-V-P-A-S-W-K-L-Q-V-V-K-Q-L-A-Y-A-L 611 - 635 191     Y-G-P-G-R-Q-S-L-R-L-V-M-E-Y-L-P-S-G-C-L-R-D-F-L-Q 891 - 915
136     G-H-L-V-P-A-S-W-K-L-Q-V-V-K-Q-L-A-Y-A-L-N-Y-L-E-D 616 - 640 192     Q-S-L-R-L-V-M-E-Y-L-P-S-G-C-L-R-D-F-L-Q-R-H-R-A-R 896 - 920
137     A-S-W-K-L-Q-V-V-K-Q-L-A-Y-A-L-N-Y-L-E-D-K-G-L-P-H 621 - 645 193     V-M-E-Y-L-P-S-G-C-L-R-D-F-L-Q-R-H-R-A-R-L-D-A-S-R 901 - 925
138     Q-V-V-K-Q-L-A-Y-A-L-N-Y-L-E-D-K-G-L-P-H-G-N-V-S-A 626 - 650 194     P-S-G-C-L-R-D-F-L-Q-R-H-R-A-R-L-D-A-S-R-L-L-L-Y-S 906 - 930
139     L-A-Y-A-L-N-Y-L-E-D-K-G-L-P-H-G-N-V-S-A-R-K-V-L-L 631 - 655 195     R-D-F-L-Q-R-H-R-A-R-L-D-A-S-R-L-L-L-Y-S-S-Q-I-C-K 911 - 935
140     N-Y-L-E-D-K-G-L-P-H-G-N-V-S-A-R-K-V-L-L-A-R-E-G-A 636 - 660 196     R-H-R-A-R-L-D-A-S-R-L-L-L-Y-S-S-Q-I-C-K-G-M-E-Y-L 916 - 940
141     K-G-L-P-H-G-N-V-S-A-R-K-V-L-L-A-R-E-G-A-D-G-S-P-P 641 - 665 197     L-D-A-S-R-L-L-L-Y-S-S-Q-I-C-K-G-M-E-Y-L-G-S-R-R-C 921 - 945
142     G-N-V-S-A-R-K-V-L-L-A-R-E-G-A-D-G-S-P-P-F-I-K-L-S 646 - 670 198     L-L-L-Y-S-S-Q-I-C-K-G-M-E-Y-L-G-S-R-R-C-V-H-R-D-L 926 - 950
143     R-K-V-L-L-A-R-E-G-A-D-G-S-P-P-F-I-K-L-S-D-P-G-V-S 651 - 675 199     S-Q-I-C-K-G-M-E-Y-L-G-S-R-R-C-V-H-R-D-L-A-A-R-N-I 931 - 955
144     A-R-E-G-A-D-G-S-P-P-F-I-K-L-S-D-P-G-V-S-P-A-V-L-S 656 - 680 200     G-M-E-Y-L-G-S-R-R-C-V-H-R-D-L-A-A-R-N-I-L-V-E-S-E 936 - 960
145     D-G-S-P-P-F-I-K-L-S-D-P-G-V-S-P-A-V-L-S-L-E-M-L-T 661 - 685 201     G-S-R-R-C-V-H-R-D-L-A-A-R-N-I-L-V-E-S-E-A-H-V-K-I 941 - 965
146     F-I-K-L-S-D-P-G-V-S-P-A-V-L-S-L-E-M-L-T-D-R-I-P-W 666 - 690 202     V-H-R-D-L-A-A-R-N-I-L-V-E-S-E-A-H-V-K-I-A-D-F-G-L 946 - 970
147     D-P-G-V-S-P-A-V-L-S-L-E-M-L-T-D-R-I-P-W-V-A-P-E-C 671 - 695 203     A-A-R-N-I-L-V-E-S-E-A-H-V-K-I-A-D-F-G-L-A-K-L-L-P 951 - 975
148     P-A-V-L-S-L-E-M-L-T-D-R-I-P-W-V-A-P-E-C-L-R-E-A-Q 676 - 700 204     L-V-E-S-E-A-H-V-K-I-A-D-F-G-L-A-K-L-L-P-L-D-K-D-Y 956 - 980
149     L-E-M-L-T-D-R-I-P-W-V-A-P-E-C-L-R-E-A-Q-T-L-S-L-E 681 - 705 205     A-H-V-K-I-A-D-F-G-L-A-K-L-L-P-L-D-K-D-Y-Y-V-V-R-E 961 - 985
150     D-R-I-P-W-V-A-P-E-C-L-R-E-A-Q-T-L-S-L-E-A-D-K-W-G 686 - 710 206     A-D-F-G-L-A-K-L-L-P-L-D-K-D-Y-Y-V-V-R-E-P-G-Q-S-P 966 - 990
151     V-A-P-E-C-L-R-E-A-Q-T-L-S-L-E-A-D-K-W-G-F-G-A-T-V 691 - 715 207     A-K-L-L-P-L-D-K-D-Y-Y-V-V-R-E-P-G-Q-S-P-I-F-W-Y-A 971 - 995
152     L-R-E-A-Q-T-L-S-L-E-A-D-K-W-G-F-G-A-T-V-W-E-V-F-S 696 - 720 208     L-D-K-D-Y-Y-V-V-R-E-P-G-Q-S-P-I-F-W-Y-A-P-E-S-L-S 976 - 1000
153     T-L-S-L-E-A-D-K-W-G-F-G-A-T-V-W-E-V-F-S-G-V-T-M-P 701 - 725 209     Y-V-V-R-E-P-G-Q-S-P-I-F-W-Y-A-P-E-S-L-S-D-N-I-F-S 981 - 1005
154     A-D-K-W-G-F-G-A-T-V-W-E-V-F-S-G-V-T-M-P-I-S-A-L-D 706 - 730 210     P-G-Q-S-P-I-F-W-Y-A-P-E-S-L-S-D-N-I-F-S-R-Q-S-D-V 986 - 1010
155     F-G-A-T-V-W-E-V-F-S-G-V-T-M-P-I-S-A-L-D-P-A-K-K-L 711 - 735 211     I-F-W-Y-A-P-E-S-L-S-D-N-I-F-S-R-Q-S-D-V-W-S-F-G-V 991 - 1015
156     W-E-V-F-S-G-V-T-M-P-I-S-A-L-D-P-A-K-K-L-Q-F-Y-E-D 716 - 740 212     P-E-S-L-S-D-N-I-F-S-R-Q-S-D-V-W-S-F-G-V-V-L-Y-E-L 996 - 1020
157     G-V-T-M-P-I-S-A-L-D-P-A-K-K-L-Q-F-Y-E-D-R-Q-Q-L-P 721 - 745 213     D-N-I-F-S-R-Q-S-D-V-W-S-F-G-V-V-L-Y-E-L-F-T-Y-C-D 1001 - 1025
158     I-S-A-L-D-P-A-K-K-L-Q-F-Y-E-D-R-Q-Q-L-P-A-P-K-W-T 726 - 750 214     R-Q-S-D-V-W-S-F-G-V-V-L-Y-E-L-F-T-Y-C-D-K-S-C-S-P 1006 - 1030
159     P-A-K-K-L-Q-F-Y-E-D-R-Q-Q-L-P-A-P-K-W-T-E-L-A-L-L 731 - 755 215     W-S-F-G-V-V-L-Y-E-L-F-T-Y-C-D-K-S-C-S-P-S-A-E-F-L 1011 - 1035
160     Q-F-Y-E-D-R-Q-Q-L-P-A-P-K-W-T-E-L-A-L-L-I-Q-Q-C-M 736 - 760 216     V-L-Y-E-L-F-T-Y-C-D-K-S-C-S-P-S-A-E-F-L-R-M-M-G-C 1016 - 1040
161     R-Q-Q-L-P-A-P-K-W-T-E-L-A-L-L-I-Q-Q-C-M-A-Y-E-P-V 741 - 765 217     F-T-Y-C-D-K-S-C-S-P-S-A-E-F-L-R-M-M-G-C-E-R-D-V-P 1021 - 1045
162     A-P-K-W-T-E-L-A-L-L-I-Q-Q-C-M-A-Y-E-P-V-Q-R-P-S-F 746 - 770 218     K-S-C-S-P-S-A-E-F-L-R-M-M-G-C-E-R-D-V-P-A-L-C-R-L 1026 - 1050
163     E-L-A-L-L-I-Q-Q-C-M-A-Y-E-P-V-Q-R-P-S-F-R-A-V-I-R 751 - 775 219     S-A-E-F-L-R-M-M-G-C-E-R-D-V-P-A-L-C-R-L-L-E-L-L-E 1031 - 1055
164     I-Q-Q-C-M-A-Y-E-P-V-Q-R-P-S-F-R-A-V-I-R-D-L-N-S-L 756 - 780 220     R-M-M-G-C-E-R-D-V-P-A-L-C-R-L-L-E-L-L-E-E-G-Q-R-L 1036 - 1060
165     A-Y-E-P-V-Q-R-P-S-F-R-A-V-I-R-D-L-N-S-L-I-S-S-D-Y 761 - 785 221     E-R-D-V-P-A-L-C-R-L-L-E-L-L-E-E-G-Q-R-L-P-A-P-P-A 1041 - 1065
166     Q-R-P-S-F-R-A-V-I-R-D-L-N-S-L-I-S-S-D-Y-E-L-L-S-D 766 - 790 222     A-L-C-R-L-L-E-L-L-E-E-G-Q-R-L-P-A-P-P-A-C-P-A-E-V 1046 - 1070
167     R-A-V-I-R-D-L-N-S-L-I-S-S-D-Y-E-L-L-S-D-P-T-P-G-A 771 - 795 223     L-E-L-L-E-E-G-Q-R-L-P-A-P-P-A-C-P-A-E-V-H-E-L-M-K 1051 - 1075
168     D-L-N-S-L-I-S-S-D-Y-E-L-L-S-D-P-T-P-G-A-L-A-P-R-D 776 - 800 224     E-G-Q-R-L-P-A-P-P-A-C-P-A-E-V-H-E-L-M-K-L-C-W-A-P 1056 - 1080
169     I-S-S-D-Y-E-L-L-S-D-P-T-P-G-A-L-A-P-R-D-G-L-W-N-G 781 - 805 225     P-A-P-P-A-C-P-A-E-V-H-E-L-M-K-L-C-W-A-P-S-P-Q-D-R 1061 - 1085
170     E-L-L-S-D-P-T-P-G-A-L-A-P-R-D-G-L-W-N-G-A-Q-L-Y-A 786 - 810 226     C-P-A-E-V-H-E-L-M-K-L-C-W-A-P-S-P-Q-D-R-P-S-F-S-A 1066 - 1090
171     P-T-P-G-A-L-A-P-R-D-G-L-W-N-G-A-Q-L-Y-A-C-Q-D-P-T 791 - 815 227     H-E-L-M-K-L-C-W-A-P-S-P-Q-D-R-P-S-F-S-A-L-G-P-Q-L 1071 - 1095
172     L-A-P-R-D-G-L-W-N-G-A-Q-L-Y-A-C-Q-D-P-T-I-F-E-E-R 796 - 820 228     L-C-W-A-P-S-P-Q-D-R-P-S-F-S-A-L-G-P-Q-L-D-M-L-W-S 1076 - 1100
173     G-L-W-N-G-A-Q-L-Y-A-C-Q-D-P-T-I-F-E-E-R-H-L-K-Y-I 801 - 825 229     S-P-Q-D-R-P-S-F-S-A-L-G-P-Q-L-D-M-L-W-S-G-S-R-G-C 1081 - 1105
174     A-Q-L-Y-A-C-Q-D-P-T-I-F-E-E-R-H-L-K-Y-I-S-Q-L-G-K 806 - 830 230     P-S-F-S-A-L-G-P-Q-L-D-M-L-W-S-G-S-R-G-C-E-T-H-A-F 1086 - 1110
175     C-Q-D-P-T-I-F-E-E-R-H-L-K-Y-I-S-Q-L-G-K-G-N-F-G-S 811 - 835 231     L-G-P-Q-L-D-M-L-W-S-G-S-R-G-C-E-T-H-A-F-T-A-H-P-E 1091 - 1115
176     I-F-E-E-R-H-L-K-Y-I-S-Q-L-G-K-G-N-F-G-S-V-E-L-C-R 816 - 840 232     D-M-L-W-S-G-S-R-G-C-E-T-H-A-F-T-A-H-P-E-G-K-H-H-S 1096 - 1120
177     H-L-K-Y-I-S-Q-L-G-K-G-N-F-G-S-V-E-L-C-R-Y-D-P-L-G 821 - 845 233     S-G-S-R-G-C-E-T-H-A-F-T-A-H-P-E-G-K-H-H-S-L-S-F-S 1101 - 1125
234 H-M-R-S-A-M-S-G-L-H-L-V-K-R-R
Amino Acid position Amino Acid position 
SAMS Peptide 
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
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Table 6-4: Peptide array spanning the human TYK2 open reading frame  
 (continued overleaf)  
  
Array Position JAK Peptide Sequence Array Position TYK2 Peptide Sequence
1     R-Y-S-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 61     F-L-R-D-F-Q-P-G-R-L-S-Q-Q-M-V-M-V-K-Y-L-A-T-L-E-R 241 - 265
2     R-Y-A-L-H-G-A-D-R-A-F-P-A-L-G-D-L-M-A-H-L-K-K-Q-I 62     Q-P-G-R-L-S-Q-Q-M-V-M-V-K-Y-L-A-T-L-E-R-L-A-P-R-F 246 - 270
3     R-Y-A-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 63     S-Q-Q-M-V-M-V-K-Y-L-A-T-L-E-R-L-A-P-R-F-G-T-E-R-V 251 - 275
4     R-Y-S-L-H-G-A-D-R-S-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 64     M-V-K-Y-L-A-T-L-E-R-L-A-P-R-F-G-T-E-R-V-P-V-C-H-L 256 - 280
5     R-Y-S-L-H-G-S-D-R-A-F-P-S-L-G-D-L-M-S-H-L-K-K-Q-I 65     A-T-L-E-R-L-A-P-R-F-G-T-E-R-V-P-V-C-H-L-R-L-L-A-Q 261 - 285
6     R-Y-S-L-H-G-S-D-R-S-F-P-A-L-G-D-L-M-S-H-L-K-K-Q-I 66     L-A-P-R-F-G-T-E-R-V-P-V-C-H-L-R-L-L-A-Q-A-E-G-E-P 266 - 290
7     R-Y-S-L-H-G-S-D-R-S-F-P-S-L-G-D-L-M-A-H-L-K-K-Q-I 67     G-T-E-R-V-P-V-C-H-L-R-L-L-A-Q-A-E-G-E-P-C-Y-I-R-D 271 - 295
8     R-Y-S-L-H-G-S-D-R-A-F-P-A-L-G-D-L-M-S-H-L-K-K-Q-I 68     P-V-C-H-L-R-L-L-A-Q-A-E-G-E-P-C-Y-I-R-D-S-G-V-A-P 276 - 300
9     R-Y-A-L-H-G-A-D-R-S-F-P-S-L-G-D-L-M-A-H-L-K-K-Q-I 69     R-L-L-A-Q-A-E-G-E-P-C-Y-I-R-D-S-G-V-A-P-T-D-P-G-P 281 - 305
10     E-Y-N-L-S-G-T-K-K-N-F-S-S-L-K-D-L-L-N-C-Y-Q-M-E-T 70     A-E-G-E-P-C-Y-I-R-D-S-G-V-A-P-T-D-P-G-P-E-S-A-A-G 286 - 310
11     T-F-L-L-V-G-L-S-R-P-H-S-S-L-R-E-L-L-A-T-C-W-D-G-G 71     C-Y-I-R-D-S-G-V-A-P-T-D-P-G-P-E-S-A-A-G-P-P-T-H-E 291 - 315
12     A-F-V-L-E-G-W-G-R-S-F-P-S-V-R-E-L-G-A-A-L-Q-G-C-L 72     S-G-V-A-P-T-D-P-G-P-E-S-A-A-G-P-P-T-H-E-V-L-V-T-G 296 - 320
Array Position TYK2 Peptide Sequence 73     T-D-P-G-P-E-S-A-A-G-P-P-T-H-E-V-L-V-T-G-T-G-G-I-Q 301 - 325
13     M-P-L-R-H-W-G-M-A-R-G-S-K-P-V-G-D-G-A-Q-P-M-A-A-M 1 - 25 74     E-S-A-A-G-P-P-T-H-E-V-L-V-T-G-T-G-G-I-Q-W-W-P-V-E 306 - 330
14     W-G-M-A-R-G-S-K-P-V-G-D-G-A-Q-P-M-A-A-M-G-G-L-K-V 6 - 30 75     P-P-T-H-E-V-L-V-T-G-T-G-G-I-Q-W-W-P-V-E-E-E-V-N-K 311 - 335
15     G-S-K-P-V-G-D-G-A-Q-P-M-A-A-M-G-G-L-K-V-L-L-H-W-A 11 - 35 76     V-L-V-T-G-T-G-G-I-Q-W-W-P-V-E-E-E-V-N-K-E-E-G-S-S 316 - 340
16     G-D-G-A-Q-P-M-A-A-M-G-G-L-K-V-L-L-H-W-A-G-P-G-G-G 16 - 40 77     T-G-G-I-Q-W-W-P-V-E-E-E-V-N-K-E-E-G-S-S-G-S-S-G-R 321 - 345
17     P-M-A-A-M-G-G-L-K-V-L-L-H-W-A-G-P-G-G-G-E-P-W-V-T 21 - 45 78     W-W-P-V-E-E-E-V-N-K-E-E-G-S-S-G-S-S-G-R-N-P-Q-A-S 326 - 350
18     G-G-L-K-V-L-L-H-W-A-G-P-G-G-G-E-P-W-V-T-F-S-E-S-S 26 - 50 79     E-E-V-N-K-E-E-G-S-S-G-S-S-G-R-N-P-Q-A-S-L-F-G-K-K 331 - 355
19     L-L-H-W-A-G-P-G-G-G-E-P-W-V-T-F-S-E-S-S-L-T-A-E-E 31 - 55 80     E-E-G-S-S-G-S-S-G-R-N-P-Q-A-S-L-F-G-K-K-A-K-A-H-K 336 - 360
20     G-P-G-G-G-E-P-W-V-T-F-S-E-S-S-L-T-A-E-E-V-C-I-H-I 36 - 60 81     G-S-S-G-R-N-P-Q-A-S-L-F-G-K-K-A-K-A-H-K-A-V-G-Q-P 341 - 365
21     E-P-W-V-T-F-S-E-S-S-L-T-A-E-E-V-C-I-H-I-A-H-K-V-G 41 - 65 82     N-P-Q-A-S-L-F-G-K-K-A-K-A-H-K-A-V-G-Q-P-A-D-R-P-R 346 - 370
22     F-S-E-S-S-L-T-A-E-E-V-C-I-H-I-A-H-K-V-G-I-T-P-P-C 46 - 70 83     L-F-G-K-K-A-K-A-H-K-A-V-G-Q-P-A-D-R-P-R-E-P-L-W-A 351 - 375
23     L-T-A-E-E-V-C-I-H-I-A-H-K-V-G-I-T-P-P-C-F-N-L-F-A 51 - 75 84     A-K-A-H-K-A-V-G-Q-P-A-D-R-P-R-E-P-L-W-A-Y-F-C-D-F 356 - 380
24     V-C-I-H-I-A-H-K-V-G-I-T-P-P-C-F-N-L-F-A-L-F-D-A-Q 56 - 80 85     A-V-G-Q-P-A-D-R-P-R-E-P-L-W-A-Y-F-C-D-F-R-D-I-T-H 361 - 385
25     A-H-K-V-G-I-T-P-P-C-F-N-L-F-A-L-F-D-A-Q-A-Q-V-W-L 61 - 85 86     A-D-R-P-R-E-P-L-W-A-Y-F-C-D-F-R-D-I-T-H-V-V-L-K-E 366 - 390
26     I-T-P-P-C-F-N-L-F-A-L-F-D-A-Q-A-Q-V-W-L-P-P-N-H-I 66 - 90 87     E-P-L-W-A-Y-F-C-D-F-R-D-I-T-H-V-V-L-K-E-H-C-V-S-I 371 - 395
27     F-N-L-F-A-L-F-D-A-Q-A-Q-V-W-L-P-P-N-H-I-L-E-I-P-R 71 - 95 88     Y-F-C-D-F-R-D-I-T-H-V-V-L-K-E-H-C-V-S-I-H-R-Q-D-N 376 - 400
28     L-F-D-A-Q-A-Q-V-W-L-P-P-N-H-I-L-E-I-P-R-D-A-S-L-M 76 - 100 89     R-D-I-T-H-V-V-L-K-E-H-C-V-S-I-H-R-Q-D-N-K-C-L-E-L 381 - 405
29     A-Q-V-W-L-P-P-N-H-I-L-E-I-P-R-D-A-S-L-M-L-Y-F-R-I 81 - 105 90     V-V-L-K-E-H-C-V-S-I-H-R-Q-D-N-K-C-L-E-L-S-L-P-S-R 386 - 410
30     P-P-N-H-I-L-E-I-P-R-D-A-S-L-M-L-Y-F-R-I-R-F-Y-F-R 86 - 110 91     H-C-V-S-I-H-R-Q-D-N-K-C-L-E-L-S-L-P-S-R-A-A-A-L-S 391 - 415
31     L-E-I-P-R-D-A-S-L-M-L-Y-F-R-I-R-F-Y-F-R-N-W-H-G-M 91 - 115 92     H-R-Q-D-N-K-C-L-E-L-S-L-P-S-R-A-A-A-L-S-F-V-S-L-V 396 - 420
32     D-A-S-L-M-L-Y-F-R-I-R-F-Y-F-R-N-W-H-G-M-N-P-R-E-P 96 - 120 93     K-C-L-E-L-S-L-P-S-R-A-A-A-L-S-F-V-S-L-V-D-G-Y-F-R 401 - 425
33     L-Y-F-R-I-R-F-Y-F-R-N-W-H-G-M-N-P-R-E-P-A-V-Y-R-C 101 - 125 94     S-L-P-S-R-A-A-A-L-S-F-V-S-L-V-D-G-Y-F-R-L-T-A-D-S 406 - 430
34     R-F-Y-F-R-N-W-H-G-M-N-P-R-E-P-A-V-Y-R-C-G-P-P-G-T 106 - 130 95     A-A-A-L-S-F-V-S-L-V-D-G-Y-F-R-L-T-A-D-S-S-H-Y-L-C 411 - 435
35     N-W-H-G-M-N-P-R-E-P-A-V-Y-R-C-G-P-P-G-T-E-A-S-S-D 111 - 135 96     F-V-S-L-V-D-G-Y-F-R-L-T-A-D-S-S-H-Y-L-C-H-E-V-A-P 416 - 440
36     N-P-R-E-P-A-V-Y-R-C-G-P-P-G-T-E-A-S-S-D-Q-T-A-Q-G 116 - 140 97     D-G-Y-F-R-L-T-A-D-S-S-H-Y-L-C-H-E-V-A-P-P-R-L-V-M 421 - 445
37     A-V-Y-R-C-G-P-P-G-T-E-A-S-S-D-Q-T-A-Q-G-M-Q-L-L-D 121 - 145 98     L-T-A-D-S-S-H-Y-L-C-H-E-V-A-P-P-R-L-V-M-S-I-R-D-G 426 - 450
38     G-P-P-G-T-E-A-S-S-D-Q-T-A-Q-G-M-Q-L-L-D-P-A-S-F-E 126 - 150 99     S-H-Y-L-C-H-E-V-A-P-P-R-L-V-M-S-I-R-D-G-I-H-G-P-L 431 - 455
39     E-A-S-S-D-Q-T-A-Q-G-M-Q-L-L-D-P-A-S-F-E-Y-L-F-E-Q 131 - 155 100     H-E-V-A-P-P-R-L-V-M-S-I-R-D-G-I-H-G-P-L-L-E-P-F-V 436 - 460
40     Q-T-A-Q-G-M-Q-L-L-D-P-A-S-F-E-Y-L-F-E-Q-G-K-H-E-F 136 - 160 101     P-R-L-V-M-S-I-R-D-G-I-H-G-P-L-L-E-P-F-V-Q-A-K-L-R 441 - 465
41     M-Q-L-L-D-P-A-S-F-E-Y-L-F-E-Q-G-K-H-E-F-V-N-D-V-A 141 - 165 102     S-I-R-D-G-I-H-G-P-L-L-E-P-F-V-Q-A-K-L-R-P-E-D-G-L 446 - 470
42     P-A-S-F-E-Y-L-F-E-Q-G-K-H-E-F-V-N-D-V-A-S-L-W-E-L 146 - 170 103     I-H-G-P-L-L-E-P-F-V-Q-A-K-L-R-P-E-D-G-L-Y-L-I-H-W 451 - 475
43     Y-L-F-E-Q-G-K-H-E-F-V-N-D-V-A-S-L-W-E-L-S-T-E-E-E 151 - 175 104     L-E-P-F-V-Q-A-K-L-R-P-E-D-G-L-Y-L-I-H-W-S-T-S-H-P 456 - 480
44     G-K-H-E-F-V-N-D-V-A-S-L-W-E-L-S-T-E-E-E-I-H-H-F-K 156 - 180 105     Q-A-K-L-R-P-E-D-G-L-Y-L-I-H-W-S-T-S-H-P-Y-R-L-I-L 461 - 485
45     V-N-D-V-A-S-L-W-E-L-S-T-E-E-E-I-H-H-F-K-N-E-S-L-G 161 - 185 106     P-E-D-G-L-Y-L-I-H-W-S-T-S-H-P-Y-R-L-I-L-T-V-A-Q-R 466 - 490
46     S-L-W-E-L-S-T-E-E-E-I-H-H-F-K-N-E-S-L-G-M-A-F-L-H 166 - 190 107     Y-L-I-H-W-S-T-S-H-P-Y-R-L-I-L-T-V-A-Q-R-S-Q-A-P-D 471 - 495
47     S-T-E-E-E-I-H-H-F-K-N-E-S-L-G-M-A-F-L-H-L-C-H-L-A 171 - 195 108     S-T-S-H-P-Y-R-L-I-L-T-V-A-Q-R-S-Q-A-P-D-G-M-Q-S-L 476 - 500
48     I-H-H-F-K-N-E-S-L-G-M-A-F-L-H-L-C-H-L-A-L-R-H-G-I 176 - 200 109     Y-R-L-I-L-T-V-A-Q-R-S-Q-A-P-D-G-M-Q-S-L-R-L-R-K-F 481 - 505
49     N-E-S-L-G-M-A-F-L-H-L-C-H-L-A-L-R-H-G-I-P-L-E-E-V 181 - 205 110     T-V-A-Q-R-S-Q-A-P-D-G-M-Q-S-L-R-L-R-K-F-P-I-E-Q-Q 486 - 510
50     M-A-F-L-H-L-C-H-L-A-L-R-H-G-I-P-L-E-E-V-A-K-K-T-S 186 - 210 111     S-Q-A-P-D-G-M-Q-S-L-R-L-R-K-F-P-I-E-Q-Q-D-G-A-F-V 491 - 515
51     L-C-H-L-A-L-R-H-G-I-P-L-E-E-V-A-K-K-T-S-F-K-D-C-I 191 - 215 112     G-M-Q-S-L-R-L-R-K-F-P-I-E-Q-Q-D-G-A-F-V-L-E-G-W-G 496 - 520
52     L-R-H-G-I-P-L-E-E-V-A-K-K-T-S-F-K-D-C-I-P-R-S-F-R 196 - 220 113     R-L-R-K-F-P-I-E-Q-Q-D-G-A-F-V-L-E-G-W-G-R-S-F-P-S 501 - 525
53     P-L-E-E-V-A-K-K-T-S-F-K-D-C-I-P-R-S-F-R-R-H-I-R-Q 201 - 225 114     P-I-E-Q-Q-D-G-A-F-V-L-E-G-W-G-R-S-F-P-S-V-R-E-L-G 506 - 530
54     A-K-K-T-S-F-K-D-C-I-P-R-S-F-R-R-H-I-R-Q-H-S-A-L-T 206 - 230 115     D-G-A-F-V-L-E-G-W-G-R-S-F-P-S-V-R-E-L-G-A-A-L-Q-G 511 - 535
55     F-K-D-C-I-P-R-S-F-R-R-H-I-R-Q-H-S-A-L-T-R-L-R-L-R 211 - 235 116     L-E-G-W-G-R-S-F-P-S-V-R-E-L-G-A-A-L-Q-G-C-L-L-R-A 516 - 540
56     P-R-S-F-R-R-H-I-R-Q-H-S-A-L-T-R-L-R-L-R-N-V-F-R-R 216 - 240 117     R-S-F-P-S-V-R-E-L-G-A-A-L-Q-G-C-L-L-R-A-G-D-D-C-F 521 - 545
57     R-H-I-R-Q-H-S-A-L-T-R-L-R-L-R-N-V-F-R-R-F-L-R-D-F 221 - 245 118     V-R-E-L-G-A-A-L-Q-G-C-L-L-R-A-G-D-D-C-F-S-L-R-R-C 526 - 550
58     H-S-A-L-T-R-L-R-L-R-N-V-F-R-R-F-L-R-D-F-Q-P-G-R-L 226 - 250 119     A-A-L-Q-G-C-L-L-R-A-G-D-D-C-F-S-L-R-R-C-C-L-P-Q-P 531 - 555
59     R-L-R-L-R-N-V-F-R-R-F-L-R-D-F-Q-P-G-R-L-S-Q-Q-M-V 231 - 255 120     C-L-L-R-A-G-D-D-C-F-S-L-R-R-C-C-L-P-Q-P-G-E-T-S-N 536 - 560
60     N-V-F-R-R-F-L-R-D-F-Q-P-G-R-L-S-Q-Q-M-V-M-V-K-Y-L 236 - 260 121     G-D-D-C-F-S-L-R-R-C-C-L-P-Q-P-G-E-T-S-N-L-I-I-M-R 541 - 565
TYK2 Wild Type:                      
513 - 537
Amino Acid Position 
Amino Acid Position 
JAK1 mutant: S518A
JAK1 mutant: S524A
JAK1 mutant:                
S515A and S518A
JAK1 mutant:               
S508A, S512A and 
S5124A
JAK2 Wild Type:           
461 - 485
JAK3 Wild Type:         
437 - 467
Amino Acid Position 
JAK1 Wild Type:         
506 - 530
JAK1 mutant:                
S508A, S512A, S515A, 
S518A and S524A
JAK1 mutant: S508A
JAK1 mutant: S512A
JAK1 mutant: S515A
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Table 6-4: Peptide array spanning the human TYK2 open reading frame  
   
Array Position TYK2 Peptide Sequence Array Position TYK2 Peptide Sequence
122     S-L-R-R-C-C-L-P-Q-P-G-E-T-S-N-L-I-I-M-R-G-A-R-A-S 546 - 570 185     T-I-L-R-D-L-T-R-L-Q-P-H-N-L-A-D-V-L-T-V-N-P-D-S-P 861 - 885
123     C-L-P-Q-P-G-E-T-S-N-L-I-I-M-R-G-A-R-A-S-P-R-T-L-N 551 - 575 186     L-T-R-L-Q-P-H-N-L-A-D-V-L-T-V-N-P-D-S-P-A-S-D-P-T 866 - 890
124     G-E-T-S-N-L-I-I-M-R-G-A-R-A-S-P-R-T-L-N-L-S-Q-L-S 556 - 580 187     P-H-N-L-A-D-V-L-T-V-N-P-D-S-P-A-S-D-P-T-V-F-H-K-R 871 - 895
125     L-I-I-M-R-G-A-R-A-S-P-R-T-L-N-L-S-Q-L-S-F-H-R-V-D 561 - 585 188     D-V-L-T-V-N-P-D-S-P-A-S-D-P-T-V-F-H-K-R-Y-L-K-K-I 876 - 900
126     G-A-R-A-S-P-R-T-L-N-L-S-Q-L-S-F-H-R-V-D-Q-K-E-I-T 566 - 590 189     N-P-D-S-P-A-S-D-P-T-V-F-H-K-R-Y-L-K-K-I-R-D-L-G-E 881 - 905
127     P-R-T-L-N-L-S-Q-L-S-F-H-R-V-D-Q-K-E-I-T-Q-L-S-H-L 571 - 595 190     A-S-D-P-T-V-F-H-K-R-Y-L-K-K-I-R-D-L-G-E-G-H-F-G-K 886 - 910
128     L-S-Q-L-S-F-H-R-V-D-Q-K-E-I-T-Q-L-S-H-L-G-Q-G-T-R 576 - 600 191     V-F-H-K-R-Y-L-K-K-I-R-D-L-G-E-G-H-F-G-K-V-S-L-Y-C 891 - 915
129     F-H-R-V-D-Q-K-E-I-T-Q-L-S-H-L-G-Q-G-T-R-T-N-V-Y-E 581 - 605 192     Y-L-K-K-I-R-D-L-G-E-G-H-F-G-K-V-S-L-Y-C-Y-D-P-T-N 896 - 920
130     Q-K-E-I-T-Q-L-S-H-L-G-Q-G-T-R-T-N-V-Y-E-G-R-L-R-V 586 - 610 193     R-D-L-G-E-G-H-F-G-K-V-S-L-Y-C-Y-D-P-T-N-D-G-T-G-E 901 - 925
131     Q-L-S-H-L-G-Q-G-T-R-T-N-V-Y-E-G-R-L-R-V-E-G-S-G-D 591 - 615 194     G-H-F-G-K-V-S-L-Y-C-Y-D-P-T-N-D-G-T-G-E-M-V-A-V-K 906 - 930
132     G-Q-G-T-R-T-N-V-Y-E-G-R-L-R-V-E-G-S-G-D-P-E-E-G-K 596 - 620 195     V-S-L-Y-C-Y-D-P-T-N-D-G-T-G-E-M-V-A-V-K-A-L-K-A-D 911 - 935
133     T-N-V-Y-E-G-R-L-R-V-E-G-S-G-D-P-E-E-G-K-M-D-D-E-D 601 - 625 196     Y-D-P-T-N-D-G-T-G-E-M-V-A-V-K-A-L-K-A-D-C-G-P-Q-H 916 - 940
134     G-R-L-R-V-E-G-S-G-D-P-E-E-G-K-M-D-D-E-D-P-L-V-P-G 606 - 630 197     D-G-T-G-E-M-V-A-V-K-A-L-K-A-D-C-G-P-Q-H-R-S-G-W-K 921 - 945
135     E-G-S-G-D-P-E-E-G-K-M-D-D-E-D-P-L-V-P-G-R-D-R-G-Q 611 - 635 198     M-V-A-V-K-A-L-K-A-D-C-G-P-Q-H-R-S-G-W-K-Q-E-I-D-I 926 - 950
136     P-E-E-G-K-M-D-D-E-D-P-L-V-P-G-R-D-R-G-Q-E-L-R-V-V 616 - 640 199     A-L-K-A-D-C-G-P-Q-H-R-S-G-W-K-Q-E-I-D-I-L-R-T-L-Y 931 - 955
137     M-D-D-E-D-P-L-V-P-G-R-D-R-G-Q-E-L-R-V-V-L-K-V-L-D 621 - 645 200     C-G-P-Q-H-R-S-G-W-K-Q-E-I-D-I-L-R-T-L-Y-H-E-H-I-I 936 - 960
138     P-L-V-P-G-R-D-R-G-Q-E-L-R-V-V-L-K-V-L-D-P-S-H-H-D 626 - 650 201     R-S-G-W-K-Q-E-I-D-I-L-R-T-L-Y-H-E-H-I-I-K-Y-K-G-C 941 - 965
139     R-D-R-G-Q-E-L-R-V-V-L-K-V-L-D-P-S-H-H-D-I-A-L-A-F 631 - 655 202     Q-E-I-D-I-L-R-T-L-Y-H-E-H-I-I-K-Y-K-G-C-C-E-D-Q-G 946 - 970
140     E-L-R-V-V-L-K-V-L-D-P-S-H-H-D-I-A-L-A-F-Y-E-T-A-S 636 - 660 203     L-R-T-L-Y-H-E-H-I-I-K-Y-K-G-C-C-E-D-Q-G-E-K-S-L-Q 951 - 975
141     L-K-V-L-D-P-S-H-H-D-I-A-L-A-F-Y-E-T-A-S-L-M-S-Q-V 641 - 665 204     H-E-H-I-I-K-Y-K-G-C-C-E-D-Q-G-E-K-S-L-Q-L-V-M-E-Y 956 - 980
142     P-S-H-H-D-I-A-L-A-F-Y-E-T-A-S-L-M-S-Q-V-S-H-T-H-L 646 - 670 205     K-Y-K-G-C-C-E-D-Q-G-E-K-S-L-Q-L-V-M-E-Y-V-P-L-G-S 961 - 985
143     I-A-L-A-F-Y-E-T-A-S-L-M-S-Q-V-S-H-T-H-L-A-F-V-H-G 651 - 675 206     C-E-D-Q-G-E-K-S-L-Q-L-V-M-E-Y-V-P-L-G-S-L-R-D-Y-L 966 - 990
144     Y-E-T-A-S-L-M-S-Q-V-S-H-T-H-L-A-F-V-H-G-V-C-V-R-G 656 - 680 207     E-K-S-L-Q-L-V-M-E-Y-V-P-L-G-S-L-R-D-Y-L-P-R-H-S-I 971 - 995
145     L-M-S-Q-V-S-H-T-H-L-A-F-V-H-G-V-C-V-R-G-P-E-N-I-M 661 - 685 208     L-V-M-E-Y-V-P-L-G-S-L-R-D-Y-L-P-R-H-S-I-G-L-A-Q-L 976 - 1000
146     S-H-T-H-L-A-F-V-H-G-V-C-V-R-G-P-E-N-I-M-V-T-E-Y-V 666 - 690 209     V-P-L-G-S-L-R-D-Y-L-P-R-H-S-I-G-L-A-Q-L-L-L-F-A-Q 981 - 1005
147     A-F-V-H-G-V-C-V-R-G-P-E-N-I-M-V-T-E-Y-V-E-H-G-P-L 671 - 695 210     L-R-D-Y-L-P-R-H-S-I-G-L-A-Q-L-L-L-F-A-Q-Q-I-C-E-G 986 - 1010
148     V-C-V-R-G-P-E-N-I-M-V-T-E-Y-V-E-H-G-P-L-D-V-W-L-R 676 - 700 211     P-R-H-S-I-G-L-A-Q-L-L-L-F-A-Q-Q-I-C-E-G-M-A-Y-L-H 991 - 1015
149     P-E-N-I-M-V-T-E-Y-V-E-H-G-P-L-D-V-W-L-R-R-E-R-G-H 681 - 705 212     G-L-A-Q-L-L-L-F-A-Q-Q-I-C-E-G-M-A-Y-L-H-A-Q-H-Y-I 996 - 1020
150     V-T-E-Y-V-E-H-G-P-L-D-V-W-L-R-R-E-R-G-H-V-P-M-A-W 686 - 710 213     L-L-F-A-Q-Q-I-C-E-G-M-A-Y-L-H-A-Q-H-Y-I-H-R-D-L-A 1001 - 1025
151     E-H-G-P-L-D-V-W-L-R-R-E-R-G-H-V-P-M-A-W-K-M-V-V-A 691 - 715 214     Q-I-C-E-G-M-A-Y-L-H-A-Q-H-Y-I-H-R-D-L-A-A-R-N-V-L 1006 - 1030
152     D-V-W-L-R-R-E-R-G-H-V-P-M-A-W-K-M-V-V-A-Q-Q-L-A-S 696 - 720 215     M-A-Y-L-H-A-Q-H-Y-I-H-R-D-L-A-A-R-N-V-L-L-D-N-D-R 1011 - 1035
153     R-E-R-G-H-V-P-M-A-W-K-M-V-V-A-Q-Q-L-A-S-A-L-S-Y-L 701 - 725 216     A-Q-H-Y-I-H-R-D-L-A-A-R-N-V-L-L-D-N-D-R-L-V-K-I-G 1016 - 1040
154     V-P-M-A-W-K-M-V-V-A-Q-Q-L-A-S-A-L-S-Y-L-E-N-K-N-L 706 - 730 217     H-R-D-L-A-A-R-N-V-L-L-D-N-D-R-L-V-K-I-G-D-F-G-L-A 1021 - 1045
155     K-M-V-V-A-Q-Q-L-A-S-A-L-S-Y-L-E-N-K-N-L-V-H-G-N-V 711 - 735 218     A-R-N-V-L-L-D-N-D-R-L-V-K-I-G-D-F-G-L-A-K-A-V-P-E 1026 - 1050
156     Q-Q-L-A-S-A-L-S-Y-L-E-N-K-N-L-V-H-G-N-V-C-G-R-N-I 716 - 740 219     L-D-N-D-R-L-V-K-I-G-D-F-G-L-A-K-A-V-P-E-G-H-E-Y-Y 1031 - 1055
157     A-L-S-Y-L-E-N-K-N-L-V-H-G-N-V-C-G-R-N-I-L-L-A-R-L 721 - 745 220     L-V-K-I-G-D-F-G-L-A-K-A-V-P-E-G-H-E-Y-Y-R-V-R-E-D 1036 - 1060
158     E-N-K-N-L-V-H-G-N-V-C-G-R-N-I-L-L-A-R-L-G-L-A-E-G 726 - 750 221     D-F-G-L-A-K-A-V-P-E-G-H-E-Y-Y-R-V-R-E-D-G-D-S-P-V 1041 - 1065
159     V-H-G-N-V-C-G-R-N-I-L-L-A-R-L-G-L-A-E-G-T-S-P-F-I 731 - 755 222     K-A-V-P-E-G-H-E-Y-Y-R-V-R-E-D-G-D-S-P-V-F-W-Y-A-P 1046 - 1070
160     C-G-R-N-I-L-L-A-R-L-G-L-A-E-G-T-S-P-F-I-K-L-S-D-P 736 - 760 223     G-H-E-Y-Y-R-V-R-E-D-G-D-S-P-V-F-W-Y-A-P-E-C-L-K-E 1051 - 1075
161     L-L-A-R-L-G-L-A-E-G-T-S-P-F-I-K-L-S-D-P-G-V-G-L-G 741 - 765 224     R-V-R-E-D-G-D-S-P-V-F-W-Y-A-P-E-C-L-K-E-Y-K-F-Y-Y 1056 - 1080
162     G-L-A-E-G-T-S-P-F-I-K-L-S-D-P-G-V-G-L-G-A-L-S-R-E 746 - 770 225     G-D-S-P-V-F-W-Y-A-P-E-C-L-K-E-Y-K-F-Y-Y-A-S-D-V-W 1061 - 1085
163     T-S-P-F-I-K-L-S-D-P-G-V-G-L-G-A-L-S-R-E-E-R-V-E-R 751 - 775 226     F-W-Y-A-P-E-C-L-K-E-Y-K-F-Y-Y-A-S-D-V-W-S-F-G-V-T 1066 - 1090
164     K-L-S-D-P-G-V-G-L-G-A-L-S-R-E-E-R-V-E-R-I-P-W-L-A 756 - 780 227     E-C-L-K-E-Y-K-F-Y-Y-A-S-D-V-W-S-F-G-V-T-L-Y-E-L-L 1071 - 1095
165     G-V-G-L-G-A-L-S-R-E-E-R-V-E-R-I-P-W-L-A-P-E-C-L-P 761 - 785 228     Y-K-F-Y-Y-A-S-D-V-W-S-F-G-V-T-L-Y-E-L-L-T-H-C-D-S 1076 - 1100
166     A-L-S-R-E-E-R-V-E-R-I-P-W-L-A-P-E-C-L-P-G-G-A-N-S 766 - 790 229     A-S-D-V-W-S-F-G-V-T-L-Y-E-L-L-T-H-C-D-S-S-Q-S-P-P 1081 - 1105
167     E-R-V-E-R-I-P-W-L-A-P-E-C-L-P-G-G-A-N-S-L-S-T-A-M 771 - 795 230     S-F-G-V-T-L-Y-E-L-L-T-H-C-D-S-S-Q-S-P-P-T-K-F-L-E 1086 - 1110
168     I-P-W-L-A-P-E-C-L-P-G-G-A-N-S-L-S-T-A-M-D-K-W-G-F 776 - 800 231     L-Y-E-L-L-T-H-C-D-S-S-Q-S-P-P-T-K-F-L-E-L-I-G-I-A 1091 - 1115
169     P-E-C-L-P-G-G-A-N-S-L-S-T-A-M-D-K-W-G-F-G-A-T-L-L 781 - 805 232     T-H-C-D-S-S-Q-S-P-P-T-K-F-L-E-L-I-G-I-A-Q-G-Q-M-T 1096 - 1120
170     G-G-A-N-S-L-S-T-A-M-D-K-W-G-F-G-A-T-L-L-E-I-C-F-D 786 - 810 233     S-Q-S-P-P-T-K-F-L-E-L-I-G-I-A-Q-G-Q-M-T-V-L-R-L-T 1101 - 1125
171     L-S-T-A-M-D-K-W-G-F-G-A-T-L-L-E-I-C-F-D-G-E-A-P-L 791 - 815 234     T-K-F-L-E-L-I-G-I-A-Q-G-Q-M-T-V-L-R-L-T-E-L-L-E-R 1106 - 1130
172     D-K-W-G-F-G-A-T-L-L-E-I-C-F-D-G-E-A-P-L-Q-S-R-S-P 796 - 820 235     L-I-G-I-A-Q-G-Q-M-T-V-L-R-L-T-E-L-L-E-R-G-E-R-L-P 1111 - 1135
173     G-A-T-L-L-E-I-C-F-D-G-E-A-P-L-Q-S-R-S-P-S-E-K-E-H 801 - 825 236     Q-G-Q-M-T-V-L-R-L-T-E-L-L-E-R-G-E-R-L-P-R-P-D-K-C 1116 - 1140
174     E-I-C-F-D-G-E-A-P-L-Q-S-R-S-P-S-E-K-E-H-F-Y-Q-R-Q 806 - 830 237     V-L-R-L-T-E-L-L-E-R-G-E-R-L-P-R-P-D-K-C-P-C-E-V-Y 1121 - 1145
175     G-E-A-P-L-Q-S-R-S-P-S-E-K-E-H-F-Y-Q-R-Q-H-R-L-P-E 811 - 835 238     E-L-L-E-R-G-E-R-L-P-R-P-D-K-C-P-C-E-V-Y-H-L-M-K-N 1126 - 1150
176     Q-S-R-S-P-S-E-K-E-H-F-Y-Q-R-Q-H-R-L-P-E-P-S-C-P-Q 816 - 840 239     G-E-R-L-P-R-P-D-K-C-P-C-E-V-Y-H-L-M-K-N-C-W-E-T-E 1131 - 1155
177     S-E-K-E-H-F-Y-Q-R-Q-H-R-L-P-E-P-S-C-P-Q-L-A-T-L-T 821 - 845 240     R-P-D-K-C-P-C-E-V-Y-H-L-M-K-N-C-W-E-T-E-A-S-F-R-P 1136 - 1160
178     F-Y-Q-R-Q-H-R-L-P-E-P-S-C-P-Q-L-A-T-L-T-S-Q-C-L-T 826 - 850 241     P-C-E-V-Y-H-L-M-K-N-C-W-E-T-E-A-S-F-R-P-T-F-E-N-L 1141 - 1165
179     H-R-L-P-E-P-S-C-P-Q-L-A-T-L-T-S-Q-C-L-T-Y-E-P-T-Q 831 - 855 242     H-L-M-K-N-C-W-E-T-E-A-S-F-R-P-T-F-E-N-L-I-P-I-L-K 1146 - 1170
180     P-S-C-P-Q-L-A-T-L-T-S-Q-C-L-T-Y-E-P-T-Q-R-P-S-F-R 836 - 860 243     C-W-E-T-E-A-S-F-R-P-T-F-E-N-L-I-P-I-L-K-T-V-H-E-K 1151 - 1175
181     L-A-T-L-T-S-Q-C-L-T-Y-E-P-T-Q-R-P-S-F-R-T-I-L-R-D 841 - 865 244     A-S-F-R-P-T-F-E-N-L-I-P-I-L-K-T-V-H-E-K-Y-Q-G-Q-A 1156 - 1180
182     S-Q-C-L-T-Y-E-P-T-Q-R-P-S-F-R-T-I-L-R-D-L-T-R-L-Q 846 - 870 245     T-F-E-N-L-I-P-I-L-K-T-V-H-E-K-Y-Q-G-Q-A-P-S-V-F-S 1161 - 1185
183     Y-E-P-T-Q-R-P-S-F-R-T-I-L-R-D-L-T-R-L-Q-P-H-N-L-A 851 - 875 246     E-N-L-I-P-I-L-K-T-V-H-E-K-Y-Q-G-Q-A-P-S-V-F-S-V-C 1166 - 1190
184     R-P-S-F-R-T-I-L-R-D-L-T-R-L-Q-P-H-N-L-A-D-V-L-T-V 856 - 880 247 H-M-R-S-A-M-S-G-L-H-L-V-K-R-R SAMS peptide
Amino Acid Position Amino Acid Position 
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 n 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 n
n 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 n 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n 241 242 243 244 245 246 247 n
n 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 n 241 242 243 244 245 246 247 n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 n n
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n
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